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Introduction 
Statistical science is central to the process of pharmaceutical clinical drug 
development.  New medicines have to be evaluated in a series of clinical trials in 
humans over many years for which the experimental design and data analysis is 
critical, requiring expert statistical input and knowledge. Traditionally trials are 
classified in relation to the phase of development: Phase I denotes the first trials in 
human volunteers and patients looking at parameters such as drug distribution, 
metabolism and excretion; Phase II denotes clinical ‘proof-of-concept’ and dose 
ranging trials where the aim is to establish probable efficacy of the new drug; Phase 
III denotes the confirmatory or ‘pivotal’ testing phase where the hope is to establish 
efficacy in controlled trials, where patients are randomized to the experimental 
drug or control, often but not always placebo, typically in a double-blinded manner 
(where neither the physician or the patient is aware of treatment assignment).  It is 
Phase III trials that form the basis of the drug manufacturer’s application for 
licensure of the new drug to the prevailing regulatory authorities; and Phase IV 
denotes post licensure trials to characterise further the safety of the drug, explore 
new medical uses and to provide any additional information as required by the 
licensing authorities.  As such, it is clear that drug development is heavily regulated 
worldwide.  This regulation includes complex statistical guidance governing trial 
design and analysis, further necessitating expert statistical input in the drug 
development process.  
 
Over the past decade, drug development has become increasingly challenging.  At 
an estimated cost of $0.8-2b, developing a drug has never been more expensive  
(Chuang-Stein et al 2011). Yet, despite increased expenditure, overall 
pharmaceutical research and development productivity remains low.   Failure rates 
of 80% in Phase II and 50% in Phase III have been reported (Arrowsmith 2011a-b). 
Two thirds of Phase III failures are reported as due to not demonstrating a positive 
treatment effect reflecting poorly on the quality of Phase II design and decision 
making (Arrowsmith 2011b).  And with high profile drug use withdrawals over 
recent years such as Vioxx, Avandia, Xigirs and Acomplia, regulators are demanding 
6
  
ever more data to support drug approval, post-approval safety assessment and 
reimbursement (EMA 2009a and 2011, MHRA 2004 and 2010, FDA 2004a, Lilly 
2011). 
 
This difficult environment has stimulated clinical researchers and statisticians to 
consider alternative approaches and flexible designs, particularly in early 
development, resulting in a jump in the associated literature.  Oncologic drug 
development has been the focus of much of this attention; medical need is high and 
improvements in molecular diagnosis and the associated potential for patient 
selection offer the opportunity to deliver targeted drugs to specific patient 
populations with breakthrough improvements in effectiveness together with a 
compelling benefit:risk balance. Statistical developments have included the 
application of flexible designs such as PII/PIII ‘seamless’ designs, novel patient 
selection strategies as well as analytical methods to evaluate the value of surrogate 
endpoints and approaches to cope with issues in survival analysis such as 
‘crossover’ from control to active treatment upon disease progression (Williams et 
al 2002, Rimawi and Hilsenbeck 2012).  At the same time there has been a surge in 
the literature regarding the use of Bayesian methodologies in drug development, 
particularly in relation to adaptive designs and in the area of health technology 
assessment with approaches such as network meta-analyses (Lumley 2002, Sutton 
et al 2008, Lu et al 2004, Caldwell et al 2005, Edwards et al 2009, Jones et al 2011).   
 
Despite these advances, many statistical issues persist in the clinical development 
of oncologic, and other, therapeutics.   Several of the key issues have been 
discussed by Carroll in a series of peer reviewed publications over past years.  These 
publications are provided in the Appendix.  The aim of this covering chapter is to 
collate and critique these publications, demonstrating how they form a coherent, 
related body of statistical work and, in so doing, provide recommendations for the 
future clinical development of oncologic medicines.  These issues and challenges 
include the following: 
7
  
1.1 The use of biomarkers and surrogate endpoints to accelerate oncologic drug 
development 
With the advent of ever more sophisticated proteomic, genomic and genetic 
technologies, efforts to gain a more in-depth biologic understanding of disease, 
particularly in oncology, is leading to the discovery of multiple new biomarkers that 
may reflect underlying disease processes.  Such biomarkers are frequently 
considered as vital patient selection tools that will help to identify those most likely 
to benefit from a new drug, and, in so doing, will reduce costs, lessen risk and 
shorten development times.  Herceptin (trastuzumab), Gleevec (imatinib mesylate) 
and Iressa (gefitinib), are often cited biomarker-led development successes others 
are encouraged to emulate (EMA 2009b, FDA 2010a and 2013a). It is further hoped 
that biomarkers can be used as surrogate endpoints in the regulatory drug approval 
process and therefore provide a substitute for clinical outcomes, accelerating the 
availability of new medicines.   However, many statistical issues remain such that 
biomarker strategies may not in all cases deliver the advantages hoped for.   
Supporting publications are: 
1. Newling D, Carroll K and Morris T.  Is prostate-specific antigen progression a 
surrogate for objective clinical progression in early prostate cancer?  Journal of 
Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 
22, No 14S (July 15 Supplement), 2004: 4652. 
2. Collette L, Burzykowski T, Carroll K,  Newling D,  Morris T and Schroder F.  Is 
prostate-specific antigen a surrogate for survival in advanced prostate cancer? 
Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-
Meeting Edition).  Vol 22, No 14S (July 15 Supplement), 2004: 4551. 
3. Collette L, Burzykowski T, Carroll KJ et al.  Is prostate-specific antigen a valid 
surrogate end point for survival in hormonally treated patients with metastatic 
prostate cancer? Joint Research of the European Organisation for Research and 
Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca 
Pharmaceuticals. 2005, Journal of Clinical Oncology; 23:6139–6148. 
4. Buyse M,  Burzykowski T,  Carroll K et al. Progression-Free Survival Is a Surrogate 
for Survival in Advanced Colorectal Cancer.  Journal of Clinical Oncology, 2007;  
25:5218-5224.  
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5. Carroll KJ.  Biomarkers in drug development: friend or foe? A personal reflection 
gained working within oncology. Pharmaceutical Statistics, 2007; 6(4): 253–260. 
 
1.2 Randomized Phase II designs: the use of progression free survival as an 
endpoint and decision making from Phase II to Phase III.  
Historically oncology Phase II studies have been relatively small, single arm 
response rate driven studies (Simon 1989).  This reflected that, in the past, 
treatments for disease were invariably cytotoxics designed to kill cells so that tumor 
shrinkage was viewed as a direct measure of drug effectiveness.  However, newer 
molecularly targeted treatments, such as the EGFR, VEGF and mTOR inhibitors as 
well as new biologic monoclonal anti-bodies such as bevacuzimab, panitumumab 
and ipilimumab, have a different, cytostatic mode of action meaning tumor 
shrinkage is no longer considered an appropriate endpoint (Korn 2001 et al, Stadler 
and Ratain 2000, Eskens et al 2000, Simon et al 2001).  Rather, the period of time 
alive and free from growth and spread of disease, typically referred to as 
progression free survival (PFS), is a more appropriate endpoint to test these 
modern cytostatics and should be subject to fewer Type II errors than would use of 
standard tumor shrinkage.   The use of PFS in Phase II oncology has given rise to 
larger and longer randomised, controlled trials which have served to raise a number 
of important statistical issues.  These issues relate mainly to the perceived 
prohibitive size of Phase II when using a PFS endpoint and the potential for bias 
when using progression as an endpoint, and further give rise to the related 
question as to how best to use more informative randomised Phase II data to better 
predict the chance of success in subsequent Phase III trials.  Supporting publications 
are: 
6. Stone A, Wheeler C, Carroll K and Barge A.  Optimizing randomized phase II trials 
assessing tumor progression. Contemporary Clinical Trials, 2007; 28(2):146-52.  
7. Carroll KJ. Analysis of progression-free survival in oncology trials: some common 
statistical issues. Pharmaceutical Statistics, 2007; Vol 6(2): 99-113. 
8. Carroll KJ.  Decision Making from Phase II to Phase III and the Probability of 
Success: Reassured by ‘Assurance’?  Journal of Biopharmaceutical Statistics, 2013; 
Vol 23(5):1188-1200. 
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1.3 Non-inferiority trial design and analysis.  
Several regulatory guidelines have been developed over past years to govern the 
various facets of active control, non-inferiority (AC, NI) trial design and analysis 
(FDA 2010b; EMA 2000 and 2005).  Despite this, much statistical discussion and 
debate remains regarding the true nature of ‘NI’ assessment and the associated 
feasibility of ‘NI’ trial design given the traditionally conservative approaches 
employed by regulators, in particular the FDA.  Issues of assay sensitivity and 
constancy are well known, but more fundamental is the question of what, primarily, 
is the statistical goal of an AC, NI trial and whether the hurdles imposed by the 
regulators in NI assessment represent an arbitrarily higher standard for drug 
approval based merely on trial design alone.   There are also illogicalities associated 
with standard ‘fixed’ margin and ‘percent preservation of effect’ approaches to NI 
assessment which need to be highlighted in addition to the relative efficiency of 
these two approaches as compared to the third most commonly used approach, the 
so-called ‘synthesis’ method.  These matters relating to AC, NI trial design and 
analysis are of relevance across all therapeutic areas, though particularly in 
oncology where gold standard randomised placebo control trials are often seen as 
unethical, necessitating the use of AC trials.  Supporting publications are: 
9. Carroll K and Milsted R. Barriers to clinical development in oncology: The impact 
of new thinking around non-inferiority.  Journal of Clinical Oncology, ASCO Annual 
Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 
2004: 6082. 
10. Carroll K, Milsted B and Lewis JA.  Design and analysis of non-inferiority mortality 
trials in oncology.  Letter to the Editor. Statistics in Medicine 2004, 
Vol 23(17): 2771-2774. 
11. Carroll KJ. Active-controlled, non-inferiority trials in oncology: arbitrary limits, 
infeasible sample sizes and uninformative data analysis. Is there another way?  
Pharmaceutical Statistics, 2006; Vol 5(4): 283-293. 
12. Carroll KJ.  Statistical issues and controversies in active-controlled, ‘non-
inferiority’ trials.   Statistics in Biopharmaceutical Research, 2013. Statistics in 
Biopharmaceutical Research 2013; 5:3, 229-238. 
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1.4 The use of parametric methods in the analysis of oncology clinical trial data.  
With the publication of Cox’s partial likelihood approach in 1972, Cox proportional 
hazards regression and the associated log rank test have become the mainstay of 
statistical testing for time to event data in oncology and beyond (Cox 1972). Given 
its widespread use and acceptance across the clinical research spectrum, 
statisticians and researchers seldom challenge its dominance or consider other 
parametric alternatives.   Yet, parametric methods, such as Weibull modelling, can 
offer greater flexibility and breadth of insight whilst still delivering core results very 
similar to their non-parametric counterpart.  For Weibull modelling, this is the case 
even when the underlying distribution of survival times is known not to be truly 
Weibull.  Further, parametric approaches can be helpful in tackling common 
problems such as the analysis of duration of response to provide an unbiased, 
unconditional evaluation based on all randomized patients rather than a  non-
randomized comparison in the subset of patients who responded, which is the 
typical approach in oncology trials despite this being in contradiction of the 
European Medicines Agency (EMA) anti-cancer guideline (EMA 2012a).   
 
Supporting publications are:  
13. Carroll KJ.  On the use and utility of the Weibull model in the analysis of survival 
data. Controlled Clinical Trials 2003; 24: 682–701. 
14. Carroll KJ.  Back to basics: explaining sample size in outcome trials, are 
statisticians doing a thorough job?  Pharmaceutical Statistics, 2009; 8: 333–345. 
15. Ellis S, Carroll KJ and Pemberton K.  Analysis of Duration of Response in Oncology 
Trials.  Contemporary Clinical Trials, 2008; 29: 456–465.  
 
The remainder of this Summary Chapter is structured as follows; Section 2 discusses 
publications relating to surrogate endpoint and biomarkers; Section 3 discusses 
publications regarding issues with PFS as an endpoint in Phase II trials and the use 
of such data in predicting the chance of success in Phase III; Section 4 discusses 
papers relating to active-control, ‘non-inferiority’ trials; and Section 5 briefly 
discusses papers on parametric models in the analysis of time to event data. 
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Section 6 then closes with a collation of the recommendations made for future 
oncology trial design.  
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2 The use of biomarkers and surrogate endpoints to accelerate 
oncologic drug development 
2.1  Background 
In oncology the gold standard clinical endpoint remains overall mortality.  This can 
typically result in long term trials, especially in adjuvant settings (i.e. where 
treatment is given as an adjunct to therapy of curative intent) and slow growing 
malignances such as prostate cancer.   As newer more effective second-line 
treatments become available, the utility of survival as means to assess drug effects 
in the first-line setting has become increasingly difficult across a range of 
malignancies, leading to an increasing focus on alternative biomarker and clinical 
endpoints such as progression-free survival to play the role of surrogates.   
Statistical evaluation of potential biomarkers and surrogate endpoints has been an 
important consideration for drug development over recent years.  Prentice (1989) 
and Freedman et al (1992) were the first to lay down formal theoretical criteria to 
assess endpoint surrogacy.  Subsequently, Fleming and DeMets (1996) wrote an 
important article regarding the use of assumed surrogate endpoints in the drug 
approval process and the high risk of drawing inappropriate conclusions.  While the 
criteria forwarded by Prentice offer a technically complete description of the 
properties required to fulfil surrogacy, these criteria can prove difficult to apply in 
practice.  For example, the requirement to prove the null (i.e. that the treatment 
effect on the true endpoint was reduced to zero conditional upon the presence of 
the surrogate) is, strictly speaking, unachievable.  More recently Molenberghs et al 
(2001, 2002, 2004, 2010), Buyse (2009) and Buyse et al (1998, 2000, 2010) have 
taken a different approach, offering pragmatic meta-analytic methods to quantify 
the relationship between treatment effects on some purported surrogate and on 
the clinical endpoint itself across a set of relevant, randomized trials.  This method 
yields measures of association between endpoints within the patient and, most 
importantly, between treatment effects across trials and, therefore, allows 
estimation of the ‘surrogate threshold effect’, i.e. the amount by which the 
surrogate would need to be impacted by treatment to result in a meaningful effect 
on the clinical endpoint itself (Burzykowski et al 2006).   
13
  
2.2 Publication 1: 
Newling D, Carroll K and Morris T (2004).  Is prostate-specific antigen 
progression a surrogate for objective clinical progression in early prostate 
cancer?  
In prostate cancer, or in healthy men deemed at risk of developing prostate cancer, 
prostate specific antigen (PSA) is a well-accepted and extensively used plasma 
biomarker of disease status.  Both clinicians and patients have used PSA for more 
than 20 years to monitor disease and even small movements in PSA level over 
relatively short time periods can result in the application of treatments such as local 
radiotherapy, surgery or systemic treatment with medical castration or oral anti-
androgen therapy.    However, despite its widespread use, the utility of PSA as a 
surrogate endpoint for clinical outcome was not formally assessed until 2004. 
Access to clinical trial data in over 8,000 prostate cancer patients from the 
bicalutamide (an oral, once daily, non-steroidal anti-androgen) Early Prostate 
Cancer Programme allowed, for the first time, thorough statistical evaluation of PSA 
as a potential surrogate for longer term objective, radiologic progressive disease 
(ORPD) on CT or MRI scan (Wirth et al 2008).  Using the Buyse and Molenberghs 
approach, this work was published in abstract form by Newling, Carroll and Morris 
at the American Society of Clinical Oncology (ASCO) 2004.  A summary slide from 
the presentation is reproduced below.  By examining the data in distinct regions, it 
was determined that while the R2 between treatment effects on PSA and ORPD was 
either 0.52 (p<0.001) or 0.65 (p<0.001) (the R2 value being dependent on the 
inclusion of a potentially influential data point), nevertheless a large treatment 
effect on PSA, i.e. a hazard ratio (HR) in the region of 0.50, was required to predict a 
modest effect on ORPD, i.e., a HR in the region 0.80 to 0.85.    
  
14
  
Publication 1.  Newling, Carroll, Morris (2004) 
 
 
2.3 Publications 2 and 3: 
Collette L, Burzykowski T, Carroll K  et al (2004).  Is prostate-specific antigen 
a surrogate for survival in advanced prostate cancer? 
Collette L, Burzykowski T, Carroll KJ  et al (2005). Is prostate-specific antigen 
a valid surrogate end point for survival in hormonally treated patients with 
metastatic prostate cancer?  
This work led to research and collaboration with the European Organisation for 
Research and Treatment of Cancer (EORTC) and the Limburgs Universitair Centrum 
Belgium regarding the utility of PSA progression as a surrogate endpoint for overall 
mortality in advanced prostate cancer.  Findings were published by Collette, 
Burzykowski, Carroll et al initially in abstract form at the 2004 ASCO meeting and 
subsequently in full in the Journal of clinical Oncology in 2005.  Data from over 2000 
patients across 5 randomized clinical trials were analyzed to produce estimates of 
patient-level and trial-level association.    Results showed that while, at the patient-
level, PSA tracked reasonably well with overall survival suggesting some utility in 
the day-day clinical management of patients, it performed poorly at the trial-level 
15
  
in terms of a true surrogate endpoint for the effect of bicalutamide treatment on 
mortality in advanced prostate cancer (PCa) patients.  Table 5 and Fig 4B are from 
the 2005 publication are reproduced below, along with a summary slide from the 
2004 ASCO Annual Meeting Proceedings: 
 
  Publication 2. Collette, Burzykowski, Carroll (2004) 
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Publication 3.  Collette, Burzykowski, Carroll (2005):  Figure 4B
 
TTPP-1: PSA value above normal (4 ng/mL), representing a first increase ≥20% above the  
nadir.  TTPP-2: PSA value >2.5 times the normal range (10 ng/mL), representing a first 
increase ≥50% above the moving average (based on three consecutive measurements) 
nadir. This increase had to be either the last  observed value or be sustained for at least  
4 weeks.  
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As can be seen,       
  was weak apart from TTPP-2 with a value of 0.66.  
Longitudinal measures also appear to have a better       
 , however the 
incompleteness of PSA measures over time make this measure somewhat 
unreliable.    
 
These data, both in early and advanced disease settings, were presented at the US 
Food and Drug Administrations’ Public Workshop on Clinical Trial Endpoints in 
prostate cancer drug development, June 21-22, 2004. It was concluded that, for 
clinical trials in early prostate cancer, some form of PSA based progression could be 
included as part of a composite disease progression endpoint based primarily on 
objective radiologic and imaging evidence; and, further, that such a composite 
endpoint could be used in support of regulatory approval.  
 
Despite this successful contribution to the debate regarding PSA surrogacy in 
prostate cancer, the approach taken was narrow and, with additional data and 
analyses, could have been more informative.  For example, research was limited in 
terms of the number of trials involving the anti-androgen bicalutamide such that 
the unit of analysis using the Molenberghs approach became region within trial.   
The extent to which this may have influenced the results is hard to judge given 
region (in terms of country) was pre-determined.  The inclusion of more trial data 
would have served to strengthen results but no further trial data were available.  
Data on other prostate cancer drugs in the same (anti-androgen) class would have 
provided both greater confidence and more generalizable results; however, the 
analytic approach at the time required individual patient data which was not 
available to the authors.  Improved meta-regression techniques available today 
may have made incorporation of published summary level data on other drugs 
more feasible.    
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2.4 Publication 4: 
Buyse M,  Burzykowski T,  Carroll K et al (2007). Progression-Free Survival Is 
a Surrogate for Survival in Advanced Colorectal Cancer  
Building further in this area, a novel presentation was made to the FDA’s 2004 
Advisory Committee Meeting panel regarding trial endpoints in colorectal cancer 
(CRCa) research in which the utility of PFS as a surrogate for overall mortality in first 
line disease was assessed based upon data from over 1200 patients in 3 
randomised clinical trials comparing the novel chemotherapy treatment raltitrexed 
with standard flouracil (FU) therapy (FDA 2004b, 2004c).  The analysis showed that 
approximately half of the treatment effect on survival was explained by the effect 
of treatment on PFS and that, given a PFS increase of 50%, survival would be 
expected to increase by 29% with 95% CI (13%, 48%).  These data helped to support 
a positive vote from the Committee to allow the use of PFS as a primary endpoint in 
first-line CRCa trials.  This work was subsequently followed by collaboration with 
Buyse and Burzykowski resulting in a JCO publication in 2007.   In this work 10 first-
line CRCa trials comparing FU + leucovorin to either FU alone or raltitrexed were 
used to characterize the relationship between PFS and overall survival and 3 
separate trials, comparing FU + leucovorin with or without irinotecan or oxaliplatin 
treatment, were used for validation purposes.  Results were very encouraging for 
the use of PFS as a surrogate for overall survival (OS).  At the patient level, PFS and 
OS were highly correlated with R2 coefficient 0.82 and, at the trial level; and 
treatment effects were also well correlated with coefficient 0.74, 95% CI (0.44, 
1.03) after exclusion of one influential trial.  The data also estimated the surrogate 
threshold effect on PFS to be hazard ratio of 0.77 to predict a non-zero beneficial 
effect on overall survival.   Finally validation using 3 separate trials showed a 
reasonable alignment between observed and predicted treatment effects on OS.  
Figure 4 and Table 2 from the publication are reproduced below. 
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Publication 4.  Buyse, Burzykowski, Carroll (2007):  Figure 4 
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This body of work evaluating potential surrogate endpoints in PCa and CRCa sits 
within a broader framework of similar research using meta-analytic methodology to 
examine intermediate endpoints, predominantly in oncology.  Examples include 
Sargent et al (2005) for 3 year disease-free survival as a surrogate for 5 years overall 
survival in adjuvant colorectal cancer; Tang et al (2007) for endpoints in colorectal 
cancer; Burzykowski et al (2008) for endpoints in advanced breast cancer; Saad et al 
(2010) for endpoints in breast cancer and colorectal cancer; Buyse et al (2011) for 
endpoints in leukaemia and Laporte et al (2013) for endpoints in non-small cell lung 
cancer (NSCLC).   Taken together, this research has had a positive impact on how 
non-survival intermediate clinical endpoints are viewed and utilised in oncologic 
research, particularly by regulatory authorities who, in some instances (such as 1st 
line treatment in CRCa and NSCLC), have changed policy regarding the endpoints 
and evidence required to support drug approval.  That said, the underlying Buyse 
and Molenberghs methodology relies upon multiple trials having been conducted in 
a given area, all of which must have collected data on both the intermediate and 
true clinical outcome.  This clearly means that any new potential biomarker will 
take many years and many millions of dollars to assess and, hence, this approach 
does not readily serve to accelerate the drug development process.  Further in all of 
the preceding referenced work, no account was taken of competing risks associated 
with long term follow-up of the surrogate and true clinical outcome; for example, 
patients can stop treatment due to an adverse event prior to meeting the surrogate 
and/or the true clinical outcome, or additional anti-cancer treatments can be given 
by the treating physician if considered medically indicated.  In either case these 
intervening events represent competing risks since they can result in curtailed 
patient follow-up such that the surrogate and/or the true clinical outcome are 
censored and unobserved.   The extent to which this issue may have affected 
published results and conclusions is unknown.   The solution is not obvious, though 
pragmatically it would seem appropriate to mandate (by informed consent) full 
intent-to-treat (ITT) follow-up of all patients for overall mortality post attainment of 
the surrogate endpoint as a condition of acceptance of the surrogate in a regulatory 
context.  
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2.5 Publication 5: 
Carroll KJ (2007).  Biomarkers in drug development: friend or foe? A 
personal reflection gained working within oncology.   
Following on from specific evaluation of surrogate endpoints in PCa and CRCa, the 
statistical and strategic usefulness of biomarkers and surrogate endpoints in 
oncologic drug development was reviewed more broadly in this paper.    
Fundamentally, the key goal researchers have in using a biomarker is to follow a 
targeted development strategy; to identify ‘responsive’ patients.  However, this is 
an over simplification.  Rather the goal should be to use the biomarker to identify 
patients ‘more likely to benefit’ from a given intervention.  And as later reiterated 
by both Chakravarty et al (2011) and Fleming and Powers (2012), of primary 
interest are predictive biomarkers, i.e biomarkers that are ‘effect modifiers’, 
associated with a differential treatment effect, as opposed to biomarkers that are 
merely prognostic for the disease.   In the paper, two critical underlying 
assumptions are identified that fundamentally determine usefulness of biomarker 
driven drug development strategies: (i) that biomarker positive patients experience 
a treatment effect while biomarker negative patients do not, and (ii) the biomarker 
diagnostic that determines whether a patient is ‘positive’ or ‘negative’ is perfect, 
with 100% sensitivity and specificity.    Examination of these assumptions reveals 
that with relatively modest departures from the ideal, the strategic advantages of a 
targeted development are quickly eroded.    Tables I-III from the paper are 
reproduced below. 
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Table I shows median survival times for drug and control in biomarker positive 
patients (25% of the overall trial population), biomarker negative patients and 
overall.   These data feed into Table II which displays the number needed to screen 
(for the biomarker) and the number of patients required to be entered into the trial 
for the biomarker positive, negative and overall populations.   A perfect test 
requires only 117 biomarker positive patients to be entered and 468 to be 
screened.  However, as the specificity and sensitivity of the test falls, the numbers 
needed to enter and to screen quickly rise.   Table III shows the impact of there 
being a small treatment effect in biomarker negative patients.   With a treatment 
effect one third of that in biomarker positive patients, a trial in the overall 
population requires fewer patients to be entered than are required to screen in a 
biomarker positive trial. 
   
With respect to utilizing biomarkers as true surrogate endpoints to support 
regulatory approval, it was argued expectations are, in general, too high.  
Longstanding clinical endpoints such as PFS are only just being accepted statistically 
as endpoints for drug approval on the basis of cumulative data from multiple, well-
controlled randomised trials.  Set against this background it was postulated as 
unlikely that new biomarkers would be quickly accepted as substitutes for clinical 
outcomes in drug evaluation. As described by Carroll et al (2008), perhaps the best 
that can be hoped for might be to utilise new routes for approval such as 
conditional approval (EU) and existing routes such as accelerated approval (FDA) on 
the basis of a biomarker endpoint, with a commitment to conduct further trials 
post-approval to confirm clinical benefit.  
 
While the preceding publications served to identify issues in the use of surrogate 
endpoints and biomarkers in oncologic development, they did not offer alternative 
trial design solutions that might make biomarker driven developments more 
statistically appealing. Over past years, several important and related papers have 
appeared which attempt to do this.  Zhao et al (2010) considers the design and 
analysis of trials with a biomarker ‘sensitive’ sub-population defined at 
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randomization, addressing issues relating to multiplicity, enrichment and optimality 
in terms of the best balance of power in the overall and biomarker defined 
subpopulations.  In earlier work, Freidlin and Simon (2005) described an adaptive 
‘signature design’ where biomarker or ‘classifier’ is derived in the first stage of a 
two stage study. The classifier is then applied to the second stage patients such that 
treatment effect is tested in the overall population as well as in the biomarker 
determined subgroup of second stage patients.   Wang et al. (2007) proposed 
another adaptive design that enables the sponsor to restrict the enrolment of non-
sensitive patients in the second stage.  They also describe a ‘prospective-
retrospective’ design where evaluation of a sensitive subgroup is pre-specified but 
testing for biomarker status can occur after randomisation or even after clinical 
outcomes have been observed.   Jenkins et al (2010) considers a Phase II/III 
seamless design that allows, via a weighted combination test, for the possible 
identification of a sensitive sub-population at Phase II based on PFS and describes 
the strategies for Phase III analysis of OS while ensuring control of the overall Type I 
error rate.  More recently Quan et al (2012) considers a very similar approach for 
adaptive, post-randomization identification of sensitive sub-population.      
 
As an alternative to the designs offered by Jenkins and Quan, it is possible to derive 
a design in which there is a prospectively defined biomarker subgroup of interest 
and an interim analysis that allows certain decisions to be made regarding the 
future conduct of the trial.  For example, suppose a trial is sized with 1- power to 
test the hypothesis                   with 1-sided Type I error where  
represents the effect of treatment.   If   is a sufficient statistic for   with  
=assumed under the alternative and          , then  
    (     )
 
  if we 
employ the simplifying assumption that          where    is the variance of   
under the null.  Suppose further there is a biomarker defined fraction s (0 ≤ s ≤ 1) of 
the trial population in whom an enhanced treatment effect is hypothesized.  Let 
       denote the true treatment effect in this subpopulation with sufficient 
statistic               such that   
           where     
   .  With an 
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interim analysis planned at information time  , the relationship between overall 
population and the subset at both the interim and final analyses is as follows: 
 
 
 
 
 
 
 
If    and     represent the test statistics for the overall and subpopulation at the 
interim, then             
      with expectation               
 , correlation 
matrix   
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At the interim we might then have the following decision rule (or some other 
variant of interest) to determine how the trial should proceed: 
 If                 or both, stop for efficacy 
 If           and          then continue recruiting all patients and 
test both overall and subpopulation for efficacy in final analysis 
 If           and       then continue recruiting only patients in the 
subpopulation and test for efficacy in final analysis 
 If          and        then continue recruiting all patients and test 
only the overall population and test for efficacy in final analysis 
 If                  stop for futility 
 
From this it is straightforward to calculate the overall Type I error given s, cj and kj, 
j=1 to 3: 
 
 
Interim final 
Subpopln           
Not Subpopln                   
Overall       
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And, similarly, the overall Type II error: 
  (             |   )    
                      ,             
                      ,     |   )    
            ,            |   )    
                                
 
Finally, an important review of the regulatory Issues associated specifically with the 
use of biomarkers in oncology is offered by Chakravarty et al (2011).  The 
observation made is that most biomarker driven analyses submitted to FDA tend to 
be retrospective and, to strengthen the credibility of such analyses, it is suggested 
that biomarker related hypotheses should have a pre-determined scientific 
(biological) basis, the associated assay should be well characterized with good 
analytical performance and there should be a predefined plan for analysis relating 
to the biomarker, including alpha control.  Further, he raises a key concern 
regarding the typically low fraction of patients for whom biomarker status is 
attained in clinical trials leading to a potentially biased convenience sample.   These, 
and other, issues are then illustrated through the example of a panitumumab in 
CRCa and the retrospective analysis of patients with KRAS mutations for which only 
a small fraction of patients were  tested in the main pivotal trial. 
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2.6 Recommendations 
Based upon the preceding publications and discussion, the following 
recommendations for oncology trial design and analysis can be made: 
 
 Trials that employ a surrogate endpoint as primary should mandate full ITT 
follow-up of all patients post attainment of the surrogate for overall 
mortality.  Only in this way can the true benefit of the intervention be 
assessed and the value of the surrogate is assessed.  
 In biomarker driven trial design, routine and naive statistical assumptions 
regarding (i) the precise  dichotomous determination of biomarker 
‘negative’  and ‘positive’ patients and (ii) the complete absence of treatment 
effect in ‘negative’ patients should be abandoned.  Rather design options 
should be offered for a range of assumptions that allow a non-zero effect in 
‘negative’ patients and accommodate a less than perfect assay for 
biomarker measurement. 
 For biomarker driven developments, flexible designs should be routinely 
considered.  In particular the designs described by Zhao (2010), Jenkins 
(2011) and Wang (2007) offer three feasible opportunities to identify 
biomarker defined patient subpopulations that achieve enhanced treatment 
benefit whilst controlling the overall Type I error.  These designs in 
particular should be evaluated when considering a biomarker driven 
oncology Phase III development strategy.       
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3 Randomized Phase II designs: the use of progression free survival 
as an endpoint and decision making from Phase II to Phase III  
3.1  Background 
With newer targeted small molecules and humanised antibody treatments 
designed to have a cytostatic effect on the tumor, the traditional single arm, open 
Phase II oncology design and routine use of response rate as the Phase II endpoint 
are increasingly no longer appropriate tools  to test and screen clinically new anti-
cancer treatments for potential effectiveness.  Rather, arguments have been 
offered in favour of double blind randomised Phase II with PFS as the endpoint. 
 
Some of the first authors to raise these issues were Stadler and Ratain (2000), Korn 
et al (2001), Eskens et al 2000 and Simon et al (2001).  However, concerns were 
subsequently raised by the FDA regarding the use of progression as an endpoint 
(Williams et al 2002).   In addition to the question as to whether improvements in 
PFS per se represent a clinical benefit to the patient, a methodological concern was 
that, unlike death, the exact time a patient progresses is not known (the data being 
interval censored between clinic visits).  The concern therefore is this might lead to 
a downward bias when estimating the hazard ratio between two treatments, 
prompting suggestions that very frequent clinic visits might be required to more 
accurately determine the time progression occurred.    A further related concern is 
asymmetric follow-up of treatment arms (perhaps due to treatments having 
different administration schedules as can be common in oncology, or worsening of 
disease prompting more frequent medical assessments on one treatment relative 
to the other) and the scope for this to introduce bias.   And, finally, there is concern 
on behalf of sponsors and regulators alike relating to the likely prohibitive size of an 
event driven randomised Phase II with PFS and the primary endpoint, leading to 
suggestions to use a short term endpoint such as the percentage of patients with 
progressive disease at some early time point, e.g. at 8 weeks (often referred to as 
the ‘rate of progressive disease’ (PD) at   weeks), in preference to PFS over the full 
trial follow-up period.  
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3.2 Publication 6: 
Stone A, Wheeler C, Carroll K and Barge A (2007) Optimizing randomized 
phase II trials assessing tumor progression.   
A selection of these issues were addressed by Stone, Wheeler, Carroll and Barge 
(2007).  Firstly, it was shown analytically that the use of a PD-type endpoint at some 
early fixed point in follow-up was highly inefficient.  Table 1 from the publication is 
reproduced below: 
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This table describes a two arm trial requiring 69 events to test the hypothesis that 
the true hazard ratio between experimental treatment and control is 0.67 with 80% 
power and a 1-sided alpha level of 20%.  Exponential PFS times are assumed with 
medians of 6 and 4 months on experimental and control respectively.  It can be 
seen that a PD endpoint requires substantially more patients than a PFS endpoint to 
deliver a given power.  This is entirely as expected since early PD endpoints are 
associated with drastically fewer PFS events than an analysis based upon all PFS 
events accruing over the full trial follow-up period.  Assuming medians of    on 
control and        on experimental where   is the hazard ratio, the probability of 
a PFS event in a trial with a planned median follow-up of   months is given by  
 ̃      
   {        
 }      where         
   ⁄ .  Therefore the 
increase in the total sample size required when using a PD endpoint at a control 
rate of   
   is given by  ̃  ̃ where  ̃      
   {        
 }     .  For 
example, if      months,        and T=8.5 months, then  ̃       so that, 
with a target of 69 events for 80% power and a 1-sided  level of 0.20,   
      ⁄     .  Comparing to an analysis at a PD rate on control of 0.10,  ̃       
and, therefore,  ̃  ̃      .   Hence, and as shown in Table 1 above, the PD rate 
analysis requires approximately 8.5 times more patients that a PFS analysis.   
 
To handle differential follow-up two approaches were suggested, the first used an 
‘event count’ approach where the proportion of events (regardless of the clinic visit 
at which they were detected) would be analysed using a complementary log-log 
link.  This approach was shown to be reasonable with little loss of power providing 
(i) proportionality of the hazard ratio over time and (ii) the data were not overly 
mature at the time of the analysis.  The second approach briefly discussed was a 
‘grouped’ or interval censored analysis (the performance of which was evaluated in 
detail in the subsequent publication Carroll 2007(b)).   With regards to the 
frequency of clinic visits to assess progression status, it was shown that, contrary to 
feedback commonly attained from FDA, very frequent visits added little in terms of 
statistical efficiency.  Table 2 from the paper is reproduced below:  
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The simulations in Table 2 show how, with a Cox analysis based upon PFS time 
assigned to the clinic visit at which it was first detected, power falls and the 
treatment effect estimate attenuates as the time interval between visits lengthens 
whereas, with a grouped or interval censored analysis, power is maintained and the 
treatment effect is estimated without bias. 
 
The last issue addressed in the paper relates to the practice of censoring PFS time 
on receipt of additional anti-cancer therapy.  Given that the decision to provide 
additional therapy to the patient is commonly related to worsening health status 
and/or toxicity associated with randomised treatment, censoring is clearly 
informative and hence statistically problematic.   To address this issue, an ITT 
approach was recommended whereby all patients would be followed for 
radiographic assessment of disease through the planned duration of the trial 
regardless of the introduction of additional anti-cancer therapy.    
3.3 Publication 7: 
Carroll KJ. Analysis of progression-free survival in oncology trials: some 
common statistical issues (2007).  
This paper further explores the issue that progression times cannot be determined 
exactly in a clinical trial and the problematic regulatory advice to censor for 
progression on receipt of additional anti-cancer treatment.    Assuming exponential 
progression times, it is shown that, even when clinic visit schedules are the same 
for drug and control treatments, the common practice of taking the time of 
progression to be the date of the clinic visit at which it was detected results in a 
downwardly biased estimate of the underlying hazard ratio, 
  (experimental:control), that consequently erodes power.  If  ̂ denotes the 
estimated hazard ratio, then:   
 
 ̂  
 ̅ 
 ̅ 
                [ ̂]  
  (   
     )
  (   
     )
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where, for   = C, E,     represents the true and event rate on treatment  , 
 ̅  ∑      ⁄
  
     represents the reciprocal of the estimated event rate,    and    
are the total number of patients and events respectively,     is the time to event or 
censoring for patient on treatment  , and    represents the time interval between 
scheduled clinic visits.  The proof of this result by maximum likelihood is provided in 
Appendix A of the paper and illustrated in Table I, reproduced below: 
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Here the expected value of the hazard ratio,  [ ̂], is shown alongside the resulting 
reduced power of a log rank test (bearing in mind the trial was originally sized for 
90% power and a 2.5% 1-sided  level).  And, in the last column, the increase in the 
number of events required to maintain 90% power is provided.    
 
Given the power loss associated with the estimate  ̂, it was further shown that to 
retain at least 100(1-)% power in a study sized for 100(1-)%  power, , the 
interval between clinic visits should be no larger than:
 
                            
 
     
 
 
(
    
    
)  
 
where   is the true hazard ratio and   |
     
     
|.  Note since  then     , and 
since   is defined as the hazard ratio for experimental to control, then    .  
Therefore the term  
    
    
  in the expression    is always positive.  The full derivation 
of    is provided in Appendix B of the paper and illustrated in Table II, reproduced 
below: 
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Publication 7.  Carroll (2007): Table II 
 
 
For example, to retain at least 80% power in a trial sized for 90% power, the interval 
between clinic visits should be no longer than around 50-60% of the expected 
median time to progression on control.   
 
In addition to bias and loss of power when clinic visit schedules are the same for 
both treatment and control, it was shown that asymmetric visit schedules were 
associated with bias and inflated Type I error.  These findings are illustrated in Table 
III of the paper reproduced below. 
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Here the expected value of the hazard ratio,  [ ̂], is displayed for a range of 
asymmetric visit schedules when the true HR is unity.   [ ̂]  is seen to be biased in 
favor of the treatment with the longer time between scheduled clinic visits and the 
associated Type I error is consequently inflated.   
 
In light of these findings, an alternative estimate of treatment effect,  ̌, was 
suggested assuming a common time interval between scheduled clinic visits 
       :    
 
 ̌  
  (  
 
 ̅ 
)
  (  
 
 ̅ 
)
 
 
In Table IV of the paper reproduced below,  ̌ was shown in simulations to be 
unbiased with essentially no loss of statistical efficiency: 
 
  
42
  
P
u
b
licatio
n
 7.  C
arro
ll (200
7): Tab
le IV
 
 
43
  
In this Table,  [ ̂] is shown alongside the geometric mean ( ̂ ) of simulated 
hazard ratio estimates where the time of progression was assigned to the clinic 
visits at which it was detected. As anticipated a close match is observed.  Also 
displayed is geometric mean ( ̌ ) and associated standard error (on the log scale) 
of simulated hazard ratio estimates based on the estimator  ̌.   Relative to  ̂, the 
alternative  ̌ is seen to be unbiased with a log scale standard error very close to 
that associated with the original powering of the trial (i.e. with 200 events, the 
standard error of the hazard ratio estimate based on a log rank test is expected to 
be √    ⁄        ).    
 
This new estimate  ̌ and its SE were shown to represent an interval-censored 
analysis which, in turn, was shown to be closely related to an analysis of the 
proportion of events observed over the follow-up period using a complementary 
log-log link.    
 
With respect to the FDA recommendation to censor PFS on the receipt of additional 
anti-cancer therapy, the serious bias and grossly inappropriate conclusions that can 
result from such informative censoring were highlighted.  Akin to the accepted 
norm for mortality, full ITT follow-up for progression assessment was 
recommended regardless of receipt of additional anti-cancer therapies.    
 
Further, as encapsulated in guidance from both FDA and CHMP at the time, with 
regards to the common request from regulatory authorities for an independent 
centralised review (ICR) of radiographic data in patients deemed to have 
progressed by the trial investigator, associated key difficulties were highlighted.  
These included (i) the handling of patients where the investigator and independent 
review disagree and radiological follow-up has ceased and (ii) common practice to 
review only data in patients who have progressed.  The challenge with (i) is the 
absence of investigator follow-up is most likely to be informative, resulting in such 
patients being closer on average to progressing than patients where neither the 
investigator nor independent reviewer assigned progression.  And (ii) will always 
44
  
lead to a less precise estimate of the treatment effect since the number of 
progression events can only go down.  It was argued that a more satisfactory 
approach would be to take (in addition to ICR of patients deemed to have 
progressed by the investigator) a random sample of non-progressing patients to 
estimate the fraction of patients without progression reclassified as progressive by 
independent review. The overall number of progression events could then be 
estimated under independent review and treatment groups compared accordingly.  
 
While addressing many PFS related issues, the paper did not evaluate other lifetime 
distributions such as the Log Normal, Weibull or Gamma family and the impact this 
might have had on the conclusions drawn with regards to determining of the timing 
of progression and the value of interval-censored analysis.   Also, the empiric non-
parametric approach offered by Turnbull (1976) for interval censored data was not 
examined.  In brief, this technique proceeds as follows: 
 Data are (Li, Ui], for i=1,…,n patients with Ui= meaning the i
th patient is right 
censored at Li.  
 t0, t1,…, tm = set of time-points that includes all the points Li and Ui, i=1,…,n.  
 For each patient define aik=1 if (tk-1, tk], k=1,…,m, is contained in the interval (Li, 
Ui], and 0 otherwise.  
 Let S(tk) be an initial estimate of the survivor function. Update S(tk) as follows: 
• Calculate pk = S(tk-1) - S(tk), k=1,…,m  
• Estimate the number of events which occurred at tk by    
∑
     
∑      
 
   
 
     
and number at risk by    ∑   
 
    
• Use dk and rk to provide an updated product-limit estimate of the 
survivor function.   Repeat until convergence.  
    and    can then be used to construct a log-rank test.  
 
In addition to not evaluating Turnbull, the non-parametric generalization of the log-
rank test to interval-censored analysis offered by Sun J et al (2005) was also not 
explored, primarily because there was no validated software available and no way 
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of providing an estimate of the hazard ratio was described.   More recently Zhang 
and Sun J (2010) and Sun X et al (2013) offer reviews of methods for interval-
censored analysis.  In particular, Sun X et al (2013) suggests two variance estimates 
for the generalised log-rank test which, together with the associated Fisher’s score, 
could potentially be used to provide a Pike estimate for the hazard ratio.  
 
In respect of the recommendation to implement ITT follow-up and analysis of PFS, 
while contrary to the FDA anti-cancer guideline (2007), this is more consistent with 
the EMA guideline (2012a, 2012b) which leans toward an ITT approach.  This 
recommendation was recently supported by Denne et al (2013) who reports a  
re-analysis of 28 Phase III trials with a PFS endpoint using both ITT and non-ITT 
approaches.  This re-evaluation showed a tendency for non-ITT analysis to result in 
upwardly biased estimates of treatment effect.  Rothmann et al (2013) performed a 
re-elevation of 14 ‘add-on’ oncology trials (where drug and control are provided as 
an adjunct to continuing background standard care) submitted to FDA looking for 
evidence whether censoring PFS on the provision of further anti-cancer treatment 
was informative.  He concluded that there was evidence, but only for the active arm 
and not the control arm.  However, this conclusion seems strange.  While blinding 
of the 14 trials is not stated, being ‘add-on’ in design, drug and control treatments 
are typically double-blind and, further, the introduction of anti-cancer therapy 
would seem most plausibly to be an event related to the worsening of disease 
independent of the randomised therapy received.    
 
Also not reviewed was the possibility of estimating informatively censored PFS 
times using methods such as (i) Inverse Probability of Censoring Weighting (IPCW) 
as described by Robins and Finkelstein (2000) and Rimawi and Hilsenbeck (2012) or 
(ii) Rank Preserving Structural Failure Time (RPSFT) analysis as described by Robins 
and Tsiatis (1991) and Branson and Whitehead (2002).  While application of such 
methods might provide some theoretical estimate of the treatment effect on PFS in 
the absence of informative censoring, the fundamental issue is that such an 
estimate has no practical meaning or value to the patient or prescribing physician.  
This is because this estimate is entirely academic and can never be realised in 
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practice as patients will fail and will receive additional anti-cancer treatments.   In 
line with Korn et al (2011) and Fleming et al (2009), the only meaningful estimate of 
treatment effect is based on an ITT analysis as this reflects the true value of 
treatment in the routine medical care of the patient.   However, to provide an ITT 
analysis of PFS will likely require a fundamental change in the philosophy of trial 
conduct with an alteration to the patient informed consent.  This change (i) would 
be explicit that patients are consenting to follow-up for the full, planned duration of 
the trial and not follow-up to the point randomised treatment stops or additional 
treatment is added and (ii) would need to be  unequivocally clear to the trial 
investigator that they must continue to monitor the patient and collect radiographic 
assessments of disease for the entire, protocol defined trial follow-up period 
regardless of the introduction of additional anti-cancer treatment or dropout due to 
toxicity or adverse event. 
 
Finally, several of the chief recommendations made in the 2007 paper were echoed 
and supported in subsequent publications by Amit et al (2011) and Stone et al 
(2011), who reported findings from a cross industry working group on PFS 
assessment in oncology trials.  Based on a reanalysis of multiple industry trials and 
simulation studies, these authors conclude that a random sample audit approach to 
ICR of progression data was sufficient; that an ITT philosophy should be followed 
for PFS and that an interval-censored analysis of PFS data should be a default 
sensitivity analysis in oncology trials.  Senior  European regulators Pignatti, 
Hemmings and Jonsson (2011) support recommendations regarding an ITT 
approach and interval censored analysis, however they expressed caution regarding 
ICR by random sample and highlighted the limitations of meta-analyses and 
simulations to substantiate important new recommendations regarding PFS 
assessment and trial design in oncology. 
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3.4 Publication 8: 
Carroll KJ (2013). Decision Making from Phase II to Phase III and the 
Probability of Success: Reassured by ‘Assurance’? 
Closely related to the issue of Phase II oncology design and choice of primary 
endpoint is how best to use the resulting data in decision making to inform drug 
developers regarding the likelihood that much larger and more expensive Phase III 
development will deliver a ‘successful’ outcome, usually meaning pivotal trials will 
deliver positive results for the primary efficacy endpoint with p<0.025 1-sided.    
Given the high failure rate observed in Phase III across industry over the past 
decade, this area has become increasingly important.   ‘Assurance’, or expected 
power, was described by O’Hagan et al (2005) and Stallard et al (2005) as a means 
of using Phase II outcomes, or other prior information regarding the assumed 
treatment effect, to predict the chance of success in proposed Phase III trials.   This 
technique is gaining favour within industry as evidenced by recent papers from 
Chuang-Stein (2006), Chuang-Stein et al (2011) and Kirby et al (2012).  Su (2010) 
looks at a variation of assurance where by the observed Phase II data and some 
assumed prior for the true treatment effect are combined to form a hybrid prior 
which is then used as the basis of calculations relating to probability of success in 
Phase III.  More recently, Nikolakopoulos et al (2013) takes a similar approach in 
combining Phase II biomarker data with an assumed prior for the predictive value 
of the biomarker versus the true clinical outcome and using this in the context of 
an assurance calculation for Phase III. 
In practice, however, the use of assurance in oncology, and elsewhere, often leads 
to confusion amongst non-statisticians and decision makers due to some of its 
seemingly strange and counter-intuitive properties.  “Decision Making from Phase II 
to Phase III and the Probability of Success: Reassured by ‘Assurance’ ” examines the 
properties of assurance when the prior for Phase III is defined by the preceding 
Phase II data.   In this case, Phase III assurance is given by:  
 
           (
   
√     
) 
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where   represents the treatment effect estimate arising in the planned Phase III 
trial which is sized to detect a true treatment effect   with Type I and Type II errors, 
α and β so that the anticipated variance of   is given by      (     )
 
⁄  where  
    
        and        represents the inverse standard Normal distribution 
function; and where       is the critical value of the test such that if     the 
null is rejected in favour of the alternative; and where the Phase II treatment effect 
estimate is , with variance   .  
 
 In particular, it was shown that, maximally, the probability of success (PoS) by 
assurance = 1- {1-sided Phase II p-value} when the intended Phase III was large 
relative to the completed Phase II.  Hence, if p=0.2 1-sided in Phase II, assurance 
cannot exceed 80% even if Phase III has a million patients and a conventional power 
>99.999%.  And when integrated over prior Phase II data, it was shown that the 
outcomes of two independent Phase III trials are Bivariate Normal with correlation  
       
  
     
  where   and   represent the treatment effect estimates from two 
identical Phase III’s each with variance   , and    represents the variance of the 
treatment effect estimate from Phase II.   The proof of this result is provided in 
Appendix B of the paper.  For example, and as discussed in the paper, if there were 
two Phase III oncology trials of identical size and design, each requiring 508 events 
to provide 90% power to detect a true PFS hazard ratio of 0.75 and a preceding 
Phase II trial that provided a PFS hazard ratio estimate of 0.75 on 70 events, then 
the assurance for each of the Phase III trials individually would be 67%; but since 
Phase IIIs outcomes are correlated by assurance with        then the probability 
of two successful Phase III trials is not simply            , but rather     . 
 
Table I of the paper displays some key observations regarding assurance and is 
reproduced below:  
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It was also argued that while statistical methods can serve to assist good decision 
making, more basic, fundamental considerations in terms of Phase II design and 
analysis were the key to effective decision making in drug development.  These 
include: (i) ensuring Phase II is well-controlled, randomised and double-blinded 
where possible. (ii) Performing two Phase II trials since positive outcomes from two 
Phase II’s of moderate size are generally more reassuring than a single larger Phase 
II, especially in disease settings with softer trial endpoints such as central nervous 
system (CNS) disorders like depression and schizophrenia   which often use 
subjective rating scales completed by the physician and not the patient.  If a single 
Phase II is designed with      (     ), where   is the hypothesized treatment 
effect of interest and    the variance of an associated unbiased estimator for  , 
then as compared to two Phase IIs each with       (     ), then     
 {(     ) √ ⁄    }.   Therefore, if α=0.05 and 1-β=0.90 (0.80), 1-
2=0.887 
(0.793) so that two Phase IIs with N/2 patients provide similar power to a single 
Phase II with N patients. (iii) Predefining the Phase III Go/No Go decision rule for 
‘success’ and, importantly, stick to it.  (iv) Minimizing the potential for serious bias 
by avoiding multiple interim analyses, particularly when the study is open.  (v) If the 
primary fails the Go/No Go, not looking for ‘signals’ elsewhere in an attempt to 
salvage by means of extensive (post-hoc) subgroup analyses (vi) Ensuring senior 
leaders and decision makers are talented, well experienced drug developers with a 
proven track record. (viii) Including an experienced, technically expert statistician in 
the heart of the decision making process.  
 
This work on decision making is limited in scope to the concept of assurance and, 
further, to the definition of success in Phase III being p<0.025 1-sided for the 
primary endpoint.   Other definitions might include achieving p<0.025 and an 
observed difference between treatments greater than some predefined amount.  
However, such variants on the definition of success would not alter the 
fundamental properties of assurance and the need to use the concept with caution 
in late stage drug development.  Other statistical approaches and strategies to 
decision making have been discussed in the literature by Senn (1996) and Julious 
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and Swank (2005) in terms of a sponsors overall development portfolio.   Also not 
addressed in this work is the interesting question to what extent a small positive 
oncology Phase II trial might over-estimate the true underlying treatment effect.   
The observation that many positive Phase II trials have been followed by negative 
Phase III’s (Arrowsmith 2011a and 2011b) suggests there may be some over 
estimation of effect in Phase II.  Analytically the question may be framed as follows: 
if    represents the treatment effect estimate from Phase II with variance   
   and 
expectation  , then we are interested in          where        
         
and        is the standard Normal cumulative distribution inverse and     is the 
one-sided Phase II p-value.   Then  
 
         ∫
     
  
  
 
   
     ∫
     
  
  
 
          
  
        
 
Hence, if proceeding to Phase III is contingent upon achieving a 1-sided Phase II p-
value      then positive Phase IIs will tend to overestimate the true treatment 
effect  .   For example if    ,   
    and       , then           1.754;  
similarly,  if     and   
    , then           5 + 4  1.754 = 12.01.   By 
focusing only on positive Phase II trials, the true treatment effect can be 
overestimated.     
 
3.5 Recommendations: 
 The routine practice of assigning the time of progression to the clinic visit at 
which it was first detected results in a downwardly biased estimate of the 
hazard ratio and, thus, reduces power.  If clinic visit schedules are not 
closely matching between treatments, this bias is increased and Type I error 
increased.  
 To ameliorate these issues: 
o Differential follow-up should be avoided 
o Interval censored analysis should be conducted as per Sun to avoid 
bias and maintain power. 
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o A Turnbull estimate of the CDF should be provided as standard 
o Under proportionality, an analysis of the number of PFS events over 
the trial period using complementary log–log link will provide for an 
unbiased comparison between treatments with reasonable power so 
long as no more than around 75% of patients have had a PFS event. 
o If a traditional approach to analyse progression at the visit where it 
was detected using a log-rank test, then number of events should be 
increased accordingly to offset the loss in power. 
 Very frequent clinic visits are not statistically necessary to provide an 
accurate estimate of the treatment effect. 
 Censoring on additional anti-cancer treatments should be abandoned and 
an ITT approach to PFS trial design and analysis employed, commensurate 
with the long established approach for overall survival. 
 Full ICR is often unnecessary; a random sampling approach that draws from 
progressed and non-progressed patients is preferable.  
 The increasing use of assurance to estimate the probability of success in 
Phase III based on Phase II data is problematic and often confusing to the 
non-statistician and, therefore, should be used with caution. 
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4 Issues with active-controlled, ‘non-inferiority’ designs 
 
Active-controlled, ‘non-inferiority’ (AC NI) trials are a key feature of many drug 
developments, not only in oncology but across the spectrum of therapeutic areas.   
Such trials commonly take place when there are issues of feasibility or ethics 
preventing the conduct of a placebo controlled trial.  In such circumstances the 
experimental drug is compared to an active control that has previously been shown 
to be safe and effective.  Blackwelder (1982) was amongst the first to argue that 
non-rejection of the null was not a valid basis for concluding equivalence, and 
rather recommended a one-sided test that the control is more effective than drug 
by some pre specified amount or ‘fixed margin’.   By rejecting the null in favour of 
the alternative allowed a conclusion that drug is non-inferior (or more correctly not 
substantially inferior) to control.  Definition of the margin is often difficult and not 
infrequently controversial (Hung et al. 2005; Lange and Freitag 2005).  The aim 
typically is to set the margin to rule out a ‘minimally clinically meaningful 
difference’, but there is considerable subjectivity and variability in doing so.  Due to 
concerns regarding ‘constancy’, i.e. the effectiveness of control being identical in 
the current AC NI trial and in previous historical trials that defined the effect of 
control, and other issues such as the relevance of the historical trial data in terms of 
items such as patient population, current medical practice, length of treatment etc., 
regulators such as FDA have typically employed conservative approaches to the 
determination of the NI.  The most common approach has been the so-called ’95-
95’ rule whereby the lower 1-sided 97.5% confidence limit for the effect of the 
control vs placebo based on historical data is chosen as the margin; or, more often, 
50% of this lower limit is set as the margin to allow demonstration that at least 50% 
of control effect has been retained by the new drug (Holmgren 1999, FDA 1999).  
Clearly use of the lower confidence limit or 50% thereof, introduces a considerable 
conservatism into the analysis, reducing power and increasing the risk effective new 
drugs will be mistakenly judged ineffective. 
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A key problem with the fixed margin approach is that despite the margin being 
informed by historical data on control, the variability inherent in these data is not 
factored into the NI analysis itself.   A simple alternative is to use the ‘synthesis’ 
approach that explicitly combines the historical estimate of control vs placebo, 
 ̂   with variance    , and the estimate of control vs drug from the current AC trial, 
 ̂    with variance    , treating both as random variables.  Under constancy, the 
true effect of experimental to placebo,      is then estimated indirectly as  ̂    ̂    
with variance          and unconditional Type I and Type II error probabilities can 
be accurately determined.  Many authors (Rothmann et al. 2003; Rothmann 2005; 
Hauck and Anderson 1999; Hung et al. 2003; Hasselblad and Kong 2001; Holmgren 
1999; Simon 1999; Wang et al. 2002; Wang and Hung 2003; Snapinn 2004) 
recommend the synthesis approach to test for preservation of a fixed, pre-specified 
non-zero fraction (usually 50% or 75%) of the control effect.   
4.1 Publications 9 and 10: 
Carroll K and Milsted R (2004). Barriers to clinical development in oncology: 
The impact of new thinking around non-inferiority. 
Carroll K, Milsted B and Lewis JA (2004).  Letter to the Editor: Design and 
analysis of non-inferiority mortality trials in oncology. 
In 2003 Rothmann of FDA published an important paper that highlighted the 
conservatism of the fixed margin approach when using 50% of the lower 1-sided 
97.5% confidence limit.  Rothmann altered this to derive the lower (1-)100% CL for 
control vs placebo that, when 50% was taken to define the NI limit and assuming 
constancy, would result in a synthesis based test for NI of exactly 2.5% 1-sided 
(Rothmann et al 2003).  Nevertheless, this fundamental approach continued to 
impose a heavy burden on researchers, often requiring impractical and infeasible 
trials and therefore threatening to inhibit the development of new medicines.    
 
This issue was highlighted by Carroll and Milsted in abstract from at the 2004 
American Society of Clinical Oncology meeting, and further by Carroll, Milsted and 
Lewis by Letter to the Editor in Statistics in Medicine in the same year in which it 
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was shown that even with a strong historical control effect with p<0.001, extremely 
challenging AC trial sizes would result.  An alternative approach was illustrated that 
did not require pre-specification of a specific margin or percent effect retention.  
Rather, having obtained the AC trial data, the comparison to historical control could 
be readily displayed on a continuum in relation to the likely fraction of the control 
effect retained, from zero to 100 percent.  In such an ‘effect retention likelihood’ 
plot, a zero effect retained allows estimation of the degree of benefit over placebo, 
albeit through indirect measures.  This would then be more in line with the efficacy 
standards required by both US and EU law, both of which call for substantial 
evidence of efficacy (versus placebo) to be established, with no requirement on 
relative efficacy with respect to existing agents.  
4.2 Publication 11: 
Carroll KJ (2006). Active-controlled, non-inferiority trials in oncology: 
arbitrary limits, infeasible sample sizes and uninformative data analysis. Is 
there another way? 
Issues surrounding the use of NI trials in the regulatory assessment of new 
anticancer medicines were thrown into sharp relief in the July 2004 FDA Advisory 
Committee discussion of pemetrexed as second line treatment for non-small cell 
lung cancer (NSCLC).  At the meeting FDA cited concerns regarding the limited 
amount of data used to support (FDA’s own) approval of the control drug. Critically, 
Dr. Richard Pazdur, Director of the Division of Oncology Drug Products, FDA opened 
the meeting stating that “A certain proportion of the control effect . . . should be 
preserved to demonstrate non-inferiority” thus introducing a double regulatory 
standard for the assessment of drug effectiveness based solely on trial design (FDA 
2004d).   FDA went on to conclude that pemetrexed could not  be proven to be 
non-inferior to docetaxel since the upper 95% CL for the hazard ratio of 1.20 
exceeded the protocol pre-defined non-inferiority limit of 1.11.  This judgement 
was despite pemetrexed demonstrating 78% retention of the docetaxel effect.   
Contrary to FDAs view, Advisory Committee members voted in favour of approval 
of the drug on the basis that it appeared to have ‘similar’ survival to docetaxel with 
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a more favourable side effect profile.  And in their positive review and subsequent 
approval, EMA judged that ‘although non-inferiority was not formally established, 
the data submitted are robust enough to conclude that a clinically significant 
inferiority of pemetrexed to docetaxel in terms of efficacy in this population is 
unlikely’ (EMA 2006).    
   
Building upon earlier publications, this case catalyzed the 2006 publication of 
‘arbitrary limits, infeasible sample sizes and uninformative data analysis’.  In the 
absence at that time of any formal guidance from FDA regarding the trial design 
and analysis of AC, NI trials, this paper took the opportunity to highlight many of 
the associated statistical issues and regulatory precedent.   The infeasibility of NI 
trials designed using FDA’s 95-95 rule was highlighted and illustrated in Table 1, as 
reproduced below.   
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Further, the fundamental purpose of an AC was discussed and argued to be to 
provide evidence that a new drug would have been better than placebo if placebo 
could have been included; with a secondary supportive purpose being to estimate 
(indirectly) the size of the effect of the new drug relative to control.   It was then 
shown that both of these goals could be simultaneously addressed using an effect 
retention likelihood approach.  In contrast to previous publications, the paper gave 
a clearer understanding of how this concept was constructed as follows:  Given the 
fundamental hypothesis to be tested is                          , due to 
concerns regarding constancy, the alternative is often replaced with        
       to allow demonstration the experimental drug retains some non-zero 
fraction f,        of the historical control effect.  Then, using the notation 
previously described regarding the synthesis method, the test statistic then 
becomes    
 ̂         ̂  
√ ̂        
  ̂  
.. Plotting the inverse cumulative Normal function 
        against f provides the ‘effect retention likelihood’ plot.    This approach is 
illustrated in Figure 1 of the paper, reproduced below: 
 
Publication 11.  Carroll (2006): Figure 1 
 
Figure 1. Effect retention likelihood plot: historical control effect, HR=1.5, p=0.005; 
Active-control trial design with 800 events, 90% power, 2.5% one-sided a level. 
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The figure shows that, with a historical control:placebo hazard ratio of 1.5, p=0.005, 
if an AC trial is conducted comparing experimental to control with 800 events and a 
hazard ratio treatment:control (HR (T:C)) of unity is observed, there is (i) a 99.4% 
probability that experimental would have beaten placebo (zero effect retention) 
and (ii) (for example) a 97.8% chance that 50% of the control effect has been 
retained by experimental.  
 
In line with Senn (2005), it was argued that while of value in trial design, the 
predefined NI fixed limit is of little value in analysing and interpreting NI trials. 
Rather, the judgement as to what is and is not an unacceptable loss of effectiveness 
of the control treatment should lie with the ‘consumer’, that is with physicians and 
their patients or the regulatory authority acting on the patients behalf.  And, 
crucially, it was further highlighted that the typical FDA requirement for at least 
50% effect retention represented an arbitrarily higher burden of evidence for drug 
approval based solely upon trial design. 
4.3 Publication 12: 
Carroll KJ (2013).  Statistical issues and controversies in active-controlled, 
‘non-inferiority’ trials 
Following release of EMA’s regulatory guidance on NI trial design and analysis (EMA 
2000, EMA 2005), which in turn followed ICH E9 (1998) and E10 (2000), FDA 
released their draft ‘Guidance for Industry Non-Inferiority Clinical Trials’ (FDA 
2010b).  The key issues offered in this  guidance, which remains draft, together with 
many other pertinent matters relating to AC, NI trial design and analysis were the 
subject the 2013 paper by Carroll “Statistical issues and controversies in active-
controlled, ‘non-inferiority’ trials.”  
 
In their draft guidance, FDA introduced not one, but two NI margins, ‘M1’ and ‘M2’.  
M1 was defined as “the entire effect of the active control” estimated from 
historical data so that meeting this margin was identified to be directly equivalent 
to the first objective an active-control ‘NI’ trial, being to establish indirectly that the 
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new drug would have beaten placebo if placebo could have been included.   FDA 
defined their M2 margin as ‘the largest clinically acceptable’ loss of effectiveness of 
drug relative to control, being broadly equivalent to some fraction of the control 
effect having been preserved by drug (often times 50%).  Meeting only M1 would 
generally be insufficient and, therefore, these newly defined margins served to 
perpetuate the arbitrarily higher standard of evidence required by FDA for 
establishing effectiveness via an AC, NI trial.  Also, in defining M1 as a fixed margin 
FDA continued to not take into account the uncertainty associated with the 
historical data on control, and in defining M2 FDA failed to address the inherent 
subjectivity, vagaries and idiosyncrasies associated with the clinically driven 
determination of this second hurdle.   Rather, M1 and M2 are considered simply as 
fixed, constant margins and the absence of a common, consistent definition for M2 
is not addressed.   Treating these margins as fixed is in certain contrast to ICH 
guidance which calls for a justification of the margin that must take into account 
the historical data and its uncertainty. To ignore the underlying uncertainty in the 
historical data giving rise to the M1 margin in particular, being used to demonstrate 
indirect effectiveness vs placebo, is arguably improper statistically. Use of the 
synthesis method is more satisfying in this regard as the uncertainty in the historical 
control effect estimate is directly accounted for.  
 
In line with Peterson, Carroll, Chuang-Stein et al (2010), this paper argued that 
regulatory standards based on fixed margins or some percent preservation of the 
historical control effect were arbitrary and lacking scientific justification, and their 
use introduced logical inconsistencies in the decision making process such that 
effective treatments could be denied approval.   Owing to these illogicalities, it was 
argued that the qualities of an experimental drug in order to allow it to be judged 
effective should be independent of the trial design evaluating that drug. This would 
then imply that if preservation of effect is not required when a new treatment is 
evaluated in a placebo-controlled trial, it should not be required when the 
treatment is evaluated in an active-controlled trial.  Hence, it was argued that after 
accounting for any methodological concerns with the trials used to establish 
efficacy, a common standard of evidence should apply regardless of trial design 
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which, therefore, should not be greater than the standard used for previous 
approvals for the same indication.   Further, it was argued that the synthesis 
method for combining results of an active-controlled trial with results of historical 
trials could, with appropriate consideration of constancy, adequately characterises 
of the efficacy of a new treatment relative to placebo and would avoid the 
illogicalities highlighted with fixed margin and preservation of effect approaches 
(Peterson, Carroll, Chuang-Stein et al (2010)) 
 
Further, the performance of the three main methods for assessing effectiveness via 
an AC, NI trial were compared.  Hypotheses were laid out for the synthesis, 
preservation of effect and ‘fixed margin’ approaches and associated formulae derived 
that specified the amount of information required to test these hypotheses with 1-
sided Type I error  and a given, common power, 1-.   In this comparison the ‘fixed 
margin’ was defined as a given fraction,       , of the lower 1-sided 97.5% CL for 
the control effect, consistent FDA’s 95-95 rule.  Key observations were thus made 
possible under the usual assumption that the true difference between drug and 
control was in the null: 
1. The synthesis method is always more efficient than the preservation of effect 
method for testing indirectly the hypothesis a new drug is efficacious.  
2. To determine effectiveness of experimental drug with 1- power, both 
synthesis and preservation of effect methods require that the historical data 
provides an estimate of the control effect with       { ( α   β)},  
meaning a historical control effect with a z-value of >3.24 or p<0.0012 is 
required to achieve 90% power to test indirectly the hypothesis that a new 
drug is efficacious.   
3. The maximum power achievable in respect of this hypothesis, via either the 
synthesis or preservation of effect method, is    {       α}, where    the z-
value for the historical control effect estimate. 
4. The same issues and power cap do not apply to the ‘fixed’ margin approach 
where any level of power can theoretically be achieved providing  ̂   
 α√     , i.e. the estimated control effect is significant with p<0.05.  
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5. For the common choice f = = 0.5, the ‘fixed’ approach is less efficient than 
the preservation of effect method when the control effect has significance 
       {     α {(   β  α⁄ )
 
  }}, or p < 0.00025 when 90% power is 
desired.    
6. Otherwise, the ‘fixed’ approach is more efficient. 
 
The observation that both the preservation of effect and synthesis methods require a 
historical control effect estimate with p ≤0.0012 is of interest since this may suggest 
there is little need to further discount historical data (Snapinn 2004).  And in contrast 
to the ‘fixed margin’ approach, the presence of a power cap for the preservation of 
effect and synthesis methods is important as it illustrates that an AC, NI approach is 
futile unless data on the historical control is relatively strong (or unless there was 
very good reason to believe the new drug would be marginally better in efficacy than 
control (Fleming 2008)).  This has implications for the amount of evidence required to 
grant licensure for the first drug in a new indication, especially in oncology.   If, for 
example, in some late stage malignant disease with no currently proven therapies, 
the FDA or EMA were to approve a drug that improved survival relative to best 
supportive care with p<0.01, then it would subsequently be impossible for other 
researchers or a pharmaceutical manufacturer to prove indirectly the effectiveness of 
any new drug via an AC, NI trial with 90% power.  
 
To illustrate these observations an example is offered of a control drug with hazard 
ratio versus placebo of 0.667 95% CI (0.524, 0.849), p=0.0010 for overall survival, 
representing a 50% increase in the event rate for placebo relative to control based on 
264 events. The ‘fixed’ NI limit would typically be = 0.8490.5 = 0.921. It is shown that,  
under constancy, an active control trial would require 6270 events (≈24x more than 
the 264 events characterising the historical effect of control) to deliver 90% power to 
test, indirectly, the effectiveness of drug.  In contrast, the preservation of effect 
method with f = 0.5 would require 35,073 events (≈130x more than for historical 
control) while the synthesis method (3) would require 8768 events (≈33x more than 
for historical control). The sensitivity of the power calculation to the strength of 
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historical evidence characterising the control effect estimate was further illustrated in 
Table 1 of the paper reproduced below: 
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Other issues addressed in the paper included per-protocol (PP) vs intent-to-treat 
(ITT) analyses within the context of an AC, NI trial.  In line with ICH E9 (1998) which 
states that “…it is especially important to minimise the incidence of violations of the 
entry criteria, non-compliance, withdrawals, losses to follow-up, missing data and 
other deviations from the protocol, and also to minimise their impact on the 
subsequent analyses.”, it was argued that the common practice of applying PP 
analyses to an AC, NI trial was not ideal.  Rather than remove violators and 
deviators from the analysis, a more appropriate strategy is to execute AC trials to 
rigorous and exacting standards, to minimize protocol non-adherence and ensure 
full ITT follow-up of all randomised patients so the trial evidence generated is of the 
highest completeness and quality (Fleming 2008).  In this way regulators and the 
scientific community can rely upon the data and what it shows. This goes to the 
heart of ‘assay sensitivity’ in terms of ensuring the AC trial is of the highest possible 
scientific standard, regardless of whether the objective is superiority or ‘NI’. 
 
In terms of design, it was argued the AC, NI trial should be powered on the basis of 
proving indirectly that the new drug is effective vs placebo and then the results 
analysed using the synthesis method. Given concerns regarding constancy, inclusion 
of analyses that discount the historical control data can, in some circumstances, be 
helpful and informative. In a manner similar to that proposed by Rothmann (2003), 
an approach was illustrated whereby the maximum degree of discounting of the 
historical control effect was calculated that would yet still provide an indirect 
estimate of drug effectiveness with p<0.025 1-sided. This, coupled with appropriate 
data display, including a likelihood effect retention plot, would provide a clear and 
transparent display of the relevant data.  Figures 2 and 3 from the paper are 
reproduced below: 
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Publication 12.  Carroll 2013(b): Figure 2 
 
 
Publication 12.  Carroll 2013(b): Figure 3 
 
 
  
67
  
Graphical display of the data in this fashion is more informative than the usual 
analysis associated with active-control, ‘NI’ trials.  Employing a Bayesian 
interpretation of the data, we can discern there is a 99.98% chance that drug is 
effective versus putative placebo; and a 99.5% chance that 50% of the effect of 
control has been retained; and a 65.8% chance that 100% of the effect of control has 
been retained, i.e. that drug is superior to control. Similarly, if the historical control 
effect is discounted by as much as 43%, there is a 97.5% chance that drug is effective 
versus putative placebo; and a 93.7% chance that 50% of the effect of control has 
been retained. Discounting further would not allow rejection of        .  Hence, 
by examining the data in terms of the effect retention likelihood, it seems clear that, 
in this example, the AC trial data provides confidence that drug is efficacious and, 
further, there is a high chance that drug retains a large fraction of the control effect. 
 
The overall aim of the preceding publications on AC, NI issues was to highlight the 
practical infeasibility, subjectivity and illogicality of FDA’s longstanding approach to NI 
assessment and, in so doing, offer a more reasonable statistical alternative for the 
design and analysis of AC, NI trials.   However, the fundamental problem with AC, ‘NI’ 
trials as a vehicle to establish drug effectiveness is the understandable mistrust of 
indirect comparisons, and this issue is only addressed briefly in the preceding work 
that advocates the synthesis method.    The constancy assumption is inherently 
unverifiable in any NI context and for any NI method that does not include a placebo 
arm in the AC trial.   In terms of the latter, several authors have discussed designs 
involving experimental (E), control (C) and placebo (P) (Munzel 2009, Mielke et al 
2008, Hasler et al 2008, Koch and Röhmel2004).  In such a design inference regarding 
the amount, , of the control effect retained by experimental is straightforward: the 
contrast    ̂       ̂    ̂     would provide a direct test of the hypothesis that 
experimental retains 100% of the control effect.   However, this kind of design is 
seldom possible in oncology, particularly in late stage disease.   Also not examined in 
detail is the method of discounting described by Snapinn (2004).  And while this 
offers a quantitative approach to address constancy concerns, it is inherently 
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subjective introducing arbitrarily defined discounting parameters into an already 
complex construct.    
 
It is of interest to consider closely related matters within the context of health 
economic assessment of medicines.  In this field there has been an upsurge in 
published papers describing the use of Network Meta-Analyses (NMA) and, to a lesser 
extent, Comparative Effectiveness (CE) assessment.   Jones (2011) gives an excellent 
summary of the statistical methodology underpinning NMA.  Broadly, NMA brings 
together the outcomes of trials involving a set of treatments but, unlike a 
conventional meta-analysis, these trials do not each have to contain the treatments 
to be compared.  Rather, trials are combined in a fashion akin to a balanced 
incomplete block design but in a Bayesian framework with priors employed for 
individual drug effects.   Interestingly there is essentially no critique or criticism in the 
literature of NMAs regarding the issue of constancy and other basic issues such as the 
comparability of trial populations, trial conduct, follow-up and analysis.  Yet the 
outcomes of such analyses are used to make critical health care decisions.    It seems 
scientifically incongruous to have such an array of scientific regulatory guidance 
relating to making indirect inference regarding the efficacy of single drug on the basis 
of an AC,NI trial, yet no scientific guidance regarding the arguably much more 
troubling matter of combining multiple trials with incomplete (if any) representation 
of a set of treatments for which the issues of constancy and combinability based on 
design, population, conduct and contemporaneousness must be considered more 
acute.    
 
An additional matter not addressed in the preceding publications relates to the 
statistical meta-analysis of historical trial data on control.  Typically, regulators such 
as FDA tend to use random effects meta-analysis to combine historical data for use as 
reference in an NI analysis.  A case in point is warfarin which is provided as an 
example in FDA’s guidance document (FDA 2010b).  These data are reproduced 
below: 
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Placebo-controlled warfarin trial data 
 
1:  RR = 
p
p
w
w
E
T
T
E .   2:  Variance log RR = 
pp
pp
ww
ww
ET
ET
ET
ET 

 ,  as per  FDA formulae. 
 
A DerSimonian and Laird (1986) random effects meta-analysis provides the 
following results:  
 
 
In order to calculate the 95% confidence interval (CI) for the RR, and thus derive the 
usual 95-95 ‘fixed’ limit, FDA employs a t-distribution on 6 degrees of freedom 
according to Follmann and Proschan (1999).  However, a t-distribution is arguably 
inappropriate in this instance as the between trial component of variance, 2b , is 
zero.   Application of a t-distribution when a z-distribution applies can easily give 
rise to confusing and counter-intuitive results when combining historical trial data.  
For example, suppose two trials, each with 250 events (and, thus, a SE ln(RR) of 
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2504 ), give similar RRs of 0.75.  Both trials are thus statistically significant with 
95% CI (0.59, 0.96), p=0.0229.  The combined estimate, either by random or fixed 
effects analysis, is therefore 0.75 on 500 events (SE ln(RR) of 5004 ).  Application 
of the z-distribution gives a 95% CI of (0.63, 0.89), p=0.0013, whereas application of 
the t-distribution gives a 95% CI of (0.24, 2.34), p=0.19.   If there were 3 rather than 
2 trials, the z-distribution gives 95% CI of (0.65, 0.87), p=0.00008 and the t-
distribution gives 95% CI of (0.55 1,03), p=0.0588.   The loss of significance despite 
the doubling or tripling of events occurs because it is assumed variability in the 
overall estimate is driven by the number of trials, either 2 or 3, and not the number 
of events within a trial.   This makes little sense when the estimated between trial 
component of variance is zero.       
 
It might be argued that the estimated between trial variance component of -0.0681  
is a point estimate and the true value of 2b  could be larger and positive.  However, 
this is not supported by bootstrap resampling analyses (Westfall and Young 1993, 
Westfall et al 1993) .  The empirical distribution for 2b  based on all possible re-
samples is shown in the following figure.   The 95% CI (based on the 2.5th and 97.5th 
percentiles) for 2b  is (–0.148, 0.001) and truncating for negative estimates gives an 
interval of  [0, 0.001).   It can be safely concluded, therefore, that the between trial 
component of variability for the warfarin placebo controlled trials is zero. 
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Empirical bootstrap distribution of the between trial component of variance 
resulting from a DerSimonian and Laird random effects meta-analysis 
 
 
 
The table below displays 95% CI estimates for the RR, warfarin:placebo, together 
with the corresponding NI limit, assuming firstly a conservative t-distribution and 
then, secondly, a more appropriate z-distribution. Also provided for comparison are 
the results of a bootstrap analysis on the RR estimate resulting from a DerSimonian 
and Laird random-effects meta-analysis. 
 
 
 
2
bˆ
* CI based on the 2.5th and 97.5th percentiles of the empirical bootstrap distribution for the log RR.  RR estimate is 
the geometric mean of resample estimates of the log RR; median is 0.362. 
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Employing a t-distribution to calculate the CI for the RR results in a conservative 
estimate for the NI limit of 1.38. The use of the z-distribution provides an NI limit of 
1.43, which is more in line with the distribution free empirical bootstrap estimate of 
1.47.   While the difference in these limits may seem modest, they have a large 
impact on the sample size for an AC, NI trial.  Using an NI limit of 1.38 requires 405 
events (13,500 patients for a 3% annual event rate) for 90% power as compared to 
329 events (10,950 patients) and 283 events (9,440 patients) for NI limits of 1.43 
and 1.47 respectively.  The use of the latter NI limits therefore result in sample size 
savings of 20% and 30% respectively.  
 
4.4 Recommendations 
 A single regulatory standard for the assessment of drug effectiveness should 
apply regardless of trial design. 
 AC, NI trials should be sized to determine efficacy vs putative placebo.  The 
use of the punitively conservative 95-95 rule and 50% effect preservation 
should be abandoned.  Both approaches are subject to serious illogicalities 
which render them unsuitable for licensing decisions. 
 Effectiveness should be assessed via the synthesis method.  This provides a 
test of size 2.5% 1-sided under constancy and is statistically more efficient 
than the ‘fixed’ margin and preservation of effect approaches. 
 Constancy should be addressed either through discounting or use of effect 
retention likelihood methodology which allows the percentage of control 
effect retained to be assessed on a continuum from 0% (= likelihood 
superior to placebo) to 100% = (likelihood superior to control). 
 The arbitrarily determined additional M2 margin should be abandoned.  The 
extent of drug effectiveness beyond beating placebo alone can be assessed 
via the effect retention likelihood.  
 To instill confidence in the reliability of an AC, NI assessment, careful a-priori 
examination of the historical trial data and their relevance to the current AC, 
NI design and setting is essential.  
73
  
 Meta-analysis of historical trial data should not employ a Follmann and 
Proschan (1999) adjustment by default.  
 In AC, NI analyses, patient exclusions and non-randomised PP analyses 
should be avoided. Stringent standards for trial conduct and execution 
should be established at the outset to ensure close adherence to the 
protocol and deliver full patient follow-up. 
  
74
  
5 The use of parametric methods in the analysis of oncology clinical 
trial data  
 
In oncology trials, the log-rank test and related Cox regression analysis are the 
established tools for time to event endpoint analysis such as PFS and overall 
survival.   Their prominence comes as a result of extensive use in clinical research 
over the past four decades.  A key appeal is that there is no need to assume a given 
form for the underlying survivor function in order to make inferences about relative 
event rates.  Yet, in direct parallel with other areas of clinical statistics such as the 
routine and widespread use of mixed models for longitudinal data or the use of 
Poisson and Negative Binomial modelling in the analysis of exacerbations in chronic 
obstructive pulmonary disease, if the distribution of survival times can be well 
approximated, parametric failure-time modelling can be powerful and informative, 
allowing a wider set of inferences to be made than either the log-rank or Cox 
approaches can offer.  
 
5.1 Publications 13 and 14: 
Carroll KJ (2003). On the use and utility of the Weibull model in the analysis 
of survival data.  
Carroll KJ (2009).  Back to basics: explaining sample size in outcome trials, 
are statisticians doing a thorough job?   
The use and potential benefits of modelling time to event data were reviewed and 
explored in this paper.   The simple two parameter Weibull                
 
 
with    ,    ,     , where   represents the event rate and   the scale, was 
explored since it is both an accelerated failure-time model (AFT) and a proportional 
hazards model, being the only member of the AFT family to possess both 
properties.  Analysis via the Weibull distribution therefore allows simultaneous 
description of treatment effects in terms of (i) the usual hazard ratio and (ii) the 
relative increase (or decrease) in the time to an event, referred to in the paper to as 
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the “event time ratio” (ETR) to illustrate the close parallel with the better known 
hazard (or event) rate ratio.   A quantification of the treatment effect in terms of 
increased time is often desired by clinicians and investigators who can find the 
concept of the HR difficult to understand. 
 
In the paper it was shown analytically that Weibull and Cox based analyses provide 
asymptotically unbiased, equally efficient estimates of the hazard ratio regardless 
of whether proportionality holds.  Model fitting and parameterisation using the 
software procedure PROC LIFEREG in SAS was explained where the scale parameter  
      and log event rate        (     ) (SAS® 2011).  Further, the 
important relationship between the ratio of percentiles of the Weibull distribution 
and the hazard ratio (HR) under proportionality was provided, being 
   
   
     
  
 
where     represents time to reach the  
   percentile,      .  These basic 
features of a Weibull analysis were illustrated by example in Tables 2 and 3 as 
reproduced below: 
  
76
  
 P
u
b
licatio
n
 13.  C
arro
ll 2003
: Tab
le 2
 
 
 
 P
u
b
licatio
n
 13.  C
arro
ll 2003
: Tab
le 3
 
 
77
  
A direct means of testing for departures from proportionality was  derived and, in 
cases where proportionality did not hold, it was described how treatments could 
still be compared statistically via the ratio of integrated hazards, ∫        
 
 
 ⁄  for 
     ,  over some time period 0-T (where typically T would represent the trial 
follow-up period).  This would provide a measure of the average event rate on 
treatment A relative to the same for treatment B over the period (0-T].   For the 
Weibull this ratio would be  
  
  
      .  The approximate standard error of this 
quantity can be derived using the delta method if the   parameters    and    , 
       together with their standard errors are estimated separately for 
treatments A and B using appropriate software (such as PROC LIFEREG in SAS® 
2011). 
An important use of the Weibull in predicting data maturation was described and 
illustrated by example.  Formulae were derived that allowed the percent of 
additional events to be estimated by simulation over the period (0,T+S] given 
current data over (0-T].   Finally, the issue of departures from the Weibull 
distribution and potential impact on inference was addressed by means of further 
simulation studies where data from a range of non-Weibull settings (LogNormal, 
Gamma and piece-wise exponential) were simulated and then analysed assuming a 
Weibull model and also by Cox regression.  A very close match was observed in 
results from Weibull and Cox analyses, underscoring the robustness of inference on 
the hazard ratio to departures from the Weibull.  However, for the estimation of 
percentiles and the ETR, a reasonable match to Weibull distribution is required.  
Weibull and Cox analyses of data from a piecewise exponential distribution is 
displayed in Table 4 of the paper, reproduced below: 
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In the ‘Back to basics’ paper the use of parametric models in sample size estimation 
for time to event endpoints was described.  The standard sizing for a time to event 
trial relies on accruing a given number of events,  , with the total number of 
patients to be recruited then determined by      where   is the probability of an 
event over the trial follow-up period.  Typically patient entry times,  , are assumed 
to be Uniformly distributed       , and times to event exponential with parameter 
   leading to     
            
  
  where F is the minimum follow-up period. 
However these assumptions are often unrealistic (Williford 1987).   It was shown in 
the paper that, more generally, the probability of an event over the trial period R+F 
is given by: 
 
∫ ∫               
   
   
 
 
   
    [ 
          ]                  
 
 
with the approximation holding if   is small (meaning, typically, that the accrual 
period R < median time to event) and where   denotes patient entry time as before 
and   denotes the time to event following a Weibull distribution with parameters  
and .   If entry times are uniform then                 
 
              
 
.  
Extension to non-uniform patient entry times, where      
     
      
 and 
     
 
 
 
     
      
,  is straightforward.  
 
5.2 Publication 15: 
Ellis S, Carroll KJ and Pemberton K (2008).  Analysis of Duration of Response 
in Oncology Trials.  
The duration of response (DoR) in the subset of responding patients is commonly 
evaluated in oncology trials.  However, a formal statistical comparison between 
drug and control for DoR is clearly biased since the groups being compared are 
defined by the post-treatment outcome of response rather than by randomisation 
and, therefore are, by definition, non-comparable.   The EMA anti-cancer guideline 
(EMA 2012a) states no formal statistical comparison between treatment groups 
should be made on the basis of DoR in the subset of responding patients.   This 
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paper built on earlier work by Temkin (1978) and Begg and Larson (1982) who 
considered the probability of being in response function (PBRF) as an alternative 
means of describing the difference between treatments in relation to response.  It 
was shown in the paper that using the stochastic  formulation of Begg and Larson 
and assuming exponentially distributed transition times, the area under the PBRF 
curve (if defined to infinity), would provide an estimate of the expected DoR (EDoR) 
in all patients and not only those that responded.   It was further shown that a 
novel, alternative formulation using a mixture distribution approach not only 
arrived at the same result as Begg and Larson when exponential times were 
assumed, but was also more flexible, allowing other, better fitting parametric 
failure-time distributions (such as the Weibull) to be employed.  This new approach 
was illustrated using data from the gefitinib INTACT trial (Herbst et al 2004) and a 
proposal for transparent presentation of analysis results offered.  Figure 3 of the 
paper, being the empiric PRBF for the gefitinib example, is reproduced below along 
with Table 3, which provides the associated EDoR analysis results, and Figure 4b 
which displays the Weibull model fit to the duration of response times in 
responding patients: 
 
Publication 15.  Ellis, Carroll, Pemberton 2008: Figure 3 
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Publication 15.  Ellis, Carroll, Pemberton 2008: Figure 4b 
 
 
When an evaluation of duration of response is desired it was argued that (i) the 
PBRF should be used to descriptively display data (ii) response rates should be 
provided for the duration of response in responding patients, including the 
associated Kaplan–Meier curves (without any formal comparison or p-value 
attached) and (iii) the expected duration of response and associated statistical 
comparison be provided; and then these measures (i)-(iii) be laid out as per the 
examples provided in Tables 2 and 3 of the paper.  This would then ensure data 
were presented and displayed transparently, allowing statisticians and non-
statisticians to most readily appreciate the relative difference between treatments. 
 
In these papers, extensions and other uses of parametric modelling of time to event 
data were briefly discussed.  For example, Wei and Glidden (1997) suggest AFT 
models may be useful for multivariate failure-time data and Keiding et al (1997) 
have suggested AFT approaches may be useful in random effects survival analyses 
(or frailty modelling), emphasizing intuitive interpretation of the Weibull.   Sposto 
(2002) examines parametric cure models, concluding that they are at least as good 
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as Cox-based approaches and are to be preferred when proportionality fails to hold, 
allowing simultaneous assessment of covariate effects on both the proportion 
cured and the failure rate among those not cured.  
 
Not addressed in either paper, however, were other important matters pertaining 
to the routine use of Weibull and other parametric models for failure time data.  
For example, the use of diagnostics to assess model fit and adequacy was not 
addressed.  Issues relating to power and sample size determination associated with 
a Weibull analysis were not covered, being an area where further research would 
be beneficial.   And while Cox and Weibull analyses were found to give similar 
estimates of the hazard ratio irrespective of the underlying time to event 
distribution, the extent to which Weibull misspecification would impact the 
estimate of percentiles and, in particular, the median time to event was not 
addressed.   Further research and guidance in this area would be most helpful in 
assessing the risk of bias when making inferences based on an assumed Weibull (or 
any other AFT) distribution. 
 
Despite the benefits and versatility of Weibull modeling of time to event data, 
surprisingly few applications in late stage clinical drug development have been 
documented.   One recent and important example is provided by the comparison of 
ticagrelor and clopidogrel in the treatment of acute coronary syndromes (Wallentin 
et al 2009).  In the large pivotal phase III registration trial, ‘PLATO’, a highly 
significant qualitative interaction was observed between randomized treatment 
and concomitant aspirin dose for the primary endpoint of time to first of CV death, 
non-fatal myocardial infarction and non-fatal stroke.    While the relationship 
between the hazard ratio and aspirin dosage was easily estimated via Cox modeling, 
US and EU regulatory authorities were particularly interested in the relationship 
between the event rate and aspirin dose on each arm and, in turn, how this related 
to the hazard ratio.    Weibull modeling was therefore used.  For each of ticagrelor 
and clopidogrel separately, the time to event was modeled as in SAS® using PROC 
LIFEREG with terms for intercept and log(aspirin dose) as a continuous covariate 
and a Weibull link function (SAS 2011).   The resulting parameter estimates were 
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thus   ̂,  ̂ and  ̂  for the intercept, regression co-efficient for log(aspirin dose) and 
scale respectively, with corresponding variance and covariance estimates  ̂   and 
 ̂   with      ̂,  ̂,  ̂ and        
 
As highlighted previously, since SAS® parameterises with       and  
       (     ), then                        ⁄   where D = 
log(aspirin dose) and    denotes the log integrated hazard over (0, T].  Hence, 
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]  ̂  .   The log hazard 
ratio can then be defined as  ̂       ̂     with variance estimate    ̂      ̂   
   ̂      ̂  .   
 
The results of the analysis are shown in the figure below: 
 
 
This analysis therefore revealed that the observed interaction with aspirin dosage 
was mainly due to an interaction with ticagrelor treatment, with the 360 day event 
rate rising from around 5% up to 25% as the aspirin dose rose, whereas a much 
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flatter relationship is seen for clopidiogrel.  These results were stated to be of 
importance in FDA’s review and eventual approval of the drug, and led to a black 
box warning that ticagrelor should not be co-administered with aspirin doses 
exceeding 100mg per day (FDA 2011a-c). 
 
5.3  Recommendations 
 In oncology trials, Weibull modelling of time to event data should be 
routinely performed in support of the more standard Cox analysis.   The 
same covariates and strata should be used for both analyses. 
 Treatment effects should be reported in terms of both the hazard ratio and 
the ETR since the latter provides a clinically useful direct measure of the 
relative improvement in the time to an event. 
 Concerns regarding an exact distributional match to the Weibull distribution 
should not be overstated given a Weibull-based analysis provides very 
similar results to a Cox based analysis regardless of the true underlying 
distribution of the time to event.   
 With respect to predicting data maturation, Weibull modelling should be 
used as standard in preference to the often used and very simplistic 
assumption of a constant event rate over time.  
 Treatments should not be formally compared on the basis of DoR in 
responding patients.  Rather, an EDoR analysis should be performed and a 
comparison made on the basis of all randomised patients.   Results of such 
an analysis should be presented clearly and transparently as recommended 
in the associated paper. 
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6 Collated Recommendations for Oncologic Clinical Trial Design and 
Analysis 
 
On the use of biomarkers and surrogate endpoints to accelerate drug 
development:  
 Trials that employ a surrogate endpoint as primary should mandate full ITT 
follow-up of all patients post attainment of the surrogate for overall 
mortality.  Only in this way can the true benefit of the intervention be 
assessed and the value of the surrogate is assessed.  
 In biomarker driven trial design, routine and naive statistical assumptions 
regarding (i) the precise  dichotomous determination of biomarker 
‘negative’  and ‘positive’ patients and (ii) the complete absence of treatment 
effect in ‘negative’ patients should be abandoned.  Rather design options 
should be offered for a range of assumptions that allow a non-zero effect in 
‘negative’ patients and accommodate a less than perfect assay for 
biomarker measurement. 
 For biomarker driven developments, flexible designs should be routinely 
considered.  In particular the designs described by Zhao (2010), Jenkins 
(2011) and Wang (2007) offer three feasible opportunities to identify 
biomarker defined patient subpopulations that achieve enhanced treatment 
benefit whilst controlling the overall Type I error.  These designs in 
particular should be evaluated when considering a biomarker driven 
oncology Phase III development strategy.  
 
Randomized Phase II designs: On the use of progression free survival as an 
endpoint and decision making from Phase II to Phase III 
 The routine practice of assigning the time of progression to the clinic visit at 
which it was first detected results in a downwardly biased estimate of the 
hazard ratio and, thus, reduces power.  If clinic visit schedules are not 
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closely matching between treatments, this bias is increased and Type I error 
increased.  
 To ameliorate these issues: 
o Differential follow-up should be avoided 
o Interval censored analysis should be conducted as per Sun to avoid 
bias and maintain power. 
o A Turnbull estimate of the CDF should be provided as standard 
o Under proportionality, an analysis of the number of PFS events over 
the trial period using complementary log–log link will provide for an 
unbiased comparison between treatments with l reasonable power 
so long as no more than around 75% of patients have had a PFS 
event. 
o If a traditional approach to analyse progression at the visit where it 
was detected using a log-rank test, then number of events should be 
increased accordingly to offset the loss in power. 
 Very frequent clinic visits are not statistically necessary to provide an 
accurate estimate of the treatment effect. 
 Censoring on additional anti-cancer treatments should be abandoned and 
an ITT approach to PFS trial design and analysis employed, commensurate 
with the long established approach for overall survival. 
 Full ICR is often unnecessary; a random sampling approach that draws from 
progressed and non-progressed patients is preferable.  
 The increasing use of assurance to estimate the probability of success in 
Phase III based on Phase II data is problematic and often confusing to the 
non-statistician and, therefore, should be used with caution. 
 
Issues with active-controlled, ‘non-inferiority’ designs: 
 A single regulatory standard for the assessment of drug effectiveness should 
apply regardless of trial design. 
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 AC, NI trials should be sized to deter-mine efficacy vs putative placebo.  The 
use of the punitively conservative 95-95 rule and 50% effect preservation 
should be abandoned.  Both approaches are subject to serious illogicalities 
which render them unsuitable for licensing decisions. 
 Effectiveness should be assessed via the synthesis method.  This provides a 
test of size 2.5% 1-sided under constancy and is statistically more efficient 
than the ‘fixed’ margin and preservation of effect approaches. 
 Constancy should be addressed either through discounting or use of effect 
retention likelihood methodology which allows the percentage of control 
effect retained to be assessed on a continuum from 0% (= likelihood superior 
to placebo) to 100% = (likelihood superior to control). 
 The arbitrarily determined additional M2 margin should be abandoned.  The 
extent of drug effectiveness beyond beating placebo alone can be assessed via 
the effect retention likelihood.  
 To instill confidence in the reliability of an AC, NI assessment, careful a-priori 
examination of the historical trial data and their relevance to the current AC, 
NI design and setting is essential.  
 Meta-analysis of historical trial data should not employ a Follmann and 
Proschan (1999) adjustment by default.  
 In AC, NI analyses, patient exclusions and non-randomised PP analyses should 
be avoided. Stringent standards for trial conduct and execution should be 
established at the outset to ensure close adherence to the protocol and 
deliver full patient follow-up.  
 In AC, NI analyses, patient exclusions and non-randomised PP analyses should 
be avoided. Stringent standards for trial conduct and execution should be 
established at the outset to ensure close adherence to the protocol and 
deliver full patient follow-up. 
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On the use of parametric methods in the analysis of oncology clinical trial data: 
 In oncology trials, Weibull modelling of time to event data should be 
routinely performed in support of the more standard Cox analysis.   The 
same covariates and strata should be used for both analyses. 
 Treatment effects should be reported in terms of both the hazard ratio and 
the ETR since the latter provides a clinically useful direct measure of the 
relative improvement in the time to an event. 
 Concerns regarding an exact distributional match to the Weibull distribution 
should not be overstated given a Weibull-based analysis provides very 
similar results to a Cox based analysis regardless of the true underlying 
distribution of the time to event.   
 With respect to predicting data maturation, Weibull modelling should be 
used as standard in preference to the often used and very simplistic 
assumption of a constant event rate over time.  
 Treatments should not be formally compared on the basis of DoR in 
responding patients.  Rather, an EDoR analysis should be performed and a 
comparison made on the basis of all randomised patients.   Results of such 
an analysis should be presented clearly and transparently as recommended 
in the associated paper. 
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Abstract 
Is prostate-specific antigen progression a surrogate for objective 
clinical progression in early prostate cancer?  
D. Newling, K. Carroll and T. Morris 
AstraZeneca, Macclesfield, United Kingdom  
4652  
Background: It is a common misconception that a correlation between endpoints is enough to 
demonstrate surrogacy. To show true surrogacy, the effect of an intervention on an intermediate 
endpoint relative to a control treatment needs to reliably predict the effect of the intervention on 
the clinical outcome of interest. Valid surrogate endpoints are needed to accelerate availability of 
information about new therapies for early prostate cancer where clinical progression and survival 
times are prolonged. The usefulness of prostate-specific antigen (PSA) progression as a 
surrogate for objective clinical progression has therefore been assessed in the bicalutamide 
(‘Casodex’) Early Prostate Cancer (EPC) Program, the world's largest prostate cancer treatment 
program. Methods: Individual data from all 8113 patients across 21 countries in the EPC 
Program were examined. Time to PSA progression and time to objective clinical progression 
were the endpoints evaluated. The effect of treatment on time to PSA progression was compared 
with the effect of treatment on time to objective clinical progression. Results: Analyses suggest 
that time to PSA progression is a modest surrogate endpoint for the effect of a hormonal 
intervention on objectively confirmed progression in patients with early prostate cancer (r2 = 0.52–
0.65, p<0.001). An intervention that produces around a 50% reduction in the risk of PSA 
progression would likely result in around a 20% reduction in the risk of objective clinical 
progression. Conclusions: The effect of treatment on PSA progression is moderately predictive 
for the effect of hormonal treatment on objective clinical progression. A large effect on PSA 
progression predicts for a smaller, but nonetheless clinically important effect on objective clinical 
progression. These data suggest that a large positive treatment effect on time to PSA 
progression is reasonably likely to reflect a clinically important delay in objective clinical 
progression, making PSA progression a valid endpoint for the evaluation of hormonal medicines 
in early prostate cancer.  
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Abstract 
Is prostate-specific antigen a surrogate for survival in advanced 
prostate cancer?  
L. Collette, T. Burzykowski, K. Carroll, D. Newling, T. Morris and F. Schroder 
EORTC Data Center, Brussels, Belgium; Limburgs Universitair Centrum, Diepenbeek, Belgium; 
AstraZeneca, Macclesfield, United Kingdom; Erasmus Medical Centrum, Rotterdam, Netherlands  
4551  
Background: Surrogate endpoints are needed to shorten the duration of Phase III clinical trials in 
advanced prostate cancer. Prostate-specific antigen (PSA) is the most studied biomarker in 
prostate cancer. This study attempts to validate PSA endpoints as surrogates for overall survival 
(OS). Methods: Individual data from 2161 patients with advanced prostate cancer treated in 
studies comparing bicalutamide (‘Casodex’), either as monotherapy or in combination with an 
LHRHa, with castration were used in a meta-analytical approach to surrogate endpoint validation. 
PSA response, several definitions of time to PSA progression and longitudinal PSA 
measurements were considered. Results: The analyses confirmed the known association 
between the PSA endpoints and OS at the individual patient level (biomarker association). 
However, when comparing patients treated with bicalutamide-based treatment or castration, the 
effect of hormonal intervention on the PSA endpoint did not predict the effect on OS with a high 
degree of precision. The association between intervention on any PSA endpoint and OS, 
measured by the determination coefficient R2 (ranging from 0.10–0.66 for PSA progression, to 
0.69 for the whole PSA profile) was generally low. Conclusions: It is a common misconception 
that a correlation at the individual level between PSA and OS is enough to demonstrate 
surrogacy. To demonstrate true surrogacy, a high correlation between the treatment effect on the 
surrogate and the treatment effect on the true endpoint needs to be established across groups of 
patients treated with two alternative interventions. The level of association observed in this study 
between the treatment effect on PSA endpoints and that observed on OS was in general low, 
showing that in Phase III clinical trials of hormonal treatments in advanced prostate cancer, 
treatment effects on OS cannot be predicted from observed treatment effects on PSA endpoints 
with a high degree of precision. This study indicates that PSA is unlikely to be a useful surrogate 
for OS in advanced prostate cancer. ‘Casodex’ is a trademark of the AstraZeneca group of 
companies.  
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Is Prostate-Specific Antigen a Valid Surrogate End Point
for Survival in Hormonally Treated Patients With
Metastatic Prostate Cancer? Joint Research of the
European Organisation for Research and Treatment of
Cancer, the Limburgs Universitair Centrum, and
AstraZeneca Pharmaceuticals
Laurence Collette, Tomasz Burzykowski, Kevin J. Carroll, Don Newling, Tom Morris,
and Fritz H. Schröder
A B S T R A C T
Purpose
The long duration of phase III clinical trials of overall survival (OS) slows down the
treatment-development process. It could be shortened by using surrogate end points.
Prostate-specific antigen (PSA) is the most studied biomarker in prostate cancer (PCa). This
study attempts to validate PSA end points as surrogates for OS in advanced PCa.
Patients and Methods
Individual data from 2,161 advanced PCa patients treated in studies comparing bicalutamide
to castration were used in a meta-analytic approach to surrogate end-point validation. PSA
response, PSA normalization, time to PSA progression, and longitudinal PSA measurements
were considered.
Results
The known association between PSA and OS at the individual patient level was confirmed.
The association between the effect of intervention on any PSA end point and on OS was
generally low (determination coefficient, , 0.69).
Conclusion
It is a common misconception that high correlation between biomarkers and true end point
justify the use of the former as surrogates. To statistically validate surrogate end points, a
high correlation between the treatment effects on the surrogate and true end point needs to
be established across groups of patients treated with two alternative interventions. The
levels of association observed in this study indicate that the effect of hormonal treatment on
OS cannot be predicted with a high degree of precision from observed treatment effects on
PSA end points, and thus statistical validity is unproven. In practice, non-null treatment
effects on OS can be predicted only from precisely estimated large effects on time to PSA
progression (TTPP; hazard ratio, , 0.50).
J Clin Oncol 23:6139-6148. © 2005 by American Society of Clinical Oncology
INTRODUCTION
Phase III cancer clinical trials that evaluate
the clinical benefit of new treatment options
often require large patient numbers and
long follow-up. Recent advances in the un-
derstanding of the biologic mechanisms of
disease development have resulted in the
emergence of a large number of potentially
effective new agents. There is also increasing
public pressure for promising new drugs to
receive marketing approval as rapidly as
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possible, in particular for life-threatening diseases such as
cancer. For these reasons, there is an urgent need to find
ways of shortening the duration of cancer clinical trials. The
duration of phase III trials results from the use of long-term
clinical end points (clinical progression and survival).
Therefore, to replace this end point (the “true” end point)
by another (“surrogate”) end point that could be measured
earlier, more conveniently, or more frequently and would
adequately reflect the benefit of new treatments on the
clinical end point(s) seems to be an attractive solution.
“Biomarkers” (ie, physical signs or laboratory mea-
surements that occur in association with a pathological
process or that have putative diagnostic and/or prognostic
utility1) are generally regarded as the best candidate surro-
gate end points. A biomarker is an intermediate outcome
that is correlated with the true clinical outcome for an
individual patient. It may be useful for diagnostic or prog-
nostic information on a particular patient. It is a common
misconception that established biomarkers necessarily
make valid surrogate end points. To this aim, it is required
that “the effect of treatment on a surrogate end point must
be reasonably likely to predict clinical benefit.”2 Thus, “sur-
rogacy” is a concept that relates to groups of patients. To
demonstrate surrogacy, a strong association between the
treatment effects on the surrogate and on the true end point
needs to be established across groups of patients treated
with the new and standard interventions.
The validation of a candidate surrogate end point is not
straightforward. Until recently, the statistical methods de-
veloped for this purpose used the data from a single trial.3-5
These methods suffer from numerous drawbacks: some of
them are too stringent to be of practical value, whereas
others are based on nontestable assumptions.6,7 To over-
come these limitations, a new methodology, known as
the “meta-analytic” validation approach, was developed
recently.8-10 This method uses large databases from multi-
ple randomized clinical trials and aims at measuring di-
rectly the association between the treatment effects on the
surrogate and the true end point.
In the field of prostate cancer (PCa), prostate-specific
antigen (PSA) has probably been the most studied biomar-
ker. It has been investigated as a potential surrogate end
point across disease stages,11-14 and in hormone-refractory
patients in particular.15-18 In a recent article, Buyse et al19
considered several PSA-based end points in androgen-
independent patients treated with liarozole (an imidazole-
like compound that causes elevation of retinoic acid,
postulated to have antitumor activity), cyproterone acetate,
or flutamide. They showed that despite a strong association
at the individual patient level, none of the end points qual-
ified as a surrogate for overall survival (OS). In early PCa,
Newling et al20 found a modest correlation between the
effect of Casodex on time to PSA progression (TTPP) and
on objectively confirmed progression. In primary meta-
static PCa, several studies demonstrated some level of asso-
ciation between a post-therapy fall in PSA or a PSA relapse
on treatment and long-term survival prognosis.21-25 How-
ever, this merely qualifies PSA as a biomarker. In trial NCI-
INT-105, treatment differences in post-therapy PSA levels
did not translate into survival differences.26 Thus, whether
PSA is a valid surrogate for survival in hormonally treated
PCa remains an open question. This question is of impor-
tance, because the use of PSA could shorten the time to the
end point from between several months in advanced dis-
ease27 to several years in early disease.28
The objective of the present research is to assess PSA-
based end points as surrogates for OS in hormone-naı¨ve
metastatic PCa using the meta-analytic approach. The data
from . 2,000 patients treated with bicalutamide (Casodex)
that were made available by AstraZeneca Pharmaceuticals
were used for this purpose.
PATIENTS AND METHODS
Individual data from three large international randomized trials of
AstraZeneca’s Casodex Development Program were used (301/
302,29,30 306/307,31 and US trial 000132,33; Table 1). In studies
301/302 and 306/307, Casodex monotherapy (50 and 150 mg/day,
respectively) was compared to medical or surgical castration. In
the US trial, Casodex (50 mg/day) in combination with goserelin
or leuprolide acetate was compared to the combination of flut-
amides (750 mg/day) and castration in a 2 3 2 factorial design.
All patients were newly diagnosed with metastatic PCa. Four hun-
dred eighty patients with T3-4 M0 disease and elevated PSA from
trial 306/307 were excluded. Survival was an end point in all studies,
although time to treatment failure (Table 1) was the primary end
point in most. PSA was monitored at months 1, 2 (except US trial),
and 3 and then every 3 months until month 18 (trial 301/302) or
death (other trials). For the analysis, the PSA test date was assumed
to be the visit date.
End Points
We considered OS calculated from randomization to the date
of death or last visit as the true end point. PCa-specific survival was
defined similarly but with deaths unrelated to PCa or treatment
censored at the last visit. PSA response, PSA normalization, TTPP,
and the complete series of PSA measurements (“PSA profile”)
were successively assessed as potential surrogate end points for OS.
Patients who had a baseline PSA level at least five times above
the normal range (. 20 ng/mL) were included in the analyses of
PSA response and PSA normalization. Patients qualified for PSA
response if their PSA declined by at least 50% from baseline level
at two subsequent observations at least 4 weeks apart. Patients
in whom the decline reached a value below or equal to normal
(4 ng/mL) qualified for PSA normalization.25
Two definitions of TTPP were assessed: (1) For TTPP-1, PSA
progression was defined as a PSA value above normal (4 ng/mL),
representing a first increase $ 20% above the nadir25 (eg, with a PSA
nadir of 2 ng/mL, a minimum increase to 4 ng/mL [100% increase] is
required, whereas with a PSA nadir of 3.5 ng/mL, a 20% increase to
4.2 ng/mL is enough). (2) For TTPP-2, PSA progression was defined
as a PSA value . 2.5 times the normal range (10 ng/mL), representing
a first increase $ 50% above the moving average (based on three
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consecutive measurements) nadir. This increase had to be either the
last observed value or be sustained for at least 4 weeks19 (eg, with a
nadir of 2 ng/mL at three consecutive occasions, a 500% increase
to 10 ng/mL is needed to reach the end point, whereas after a nadir
of 7 ng/mL, a 50% increase to 10.5 ng/mL is enough).
Patients who died or are alive without PSA progression were
censored at the time of death or last visit, respectively.
Statistical Methods
The meta-analytic approach to surrogate end-point valida-
tion has been detailed extensively elsewhere.6,9,34-36 Thus, we shall
only summarize the key features. The method is rooted in the
concept that a valid surrogate end point must enable one to predict
with sufficient precision the treatment effect on the true clinical
end point (OS) from the observed treatment effect on the surro-
gate (PSA-based) end point. Unlike traditional validation meth-
ods such as the Prentice criteria,3 this new methodology does not
require that any of those effects be statistically significant. Indeed,
when data from several trials are available, the method consists of
simultaneously estimating the relative treatment effects on the
survival end point and on the PSA end point (log odds ratio of PSA
response or normalization, log hazard ratio [HR] of PSA progres-
sion, treatment effect on the longitudinal PSA measurements) in
each trial. A model that estimates the association between the
treatment effects on the true end point and the corresponding
effects on the PSA end points (PSA response,34 TTPP,35 or longi-
tudinal PSA measurements36) in a way similar to standard linear
regression (although mathematically more sophisticated) is then
adjusted. As in linear regression, the strength of the association is
measured by the squared correlation coefficient that we shall de-
note Rtrial
2 . This coefficient also indicates the precision with which
the treatment effect on the survival end point can be predicted
from the observed treatment effect on the surrogate. The maximal
possible value of Rtrial
2 is 1, which indicates a perfect prediction. In
practice, observing Rtrial
2
5 1 is not possible, and one rather seeks a
value close to 1, which indicates a strong association between the
treatment effects and thus a relatively precise prediction.9,35 Addi-
tionally, the model quantifies the association between the PSA-based
end point and the survival end point at the individual patient level.
Parameters quantifying the strength of the association at this level will
be denoted by the subscript “patient.” They can be regarded as mea-
sures of validity of the PSA end point as a biomarker for predicting
duration of survival.
Only three trials were available, which is too few to allow a
precise estimation of Rtrial
2 . Therefore, the patients were grouped
Table 1. Trials Used in the Analysis
Trial
301/30228,29
Patients Stage D2, fit for orchidectomy; ECOG performance status 0-2; no prior systemic therapy for prostate cancer, no previous
radiotherapy to the prostate within 3 months of entry
Treatments Bicalutamide (50 mg/d) v castration (orchidectomy in trial 301, orchidectomy or goserelin 3.6 mg monthly injection in trial
302)
Design Open two-arm randomization
Objective To compare bicalutamide to castration in a pooled analysis
Efficacy end points Time to treatment failure (objective progression, change of treatment, death as a result of any cause)p; overall survival
Results Bicalutamide (50 mg/d) demonstrated significantly worse time to progression and survival in trial 301; the trend was not
significant in trial 302; by pooled analysis, both end points were significantly worse with bicalutamide than with
castration
306/30730
Patients Metastatic (M1) or locally advanced with PSA five-fold in excess of the upper normal limit (T3-4 M0); only the M1
patients were included in the presently reported analyses; fit for orchidectomy; ECOG performance status 0-2; no prior
systemic therapy for prostate cancer, no previous radiotherapy to the prostate within 3 months of entry
Treatments Bicalutamide (100 or 150 mg/d) or castration (medical or surgical at the patient’s discretion)
Design Initially 2 (Casodex 100 mg):2 (Casodex 150 mg):1 (castration) then changed to 2:1 randomization between Casodex
150 mg and castration
Objective To demonstrate noninferiority of Casodex 150 mg in comparison to castration by excluding a risk increase of 25%
Efficacy end points Time to treatment failure (addition of systemic therapy or withdrawal from therapy, objective progression, or death)p;
overall survival; objective response
Results (in M1) Significant differences in favor of castration were found for time to treatment failure (HR, 1.43; 95% CI, 1.20 to 1.71 in
favor of castration) and overall survival (HR, 1.30; 95% CI, 1.04 to 1.64)
US trial31,32
Patients Stage D2 only; ECOG performance status 0-2; no prior systemic therapy for prostate cancer
Treatments Bicalutamide (50 mg/d) v flutamide (250 mg tid) in combination with goserelin acetate (3.6-mg monthly injection) or
leuprolide acetate (7.5-mg monthly injection)
Design 2 3 2 factorial design, blinding for the LHRH-A randomization
Objective To demonstrate noninferiority of bicalutamide 1 LHRH-A relative flutamide 1 LHRH-A by excluding a relative-risk
increase of 25%
Efficacy end points Time to treatment failure (addition of systemic therapy or withdrawal from therapy, objective progression, or death)p;
overall survival
Results Noninferior time to treatment failure (HR, 0.93 in favor of bicalutamide; 95% CI, 0.79 to 1.10) Noninferior overall survival
(HR, 0.87 in favor of bicalutamide; 95% CI, 0.72 to 1.05)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen; HR, hazard ratio; LHRH-A, luteinizing hormone-releasing
hormone agonist.
pA rising PSA was not considered a sign of progression in any of the studies.
Is PSA a Valid Surrogate End Point?
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by the trial they entered and their country of residence, as done
by Buyse et al.19 These groups will be henceforth referred to as
“trial units.”
RESULTS
After excluding nonmetastatic patients and those with no
baseline or follow-up PSA measurements, the individual
data from 2,161 patients classified into 21 trial units were
available for the analysis (Table 2). Their baseline and treat-
ment characteristics are listed in Table 3. More than half of
the patients presented with six or more bone metastases.
After a median follow-up of 3.25 years, 1,018 patients
(52.9%) had died, 815 (71.3%) as a result of PCa (Table 4).
The median OS was 2.2 years (95% CI, 2.1 to 2.5) for the
Casodex-treated patients and 2.3 years (95% CI, 2.1 to 2.6)
in the pooled control groups (Fig 1). The average number of
PSA assessments per patient was 6.9 (range, 1 to 23)
PSA Response (> 50% Decline From Baseline)
and PSA Normalization
PSA response could be assessed for 1,853 patients. A total
of 974 (89.4%) and 687 (90.0%) assessable patients on the
Casodex and control groups, respectively, achieved a PSA re-
sponse (Table 4). Only thirteen trial units representing 1,606
patients were used in the analysis: two trial units were removed
because no deaths were observed in the castration group, and
six were removed because all patients responded in one or both
treatment arms. At the individual level, PSA response was a
strong predictor of prolonged survival with a survival odds
ratio upatient of 1.94 (SE, 0.33), representing a two-fold increase
in the odds of surviving beyond any specified time t for the PSA
responders compared to the nonresponders. At the trial level,
the effects of hormonal intervention on PSA response and on
OS were poorly correlated with Rtrial
2
5 0.08 (SE, 0.14; 95% CI,
0.0 to 0.49). Figure 2A presents the estimated treatment effects
on the response (log odds ratio) and OS (log HR).
One should be careful in interpreting these results,
because eight trial units with extreme results were excluded
from the analysis.
In 399 (36.6%) and 380 (49.8%) of the assessable pa-
tients, the PSA declined to a value # 4 ng/mL. Seventeen
trial units representing 1,778 patients could be used for this
analysis: four were excluded for same reasons as above. At
the individual level, the survival odds ratio upatient for pa-
tients with PSA normalization compared to those without
was 4.90 (SE, 0.52), indicating a 4.9-fold greater odds
of surviving any specified time t for the patients whose
PSA normalized. At the trial level, the treatment effects on PSA
and on OS were moderately correlated with Rtrial
2
5 0.41 (SE,
0.18; 95% CI, 0.05 to 0.72; Table 5). Figure 2B presents the
estimated treatment effects on PSA normalization and OS.
PSA Progression
Nineteen trial units (2,070 patients) and 18 trial units
(2,043 patients) could be used for the analysis of TTPP-1 and
TTPP-2, respectively (two trial units were excluded from both
analyses because of absence of deaths in the castration arm and
one from the TTPP-2 analysis because of the absence of PSA
progressions in both treatment arms).
The TTPP-1 is presented in Figure 3A: 54.6% of the
patients progressed according to this definition (Table 4)
within a median time of 11.1 months after being randomly
assigned. TTPP-1 was somewhat shorter for the pooled
Casodex group than for the control group. TTPP-1 was
moderately associated with OS at the individual patient
level: the concordance coefficient tpatient 5 0.52 (SE, 0.004)
indicates that for each individual patient there is an approx-
imately 50% chance to observe a long (short) OS given a
long (short) TTPP. At the trial-unit level, the association
between the effects of Casodex on TTPP-1 and on OS was
low, with Rtrial
2
5 0.21 (SE, 0.17; 95% CI, 0.0 to 0.56; Table
5). This analysis is depicted in Figure 4A, where the treat-
ment effect on survival is regressed against the treatment
effect on TTPP-1: the size of the circles represents the trial-
unit size. The low trial-level association may be partly be-
cause of the outlying data from one trial unit. Excluding this
unit from the analysis leaves the individual-level association
unchanged (tpatient 5 0.52; SE, 0.004) but increases Rtrial
2 to
0.58 (SE, 0.15; 95% CI, 0.20 to 0.81).
Only 31.8% of the patients met the more stringent
criterion TTPP-2 (Table 4) at a median time of 24.9 months
(Fig 3B). At the patient level, the association of TTPP-2
and OS was somewhat stronger than for TTPP-1, with a
Table 2. Trial Units Available for the Analysis (N 5 2,161)
Trial Country N
US Canada 114
US United States 647
301 Denmark 158
301 Norway 75
301 Sweden 63
302 Austria 46
302 The Netherlands 29
302 United Kingdom 159
306 Denmark 83
306 Finland 69
306 Norway 83
306 Sweden 86
307 Australia 35
307 Austria 14
307 Belgium 95
307 Germany 47
307 The Netherlands 35
307 Italy 11
307 Republic of South Africa 48
307 Spain 22
307 United Kingdom 242
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concordance coefficient tpatient 5 0.61 (SE, 0.02). The asso-
ciation between the treatment effects on TTPP-2 and OS
was somewhat higher than for TTPP-1, with Rtrial
2
5 0.66
(SE, 0.13; 95% CI, 0.30 to 0.85; Fig 4B and Table 5).
Longitudinal Measurements of PSA
All previously considered PSA-based end points are sum-
mary measures derived from the longitudinal PSA measure-
ments and use only a limited amount of the available
information. It thus seemed logical to investigate if the longi-
tudinal series of PSA measurements would not be a better
surrogate end point for OS. Figure 5A presents the mean
profiles of log-transformed PSA measurements for groups of
patients with similar observation time: all profiles eventually
end with a PSA increase (progression), and patients with an
early progression tend to have a higher initial PSA that does not
decrease as much early on.
Figure 5B displays the mean PSA profiles per treatment
group: starting from week 52 the curves show a relatively stable
linear decrease rather than the increasing curvature observed
in Figure 4A. This distortion results from attrition: progressive
patients, in whom PSA increases, tend to leave the study, and
thus the curve in Figure 5B reflects only those with stable PSA.
In view of Figure 5A, the treatment effect on the log-
transformed PSA levels was expressed as a function of time and
its square root in a joint model of PSA measurements and
survival times. In that model, the individual patient-level asso-
ciation between the PSA process and the hazard of dying is a
function of time and cannot be easily summarized into a single
measure.35 The results indicated that the correlation between
the individual PSA and mortality hazard processes was . 0.90
at any time . 7 months, which suggests a strong association
between the PSA profile and the hazard of dying for individual
Table 3. Patient Characteristics
Age
Performance Status
0/1/2/3/4, %
Baseline PSA
Mean SD Median
First and Third
Quartiles Mean SD Median
First and Third
Quartiles
301/302
Total (N 5 530) Data not available Data not available 839.1 1,551.3 267.9 98.6, 784.7
Casodex 50 mg (N 5 262) Data not available Data not available 811.2 1,477.8 273.2 98.3, 840.0
Castration (N 5 268) Data not available Data not available 866.3 1,622.2 266.7 99.4, 713.3
306/307 (UICC M1 pts.)
Total (N 5 870) 71.6 8.2 72 66, 78 53.8/32.8/13.3/0/0.1 747.3 1,657.2 179.1 65.7, 634.7
Casodex 100/150 mg (N 5 617) 71.2 8.2 72 66, 77 54.0/31.9/14.1/0/0 772.6 1,772.5 189.8 64.5, 658.4
Castration (N 5 253) 72.7 8.1 73 67, 78 53.4/34.8/11.5/0/0.4 685.6 1,336.0 156.0 67.0, 587.3
US (D2 pts.)
Total (761) 70.2 8.7 70 65, 76 51.4/37.2/11.4/0/0 694.2 1,444.2 174.3 45.6, 580.6
Casodex 1 castration (N 5 377) 69.8 8.2 70 65, 75 53.8/36.1/10.1/0/0 650.4 1,382.8 170.0 53.8, 588.1
Flutamide 1 castration (N 5 384) 70.5 9.2 71 65, 77 49.0/38.3/12.8/0/0 737.3 1,502.6 178.3 38.7, 576.5
Abbreviations: PSA, prostate-specific antigen; SD, standard deviation.
Table 4. Survival and Prostate-Specific Antigen Outcome
Casodex (n 5 1,256) Control (n 5 905) Total (N 5 2,161)
No. % No. % No. %
Alive 571 447 1,018
Dead 685 458 1,143 52.9
Because of prostate cancer 496 319 815 71.3
Because of another cause 189 139 328 28.7
PSA response
Evaluable 1,090 763 1,853
Decline to # 4 ng/mL 399 36.6 380 49.8 779 42.0
Decline by $ 50% of baseline 575 52.8 307 40.2 882 47.6
No response 116 10.6 76 10.0 192 10.4
Not evaluable 142 166 308
PSA progression (TTPP-1) 415 729 1,144
PSA progression (TTPP-2) 432 233 665
Not evaluable for PSA progression 35 32 67
Abbreviations: PSA, prostate-specific antigen; TTPP, time to PSA progression.
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patients. At the trial-unit level, the association between the
effect of Casodex on the longitudinal PSA and OS was slightly
higher than that for TTPP-2 (Rtrial
2
5 0.68; SE, 0.12; Table 5).
DISCUSSION
Using data from the Casodex Development Program, we
investigated whether the biomarker PSA could be used to
define a valid surrogate for OS in patients with metastatic
PCa. The analyses confirm the known value of PSA as a
biomarker of prognosis and disease activity (individual-
level association). When comparing groups of patients
treated with Casodex-based or control treatment, however,
the association between the treatment effect on any PSA-
based end point and the treatment effect on OS was low in
general (Rtrial
2
, 0.69 with wide confidence intervals).
The choice of the threshold for Rtrial
2 required for a valid
surrogate is still a matter of debate.6 Nevertheless, one can
argue that the precision of the prediction of the treatment
effect on OS from the effect on the PSA-based end points,
indicated by the Rtrial
2 values observed in the present
study, is insufficient to claim any of the assessed PSA-
based end points as a statistically valid surrogate end
point for OS in phase III clinical trials of hormonal
treatment in metastatic PCa.
To illustrate the problem, let us consider a new trial
with TTPP as the primary end point (defined as TTPP-2),
where data analysis occurs after 400 events and yields an HR of
0.75 for PSA progression (with 400 events, SE [log{HR}]
would be of the order of 0.10, resulting in P , .01). Without
adjusting for the estimation error in the parameters of the
prediction model, one could predict with approximately 95%
confidence that the corresponding survival HR would lie
within the interval 0.48 to 1.12. Adjustment for the estimation
error would widen the confidence interval even further; thus,
non-null treatment effects on survival would potentially be
identifiable only in large new trials showing a large effect on the
PSA end point (eg, HR approximately 0.50 with SE 5 0.10).
Buyse et al19 assessed similar PSA-based end points as
candidate surrogates for OS in patients with androgen-
independent PCa treated with liarozole versus antiandro-
gen monotherapy. In their study, the association between
treatment effects at the trial level were generally low, with
Rtrial
2
, 0.45 for all tested PSA end points. They concluded
that PSA end points could not be regarded as valid surro-
gates for OS. The reasons for the lack of association in their
study may be different than ours; the disease was more
advanced, and treatment mode of action differed. In early
disease, for which the time savings of using PSA could be
greater than in advanced disease, Newling at al20 also found
only moderate correlation between the effect of Casodex on
PSA progression and objective clinical progression.
Unfortunately, in cancer and other diseases, biomark-
ers that are strong predictors of the clinical end point for the
individual patient often proved to be poor surrogate end
points.37-43 Several authors have discussed biologic and
medical reasons why biomarkers often fail to validate as
Fig 1. Overall survival by randomized treatment.
Fig 2. The treatment effects on survival and prostate-specific antigen (PSA)
response. The circles represent the observations in the trial units, and their
size is proportionate to the trial-unit sample size. The line represents the
prediction from an estimated (weighted) regression line. (A) $ 50% decline
from baseline level: Rtrial
2
5 0.08. (B) PSA normalization (PSA # 4 ng/mL):
Rtrial
2
5 0.41. HR, hazard ratio; OR, odds ratio.
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surrogate end points.2,37,39,44 The principal explanation is
that only a part of the treatment effect on the true clinical
end point will be reflected in the biomarker, which may lead
to over- or underestimation of the treatment effect on the
true end point from the observed effect on the biomarker.
Baker and Kramer45 mention that perfect predictors of the
true end point at the patient level do not necessarily make
good surrogate end points, because the prediction function
could differ between randomized treatments and thus
would induce incorrect inference on the true end point.
The inability thus far to demonstrate surrogacy for PSA
can be explained by several biologic mechanisms. PSA is also
produced by normal prostatic tissue, and the amount present
may vary between patients. Poorly differentiated tumors
Table 5. Summary of the Results
PSA End Point
Patient-Level Association Between PSA
and Survival
Trial-Level Association Between PSA
and Survival
SE R
trial
2 SE 95% CI
PSA response (decline by $ 50% from baseline) upatient 5 1.94 0.33 0.08 0.14 0 to 0.49
PSA normalization (# 4 ng/mL) upatient 5 4.90 0.52 0.41 0.18 0.05 to 0.72
TTPP-1 tpatient 5 0.52 0.004 0.21 0.17 0 to 0.56
TTPP-2 tpatient 5 0.61 0.02 0.66 0.13 0.30 to 0.85
Longitudinal PSA measurements R
patient
2
. 0.9 at all times . 7 mo — 0.68 0.12 Undetermined
Abbreviations: PSA, prostate-specific antigen; TTPP, time to PSA progression; upatient, survival odds ratio; tpatient, concordance coefficient between time to
PSA progression and duration of survival.
Fig 3. Time to prostate-specific antigen (PSA) progression (TTPP) by
randomized treatment. (A) TTPP-1: time to the first 20% increase of PSA
over previously observed nadir to a value above the upper limit of the normal
PSA range (4 ng/mL). (B) TTPP-2: time to the first 50% increase of PSA over
previously observed moving average nadir to a value . 2.5 times the upper
limit of the normal PSA range (10 ng/mL), sustained for at least 4 weeks.
Fig 4. The treatment effects on time to prostate-specific antigen (PSA)
progression (TTPP) and on overall survival. The circles represent the
observations in the trial units, and their size is proportionate to the trial-unit
sample size. The line represents the prediction from an estimated
(weighted) regression line. (A) TTPP-1: Rtrial
2
5 0.21. (B) TTPP-2: Rtrial
2
5 0.66.
HR, hazard ratio.
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may produce proportionally less PSA for the level of tumor
burden compared with better differentiated tumors. In ad-
dition, PSA is studied in the serum, although the source is
prostatic tissue. Conceptually, serum levels can be related to
unknown factors promoting or inhibiting leakage from PCa
cells into the blood, to cellular levels of PSA and their
interindividual variation, and obviously to the total tumor
mass present in a given patient.46,47 PSA in itself is an
endocrine-dependent enzyme, and its expression is regu-
lated by a promoter that contains androgen-responsive el-
ements.48,49 The treatment effects seen on PSA in trials of
endocrine treatment of PCa thus may result, at least in part,
from a direct, nontumor-mass–related effect. Such consid-
erations led Scher et al18 to conclude that PSA may not be an
appropriate end point for clinical trials of first-line hor-
monal treatment.
Part of the imprecision in the prediction achieved in
our study may be because of the limited number of obser-
vations available in each trial unit. The database we used,
however, is the largest available. There is also some hetero-
geneity in trial design between the two monotherapy trials
and the combined androgen-blockade trial. However, re-
analysis excluding the latter did not change the results.
One also could argue about the use of overall rather
than disease-specific survival as the true end point in our
study. Analyses using disease-specific survival as the true end
point, however, led to essentially similar conclusions (Rtrial
2
for TTPP-2 was then 0.49; SE, 0.17; 95% CI, 0.11 to 0.76).
Finally, it was not possible to assess dynamic measures
of PSA such as PSA doubling time or PSA velocity in these
analyses; as suggested by Kelloff et al50 and D’Amico et al,51
such measures of PSA may carry more information than the
ones we could assess.
Our study indicates that PSA surrogacy could not be
statistically validated in trials of hormonal treatments against
metastatic PCa. However, if large effects on time to PSA end
point (HR, , 0.50) could be demonstrated with high precision
in a new trial, the results of the present study would still pro-
vide evidence of a likely non-null effect (upper bound of the
95% prediction interval for HR,,1) on OS. This suggests that,
in such an instance, TTPP could potentially serve as a basis for
accelerated drug approval, together with other trial data doc-
umenting safety and other measures of patient benefit, until
firm evidence on the basis of the true end point becomes
available. Nevertheless, additional research for more powerful
surrogate end points in PCa is still needed. Such research
should probably focus on dynamic PSA measurements or new,
hopefully more specific markers or combinations of markers.
n n n
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Progression-Free Survival Is a Surrogate for Survival in
Advanced Colorectal Cancer
Marc Buyse, Tomasz Burzykowski, Kevin Carroll, Stefan Michiels, Daniel J. Sargent, Langdon L. Miller,
Gary L. Elfring, Jean-Pierre Pignon, and Pascal Piedbois
A B S T R A C T
Purpose
The traditional end point for assessing efficacy of first-line chemotherapies for advanced cancer is
overall survival (OS), but this end point requires prolonged follow-up and is potentially confounded
by the effects of second-line therapies. We investigated whether progression-free survival (PFS)
could be considered a valid surrogate for OS in advanced colorectal cancer.
Patients and Methods
Individual patient data were available from 10 historical trials comparing fluouracil (FU) 1
leucovorin with either FU alone (1,744 patients) or with raltitrexed (1,345 patients) and from three
validation trials comparing FU 1 leucovorin with or without irinotecan or oxaliplatin (1,263
patients). Correlation coefficients were estimated in historical trials between the end points of PFS
and OS, and between the treatment effects on these end points. Treatment effects on OS were
predicted in validation trials, and compared with the observed effects.
Results
In historical trials, 1,760 patients (57%) had progressed or died at 6 months, and 1,622 (52%) had
died at 12 months. The rank correlation coefficient between PFS and OS was equal to 0.82 (95%
CI, 0.82 to 0.83). The correlation coefficient between treatment effects on PFS and on OS ranged
from 0.99 (95% CI, 0.94 to 1.04) when all trials were considered to 0.74 (95% CI, 0.44 to 1.04)
after exclusion of one highly influential trial. In the validation trials, the observed OS hazard ratios
were within the 95% prediction intervals. A hazard ratio of 0.77 or lower in terms of PFS would
predict a benefit in terms of OS.
Conclusion
PFS is an acceptable surrogate for OS in advanced colorectal cancer.
J Clin Oncol 25:5218-5224. © 2007 by American Society of Clinical Oncology
INTRODUCTION
Approximately 50% of patients diagnosed with
colorectal carcinoma have metastatic or nonresect-
able disease at time of diagnosis or will develop me-
tastases or a locoregional recurrence after their
initial diagnosis. Substantial progress has been made
during the last 20 years in the use of fluorouracil
(FU) to treat advanced colorectal cancer, with a dou-
bling of tumor response through modulation of FU
by leucovorin or methotrexate, or through continu-
ous intravenous infusion of FU instead of a bolus
injection.1 These therapeutic approaches were
shown to yield a modest but statistically significant
impact on overall survival (OS).2 More recently, the
chemotherapeutic agents irinotecan and oxaliplatin
have become available after randomized trials
showed they increased response rates, progression-
free survival (PFS), and OS.3-6
Most patients with metastatic colorectal can-
cer still die as a result of their disease. The ulti-
mate goal of chemotherapy is to cure the disease,
or failing that, to improve patient symptoms,
quality of life, and OS. It seems justified, there-
fore, to use OS to assess the efficacy of chemother-
apies for advanced colorectal cancer. However,
patient death can be observed only after pro-
longed follow-up, and with the increasing num-
ber of active compounds available in this
disease, any effect of first-line therapies on OS
may be confounded or diminished by the effects
of subsequent therapies. It is therefore of inter-
est to investigate whether PFS could replace OS
as the primary end point in randomized trials
for the treatment of patients with advanced
colorectal cancer.
In this article, we quantify the relationship be-
tween PFS and OS in a set of historical trials, and we
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investigate whether the results observed in these trials could have been
used to predict the effects of irinotecan and oxaliplatin in a set of more
recently conducted validation trials that played a pivotal role in the
development of these newer drugs.
PATIENTS AND METHODS
Trials
Individual patient data were available on 10 historical trials2,7-9 and three
validation trials3-5 that all had a FU 1 leucovorin treatment group (Table 1).
Historical trials consisted of all trials comparing FU 1 leucovorin with FU
alone (seven trials, 1,744 patients), and all trials comparing FU 1 leucovorin
with raltitrexed (three trials, 1,345 patients). They accrued patients between
1981 and 1990 (median follow-up, 30.4 months). Validation trials (1,263
patients in total) consisted of all trials comparing FU 1 leucovorin with the
same plus irinotecan (two trials, 843 patients) or with the same plus oxaliplatin
(one trial, 420 patients). They accrued patients between 1995 and 1998 (me-
dian follow-up, 22.0 months). A meta-analysis of trials comparing FU 1
leucovorin with FU was previously reported.2 The other trials were those
carried out for the registration of the new drugs raltitrexed,7-9 irinotecan,3,4
and oxaliplatin.5
Data
The following data were requested for individual patients in all trials:
patient identifier, center identifier, randomization date, treatment assigned by
randomization, tumor measurability (ie, measurable or nonmeasurable tu-
mors), age, sex, performance status, primary tumor site (colon or rectum), site
of metastases, overall response status with the first assigned treatment, date of
response, date of progression with the first allocated treatment, date of death or
last visit, survival status, and cause of death if applicable.
Survival Analyses
PFS and OS analyses were based on all randomly assigned patients using
the intention-to-treat approach. PFS was defined as the time from random
assignment to progressive disease (as assessed in each individual trial) or death
from any cause. OS was defined as the time from random assignment to death
from any cause. The distributions of PFS and OS were estimated using the
Kaplan-Meier method. Estimation procedures and hypothesis tests were strat-
ified for trial. The effect of treatment on PFS and on OS was quantified through
hazard ratios (HRs), respectively HRPFS and HROS, estimated through a pro-
portional hazards model with treatment as the only factor.10
Surrogacy Criteria
A correlation approach was used to assess the validity of PFS as a surro-
gate for OS, which is appropriate when multiple randomized trials are avail-
able in which both end points are measured.11 The method comprised
estimation of r, the rank correlation coefficient between PFS and OS, and of R,
the correlation coefficient between the treatment effects on PFS and on OS,
expressed respectively as log HRPFS and log HROS. For small treatment effects,
log HR ' 1 – HR; hence, log HR is an approximate estimate of the risk
reduction. PFS would be claimed an acceptable surrogate end point for OS if
(a) r were close to 1, indicating a strong correlation between PFS and OS, and
(b) R were close to 1, indicating a strong correlation between treatment effects
on PFS and on OS.12
Correlation Coefficients
The rank correlation coefficient r between PFS and OS was estimated
through a Hougaard bivariate copula distribution of these end points over the
entire time range,13 or using the Kaplan-Meier estimates of PFS at 6 months
and OS at 12 months. The correlation coefficient R between treatment effects
on PFS and OS was estimated though a linear regression model, using all events
over the entire time range, or up until 6 months for PFS and 12 months for OS.
Validation Strategy
Correlations between treatment effects were estimated in the historical
trials, and used to predict the treatment effects on OS in the validation trials,
based on the treatment effects on PFS actually observed in the validation trials.
Table 1. Clinical Trials Included in the Analyses
Trial Treatments
No. of
Patients
Historical
FU
Crema2,14 FU 370 bolus 1 LV 200 bolus, days 1-5,
every 28 days
100
FU 370 bolus, days 1-5, every 28 days 50
NCCTG2 FU 370-425 bolus 1 LV 20 bolus, or FU 500
bolus 1 LV 200 bolus, days 1-5, every
28-35 days
142
FU 500 bolus, days 1-5, every 35 days 70
Siena2 FU 400 1 LV 200, days 1-5, every 21 days 94
FU 400, days 1-5, every 28 days 91
EORTC2 FU 2,600 24-hour infusion 1 LV 500 2-hour
infusion, once weekly, for 6 weeks
followed by a 2-week rest
165
FU 2,600 24-hour infusion, once weekly, for
6 weeks followed by a 2-week rest
166
SWOG2 FU 425 bolus 1 LV 20 bolus, days 1-5,
every 28-35 days, or FU 600 bolus 1 LV
500 3-hour infusion, once weekly, for 6
weeks, followed by a 2-week rest
178
FU 500 bolus, days 1-5, every 35 days 93
SAKK2,13 FU bolus 400 1 LV 20 bolus, days 1-5,
every 28 days
152
FU 400 bolus, days 1-5, every 28 days 158
HECOG2 FU 500 1-hour infusion 1 LV 200 2-hour
infusion, once weekly, for 6 weeks
followed by a 2-week rest
70
FU 600 2-hour infusion, once weekly, for 6
weeks followed by a 2-week rest
68
Raltitrexed
TCCSG-EU17 FU 400 bolus 1 LV 200 bolus, days 1-5,
every 28 days
248
Raltitrexed 3 bolus, every 21 days 247
TCCSG-US8 FU 425 bolus 1 LV 20 bolus, days 1-5,
every 28-35 days
210
Raltitrexed 3 bolus, every 21 days 217
TCCSG-EU29 FU 425 bolus 1 LV 20 bolus, days 1-5,
every 28 days
216
Raltitrexed 3 bolus, every 21 days 223
Validation
Irinotecan
Irinotecan-US3 Irinotecan 125 1 FU 500 bolus 1 LV 20
bolus, once weekly for 4 weeks, followed
by a 2-week rest
231
FU 425 bolus 1 LV 20 bolus, days 1-5,
every 28 days
226
Irinotecan-EU4 Irinotecan 80 1 FU 2300 24-hour infusion 1
LV 500, weekly OR irinotecan 180 1 FU
400 bolus and 600 22-hour infusion 1 LV
200 days 1-2, every other week
198
FU 2600 24-hour infusion 1 LV 500,
weekly, OR FU 400 bolus and 600 22-
hour infusion 1 LV 200 days 1-2, every
other week
187
Oxaliplatin
Oxaliplatin-EU5 Oxaliplatin 85 1 LV 200 2-hour infusion 1
FU 400 22-hour infusion, day 1, LV 200
2-hour infusion 1 FU 400 22-hour
infusion, day 2, every other week
210
LV 200 2-hour infusion1 FU 400 22-hour
infusion, days 1-2, every other week
210
NOTE. All dosages are in mg/m2. Control treatment is FU 1 LV.
Abbreviations: FU, fluouracil; LV, leucovorin; EU, European Union; NCCTG,
North Central Cancer Treatment Group; EORTC, European Organisation for
Research and Treatment of Cancer; SWOG, Southwest Oncology Group;
SAKK, Swiss Group for Clinical Cancer Research; HECOG, Hellenic Coopera-
tive Oncology Group; TCCSG, Tomudex Colorectal Cancer Study Group.
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The observed treatment effect on OS (and its 95% CI) was compared with the
predicted effect (and its 95% prediction interval). The linear regression model
between treatment effects was used to compute the surrogate threshold effect,
the minimum treatment effect on PFS required to predict a nonzero treatment
effect on OS in a future trial.12
RESULTS
Correlation Between End Points
In historical trials, similar numbers of events were observed for
PFS at 6 months (1,760 events) as for OS at 12 months (1,622 events).
The degree of association between Kaplan-Meier estimates of
6-month PFS and 12-month OS was weak, with a rank correlation
coefficient r equal to only 0.32 (95% CI, 20.14 to 0.67; Fig 1). There
was no evidence that the correlation between PFS and OS differed
between treatments (Fig 1). In contrast, PFS and OS over the entire
time range were reasonably well correlated, with a rank correlation
coefficient r equal to 0.82 (95% CI, 0.82 to 0.83).
Treatment Effects
Figure 2 shows the PFS and OS curves by treatment group: FU 1
leucovorin (solid lines) versus FU or raltitrexed (dotted lines) versus
irinotecan or oxaliplatin (dashed lines).
Figure 3 shows good overall agreement between the HRs for PFS
and for OS in both the historical trials and the validation trials; trials
tended to show large treatment benefits for both end points or small
benefits for both end points. The FU 1 leucovorin group tended to
fare better than FU alone or raltitrexed (HRs , 1) but worse than
FU 1 leucovorin with either irinotecan or oxaliplatin.
Correlation Between Treatment Effects
The correlation coefficient between log HRPFS and log HROS over
the entire time range, R, was equal to 0.99 (95% CI, 0.94 to 1.04).
Figure 4 shows the linear regression line used to predict treatment
effects on OS from the observed treatment effects on PFS. The regres-
sion equation was log HROS 5 0.003 1 0.81 3 log HRPFS, indicating
that the risk reductions were approximately 19% (5 1 2 0.81) lower
on OS than on PFS. The correlation coefficient between log HRPFS up
until 6 months and log HROS up until 12 months was equal to 0.94
(95% CI, 0.87 to 1.01).
Sensitivity Analyses
The Swiss Group for Clinical Cancer Research (SAKK) trial (310
patients)14 had a very long follow-up but surprisingly few events,
whereas the Crema trial (150 patients)15 exhibited extreme treatment
benefits in terms of both PFS and OS. Exclusion of the SAKK trial, and
of other trials than the Crema trial, had little impact on the results
(data not shown). Exclusion of the Crema trial resulted in a much
weaker association between the treatment effects, with a correlation
coefficient between log HRPFS and log HROS equal to 0.74 (95% CI,
0.44 to 1.04). Both of these trials were further scrutinized, but no
obvious defect or methodological problem could be found to explain
their atypical behavior.
Surrogate Threshold Effect
The surrogate threshold effect, as shown on Figure 4, corre-
sponds to PFS HRs of 0.86 (or 1.16 if new treatment was worse). Thus,
in order to predict a nonzero treatment effect on OS in a future trial, a
hazard ratio of at most 0.86 (or at least 1.16) would need to be
ascertained. After exclusion of the Crema trial, the surrogate threshold
effect corresponded to hazard ratios of 0.77 (or 1.30).
Predicted Effects on OS
In validation trials, the observed treatment effect on OS was
compared with the predicted treatment effect on OS, on the basis of
the observed treatment effect on PFS. Table 2 compares predicted with
observed treatment effects, and also shows the proportion of patients
receiving second-line therapy after experiencing failure of their ran-
domized first-line treatment: any second-line therapy, a second-line
regimen containing the same new drug as their first-line therapy
(irinotecan or oxaliplatin), or a second-line therapy with crossover to
the other new drug (oxaliplatin or irinotecan).
DISCUSSION
Fast progress has been made in the treatment of advanced colorectal
cancer during the last decade, and a number of promising new drugs
are now entering clinical development for this condition. In just a few
years since the approval of irinotecan and oxaliplatin, monoclonal
antibodies targeting the vascular endothelial growth factor (bevaci-
zumab) and epidermal growth factor receptor (cetuximab) have been
approved as additional therapies, respectively, for the first- and
second-line treatment of metastatic colorectal cancer.16-17 It is clearly
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in the best interest of future patients that new drugs be made available
as soon as their efficacy is established beyond doubt on the most
clinically meaningful end point, or on some earlier end point that can
be considered a surrogate for it. Our analyses indicate that in advanced
colorectal cancer, an analysis of PFS at 6 months would include ap-
proximately the same number of events as an analysis of OS at 12
months and would, therefore, have approximately the same statistical
power to detect any given risk reduction.
Reviews of the literature suggest a tight correlation between PFS
and OS in advanced colorectal cancer,18 but this observation alone
does not make PFS a good surrogate for survival.19 Although there is
no consensus regarding the theoretical conditions required for a sur-
rogate end point to be valid, recent work suggests that surrogacy can be
assessed through the correlation between the end points and the treat-
ment effects on these end points in a series of trials.11-12 In resectable
colorectal cancer, this approach was used successfully to show that
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3-year DFS was an excellent surrogate for 5-year OS.20 In metastatic
colorectal cancer, this approach was also used to investigate the rela-
tionship between tumor response and OS. Although patients who
achieved a response had a significantly prolonged OS, treatment ef-
fects on response were poorly correlated with treatment effects on OS,
making tumor response an unacceptable surrogate in this disease.1,21
The analyses presented here show that, in historical trials comparing
FU 1 leucovorin with single-agent FU or with raltitrexed, PFS was an
acceptable surrogate for OS. Indeed, the two end points were well
correlated (r 5 0.82), and so were the effects of treatment on the two
end points (R 5 0.99), although the latter finding was heavily influ-
enced by one trial that had a much larger treatment effect than all
others. When this trial was excluded, the treatment effects were still
correlated, but less impressively so (R 5 0.74). This observation is in
line with previously reported analyses of another data set, wherein the
lack of treatment effect on either end point made it impossible to
validate PFS as a surrogate for OS.13 Hence for the validation to be
effective, a range of treatment effects is desirable on both the surrogate
and the true end points.
When our analyses were censored at 6 months for PFS and at 12
months for OS, the effects of treatment on the two end points re-
mained highly correlated (R 5 0.94), but the correlation between the
Kaplan-Meier estimates of 6-month PFS and 12-month OS was much
lower (r 5 0.32; Fig 1). This finding indicates that using summary
statistics for time-related end points (such as medians or Kaplan-
Meier estimates at a given time point) is insensitive and potentially
misleading. This approach should not be used to validate potential
surrogate end points when complete individual patient data are avail-
able.22 In practice, however, the estimate of a surrogate end point at a
single time point will often be used to predict the true end point at a
later time point.
In the present article, we extended the validation methodology to
investigate the predictive value of PFS as a surrogate end point for OS.
We calculated the surrogate threshold effect and showed that if a
treatment achieved an HR for PFS of 0.86 or less, it would be expected
to ultimately achieve a benefit in terms of OS (Fig 4). After exclusion of
the Crema trial, the surrogate threshold effect corresponded to HRs of
0.77, suggesting the need for much larger but still achievable treatment
effects on PFS. HRs in the range of 0.7 to 0.8 for PFS are realistic and
have, in fact, been achieved by several treatments recently approved
for the treatment of advanced colorectal cancer.3-6,16-17 Similar con-
clusions were reached independently in a meta-analysis of a large
number of published trials.23 In practice, the threshold effect depends
on the size of the future trial, because the estimation error of the PFS
HR must be accounted for in the construction of the prediction limits
for the OS HR.
The trials used in our analyses were conducted over a long period
of time. The correlation between PFS and OS could largely be ex-
plained by a trend for both PFS and OS to improve over time, the
former as a result of more effective first-line treatments, and the latter
as a result of more effective second-line treatments. However, our
claim of surrogacy is also based on a high correlation between the
effects of treatment on PFS and OS, and there is no plausible way in
which the correlation between treatment effects could simply be a
result of time trends.
To validate results from historical trials in independent, more
recent trials, we also investigated whether treatment effects on OS were
reliably predicted by the treatment effects on PFS in three validation
trials testing the new drugs irinotecan and oxaliplatin. In these trials,
the prediction intervals of the predicted effect were narrower than the
CI of the observed effect (Table 2), which underscores the potential
gain arising from the use of surrogate end points for which more
Table 2. Observed Versus Predicted OS HRs
Trial
Observed
OS HR 95% CI
Predicted
OS HRp
95%
Predicted
Interval
%
FU 1 LV 1 New Drug FU 1 LV
Total
Receiving
Second-Line
Treatment
Receiving
New Drug
Crossed Over
to New Drug
Other
Second-Line
Treatment
Total
Receiving
Second-Line
Treatment
Receiving
New Drug
Crossed Over
to New Drug
Other
Second-Line
Treatment
Irinotecan-EU4 1.31 1.02 to 1.67 1.25 1.00 to 1.55 39 0 16 23 58 31 13 14
Irinotecan-US3 1.24 1.00 to 1.53 1.17 0.96 to 1.43 52 0 5† 47 70 56 5† 9
Oxaliplatin-EU5 1.21 0.94 to 1.55 1.40 1.12 to 1.75 58 0 30 28 61 28 20‡ 23
NOTE. HRs are HR of FU 1 LV v FU 1 LV 1 new drug.
Abbreviations: OS, overall survival; HR, hazard ratio; FU, fluouracil; LV, leucovorin; EU, European Union.
pPrediction based on observed progression-free survival HR.
†Reported as , 5%.
‡10% of patients received both oxaliplatin and irinotecan in second-line treatment and are counted only once in the overall 61%.
Tr
e
a
tm
e
n
t 
E
ff
e
c
t 
(H
R
) 
o
n
 
O
ve
ra
ll 
S
u
rv
iv
a
l
Treatment Effect (HR) on 
Progression-Free Survival
1.75
1.50
1.25
0.75
1.00
0.50
0.25
0.25 0.50 0.75 1.251.00 1.751.50
Historical trials Irinotecan-EU
Irinotecan-US Oxaliplatin-EU
Prediction line 95% prediction limits
 
Fig 4. Correlation between treatment effects on progression-free and on overall
survival in historical trials (circles), in irinotecan trials (squares), and in oxaliplatin
trial (diamond). A logarithmic scale is used for both axes. Symbol size is
proportional to the number of patients. HR, hazard ratio; EU, European Union.
Buyse et al
5222 JOURNAL OF CLINICAL ONCOLOGY
Copyright © 2007 by the American Society of Clinical Oncology. All rights reserved. 
2007 from 193.132.159.169. 
Information downloaded from jco.ascopubs.org and provided by AstraZeneca - Discovery Information on November 19,
Publication 4: Buyse, Burzykowski, Carroll 2007
134
events are available than for the true end point. Such a gain would be
even more pronounced for trials with less mature OS data, although
those trials would also have less mature PFS data, and therefore more
uncertainty in the estimated treatment effect on PFS. The predicted
effects agreed extremely well with the observed effects in trials testing
irinotecan, but less well in the trial testing oxaliplatin, in which the
predicted effect overestimated the observed effect (Table 2). However,
all of the observed effects fell within the prediction limits (Fig 4), and
these differences could be a chance finding. They could also be a result
of the effect of second-line treatments. In a recently reported US
Intergroup trial testing oxaliplatin added to FU 1 leucovorin versus
irinotecan added to FU 1 leucovorin (not included in our analyses), a
much higher proportion of patients were crossed over to the other
drug on disease progression in the first-line oxaliplatin arm (60%)
than in the first-line irinotecan arm (24%). The observed OS benefit of
first-line oxaliplatin compared with first-line irinotecan was larger
(HR 5 0.57) than would have been predicted from the benefit on PFS
(predicted HR 5 0.79), possibly because of the larger number of
crossovers.6 Second-line use of new agents is likely to produce lesser
antitumor effect than first-line use,24 but recent observations strongly
suggest that use of effective second-line therapies may extend the time
between first-line disease progression and death.25,26 Thus, the ulti-
mate OS benefits of improvements in first-line PFS may be reduced as
greater numbers of effective second-line therapies are introduced. Our
analyses indicate that PFS would have been an acceptable surrogate for
OS in developing the drugs considered here. Similar analyses should
be repeated with data from randomized trials testing newer drugs in
patients receiving effective second- or even third-line therapies.
PFS offers a direct measure of new drug activity that is not
obscured by subsequent therapies. Unlike response rate, PFS also has
the intrinsic advantage of assessing the time of tumor control. As more
active drugs enter the clinic, PFS will become an even more desirable
end point than OS as the primary efficacy end point for trials in
colorectal cancer.27,28 Its use can reduce sample size, shorten accrual
time, and speed time until first analysis, besides serving as an appro-
priate indicator of clinical benefit. Of course, increasing reliance on
assessment of PFS raises the challenge of ensuring that ascertainment
of tumor progression in clinical trials is reliable and unbiased.29
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Biomarkers in drug development: friend
or foe? A personal reflection gained
working within oncology
Kevin J. Carroll*,y
AstraZeneca Pharmaceuticals, Global Clinical Function, Alderley Park,
Macclesfield, UK
Hopes and expectations for the use and utility of new, emerging biomarkers in drug development have
probably never been higher, especially in oncology. Biomarkers are exalted as vital patient selection
tools in an effort to target those most likely to benefit from a new drug, and so to reduce development
costs, lessen risk and expedite developments times. It is further hoped that biomarkers can be used as
surrogate endpoints for clinical outcomes, to demonstrate effectiveness and, ultimately, to support
drug approval. However, I perceive that all is not straightforward, and, particularly in terms of the
promise of accelerated drug development, biomarker strategies may not in all cases deliver the
advances and advantages hoped for. Copyright # 2007 John Wiley & Sons, Ltd.
Keywords: biomarkers; surgery; prognostic; predictive; oncology
1. INTRODUCTION
With the advent of ever more sophisticated
proteomic, genomic and genetic technologies, the
era of personalized medicine is dawning, or at least
that appears to be the view coalescing across
industry, academia and regulatory health autho-
rities alike. In addition, efforts to gain a more in-
depth biologic understanding of disease, particu-
larly in oncology, is simultaneously leading to the
identification of a whole host of biomarkers that
reflect underlying biologic processes and the
aetiology of disease. But what exactly is a
‘biomarker’? For the purposes of this short article,
the terms ‘biomarker,’ ‘surrogate endpoint’ and
‘clinical endpoint’ will be defined as per Gruttola
et al. [1]:
Biomarker: A characteristic that is objectively
measured and evaluated as an indicator of normal
biologic processes, pathogenic processes, or phar-
macologic responses to a therapeutic intervention.
Clinical endpoint (or outcome): A characteristic
or variable that reflects how a patient feels or
functions, or how long a patient survives.
Surrogate endpoint: A biomarker intended to
substitute for a clinical endpoint.yE-mail: kevin.carroll2@astrazeneca.com
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Despite clear definitions in the literature, I, like
many of my fellow statistical colleagues, have not
found it uncommon in practice for biomarkers and
surrogate endpoints to be confused, with the terms
often (and incorrectly) used interchangeably.
Whereas biomarkers can perhaps help us define
patient populations that may stand to benefit to a
greater extent or provide some reassurance that
the drug is biologically active, interfering with the
underlying disease process as was hoped for,
biomarkers are infrequently true surrogates for a
relative improvement in clinical outcome. The
distinction between a biomarker and a true
surrogate endpoints is particularly important in drug
development and more will be said about this later.
As evidenced by FDA’s Critical Path Initiative
and EMEA’s Pipeline Program, regulatory autho-
rities are looking at the drug development process,
hoping to see and encourage the prospective
identification of patients who will gain most
benefit from new medicines while reducing ever-
lengthening development times.
With an increased focus on biomarkers come
high expectations. Herceptin (trastuzumab) and
Gleevec (imatinib mesylate) are two often-sited
biomarker-led development successes which others
are encouraged to emulate. For such develop-
ments, one frequently encounters the general belief
pivotal trials will be smaller in size (since effect
sizes will be larger), less costly and more secure in
terms carrying a lesser risk of failure. The
benefit:risk ratio will be clearer and reimbursement
arguments strengthened by virtue of a narrower
indication and a larger treatment effect. The public
is looking for the ‘right drug, right patient, right
time’ and biomarkers seem to offer this promise.
But all is not rosy in the garden.
Biomarkers are too often and too quickly
labelled as surrogate endpoints for clinical out-
come without proper qualification, which can
falsely raise expectations. Also, care needs to be
taken to avoid the risk of missed opportunities in
phase II trials designed to examine only biomarker
‘positive’ patients on the assumption of no
possible chance of therapeutic efficacy in ‘negative’
patients. Further, care needs to be taken with
early, apparently promising data showing separa-
tion in clinical outcomes between biomarker
‘positive’ and ‘negative’ patients treated with a
new drug, since the observed difference might not
in fact be due to the new drug. Over enthusiasm
with such data will increase chance of failing in
Phase III. And, finally, the widespread belief that
biomarker-led developments will, in all cases, be
cheaper and less risky is not necessarily true.
The remainder of this article is therefore
structured as follows: in Section 2, the role of
biomarkers as a part of a patient selection strategy
is discussed including the issue of prognostic
versus predictive biomarkers and issues in phase
II and phase III trial design. Section 3 then briefly
examines the use of biomarkers as endpoints in the
drug approval process, examining what might be
needed to elevate a biomarker to the status of
surrogate endpoint and reflecting on the sponsors
versus the regulators risk. Section 4 closes the
article with a brief summary of the main points
discussed.
2. BIOMARKERS TO SELECT
PATIENTS MORE LIKELY TO
BENEFIT FROM DRUG
A chief and increasing use of biomarkers in drug
development is to select patients thought more
likely to benefit from a new drug (or to deselect
patients thought more likely to experience un-
wanted side effects of drug). This is nothing new
per se since all approved therapies are selective to a
lesser or greater extent by virtue of their indica-
tion. Rather, biomarkers offer the opportunity for
a more sophisticated and refined selection of
patients on the basis of disease or target biology.
It is important to note that the aim is to select
patients more likely to benefit from drug; the aim is
not, as is commonly perceived, to identify
‘responders’ (and therefore exclude ‘non-re-
sponders’) to drug. Such absolute dichotomization
rarely occurs in nature because, in many instances,
underlying biology is a continuum. Prostate-
specific antigen (PSA) level in prostate cancer or
epidermal growth factor receptor (EGFR) protein
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expression level in NSCLC or even PANSS score
in depression or NIHSS score in stroke are
markers and scales that measure and reflect a
continuum of disease status and, consequently,
there is no magic cut point that separates patients
into ‘responders’ and ‘non-responders’.
Along similar lines, and as gratefully highlighted
by a reviewer, Senn points out that while selection
strategies assume a patient is either responsive or
unresponsive to drug, it is just as possible that all
patients are responsive but to a varying and
variable degree [2]. As a simple example, he
considers a hypothetical 1000 patient trial in which
700 patients achieve a clinical response and the
remaining 300 do not. The commonplace inter-
pretation of such data is that the treatment works
for 70% of patients 100% of time and for 30%
patients 0% of time, whereas another equally valid
and plausible interpretation is the drug works for
100% of patients 70% of time. He goes on to
correctly point out that we can never really know
which patients are more likely to benefit from a
given intervention unless we have within-patient
repeat assessments of response to drug (and
control) from the likes of repeat period crossover
trials. However, such trial designs are impossible
in oncology, so researchers seemingly have little
option but to think in terms of drugs working for
some fraction patients 100% of the time.
Still, it is easy to see that over simplification of
biomarkers in this fashion could result an in-
creased risk of both type I and type II errors
depending on the stage of development. What we
are actually looking to do statistically with a
biomarker is to ascertain if the apparent variability
in patient response to treatment – or more
precisely variability in the treatment effect, drug
relative to control, – is likely to be dictated on the
average by the biomarker.
2.1. Prognostic versus predictive biomarkers
Before discussing trial design issues it is important
to emphasize the crucial distinction between
prognostic and predictive biomarkers.
Prognostic markers tell you something about
clinical outcome independent of therapeutic inter-
vention. An example of a biomarker that was
thought to be predictive but was found to be more
prognostic might be epidermal growth factor
receptor (EGFR) mutations in non-small cell lung
cancer (NSCLC). Initially data emerged that, in
Western patients receiving EGFR inhibitors,
clinical outcomes were better in patients with a
mutation than in patients without a mutation [3,4].
Subsequently, however, further data emerged in
Western patients treated with chemotherapy which
showed that clinical outcomes were better in those
with a mutation relative to those without a
mutation [5]. So it would seem that having the
mutation is probably a good thing per se, irre-
spective of therapeutic intervention, meaning that
mutations are probably prognostic for outcome in
Western patients.
While prognostic biomarkers may have utility in
patient enrichment strategies, predictive biomar-
kers are arguably more important to successful
drug development. A predictive biomarker tells
you that the effect of a new drug relative to control
is related to the biomarker. Examples might be high
EGFR gene copy number in NSCLC, which
appears to be predictive for the effect of EGFR
inhibitors relative to control, and high her-2 gene
copy number in advanced breast cancer, which is
predictive for the effect of trastuzumab.
If a predictive biomarker can be found early in
the development process for a given drug, then this
may well provide a sensible and secure direction
for further development. The challenge is how do
we do this? What early work is needed and how
should we design phase II trials to help us
understand whether a biomarker is likely to be
predictive as opposed to prognostic and so provide
data and information to help guide further
development?
2.2. Some design issues in phase II and phase III
Where a new drug is not first in class, it is likely
that the path for the use of a biomarker as a
selection tool will already have been established.
However, for a new drug with a novel mechanism
of action, the situation is likely to be different.
While pre-clinical and translational science work
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may shed light on the biology of the disease and
therapeutic target and thus, in doing so, may
further suggest a biomarker that might identify
patients more likely to benefit from drug, this body
of work is only ever hypothesis generating – it does
not prove that a given biomarker-based selection
strategy will be successful. What is needed is a
well-designed phase II trial(s) to examine the
biomarker hypothesis and, in doing so, to guide
the shape and direction of large-scale phase III
trials.
Phase II designs can be complex but, broadly
speaking, options range as follows:
* trials where all patients are treated with the new
drug and outcomes in biomarker ‘positive’
patients are compared to outcomes in biomar-
ker ‘negative’ patients – these are poor,
relatively uninformative non-randomized de-
signs;
* trials including only biomarker ‘positive’ pa-
tients randomized to drug and control – these
are better designs but assume the new drug will
benefit only biomarker ‘positive’ patients;
* trials including both biomarker ‘positive’ and
biomarker ‘negative’ patients randomized to
drug and control – these are the preferred
designs which attempt to maximize information
about the predictive value of the biomarker.
Breaking with traditional statistical thought, it
may be better to design phase II trials not to look
for p50.05 in the comparison of drug to control,
but to provide data that allows the chance of
improved efficacy to be gauged both overall and in
relation to the biomarker. Knowing, for example,
from phase II that the chance of an improved
outcome across all patients is, say, 80%, rising to
90% in those who were biomarker positive and
slipping to 75% in those who are biomarker
negative, a rational and informed decision could
be made about how to proceed in phase III. The
design of phase II would then be driven not by
hypothesis testing and concerns about showing
significant differences, but more by the quantity of
information it was desired to generate and the
fraction of patients expected to be biomarker
‘positive.’
With respect to phase III programme design,
there is a widespread belief that a biomarker
selection strategy will result in smaller, more
efficient and lower risk developments. However,
this is not necessarily true in all cases. Two crucial
assumptions frequently made to support this
notion are (i) that the selected, biomarker
‘positive’ patients will experience a treatment effect
while the unselected, biomarker ‘negative’ patients
will be associated with no treatment effect and (ii)
that the diagnostic that evaluates the biomarker is
perfect, with 100% sensitivity and specificity.
Again, as highlighted by a reviewer, several
authors have previously considered similar con-
cepts in the context of assessing the value of
placebo run-in periods, where the aim is to
maximize the fraction of compliant patients
randomized while recognizing the classification of
patients as ‘compliant’ and ‘non-compliant’ is not
error free [6–8]. More recently, Maitournam and
Simon have looked specifically at biomarker or
genomic patient selection strategies, reaching
similar conclusions [9].
To appreciate the issues a little better, consider
the example situation described in Table I.
Assuming a median follow-up of 18 months, it
can be shown that a trial in all patients will require
approximately 1000 patients to provide 90%
power for a one-sided 2.5% a level. However, if
Table I. True median survival for new and control anti-cancer drugs.
Median survival
on control (months)
Median survival
on new (months)
Treatment effect
HRn new:control
Biomarker positive (25%) 6 12 0.50
Biomarker negative (75%) 6 6 1.00
All patients 6 7.5 0.80
nHR ¼ hazard ratio.
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the trial selects only biomarker ‘positive’ patients,
then only 117 patients would be required to
achieve the same power, but 468 patients would
have to be screened to allow for only 1 in 4 being
biomarker ‘positive.’
Table II shows how the efficiency gain in
selecting only biomarker ‘positive’ patients is
highly dependent on the performance of the
diagnostic. With 75% sensitivity and specificity,
the treatment effect is diluted by the erroneous
inclusion of biomarker ‘negative’ patients, which
consequently pushes up the sample size and the
number needed to screen so that, at 845 patients,
we begin to approach the trial size required for the
unselected approach.
In a similar fashion, Table III shows the impact
of assuming a small treatment effect in biomarker
‘negative’ patients.
With a modest, non-zero treatment effect in
biomarker ‘negative’ patients, the number of
patients required in the unselected trial reduces
from 1000 to 384 so that the unselected trial
requires fewer patients than are required to be
screened for the selected design.
Thus, while it is clear that a biomarker-directed
development strategy can deliver efficiencies
and greater security, much depends on how
confident we are that the biomarker is predictive
as opposed to prognostic, the size of the treatment
effect in biomarker ‘negative’ patients and the
performance of the diagnostic. Violation of any
one of these assumptions can quickly erode the
value of a selected approach. This tends to
underscore the importance of well-designed phase
II trials to provide data to investigate these crucial
assumptions.
3. MOVING ON FROM PATIENT
SELECTION – BIOMARKERS AS
ENDPOINTS TO EVALUATE THE
RELATIVE EFFECTIVENESS OF
NEW DRUGS
Moving on from patient selection, another key use
for biomarkers in drug development is to employ
the biomarker as endpoint. In considering the
issues associated with this use of a biomarker, it is
helpful to clarify (i) what stage of development are
we in, what question is being asked and (ii) to what
extent to drug-induced effects on biomarker reflect
a drug-induced effect on clinical outcome.
The first of these questions is related to whether
the decision we are making and, hence, the risk
Table II. The impact of an imperfect test.
Sensitivity (%),
specificity (%)
PPVn
(%)
Median survival
on control (months)
Median survival
on new (months)
HR
new:control
Number required
to enter
Number required
to screen
100, 100 100 6 12 0.50 117 468
95, 75 56 6 9.4 0.64 260 613
75, 95 83 6 11 0.55 149 663
75, 75 50 6 9 0.68 317 845
nPPV ¼ positive predictive value.
Table III. The impact of a small, non-zero effect in biomarker ‘negative’ patients.
Median survival
on control (months)
Median survival
on new (months)
Treatment effect
HRn new:control
Number of patients
required (screened)
Biomarker positive (25%) 6 12 0.50 117 (468)
Biomarker negative (75%) 6 7.5 0.80n }
All patients 6 8.7 0.69 384 (384)
nEffect size in ‘negative’ patients ¼ 1=3 effect size in ‘positive’ patients.
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being taken is largely the sponsors (internal) risk
or the regulators (external) risk. For example,
using a biomarker to screen drug candidates early
in development for likely efficacy or to choose
between doses in phase II is largely the sponsor’s
risk. If an error is made, the use of the biomarker
results in taking forward an ineffective agent or the
wrong dose, the burden falls on the sponsor to
rethink the development strategy. Little risk is
borne by the regulator.
However, the use of a biomarkers as substitute
for clinical outcome for purpose of directly
supporting approval is more troublesome. Here
we are using the biomarker as a surrogate
endpoint and a large part of the risk falls on the
regulator. The burden to demonstrate true surro-
gacy of an endpoint is known to be considerable.
Statisticians know that simple correlation between
the (assumed) surrogate and clinical outcome is a
necessary, but insufficient condition to show
surrogacy. Prentice [10] and Freedman [11] and,
more recently, Buyse and Molenbergs [12,13] have
provided a framework for assessing surrogacy, a
framework that requires large, randomized con-
trolled trials which capture both the (assumed)
surrogate and clinical outcome – i.e., that require
the very trials drug developers hope to avoid by
use of the surrogate. PSA in prostate cancer
illustrates how very difficult it can be to establish
a biomarker as a surrogate endpoint. Despite more
than 15 years of routine use in the management of
patients with prostate cancer coupled with multi-
ple large randomized, controlled trials looking at
both PSA and clinical outcome and, more recently,
formal published analyses [14] to examine surro-
gacy via the Buyse and Molenbergs method, PSA
is still not accepted as an endpoint for drug
approval. However, there is some hope – recent
FDA workshops on cancer endpoints, including
endpoints in prostate cancer, that may yet result in
at least a composite endpoint that includes some
component of PSA change as a measure of disease
progression [15].
In a similar vein, longstanding clinical endpoints
like progression-free survival in colorectal cancer
are only just being accepted as endpoints for drug
approval. This again is after years of use in the
clinical management of patients and on the basis
of multiple, well-controlled randomized trials that
have recently been analysed to look formally at
surrogacy for overall survival outcome [16].
So, set against this background, what realistic
hope is there for novel biomarkers in new disease
areas for their use as substitutes for clinical
outcome in the evaluation of efficacy and safety
and, ultimately, for drug approval?
The road for new biomarkers would therefore
seem very difficult unless the level of evidence
required to elevate a biomarker to surrogate
endpoint status is lowered in some fashion. Many
biomarkers in routine use today did not undergo
rigorous evaluation for surrogacy using any kind
of statistical criteria. For example, blood pressure,
lipid lowering and response rate have all been used
as primary endpoints to support drug approval,
yet the evidence base for the surrogacy of these
endpoints versus clinical outcome was not in hand.
Rather, a judgement was applied at the time that a
drug effect on these endpoints, whilst not being the
ultimate clinical goal, was likely to reflect a (long-
term) benefit to the patient.
For some of the newer biomarkers emerging
today and given current concerns over the long-
term safety of drugs, there may be some reluctance
to make the leaps of faith made in the past. This
suggests that the best we can realistically hope for,
at least initially, is biomarker endpoints to support
approval meaning that trials which examine
biomarker endpoints will likely still have to be
designed and powered to examine accepted clinical
endpoints. However, it might be possible to argue
for conditional approval on the basis of the
biomarker endpoint, with a commitment to either
conduct further trials to confirm clinical benefit or
to continue trial follow-up beyond the point of
having obtained biomarker endpoint data to
collect long-term clinical outcome data and thus
confirm clinical benefit.
4. SUMMARY
In my experience, founded mainly in oncology,
biomarkers are increasingly seen as the route to
Copyright # 2007 John Wiley & Sons, Ltd. Pharmaceut. Statist. 2007; 6: 253–260
DOI: 10.1002/pst
258 K. J. Carroll
Publication 5: Carroll 2007(a)
143
faster, cheaper and more secure drug development.
They are seen by academia and industry alike as
important tools in the drug development process
and in helping to formulate drug development
strategies. With the right biomarker in hand and
well-designed early phase clinical trials, biomarker
patient selection strategies can confer development
advantages but there are crucial assumptions that
must be highlighted and tested. Experienced
statistical input to aid in the design phase II trials
to evaluate these assumptions and guide phase III
development is crucial. The use of biomarkers as
endpoints per se is also important going forward.
Where biomarkers are use for candidate drug
screening for intrinsic activity or proof of mechan-
ism or for any internal decision-making purpose,
there seems little impediment to their use and the
burden falls squarely on the sponsor to be sure the
biomarker endpoint helps to make the right, not
the wrong decisions. However, using biomarkers
as surrogate endpoints for clinical outcome to
support drug approval is more troublesome.
Establishing a new biomarker as a true surrogate
endpoint using published statistical criteria is
extremely demanding, if not impossible. This
suggests acceptance of a lower burden of evidence
is required and, consequently, that greater
risks must be taken, in order to use new
biomarkers as substitutes for clinical outcome.
At the present time and in the present climate, the
prospect of this seems rather remote. In due
course, however, with experience and completed
trials in hand, we might be able to move to a
position where confidence with novel biomarker
endpoints is such that they can form the basis
of drug approval though, based on past perfor-
mance, the time frame may not be a quick as some
would wish.
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Abstract
The traditional development paradigm for phase II trials in oncology has been challenged in recent years by the introduction of
cytostatic therapies. These agents slow the growth of tumors rather than cause high rates of shrinkage, this argues for the use of
endpoints that measure growth inhibition such as progression free survival. We have previously argued the need for randomized
trials in this setting. Here we discuss methodological solutions to enhance the development decision at the end of phase II in the
context of progression endpoints employed in randomized trials. There are well recognized issues associated with progression
endpoints relating to bias in the timing and interpretation of assessments. In this paper we present design and analysis solutions that
will minimize bias by using methods that are either partially or completely time independent. We also discuss other design features
to maximize the information yielded in a phase II setting. We advocate the creation of progression endpoints that utilize all
available progression data rather than early fixed timepoint analyses and show that little is to be gained by assessing progression
status any more frequently than would be required in routine clinical practice. Such design and analysis measures will optimize the
development decision made at the end of phase II clinical evaluation.
© 2006 Elsevier Inc. All rights reserved.
Keywords: Phase II trials; Cancer; Bias; Randomization; Sensitivity
1. Introduction
Recent advances in molecular biology are making available an increasing number of cancer therapies, these agents
often demonstrate tumor growth inhibition in preclinical models, rather than cytoreduction (tumor shrinkage) the
classic action of cytotoxic therapies. This suggests that a delay in tumor progression may be an appropriate clinical
endpoint for assessment of efficacy in early development of these agents [1–4]. Indeed, recent data appear to confirm
this hypothesis [5–7]. For example, five times as many patients would be required to replicate the observed difference
in response rate compared with the difference in progression-free survival in the trial reported by Hurwitz et al. [5].
Time to progression, however, has been regarded with suspicion by investigators and regulatory authorities.
Progression-free survival differs qualitatively from overall survival in that the exact time a patient progresses (unlike
death) is never actually observed: the event is recorded as having occurred in an interval between two visits. The time
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of progression is usually assigned to the study visit at which the progression is detected. These properties mean that
differential rates of assessment between treatment arms can lead to bias [8], which is of particular concern if the trial is
not blinded, or if one of the treatment groups has a prevalent and distinctive side effect. To enable a treatment effect to
be estimated free from bias, additional design and analysis measures need to be considered.
There is a perception that unless a time to event analysis technique is used, any analysis is hopelessly underpowered.
However, a number of authors have noted that a comparison of the count of events can be nearly as powerful, which creates
the option of using time independent endpoints [9–11]. As the power of statistical tests depends on the number of events
observed and not the number of patients studied [12,13], any endpoint created should incorporate all available progression
data. Additionally, it is often assumed that an increase in the frequency of assessment is necessary to increase the chance of
revealing a difference in the rate of progression. Another concern is lead-time bias, which is particularly problematic in
single-arm trials in which there is no correction for potential variability in the time course of the patient's disease at
enrolment but which is unlikely to be a problem in randomized trials. Finally, the relationship of disease progression to
measures of clinical benefit, such as survival or quality of life, is poorly defined in many disease settings [14].
We believe that phase II assessment of cytostatic agents should be based on randomized and controlled trials, and
have previously suggested that the most natural endpoint to assess the activity of an agent is the rate of progression of
disease. Here we focus on issues in trial design with time to progression endpoints in phase II and suggest methods to
control for bias that will optimize decision-making at the end of phase II development.
There are a variety of terms, variably defined, which are used to capture the notion of progression, such as
progression-free survival, time to progression, and time to treatment failure. Here we will use the term ‘progression-free
survival’ and we will assume patients who die in the absence of progression will be included in the analysis as having
an event at the time of death.
2. Trial design and analysis
2.1. Study endpoints — fixed early timepoint analyses?
This section will compare the sensitivity of two endpoints that measure the rate of disease progression:
• Progression-free survival (PFS), where the earlier of the ‘time to death’ and ‘observed time to progression’ is
analyzed.
• Progressive disease (PD) rate, where we analyze the proportion of patients who have progressed before a fixed
timepoint.
Eisenhauer [15] has proposed using the PD rate, specifically at 8 weeks, as a rapid measure of assessing the
effectiveness of a new therapy. This is based on an observed association between the rate of progression at 8 weeks and
survival in a series of trials conducted at the National Cancer Institute of Canada (NCIC). In these trials, the survival of
patients whose best response at 8 weeks was partial response or stable disease was similar to each other, but in marked
contrast to those whose best response was PD. This led the authors to consider whether the rate of PD could be used in
conjunction with the response rate to determine whether a new agent was active. Can a PD rate at 8 weeks therefore be
considered the endpoint of choice in a randomized setting, particularly as patients would only need to be followed for
8 weeks? This would be a very attractive approach to early drug development.
When evaluating such an approach it should be recognized that the power of any statistical analysis depends on the
number of events observed and not the number of patients recruited [12,13]. Therefore a PD rate endpoint is statistically
inefficient as it does not incorporate data from patients who progress after 8 weeks. With staggered recruitment, there will
always be many observed progression events excluded from the analysis if a PD rate endpoint is used.
In general and assuming proportional hazards, the correspondence between the PD rate and hazard ratio (HR) is
described using the following relationship:
HR ¼ logð1−PD0ðtÞÞ=logð1−PD1ðtÞÞ
PD0(t), proportion of patients progressing at time t for the new agent; PD1(t), proportion of patients progressing at
time t for the control; HR = hazard ratio (new:control) [13].
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Using this relationship, it is easy to quantify the number of patients required to detect a common treatment effect
dependent on endpoint using standard sample size calculations for time to event and proportions [12,16]. Examples are
displayed in Table 1, where each row is an identical test of treatment effect measured by a common HR of 0.67. It is
assumed that a convenient timepoint is chosen where the expected control PD rate is 10, 20, 30 or 50%. Therefore, the
results are independent of the rate of progression and hence the timepoint chosen for PD rate comparison. Data in Table
1 show that PFS is a far more sensitive endpoint to treatment effects than an early PD rate. With the assumptions
described, a trial sized on a 50% difference in medians would require 100 patients when using PFS, and 11 months
would elapse before the required number of events had occurred. In contrast, if treatment arms were compared using
the PD rate at the timepoint where it was anticipated 20% of the control group would have progressed, over 400 patients
would need to be recruited to detect the same treatment effect. Furthermore, given the same rate of recruitment, the trial
would take 11 months longer.
Any perceived benefit in speed using a PD rate endpoint (or early fixed timepoint analysis), is negated by the need to
recruit larger numbers of patients to maintain sensitivity. The greatest source of the extra sensitivity with a PFS
endpoint is the inclusion of all available progression events and not the use of the time of the event [9]. We therefore
recommend the use of a PFS endpoint that utilizes all available data. Examples of such endpoints are presented in the
next section.
2.2. Differential follow-up
As patient progression is assessed at study visits only, the exact timing is never documented and an estimate of the
size of the true therapeutic benefit can be subject to bias. Here we present alternative analyses, event counts and
grouped survival methods, which can minimize or remove time assessment bias.
Williams et al. [8] have demonstrated that if there is an asymmetric visit schedules between treatment arms, bias in
the underlying assessment of time to progression can occur if data are analyzed using the log–rank test or Cox
proportional hazard model. Even if by design, visit schedules are identical between treatment arms, there is still a
concern regarding bias if there is a tendency for investigators to look earlier, or more frequently, in one treatment group.
This may be of particular concern if the trial is not blinded, or if one of the treatment groups has a prevalent and
distinctive side effect. For example, in the absence of an effect on progression, if patients in one treatment arm present
more frequently on the basis of symptoms there is the opportunity to assess the progression status in that treatment arm
sooner and hence increase the chance of falsely revealing a treatment effect.
Instead of using a log–rank test, an alternative approach would be to ignore time altogether and compare a count of
the number of progression events (including deaths in the absence of progression). Unlike in a fixed timepoint analysis,
events would be counted regardless of how long after randomization they occurred. The only stipulation required for
the timing of assessments would be that all non-progressing should be assessed within a time-window at the end of
follow-up. Results can be approximated to HRs by using a binary analysis with a complementary log–log link [17]. As
long as the number of non-progressing patients completing the end of follow-up assessment was comparable between
arms, this method would minimize any potential for time assessment bias.
A number of authors have noted that a comparison of event counts results in a relatively small reduction in power
compared with a traditional time to event analysis [9–11]. In cases where only a small proportion of patients have
Table 1
Number of patients and duration of trial to detect a hazard ratio of 0.67 with 80% power and a one-sided significance level of 20%
Endpointa No. of patientsb Durationc (months)
PFS 100d 11
PD rate 10% vs. 6.8% 852 43
PD rate 20% vs. 13.8% 414 22
PD rate 30% vs. 21.2% 278 16
PD rate 50% vs. 37.0% 164 12
a For PD rate — comparison that results in a hazard ratio of 0.67.
b Total number of patients for a two-arm trial.
c Assumes patients are recruited uniformly at 20/month; events follow an exponential distribution with medians of 4 and 6 months, respectively.
d Sixty-nine events are required, a greater number of patients would reduce the duration for this endpoint.
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progressed, such as in an early disease setting, event count and time to event analyses are virtually indistinguishable in
terms of power. In situations normally encountered in an advanced setting, as long as the data are analyzed when the
proportion of patients with an event is not too large, for example 75% or less, sample size is increased by less than 25%
when using an event count [10].
Another alternative would be to use a grouped survival method, which categorizes the events according to the period
in which the events are known to occur [17,18]. For example, if patients are scheduled to be assessed for disease
progression every 8 weeks, time periods of 0–8 weeks, 8–16 weeks, 16–24 weeks, etc. are created. Progression events
are then assigned to the period in which they occurred and for non-progressing patients, data are censored in the period
in which the latest scan was performed. The proportion of patients progressing within each period is then compared
between each treatment arm and the results combined across all of the periods and expressed as a HR. For example, if a
patient presented with symptoms at 12 weeks and was found to have progressed, their event would be assigned to the
same period (8–16 weeks) as an event observed at 16 weeks from a patient who had adhered to the protocol. This is in
contrast to using a classical time to event assessment, which would differentiate between these patients (the times to
event being 12 and 16 weeks, respectively) when in fact we cannot determine who progressed first.
Differential schedule frequencies, and hence visit frequencies, would not present a problem to either analysis
method. For example, if a 2-weekly schedule is compared with a 3-weekly schedule, to prevent any bias, progression
assessments could be made every 6 weeks.
Given concerns regarding time assessment bias, alternative design and analysis strategies should be considered
when evaluating, in randomized phase II trials, whether new agents alter the rate of progression of disease. The loss in
power or increase in sample size may be considered small in comparison to the extra reassurance given to the end of
phase II development decision.
2.3. Assessment frequency
The belief that it is necessary to scan patients as frequently as practically possible to optimize the comparison of the
rate of progression is widely held. We have addressed this question by simulation and considering both a Cox
proportional hazards model and the grouped survival method proposed earlier (Table 2).
For the Cox proportional hazards model, there is only a marginal loss of power (<3%) when assessments are made at
a frequency that is half the control median. Less frequent assessments are, however, associated with a greater loss of
power. Similar results have been described by others, the extent of the effect on power being affected by the proportion
of patients censored [19]. In contrast, for the grouped survival method there is no appreciable deterioration of power as
the frequency of assessments and hence the number of periods reduces. However, given the results in the previous
section, if data were analyzed after a high proportion (>75%) of patients had progressed then we would also expect the
power of this method to reduce with frequency.
Also shown in Table 2 is the time taken for the required number of events to be observed. Not surprisingly, when
patients are being assessed less frequently a greater time elapses before the progression information becomes available.
Only when there is very infrequent assessment, approaching the median event times, would these adversely effect the
duration of the trial.
A number of conclusions can be drawn concerning an optimum assessment frequency. First, there are other
considerations apart from statistical efficiency. When patients are being treated outside of a clinical trial, they would not
remain on treatment indefinitely without monitoring whether their disease had progressed. Therefore, there will be a
minimum frequency at which it would be acceptable to assess disease status. However, these results do show that
assessing patients in the context of a clinical trial more frequently, adds only burden with little gain in sensitivity.
2.4. Informed censoring
Censored data arises when the event of interest has not been observed (i.e. progression or death) at the time of
analysis. Censored data should be considered as missing data and therefore we should always consider carefully the
potential for resultant bias and take steps to minimize this potential; just because censoring is permitted by analysis
techniques it does not mean reliable analyses necessarily follow. For example, observation may stop because the patient
is considered to be progressing symptomatically and their tumor dimensions are getting close, but not quite achieving
protocol-defined criteria. Survival analysis methods assume that such a patient is no closer to protocol-defined
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progression than patients who have not progressed. This assumption would clearly not hold and is termed informative
censoring. In this example, if censoring occurs more frequently in one arm than another then bias will result as the
number of events will be differentially undercounted in one treatment arm.
If these issues are problematic what alternatives do we have? We could create a treatment failure endpoint where
withdrawal of therapy in the absence of progression is also counted as an event. This would remove the need to censor
but would be at the expense of creating a more subjective endpoint that is further removed from eventual approval
endpoints used in phase III trials. A second alternative would be to impute a date of progression on the basis of the
serial tumor measurements already observed. This analysis would, however, require a whole new set of assumptions to
be made instead. The best solution is to continue to follow up as many patients as possible until they achieve protocol-
defined criteria for progression [20]. This would mean that regardless of whether patients have withdrawn from
randomized therapy or taken other therapy prior to progression, they should continue to be assessed until they meet the
protocolled definition of progression. In cases where patients take another cancer therapy prior to progression, there is
the possibility that this therapy could influence the outcome, particularly if it is administered more frequently in one
treatment arm and is efficacious. However, only by collecting data up to the point of progression can we hope to tease
out the potential biases at play. This approach is consistent with an intention-to-treat philosophy that attempts to
address the effect of a new therapy when it is introduced into clinical practice. The need to obtain complete follow-up
should be stressed to investigators at trial initiation, as only with the actual dates of progression can we hope to assess
what impact intervening events have had on the outcome of the trial.
3. Discussion
We previously have argued, with others, that the phase II assessment of cytostatic agents should be based on
randomized and controlled trials [2–4]. Herewe propose that themost natural endpoint to assess the activity of these agents
is the rate of disease progression. We have compared the statistical efficiency of this endpoint to an early fixed timepoint
analysis. Despite the apparent attractiveness of an early timepoint analysis, we found that a classic PFS endpoint will
always be more sensitive and often substantially so. The intuitive explanation is that as the number of progression events
drives the power of any analysis, an early timepoint analysis will always result in relevant information being excluded.
Table 2
Simulated power for a trial designed to have 80% power to detect a hazard ratio of 0.67 at a one-sided significance level of 20%, for various scanning
frequencies
Visit
frequency
Cox proportional hazards Grouped analysis
Powera Hazard ratiob Follow-upc (weeks) Powera Hazard ratiob Follow-upc (weeks)
a) Comparison of treatments with medians of 4 and 6 months
Constant 79.8% 0.67 50 NA NA NA
2 weeks 79.6% 0.67 51 79.9% 0.66 51
1 month 79.0% 0.67 52 79.8% 0.66 52
2 months 78.1% 0.67 54 80.1% 0.66 54
4 months 74.5% 0.69 59 79.4% 0.66 59
b) Comparison of treatments with medians of 8 and 12 months
Constant 79.6% 0.67 86 NA NA NA
2 weeks 79.6% 0.67 87 80.0% 0.66 86
1 month 79.2% 0.67 88 80.0% 0.66 87
2 months 78.8% 0.67 91 80.0% 0.66 90
4 months 77.5% 0.68 95 79.7% 0.66 94
6 months 76.0% 0.69 100 79.6% 0.66 98
8 months 73.4% 0.70 104 79.5% 0.66 103
Each row is the result of 5000 simulations, each with 50 observations per treatment arm and waiting for 69 events to occur, assuming an exponential
distribution with the stated medians.
NA, not applicable.
a Proportion of simulations with a one-sided p-value <0.2 in favor of the more effective therapy.
b Calculated as the geometric mean of the hazard ratios estimated from each dataset.
c Calculated as the time from start of recruitment to the 69th event observed, patients recruited over 26 weeks.
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Randomization alone is not sufficient to obtain an estimate of the treatment effect free from bias. Other authors have
highlighted deficiencies and potential pitfalls in the use of PFS as an endpoint due to the imprecise nature of
documentation and the potential for differential follow-up [8,14]. If there is potential to scan one treatment arm more
frequently than another due to the differential presence of signs and symptoms, we have recommended alternative
analyses that either group or count events. The event count analysis should be distinguished from a fixed timepoint
analysis as all events are included regardless of how long an individual patient has been in the trial. Which of these
alternatives should be preferred? Compared to an event count analysis, the grouped survival method has the advantage
of fully maintaining power and describing the treatment effect over the whole period of follow-up and not just at the
end of follow-up. Its drawback is the need for investigators still to follow a protocolled schedule. If this schedule is not
followed, its application will be complicated by decisions regarding the handling of missing assessments and bias,
although reduced, may still persist. The advantage of an event count lies in its simplicity, as the only constraint is that
non-progressing patients are assessed at the end of follow-up. Careful planning would be required to prevent the
possibility that either the treatment arms were compared when nearly all patients had progressed or when so few
patients had progressed that the trial was greatly underpowered.
We recognize neither the grouped survival method or event count represent the standard approach to the analysis of
time-to-event data. However, grouped methods have been available for some time [17] and the event count has been the
subject of recent debate. The use of PFS and the consequences for design and analysis have been the subject of
regulatory debate at recent open discussions initiated by the U.S. Food and Drug Administration (FDA) [21] and in a
Draft Guidance for Industry on Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics [22]. The
event count has been presented as an alternative by Carroll [23] who demonstrated the high concordance in results
obtained using an event count analysis and a log–rank test in a large randomized controlled trial. Further, such an
approach, in this case referred to as a single timepoint assessment, is discussed as a possible future method in the recent
draft FDA guidance. This approach is also being prospectively applied in the design of recently initiated phase II trials
sponsored by AstraZeneca. A more detailed assessment of the event count analysis will be presented in a separate
paper. We believe, either of the analyses presented has the potential to minimize, and possibly remove, any bias and
should give extra reassurance to the end of phase II development decision.
We have also presented results showing the minimal gain in statistical sensitivity by scanning patients more
frequently, and therefore recommend that protocols do not place an undue burden in terms of assessment frequency,
especially as this increases the likelihood of poor protocol compliance and the resultant problems in analysis
interpretation. Finally, we re-affirmed as with any phase III survival trial, one should continue to assess all patients until
they have the event of interest regardless of intervening events.
There are also more radical alternatives to the analysis of data that we have not discussed, which might be valuable
in a phase II setting. In our analysis we reduce tumor volume data, recorded on a continuous scale and on multiple
occasions, into a binary assessment of whether or not the patient progressed. This can be regarded as statistically
wasteful as there exist more powerful statistical techniques that could utilize the continuous nature of the data recorded
and assess the relative rates of the increase in tumor burden. This should be the subject of further research as it has the
potential to enable the same questions to be answered with fewer patients.
Another advantage of a randomized phase II trial is that an initial assessment can be made of the impact of the new
therapy on survival. This would require prolonged follow-up of the trial after the progression data are available but may
allow the trial to act as a supportive trial to any subsequent pivotal trial and may prove helpful in the end of phase II
development decision if the progression data are equivocal.
4. Recommendations
The following recommendations are proposed:
• A PFS endpoint that incorporates all available progression data is preferred to an early fixed timepoint analysis.
• In order to minimize any potential bias in the estimate of the treatment effect, trials should be double-blind where
possible and the primary analysis technique should either be a grouped survival method or a comparison of the count
of progression events.
• All patients should be assessed until progression, regardless of intervening events.
• Protocols should not impose an undue assessment frequency in the false belief that this will improve sensitivity.
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With the advent of ever more effective second and third line cancer treatments and the growing use of
‘crossover’ trial designs in oncology, in which patients switch to the alternate randomized treatment
upon disease progression, progression-free survival (PFS) is an increasingly important endpoint in
oncologic drug development. However, several concerns exist regarding the use of PFS as a basis to
compare treatments. Unlike survival, the exact time of progression is unknown, so progression times
might be over-estimated and, consequently, bias may be introduced when comparing treatments.
Further, it is not uncommon for randomized therapy to be stopped prior to progression being
documented due to toxicity or the initiation of additional anti-cancer therapy; in such cases patients
are frequently not followed further for progression and, consequently, are right-censored in the
analysis. This article reviews these issues and concludes that concerns relating to the exact timing of
progression are generally overstated, with analysis techniques and simple alternative endpoints
available to either remove bias entirely or at least provide reassurance via supportive analyses that
bias is not present. Further, it is concluded that the regularly recommended manoeuvre to censor PFS
time at dropout due to toxicity or upon the initiation of additional anti-cancer therapy is likely
to favour the more toxic, less efficacious treatment and so should be avoided whenever possible.
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advent of a new generation of biologically
targeted cytostatic anti-cancer agents, drug
developers and researchers can no longer
rely on uncontrolled phase II trials and response
rate to screen new medicines for clinical utility
[1–3]. For drugs designed to stabilize disease,
the most sensible phase II approach has
been argued to be randomized trials with PFS
as the primary endpoint [4,5]. Further, with
the advent of ever more effective second and
third line cancer treatments and the growing
use of ‘crossover’ designs, in which patients
switch to the alternate randomized treatment
upon disease progression, detecting an improve-
ment in survival in confirmatory phase III
trials has been recognized as an increasingly
difficult goal [6–8]. The recently issued
EMEA anti-cancer guideline acknowledges these
issues and states that either survival or PFS
can be used as a primary endpoint in pivotal
trials seeking approval for a new drug; when
PFS is used and justified as the primary
endpoint, survival should be a stated secondary
endpoint with follow-up sufficient ‘to ensure
that there are no relevant negative effects
on this [survival] endpoint’ [9]. In light of the
issues, there has recently been a number of open
discussions initiated by the US Food and
Drug Administration (FDA) to examine the
utility of progression and other measures as
endpoints for oncologic drug approval [6–8,10].
In particular, at the Oncologic Drugs Advisory
Committee (ODAC) discussion in December 2003
on approval endpoints in non-small cell lung
cancer, the vote was 18 ‘yes’, 0 ‘no’ and 1
abstention for the use of PFS as an endpoint to
support accelerated approval in the advanced
disease setting [6]. Similarly, at the ODAC
discussion in May 2004 on approval endpoints in
colorectal cancer, the vote was 8 ‘yes’, 5 ‘no’ for
the use of PFS as an endpoint to support full
approval in the advanced setting [8]. More
recently, PFS has been used as the sole basis to
provide full drug approval for sorafenib in the
treatment of advanced renal cell carcinoma and
panitumumab in the treatment of advanced color-
ectal cancer [11,12].
However, despite such support for the use of
PFS as a primary endpoint to support drug
approval, key concerns remain regarding the use
of PFS to compare treatments for relative effec-
tiveness:
(i) Unlike survival, the exact timing of
progression is unknown. Discrete clinic visit
schedules for disease assessment means that
progressions that occur in between visits are
commonly assigned to the visit at which progres-
sion was detected, leading to over-estimation of
the time to progression [13]. Consequently bias
may be introduced in the comparison of treat-
ments as was suggested in the FDA’s review of
oblimersen sodium [14]. This concern has led to a
consensus emerging that clinic visits need to be
frequent and identically scheduled between treat-
ments to ensure an accurate determination of the
time of progression and a fair comparison of
treatments.
(ii) It is not uncommon for randomized
therapy to stop (say, due to toxicity) or for
additional anti-cancer therapies to be initiated
prior to progression being documented. Handling
of such patients in the analysis is problematic;
recent FDA draft guidelines have suggested that
progression time should be censored at the time of
the intermediate event [15]. However, this view
does not appear to be entirely shared by EU
regulatory authorites based on the recently issued
appendix to the CHMP’s anti-cancer guideline
[9,16].
This paper discusses these issues, their practical
implications and importance when comparing
treatments, and explores if there are ways in which
they might be addressed or ameliorated. The
remainder of the paper is therefore structured as
follows: Section 2 describes a typical oncology trial
design with PFS as the primary endpoint. Section 3
examines the practice of assigning the time of
progression to the visit at which it was detected
and Section 4 examines censoring PFS time on
drop-out due to toxicity or the initiation of
additional anti-cancer therapy. Section 5 then
closes the paper with recommendations for trial
design and analysis and a brief discussion of some
other, key issues.
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TYPICAL ONCOLOGY TRIAL
DESIGN
Suppose two treatments, experimental (E) and
control (C), are to be compared in terms of PFS
time in a clinical trial powered to detect an
underlying hazard ratio, E:C, of size y, with a
1-sided Type I error rate of a and power 1ÿb so
that a total of d events are required [17]. Assuming
event rates of lE and lC, uniform accrual over a
period of R months and a minimum follow-up
period of F months (giving a maximum follow-up
of R+F months, which is hereafter referred to as
the ‘trial follow-up period’), a total of 2N patients
are to be randomized on a 1:1 basis [18–20].
Assume also that disease status is assessed at
regular, scheduled clinic visits, every V months,
say. For simplicity, further assume that V is
chosen such that R
V
and F
V
are both integer so
that F
V
is the minimum and RþF
V
the maximum
number of scheduled assessments per patient and a
clinic visit always takes place at the end of the trial
follow-up period.
In advanced disease, PFS time is defined as the
interval from randomization to the first of either
disease progression or death from any cause. The
equivalent measure in adjuvant settings is disease-
free survival (DFS), being the interval from
randomization to the first of either disease recur-
rence or death from any cause. The discussion that
follows is framed in terms of PFS but can equally
be applied to DFS. Since disease is normally
assessed at regular, scheduled clinic visits, the exact
time of progression is typically unknown. The time
of progression is therefore usually assigned to the
date of the clinic visit at which it is detected.
Patients who are lost to follow-up prior to
progression or who reach the end of the trial
follow-up period without progression are right
censored in the analysis. Patients may also stop
randomized therapy during the trial follow-up
period prior to reaching a confirmed progression
event due toxicity or the addition of further anti-
cancer therapy. Such patients are commonly not
followed further for progression status, being
censored at the time of the event associated with
the cessation of randomized therapy.
THE IMPACT OF NOT KNOWING
THE EXACT TIMING OF
PROGRESSION
When the time of progression is assigned to the
visit at which progression was first detected, the
extent to which bias is introduced can be gauged
directly for exponentially distributed lifetimes
using maximum likelihood methods (see Appendix
A). If Ti denotes the observed PFS time, event or
censored, for the ith patient then
T ¼
PN
i¼1 Ti
d
¼
1
observed event rate
is approximately
N
V
1ÿ eÿlV
;
V2eÿlV
d 1ÿ eÿlVð Þ
2
 !
or, more conveniently,
ln T
 
 N ln
V
1ÿ eÿlV
 
;
eÿlV
d
 
If comparing E to C, then the observed hazard
ratio
#y ¼
observed event rateE
observed event rateC
¼
TC
TE
ð1Þ
is a biased estimate since
E½#y ¼
VC 1ÿ e
ÿlEVE
ÿ 
VE 1ÿ eÿlCVCð Þ
6¼
lE
lC
ð2Þ
Note that bias is introduced even if visits are
scheduled symmetrically between treatments
(VE=VC) and, as one would expect, the degree
of bias depends upon the ratio of the interval
between visits and the expected PFS time
(that is on lEVE and lCVC). The bias in the
hazard ratio erodes the power of the standard log
rank test to
fÿ1 za þ zb
ÿ 
oÿ za
 
ð3Þ
where o ¼ abs
ÿ
lnð#yÞ
ln yð Þ

and fÿ1(.) is the inverse of
the cumulative normal distribution; to restore
power, the target number of events would have
to increase to
d 0 ¼
d
o2
ð4Þ
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(see Appendix B). Table I illustrates the degree of
bias that can be introduced by assigning progres-
sion time to the clinic visit at which it was detected
and the consequences on power.
Table I shows that as the interval between visits
lengthens and the number of clinic visits declines,
then the hazard ratio is increasingly biased toward
the null. Consequently, power falls and, in the
examples given, the number of events required to
maintain 90% power increases by between 7% and
16% even when visits are as frequent as every
month.
Assuming a common visit schedule between treat-
ments, it is of interest to note that to ensure retention
of at least 100(1ÿg)% power g>b, visits must be
scheduled approximately every V 0 months where
V 0 ¼ ðmedian PFS on CÞ 
2
lnð2Þ
1
y
yk ÿ y
1ÿ yk
 !
ð5Þ
and k ¼ abs
ÿ zaþzg
zaþzb

. This result follows since
V
1ÿeÿlV
 1
l
þ V
2
for small lV so that #yyð1þtÞ
1þty
,
where t¼VlC
2
(see Appendix B). Table II provides
V 0 for varying y and median PFS values.
Table II suggests that, for hazard ratios between
0.80 and 0.667, the interval between visits can
afford to be no more than about 1
2
the median PFS
time on control to ensure power does not fall
below 80%. With a larger hazard ratio of 0.50, the
interval between visits can be longer, up to
approximately 2
3
the median PFS time on control.
The Type I error is not inflated providing the
scheduling of visits is the same on E and C.
However, Table III illustrates the degree to which
the Type I error can be increased when clinic visits
are asymmetric between treatments.
While it is unlikely that clinic visits would
intentionally be scheduled asymmetrically, Table III
serves to illustrate the importance in practice of
closely matching visit schedules when performing
routine log rank analyses of PFS time.
Possible design and analysis strategies when the
exact timing of progression is unknown and assigned
to the clinic visit at which it was detected
When assigning the time of progression to the visit
at which it is detected, bias is introduced and
Table I. Bias and loss of power associated with assigning time of progression to the scheduled clinic visit at which it was
detected.
Hazard
ratio, y
Median PFS
on E
(months)
Median PFS
on C
(months)
Interval between
clinic visits,
V, (months)
Expected
HRa, #y
Log rank
powerb (%)
Relative increase
in d to compensate
for loss in powerc
0.667 6 4 0.5 0.677 87.8 1.07
1 0.686 85.4 1.16
2 0.705 80.0 1.34
4 0.740 67.2 1.81
0.75 8 6 0.5 0.755 88.5 1.05
1 0.761 86.9 1.11
2 0.771 83.3 1.23
4 0.792 75.0 1.51
0.80 12 9.6 0.5 0.803 89.1 1.03
1 0.806 88.1 1.07
2 0.811 85.9 1.14
4 0.822 81.1 1.30
aHR = hazard ratio via equation (2).
bLog rank power via equation (3); assuming trial originally powered at 90% (b=0.1), 2.5% 1-sided a level to detect a HR size y.
cVia equation (4).
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power is decreased. Some options to address this
problem are as follows:
(i) Do nothing. If clinic visits are scheduled
symmetrically between treatments, ensure they
occur at least every V 0 months as per equation
(5) and accept some loss in power. This is the
approach most commonly taken in the analysis of
PFS times. Some other approaches that might be
adopted are given below.
(ii) Increase the target number of events to
d 0 ¼ d
o2
. Note that since PFS is a mixture of
assumed progression times and known times to
death, this increase will be somewhat conservative.
(iii) Since #y is known to be biased, use rather
&y ¼
ln 1ÿ V
TE
 
ln 1ÿ V
TC
  ð6Þ
as the asymptotically unbiased maximum like-
lihood estimate of the hazard ratio with estimated
variance
#Var½lnð&yÞ¼
V2
dET
2
E ln 1ÿ
V
TE
 n o2
1ÿ V
TE
 
þ
V2
dCT
2
C ln 1ÿ
V
TC
 n o2
1ÿ V
TC
  ð7Þ
(see Appendix A). The lack of bias in this estimate
is illustrated by simulation in Table IV.
This approach represents an interval-censored
analysis as described by Stone et al. [21] and
Whitehead [22]. Note that, with SE &y being close
to that expected from a log rank analysis of actual
PFS times
ﬃﬃﬃﬃﬃ
4
200
q
¼ 0:1414
 
; this approach re-
quires little if any increase in trial size. It is also
important to note that both &y and SE &y vary
little as V increases. This suggests, contrary to
common belief, there is little to be gained by the
imposition of very frequent clinic visits – when
data are analysed on an interval-censored
basis, frequent visit scheduling is unnecessary
and would serve only to impose an unnecessary
burden on patients and investigators alike. Note
that while simulations in Table IV are based on
exponentially distributed PFS times, distribution-
free interval-censored analyses are possible via
PROC LIFETEST in SAS [23] and Prentice and
Gloeckler provide a method for interval-censored
analyses via Cox regression [24]; both approaches
require a common visit schedule between treat-
ments.
(iv) If, despite protocol intent, clinic visits are
not executed exactly as planned leading to variable
spacing between visits and asymmetry in schedules
between treatments, PROC LIFEREG can be
used to estimate event rates on E and C assuming
exponentially distributed PFS times (and alter-
native distributions), and thus provides an un-
biased comparison of treatments. In practice, PFS
times will not always follow an exponential
distribution making interval-censored analyses in
these circumstances difficult. However, Sun et al.
give a generalized formulation of the log rank test
applicable to interval-censored data that provides
a score statistic to test equality of survival
Table II. Maximum inter-visit interval length to main-
tain at least 80% powera for varying y and median PFS
values.
Hazard
ratio, y
2
lnð2Þ
1
y
yk ÿ y
1ÿ yk
 !
Median
PFS on
C (months)
Visits
at least
every V 0
months
0.8 0.5058 4 2.0
6 3.0
9 4.6
12 6.1
0.75 0.5219 4 2.1
6 3.1
9 4.7
12 6.3
0.667 0.5520 4 2.2
6 3.3
9 5.0
12 6.6
0.50 0.6315 4 2.5
6 3.8
9 5.7
12 7.6
aAssuming trial originally powered at 90% (b=0.1), 2.5%
1-sided a level to detect a HR size y.
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Table IV. Hazard ratio estimates resulting from 1000 simulations of a trial with 200 patients (100 per arm) in which all
patients achieve an event.
Hazard
Ratio, y
Median PFS
on E (months)
Median PFS
on C (months)
Interval between clinic
visits, V, (months)
Expected
value of #ya
#yb &yc SE ln &y
ÿ 
d
0.667 6 4 0.5 0.677 0.679 0.672 0.1438
1 0.686 0.681 0.669 0.1418
2 0.705 0.690 0.664 0.1388
4 0.740 0.718 0.668 0.1428
0.75 8 6 0.5 0.755 0.751 0.746 0.1483
1 0.761 0.759 0.750 0.1438
2 0.771 0.764 0.748 0.1376
4 0.792 0.782 0.751 0.1433
0.80 12 9.6 0.5 0.803 0.804 0.802 0.1425
1 0.806 0.808 0.803 0.1440
2 0.811 0.811 0.802 0.1377
4 0.822 0.817 0.799 0.1474
aExpected value of #y via equation (2) to illustrate the closeness of the simulation to the theoretical result.
b #y=geometric mean of 1000 hazard ratios based on analysis of PFS time where timing of progression is assigned to the visit at which is
was detected.
c &y=geometric mean of 1000 simulated hazard ratios based on equation (6).
dSE &y = standard deviation 1000 simulated hazard ratios based on equation (6).
Table III. Inflation in Type I error resulting from asymmetric visit scheduling in a trial with 508 events (sized to detect
an assumed hazard ratio of 0.75, 90% power, 2.5% 1 sided a).
Median PFS
on E and
C (HR=1)
Interval between
visits on C (months)
Interval between
visits on E (months)
Expected
HRa, #y
Type I errorb
(1-sided)
4 0.5 1 0.959 0.069
1 2 0.920 0.152
6 1 1.5 0.972 0.050
1 2 0.945 0.092
2 3 0.946 0.090
9 1 1.5 0.981 0.040
2 3 0.963 0.062
3 4 0.964 0.061
12 1 2 0.973 0.050
2 3 0.972 0.050
3 4 0.972 0.050
4 6 0.946 0.090
aHR=hazard ratio via equation (2).
bType I error = fÿ1 ÿ1:96ÿ
ln #y
 
ﬃﬃﬃﬃﬃ
4
508
q
2
64
3
75.
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distributions [25]. While there is no means
given for estimating an overall treatment effect
such as the hazard ratio, at least a p-value can be
obtained to assess the strength of evidence against
the null.
(v) As an alternative to the analysis of PFS
time, treatments could be compared on the
basis of the overall number of PFS events
occurring at any time during the trial follow-up
period thus circumventing issues associated
with the over-estimation of PFS time,
scheduling of visits and any asymmetry between
treatments.
Under proportionality, an analysis with a
complementary log-log link function [21,24,26,27]
would provide an unbiased estimate of the hazard
ratio as
*y ¼
lnð1ÿ pEÞ
lnð1ÿ pCÞ
ð8Þ
where pE and pC are the proportions of patients
with a PFS event on treatment E and C. The
estimated variance of ln *y by Taylor series
expansion is
#Var½ln ð*yÞ ¼
pE
Nð1ÿ pEÞ lnð1ÿ pEÞf g
2
þ
pC
Nð1ÿ pCÞ lnð1ÿ pCÞf g
2
ð9Þ
It is interesting to note that *y and #Var½ln ð*yÞ
coincide with *y and #Var½lnð*yÞ when V=R+F,
that is, when there is just one assessment of
progression coinciding with the end of the trial
period.
Further, by noting that SC(t)
y= SE(t) where y is
the true hazard ratio and, with no censoring, that
SE(R+F)=pE and SC(R+F) = pC so that *y ¼ y
and the number of events expected on E and C are
N[SE(R+F)] and N[SC(R+F)] = NpE and NpC, it
is possible to compare the power of the log rank
test on exact PFS times with the power of an
analysis with a complementary log–log link based
only on the total number of events occurring over
the trial follow-up period. Under these circum-
stances, the relative efficiency of the two tests is
given by
1
NpE
þ 1
NpC
Var ½ln ð*yÞ
¼
1
pE
þ
1
pC
 

pE
ð1ÿ pEÞ lnð1ÿ pEÞf g
2

þ
pC
ð1ÿpCÞ lnð1ÿpCÞf g
2
ÿ1
Assuming 90% power in the log rank test, Figure 1
plots the relative efficiency for values of SC(t) from
0.05 to 0.95.
In line with work earlier work, Figure 1
indicates that, under proportionality, a compar-
ison on the overall number of PFS events over the
follow-up period is associated with little loss of
power relative to the log rank test on exact PFS
times providing fewer than around 50% of
patients have reached an event [28,29]. If fewer
than 75% of patients have reach an event, the loss
in power is, at most, 5%. It is not until 90% or
more have reached an event that the power of the
relative risk test dips below 80% to around 77%.
For exponentially distributed times to event, since
the probability of an event over the trial follow-up
period  1ÿeÿl(0.5R+F), fewer than 75% events
will in general be assured if the median follow-up
at the time of the analysis is not more than two
times the median PFS time [20].
This suggests that in those trial settings where
progression of disease is the primary focus but
significant concerns persist regarding the assumed
time of progression, a supportive analysis based on
the number of patients with a PFS event over the
trial follow-up period can provide reassurance.
This analysis is unbiased under proportionality
and suffers relatively little loss of power under
common trial circumstances. It also offers the
opportunity to simplify clinical trial design. It
might be possible, for example, to envisage a trial
where progression is assessed as per clinical
practice with a requirement for objective verifica-
tion of any suspected disease progression. At a
minimum and in addition to the baseline assess-
ment of disease, a single mandatory assessment at
the end of the trial follow-up period would be
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required in patients who had not previously
progressed in order to catch any missed progres-
sions. PFS events would then be counted over the
trial follow-up period and treatments compared
via an analysis with a complementary log-log link
function.
CENSORING ON DROPOUT DUE TO
AE OR ADDITIONAL ANTI-CANCER
THERAPY
FDA’s recent Draft Guidance for Industry on
Clinical Trial Endpoints for the Approval of
Cancer Drugs and Biologics recommends that
patients who stop taking randomized therapy
prior to documented progression are censored at
the time randomized treatment is stopped [15]. The
rationale for this recommendation is not provided
explicitly, but seems to be related to a concern that
PFS times may be over-estimated otherwise.
Patients who die in the absence of documented
progression remain an event, irrespective of
whether the death occurred whilst the patient
was still receiving or some time after stopping
randomized therapy.
This approach is, unfortunately, highly proble-
matic since it ignores the issue of informative
censoring. Patients who stop taking randomized
therapy prior to documented progression fre-
quently do so due to either toxicity of the drug
or due to a deterioration in the status of their
disease. In such cases, the treating physician often
judges that immediate intervention, commonly in
terms of the introduction of a new cancer
treatment, is in the best interests of the patient
without necessarily waiting for confirmatory,
radiographic evidence of progressive disease.
Time to progression therefore cannot be cen-
sored in the analysis as the censoring mechanism is
self evidently informative. In such circumstances,
if the prevalence of censoring differs between arms,
naive censoring could lead to extremely biased
results and, ultimately, incorrect licensing deci-
sions [30]. Figure 2 provides a simple illustration
of the problem.
Suppose E is compared to C in a trial of 100
patients, 50 per arm. Suppose on C that 25
patients progress whilst taking drug at a mean
100%
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Figure 1. Power of a comparison based on the number of patients with a PFS event over the trial period relative to the
log rank test on PFS time with 90% power.
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time of 5 months and the other 25 patients receive
additional anti-cancer treatment prior to docu-
mented progression at a mean time of 3 months.
Suppose on E that all 50 patients progress at a
mean time of 6 months; no patients received
additional anti-cancer treatment. It is obvious that
E is the better treatment, with a longer time to
progression and no need for additional anti-cancer
treatment. However, suppose now that the data
are subject to formal statistical analysis with the 25
patients on C who received additional anti-cancer
treatment censored for progression. The progres-
sion event rate on drug C is therefore 1
8
progres-
sions per patient per month compared to 1
6
progressions per patient per month on drug E,
giving mean PFS times of 8 and 6 months for C
and E, respectively, and a hazard ratio of 1.33,
leading to a conclusion that, in fact, drug C is
better than E. Clearly, there is a problem with a
recommended statistical analysis when it leads to a
conclusion that the less efficacious and more toxic
treatment is better. If, however, those on C who
received additional anti-cancer therapy are treated
rather as failures as in Figure 3, a more sensible
conclusion is reached that E is in fact better than C.
Hence, recommendations to censor patients who
stop taking randomized treatment prior to docu-
mented progression, perhaps due to the use of
additional anti-cancer therapy owing to a dete-
rioration in their condition or due to toxicity, are
inherently flawed and should be avoided. This
practice, if adopted, not only results in informative
censoring but also contravenes the basic principle
of an intent-to-treat analysis which is the accepted
standard for the comparison of treatments for
survival. If a similar approach was applied to the
analysis of survival, then only those deaths
occurring on randomized treatment would be
considered when comparing treatments with all
other deaths censored. The interpretation of such
an analysis is, at best, unclear and its relevance to
the assessment of treatment policies questionable.
Overall, it would seem better and more consistent
to apply a common standard to important efficacy
variables such as PFS and survival to allow both
to be interpreted within the same framework. For
8
1
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E
6
1
50*6
50
==
25*5+25*3
25
cancer treatment
25 censored at
mean=3 mo mean=6 mo
25 progressions
C
N=50N=50
additional anti-
mean=5 mo
HR E:C = 1.33
Conclusion: 2 mo advantage for C compared to E
Overall mean time = 8 mo Overall mean time = 6 mo
per month per month
~Events ~Events
50 progressions
Figure 2. Censoring on the addition of further anti-cancer therapy.
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progression (like survival) this would mean the
routine follow-up patients for documented evi-
dence of progression irrespective of when and why
they stop taking randomized treatment so that
treatment policies could be compared on the basis
of data that reflect actual clinical practice. This is
essentially the same approach as forwarded in the
recently published appendix to the CHMP anti-
cancer guideline [16].
SUMMARY, RECOMMENDATIONS
AND DISCUSSION
This paper has focused on some key statistical
issues associated with the analysis of PFS in
oncology trials. The routine practice of assigning
the time of progression to the clinic visit at which it
was first detected results in a downwardly biased
estimate of the hazard ratio and, thus, reduces
power. Further, if clinic visit schedules are not
closely matching between treatments, the Type I
error can also be increased. Fortunately, these
issues can be addressed as follows:
* Size the trial to detect a true HR of size y via the
log rank test. Assume E events are required to
provide power of 1ÿb with a 1-sided Type I
error rate of a Plan for, and maintain during
conduct, a common clinic visit schedule.
* Employ an interval-censored analysis of PFS.
* Alternatively, PFS times can be assigned to
clinic visit at which they were first detected and
PFS time analysed via the usual log rank test;
however, to maintain power at 1ÿb the target
number of events should be increased to d 0 (as
defined in equation (4)).
* If, as is common in practice, the visit schedule is
not as closely adhered to as intended, resulting
in variability in the interval between visits and,
possibly, between treatments also, a supportive
analysis based on the number of PFS events
over the trial period will provide for an
4
1
==
C E
6
1
==
25 progressions 25 ‘fail’ at
additional anti-
cancer treatment
Overall mean time = 4 mo Overall mean time = 6 mo
Conclusion: 2 mo advantage for E compared to C
HR E:C = 0.667
25*5+25*3
5050
50*6per month
~ Events
per month
~ Events
N=50N=50
mean=5 mo mean=3 mo mean=6 mo
50 progressions
Figure 3. Addition of further anti-cancer therapy considered as a ‘failure’.
Copyright # 2007 John Wiley & Sons, Ltd. Pharmaceut. Statist. 2007; 6: 99–113
DOI: 10.1002/pst
108 K. J. Carroll
Publication 7: Carroll 2007(b)
164
unbiased comparison between treatments. An
analysis with a complementary log–log link will
provide an estimate of the hazard ratio with
reasonable power so long as no more than
around 75% of patients have an event.
To illustrate the problems associated with
assigning the time of progression to the visit at
which it was first detected, it has been assumed
event times are exponentially distributed since this
allows the reader to most easily appreciate the
extent to which bias can be introduced and how
alternative estimators might be formulated to
eliminate this bias. An area of further work might
be to look at how rank based estimators of the
hazard ratio (such as the Pike estimator or the
exponent of the ratio of observed minus expected
deaths to the variance from the log rank test)
perform when PFS times are not known exactly
[31,32]. It might also be of interest to examine
other distributions for PFS times, such as the
Weibull or log Normal and the performance of &y
when proportionality holds but the underlying
distribution of PFS times is not exponential.
With respect to patients who stop randomized
therapy during the trial follow-up period prior to
reaching a confirmed progression event due to
toxicity or the addition of further anti-cancer
therapy, the common practice of censoring at the
time of the intermediate event is highly proble-
matic and is likely to favour the less efficacious,
more toxic treatment. Adopting the ITT approach
used in the analysis of survival, whereby all
patients are followed for a documented evidence
of progression irrespective of when and why they
stop taking randomized treatment, would provide
(i) a better basis for comparing treatment policies
and (ii) data that more closely mimic actual
clinical practice. If desired, a supportive analysis
could still be conducted censoring dropouts in the
absence of documented progression, though con-
siderable care would be needed when interpreting
the results.
The issues raised in this article are not the only
concerns that impact the use of PFS as an
endpoint to demonstrate drug effectiveness. Two
key issues worth raising briefly are (a) whether an
improvement in PFS is a clinical benefit in and of
itself or is at least reasonably likely to predict
clinical benefit in terms of symptomatic improve-
ment and/or overall survival and (b) the need for
independent review of radiological data relating to
disease progression. With respect to the first of
these issues, recent work in prostate and colorectal
cancer has seen the question of surrogacy of PFS
for survival carefully and formally examined using
contemporary statistical methodology [33–35].
This work supports the use of PFS as a true
surrogate endpoint in these disease settings and, in
doing so, lends support to the view offered by
Williams, that few in the oncology community
doubt that delaying the growth of a cancer is of
benefit to patients; rather, issues relate to whether
progression can be reliably measured in trials and,
if so, what a given improvement in progression
means clinically [6, transcript p. 30].
The use of open trials in oncology raises the
possibility of bias in the assignment of progression
status by the treating investigator. As evidenced in
both FDA and CHMP guidelines, this concern
frequently results in a request from regulatory
agencies for independent review of radiographic
and imaging data in patients said to have
progressed by the investigator [9,15,16]. While this
may make sense in open, small scale trials with few
investigational sites, the value of independent
review in large-scale international trials with
possibly hundreds of sites is questionable – when
seeking a large effect on progression, a false claim
would seem rather unlikely in the absence of a
systematic intent to defraud across multiple
countries and sites. A further difficulty introduced
when incorporating an independent review, is how
to handle patients where the investigator and
independent review disagree on progression status
and where the investigator believes the patient has
progressed. In this situation, radiological assess-
ment will cease and any censoring of this data will
be informative as such patients will be closer on
average to progressing than patients neither the
investigator or independent reviewer believe have
progressed.
Even when an independent review is deemed
worthwhile, the common practice to review only
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data in patients who have progressed is unsatis-
factory at best and misleading at worst. This
approach will always lead to a less precise estimate
of the treatment effect since the number of
progression events can only go down. A more
satisfactory approach would be to also take a
random sample of non-progressing patients to
estimate the fraction of patients without progres-
sion reclassified as progressive by independent
review. The overall number of progression events
could then be estimated under independent review
and treatment groups compared accordingly. This
approach was used in the review of progression
events in the bicalutamide early prostate cancer
programme where it was concluded that there was
no evidence of bias in the investigator assessment
of progression [36].
The trend toward the use of PFS as a primary
endpoint to assess the effectiveness of new anti-
cancer treatments is, on the whole, beneficial to
drug development and consistent with the aim of
FDA’s Critical Path and EMEA’s Road Map
initiatives which actively seek ways to accelerate
the drug development process [37,38]. It is hoped
that this article will help to address some of the
perceived statistical issues related to trial design
and analysis and, in doing so, will help to alleviate
the concerns and barriers that might otherwise
discourage or even prevent the use of PFS as a
primary endpoint in oncologic drug development.
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APPENDIX A
Suppose N patients are followed for some event of
interest with the time to the event denoted as t.
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Suppose t is an exponentially distributed random
variable with parameter l. Suppose the process is
monitored at r equally spaced intervals of length V
for a total follow-up time of rV. Events therefore
occur in intervals (0, V], (V, 2V],...,((rÿ1)V, rV]
with the event for the ith patient occurring in
((kiÿ1)V, kiV]. Events times are assigned to the
start of the interval in which they are detected.
There are d patients with an event. Furthermore,
c patients are randomly censored prior to time rV
with censoring times of kgV for the gth patient.
The Nÿdÿc remaining patients who are without
an event at the end of the follow-up period are
right censored at time rV. The likelihood function
is therefore given by
L ¼
Yd
i¼1
eÿlðkiÿ1ÞV ÿ eÿlkiV
ÿ Yc
g¼1
eÿlkgV
YNÿdÿc
j¼1
eÿlrV
ðA1Þ
‘ ¼ lnðLÞ ¼ d ln elV ÿ 1
ÿ 
ÿ l
Xd
i¼1
kiV þ
Xc
g¼1
kgV þ
XNÿdÿc
j¼1
rV
" #
ðA2Þ
@‘
@l
¼
dVelV
elV ÿ 1
ÿ
Xd
i¼1
kiV þ
Xc
g¼1
kgV þ
XNÿdÿc
j¼1
rV
" #
ðA3Þ
@‘
@l
¼ ÿd
PN
i¼1 Ti
d
ÿ
V
1ÿ eÿlV
" #
ðA4Þ
where Ti denotes the observed time, event or
censored, of the ith patient. Thus
T ¼
PN
i¼1 Ti
d
¼
1
observed event rate
is the MLE for
V
1ÿ eÿlV
and Var T
h i
¼
V2eÿlV
d 1ÿ eÿlVð Þ
2
If comparing two treatments, experimental (E) and
control (C), the estimated hazard ratio
#y ¼
observed event rateE
observed event rateC
¼
TC
TE
is biased since
E ½#y ¼
1ÿ eÿlEV
1ÿ eÿlCV
6¼
lE
lC
ðA5Þ
Further,
Var ½ln ð#yÞ ¼
eÿlEV
dE
þ
eÿlCV
dC
ðA6Þ
and, thus,
#Var ½ln ð#yÞ ¼
1ÿ V
TE
dE
þ
1ÿ V
TC
dC
ðA7Þ
An approximately unbiased estimate of the HR is
given by
&y ¼
ln 1ÿ V
TE

ln 1ÿ V
TC
  ðA8Þ
with variance
Var ½lnð&yÞ ¼
elEV 1ÿ eÿlEV
ÿ 2
dEl
2
EV
2
þ
elCV 1ÿ eÿlCV
ÿ 2
dCl
2
CV
2
ðA9Þ
and, thus,
#Var½ln ð&yÞ ¼
V2
dET
2
E ln 1ÿ
V
TE
 n o2
1ÿ V
TE
 
þ
V2
dCT
2
C ln 1ÿ
V
TC
 n o2
1ÿ V
TC
 
ðA10Þ
APPENDIX B
Suppose two treatments are to be compared in a
clinical trial on a time to event endpoint using the
log rank test. To test the hypotheses H0: hazard
ratio=1 vsH1: hazard ratio=y (51) with a 1-sided
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Type I error rate of a and power 1ÿb a total of
d ¼
4 za þ zb
ÿ 2
ln yð Þ2
ðB1Þ
events are required [18]. It therefore follows
immediately that
(i) if the power to detect #y; #y > y; with d events
is 1ÿg, then
zg ¼ za þ zb
ÿ 
oÿ za ðB2Þ
so that
1ÿ g ¼ fÿ1 za þ zb
ÿ 
oÿ za
 
ðB3Þ
where o ¼ abs
ÿ
ln ð#yÞ
lnðyÞ

and fÿ1(.) is the inverse of
the cumulative normal distribution.
(ii) there is a simple relationship between y and #y
such that
#y ¼ yk ðB4Þ
where k ¼ abs
ÿ zaþzg
zaþzb

(iii) to maintain power of 1ÿb to detect #y a total
of
d 0 ¼
d
o2
ðB5Þ
events are required.
Suppose now that #y ¼ 1ÿe
ÿlEV
1ÿeÿlCV
: If lV is small,
then
V
1ÿ eÿlV

1
l
1
1ÿ lV
2
þOðl2V2Þ
" #
¼
1
l
1þ
lV
2
þOðl2V2Þ
 

1
l
þ
V
2
ðB6Þ
so that
#y ¼
1ÿ eÿlEV
1ÿ eÿlCV

1
lE
þ V
2
1
lC
þ lC
2
¼
yð1þ tÞ
1þ ty
ðB7Þ
where t ¼ VlC
2
. Substitution of (B7) in to (B4)
reveals that if a common visit schedule is used
when assessing PFS such that PFS times are
assigned to the visit at which progression was first
detected, to ensure retention of at least 1ÿg power,
g>b, visits must be scheduled approximately
every V 0 months where
V 0 ¼ ðmedian PFS on CÞ 
2
lnð2Þ
1
y
yk ÿ y
1ÿ yk
 !
ðB8Þ
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DECISION MAKING FROM PHASE II TO PHASE III
AND THE PROBABILITY OF SUCCESS: REASSURED
BY “ASSURANCE”?
Kevin J. Carroll
Independent Statistical Consultant, Cheshire, United Kingdom
With Phase III failure rates of 50%, better ways of predicting late-stage success are
needed. One concept that has been used is “assurance.” Rather than conventional power
calculations hypothesizing a known effect of a drug, assurance provides an expected
power calculation based on some prior distribution for the treatment effect. It therefore
has appeal in Phase III planning and decision making, especially when the prior is
based on Phase II data. However, assurance has counterintuitive properties that can
serve to confuse and concern the nonstatistician. Appreciation of these properties is
helpful to ensure an informed use of assurance in strategic drug development.
Key Words: Assurance; Decision making; Phase II to phase III.
1. INTRODUCTION
An ongoing and serious challenge facing the pharmaceutical industry is the high
failure rate in the latter stages of drug development, resulting in low research and
development (R&D) productivity. Failure rates of 80% in Phase II and 50% in Phase
III have been reported (Arrowsmith, 2011a,b). Two-thirds of Phase III failures are
reported as due to not demonstrating a positive treatment effect reflecting poorly on
the quality of Phase II design and decision making (Arrowsmith, 2011b). While Prinz
et al. (2011) point to unreliablemodels used in drug screening programs, broader issues
in late stage development are highlighted by Arrowsmith (2011b) where he cites:
a result of the pressure on companies to replenish pipelines with drugs that have
high potential for approval and reimbursement, particularly in a period during
which patent expiries for major products are threatening future revenues. Owing
to this urgency, it seems that companies have progressed drugs into Phase III
trials even though they only displayed marginal statistically significant efficacy
in Phase II proof-of-concept studies; consequently, these drugs carry a greater
than average risk of failure.
Arrowsmith (2011b) further notes:
The way to improve Phase III success rates is to avoid wishful thinking and to
rely on high-quality scientific evidence by fully testing mechanisms against each
Received November 29, 2012; Accepted March 19, 2013
Address correspondence to Kevin J. Carroll, 79 Albany Road, Bramhall, Cheshire SK7 1NE,
UK; E-mail: kevincarroll2@sky.com
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target indication, using well-defined endpoints in the right patient population in
Phase II trials. Initially, this may lead to higher failure rates in Phase II trials,
but some companies have already shown that good science can deliver a steady
flow of robust positive proof-of-concept data.
While the lack of statistical significance in Phase II is, arguably, not a major
contributor to Phase III failure, Phase II design and decision making are self-
evidently critical. Given that the cost of developing a new drug is estimated to
be $800 million to $2 billion, high Phase II and Phase III failure rates are clearly
unsustainable and pressure is on to improve the situation (Chuang-Stein et al.,
2011). Over recent years this has led to the demand for more adaptive Phase II
and Phase III trial designs and alternative statistical methodologies such as Bayes
that purport to offer greater flexibility, lower cost, and better success rates. Despite
the promise, to date very few new medicines have been approved based upon a
truly adaptive Phase III trial design. Another area of focus is to find better ways of
decision making when transitioning from Phase II to Phase III and, in particular,
better ways using Phase II data to predict the chance of success in Phase III.
One statistical concept that has been used in this regard is “assurance”
(Chuang-Stein, 2006; O’Hagan et al., 2005). Rather than a traditional power
calculation that hypothesizes a fixed treatment effect, assurance provides an
unconditional expected power calculation based on some prior distribution for the
treatment effect. As such, it has a natural appeal in late-stage decision making
and Phase III design, particularly when the prior is not arbitrarily chosen but
rather based on objective data generated in preceding Phase II trials. Chuang-
Stein et al. (2011) consider the use of assurance in late-stage development decision
making, and Kirby et al. (2012) consider its use in designing Phase III studies given
prior, discounted Phase II data. Despite its increasing prominence in the literature,
assurance has some strange and counterintuitive properties that can serve to confuse
and concern the nonstatistician decision maker. It is helpful for these properties
to be understood by statisticians and nonstatisticians alike in order to ensure an
informed use of the concept in strategic drug development. Aside from assurance,
there are some basic steps the drug developer can take to enhance and improve
late-stage decision making. In the end it is probably these basic steps, coupled with
experience and good judgment, that are more likely to result in an improved Phase
III success rate than the application of concepts like assurance per se, since without
the former, the latter is entirely academic.
The remainder of this article is structured as follows. Section 2 reviews power
and assurance, making several observations regarding the nature of assurance
when the prior is defined by preceding Phase II data. Section 3 discusses
assurance for two independent Phase III trials. Section 4 provides an example,
and Section 5 summarizes the key features of assurance. Section 6 offers some
basic recommendations for good decision making and Section 7 closes with a brief
discussion.
2. POWER AND ASSURANCE
Consider the planning of a Phase III clinical trial. Typically, the hypothesis
to be tested is H0 2 TRUE = 0 vs. H1 2 TRUE 6= 0, where TRUE denotes the true
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treatment effect. For the purposes of sizing, a positive effect TRUE =  4>05 is
usually assumed under the alternative. Let x be a sufficient statistic for  with
distribution f4x  5 ∼ N41 25, where N401 05 represents the normal distribution.
Trial size is then governed by Type I and Type II errors,  and , and the need to
deliver the required information content, 1/2 = 4z + z52/2, where zu = ê−141−
u5 and ê−14·5 represents the inverse standard Normal distribution function. The null
hypothesis is rejected in favor of the alternative when x > c = z. Suppose further
that a preceding Phase II trial has been conducted using the same patient population
and endpoint; if there are two or more similar Phase II trials, assume results are
statistically consistent and the data combined. Suppose these Phase II data provide
an estimate of the treatment effect, m, with variance s2, and the data are then used
to define a prior for : f45 ∼ N4m1 s25.
It is important to note at this stage, and as highlighted by an anonymous
referee, that choices for f45 other than as defined by preceding Phase II data could
be considered. However, the intent of this article is to examine assurance in the
context of a prior for  specifically determined by preceding Phase II data since this
most accurately reflects the decision-making process in practice. It is the Phase II
data themselves that guide and heavily influence Phase III planning, and in some
pharmaceutical companies these data are used to directly predict the chances of
success in Phase III. With well-conducted and controlled Phase II data in hand,
there seems little rationale in introducing an assumed, informative prior for Phase
III. To do so would serve to render the decision-making process somewhat academic
as the real (Phase II) data may be diluted (or strengthened) or even overlooked
by the choice of some possibly arbitrary prior. Arguably, it is the Phase II data in
and of themselves that best inform the decision makers regarding the true treatment
effect and, hence, form the most appropriate prior for Phase III planning and
decision making.
With f45 ∼ N4m1 s25 as the prior for , it then follows that the joint (posterior)
distribution of x and  is given by f4x1 5 = f4x  5f45. As shown by O’Hagan et al.
(2005),
f4x5 =
∫ +
−
f4x1 5d =
∫ +
−
f4x  5f45d = N4m1 s2 + 25 (1)
“Assurance” is then defined as the probability of a “successful” Phase III trial, that
is, the probability of achieving p < 00025 (O’Hagan et al., 2005). This is given by
pr4x > c5 = pr
(
z >
c −m√
s2 + 2
)
= 1−ê
(
c −m√
s2 + 2
)
(2)
where ê4·5 represents the standard Normal cumulative distribution function.
Therefore assurance is the expected value of conventional power over the prior
for . It should be noted at this point that other definitions of “success” could be
used, such as p < 00025, and the point estimate of the treatment effect attaining
some minimum, prespecified value (Chuang-Stein et al., 2011; Kirby et al., 2012).
However, for the purposes of exploring the properties of “assurance” in terms of
expected power, “success” is defined as achieving p < 00025. Some observations can
now be made regarding assurance.
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(i) When Phase II is Small For a small Phase II, that is, as s2 →, then,
regardless of the size of Phase III,
pr
(
z >
c −m√
s2 + 2
)
→ pr4z > 05 = 0050 (3)
Equation (3) tells us that even the very largest Phase III trial has only a 50%
probability of success (PoS) when the Phase II data are very few. This may seem
obvious to the statistician, considering that the conventional power function is
integrated over an essentially flat prior for  such that all values on the real
line are equally plausible. However, this situation can be rather confusing and
counterintuitive to the nonstatistician who would consider the chance of achieving
p < 00025 to be virtually guaranteed in the largest of Phase III trials where there
would be essentially 100% power for any TRUE > 0, even if the observed difference
was very small.
(ii) When Phase II is Large For a large Phase II, that is, as s2 → 0, then
pr
(
z >
c −m√
s2 + 2
)
→ pr
(
z >
c −m√
s2 + 2
)
= pr
(
z > z −
m

4z + z5
)
(4)
Hence, equation (4) is the power of the Phase III study under H1: TRUE = m. This
clearly makes sense since the larger the Phase II is, the closer the estimated effect
is to truth. If the Phase III is sized with  = m, the chance of success by assurance
is 1− , that is, regular power. However, it is unlikely in practice that s2 would be
smaller than 2. At best one might expect s2 ≈ 2 so that assurance would be given
by pr4z > z/
√
25 = 82% if  = 001.
(iii) When Phase III is Large As 2 → 0, then
pr
(
z >
c −m√
s2 + 2
)
→ pr
(
z >
−m
s
)
(5)
Hence, equation (5) = 1− {one-sided Phase II p-value}. Consequently, if the
proposed Phase III is very large, the chance of success by assurance is maximally
1 minus the one-sided p-value from Phase II. For example, a Phase II with p =
0020 one-sided means that assurance in Phase III cannot exceed 80% even with
infinitely many patients entered. More generally, as 2 → 0 then c→ 0 and the
conventional power curve approaches a step function. Then any observed difference
> 0 rejects the null with 100% probability, and any difference ≤ 0 rejects with
probability zero. Therefore, for any prior f45, assurance = ∫ +− 4power  5f45d→∫ +
0
f45d, which is the fraction of the prior density that lies to the right of zero.
(iv) If Phase III is k Times Larger than Phase II More commonly, 2 > 0
and s2 > 0 with 2 ≤ s2. In this circumstance, if the size of the Phase III is k times
that of Phase II then
pr
(
z >
c −m√
s2 + 2
)
→ pr
(
z >
−m√
24k+ 15
)
− pr
(
z >
z − m 4z + z5√
k+ 1
)
(6)
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Table 1 Summary of key features of assurance
Phase III
Small Large
Phase II Small s2 →1 s2 ≫ 2 2 → 01 s2 ≫ 2
Assurance = Phase II one-sided
p-value (= 50%)
Assurance = Phase II one-sided
p-value
Large s2 → 01 s2 ≪ 2 s2 > 01 2 > 0 with s2 = k2
Assurance = Power of Phase III
trial at TRUE = m
Assurance = ê−1
(
z√
k+1
)
if Phase
III sized in region of TRUE = m
Therefore, if Phase III is sized with  hypothesized in the region of m, then then PoS
by assurance is approximately pr4z > z√
k+1 5. Hence, for Phase III trials 3 to 5 times
larger than Phase II, which inthe authors’ experience is not uncommon, assurance
will routinely be in the region of 70% since equation (6) = 0.74 for k = 31 0072 for
k = 4, and 0.70 for k = 5. Table 1 summarizes key observations thus far regarding
assurance.
3. POWER AND ASSURANCE FOR TWO PHASE III TRIALS
In most new drug applications, the regulatory requirement is for substantial
evidence from adequate and well-controlled trials, leading many developments to
have at least two Phase III trials. When asked what is the chance that two
independent Phase III trials are successful the answer is clearly 41− 52. However,
this is no longer the case for assurance as the incorporation of prior information
induces a correlation between the outcomes of the two Phase III’s.
To see this, consider
E6x1 7 =
∫ −
+
∫ −
+
xf4x1 5ddx =
∫ −
+
f45
∫ −
+
xf4x  5dxd
=
∫ −
+
2f45d = s2 +m2
Hence,
Cov4x1 5 = E6x1 7− E6x7E67 = s2 +m2 −m ·m = s2
so that
4x1 5 =
√
s2
s2 + 2 (7)
In relation to a second Phase III trial, let y represent a sufficient statistic for  with
probability distribution f4y  5 ∼ N41 25. Then, as shown in Appendix A,
4x1 y5 = 4x1 54y1 5 =
√
s2
s2 + 2
√
s2
s2 + 2 (8)
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When 2 = 2,
4x1 y5 = s
2
s2 + 2 (9)
Furthermore, as shown in Appendix B and consistent with equation (9), when
integrated over the prior for  outcomes x and y from the two Phase III trials are
bivariate normal:
f4x1 y5 =
∫ −
+
f4x1 y1 5d =
∫ −
+
f4x  5f4y  5f45d
= N
[(
m
m
)(
s2 + 2 s2
s2 s2 + 2
)]
(10)
Therefore equation (10) allows the PoS by assurance associated with two Phase III
trials to be calculated.
Further observations are as follows.
(v) 4x1 y5 → 1 As 2/s2 → 0 then 4x1 y5→ 1. This occurs when either
Phase III is very large relative to Phase II or, equally, when Phase II is very small.
In such cases, assurance for the two trials individually and combined are again
maximally 1− {one-sided Phase II p-value}.
This means if Phase II delivers a one-sided p-value of 0.2, 2× Phase III’s of
any size will each have at most an 80% chance of success by assurance, and, further,
the overall chance of success for both by assurance is also 80%.
(vi) 4x1 y5 → 0 If the Phase II is large relative to Phase III such that s2 → 0,
then 4x1 y5→ 0. If this is the case, two Phase III’s sized with m =  will each have
1−  chance of success, and the overall chance of success for both will be 41− 52.
However, as noted earlier, in practice s2 ≥ 2 so that typically 1
2
≤ 4x1 y5 ≤ 1.
4. AN EXAMPLE
Consider a randomized Phase II oncology trial with 70 events (corresponding
to a design with  =  = 002, hypothesized hazard ratio [HR] of 0.667) and an
observed HR of 0.75, p = 0011. Suppose a Phase III trial is planned with a
hypothesized HR of 0.75, requiring 508 PFS events for  = 00025 one-sided and
power 90%. The assurance via equation (1) is 67%. Hypothesizing an HR of 0.8
in the Phase III and increasing the number of events by more than 80% to 844
increases assurance only by 6%, to 73%. As noted earlier, the assurance cannot
exceed 1− p = 89% even with a vast number of events in Phase III. The Phase II
data and power in Phase III are displayed graphically in Fig. 1. Examination of this
figure quickly reveals why a large jump in the number of events in Phase III has little
impact on assurance. As noted by King (2009), it’s generally not the steep Phase III
power curve that most drives assurance but rather the spread of the prior based on
Phase II where a sizable portion of the density for the HR lies to the right of unity.
To meaningfully impact assurance requires either a larger Phase II or a better result,
shifting the density for the HR to the left. Also, the maximum assurance attainable
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Figure 1 Phase II data, HR = 0075 on 70 events, and Power in Phase III with 508 events and  =
00025 1-sided. (Color figure available online.)
is represented by the shaded area shown, which is equal to 1 minus the Phase II
one-sided p-value. As Phase III size increases, the power curve becomes ever steeper
until, in the limit, it becomes a step function equaling 1 for all hazard ratio values
less then unity, and 0 otherwise. Hence, when averaged over the Phase II data prior,
assurance is represented by the area of prior density to the left of unity. Finally,
recalling via equation (3) that Phase III assurance results from averaging the power
curve over the prior distribution for , this is more readily seen in Table 2, which
provides a rough approximate derivation of assurance. The approximate figure of
67.01% is a very close match to the exact figure of 67%.
Table 2 Approximate value of assurance for a single Phase III and two identical Phase IIIs
Column 1 Column 2
Range for
TRUE
Phase IIIa power
TRUE = midpoint
of range
Pr(TRUE in
range) based on
PIIb data
Assurance for
single PIII 1× 2
Assurance for
two PIIIs 12 × 2
0.15–0.25 100.00% 0.00% 0.00% 0.00%
0.25–0.35 100.00% 0.07% 0.07% 0.07%
0.35–0.45 100.00% 1.56% 1.56% 1.56%
0.45–0.55 100.00% 8.09% 8.09% 8.09%
0.55–0.65 99.99% 17.75% 17.75% 17.74%
0.65–0.75 98.03% 22.53% 22.08% 21.65%
0.75–0.85 71.05% 19.97% 14.19% 10.08%
0.85–0.95 21.99% 13.89% 3.05% 0.67%
0.95–1.05 2.50% 8.17% 0.20% 0.01%
1.05–1.15 0.12% 4.28% 0.01% 0.00%
1.15–1.25 0.00% 2.06% 0.00% 0.00%
Total 67.01% 59.88%
aPhase III: 508 events to provide 90% power to test the hypothesis TRUE = 0075 at the 0.025 one-
sided -level.
bPhase II: Observed HR = 0.75 on 70 events.
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Now suppose a second, duplicate Phase III is planned. Then, in averaging over
the Phase II data, outcomes for the two Phase IIIs are highly correlated with  =
0088. The probability of success in both Phase IIIs via equations (9) and (10) is 60%.
Again, Table 2 provides a rough approximation of assurance for two identical Phase
III trials. The approximate figure is 59.88%, as compared to the exact figure of 60%.
5. ASSURANCE SUMMARY
Taken at face value, assurance is an appealing concept in relation to Phase III
decision making as it helps to inform regarding the likelihood of success given the
data observed in Phase II. With Phase III failure rates continuing to be on the order
of 50%, pharmaceutical and biotech companies and their statisticians or statistical
advisors are increasingly turning to concepts like assurance in an attempt to improve
decision making.
However, when looked at carefully, assurance has several strange and
counterintuitive properties that may give the nonstatistician good reason to pause
and think. These include:
• PoS = 50% when Phase II is very small regardless of the size of Phase III.
 While not surprising to the statistician, to the nonstatistician, this says a small
and relatively uninformative Phase II will deliver approximately 50% assurance
regardless of whether Phase III has 100 or 100,000+ patients.
• PoS = 1− {one-sided Phase II p-value} when Phase III is large relative to
Phase II
 So if p = 002 one-sided in Phase II, assurance cannot exceed 80% even if Phase
III was huge in the extreme with, say, 100,000+ patients and a conventional
power > 99.99%
• The outcomes of two independent Phase III trials are in fact correlated when
integrated over the prior Phase II data, with correlation typically ≥1/2.
 When either the Phase III’s are large relative to Phase II, or when Phase II is
small relative to Phase III, the correlation between Phase III outcomes is 1 and
the assurance for the two trials individually and combined is, again, maximally
1− {one-sided Phase II p-value}.
In the author’s experience, these observations when presented to medical and other
nonstatistical colleagues are invariably met with a mix of confusion and disbelief.
They understandably lead to concern and wariness in using assurance to help
guide Phase III decision making. The confusion boils down to a failure, often on
behalf of the statistician, to recognize the fundamental switch that takes place with
assurance: the move away from considering the treatment effect as a fixed parameter
to assuming it is a random variable; and then a further failure to realize that
assurance only really makes sense if the Phase III is analyzed in the same way it was
designed—by formally incorporating the Phase II data as a prior and performing a
Bayesian analysis.
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With perhaps the exception of noninferiority trials using the synthesis method,
Phase III trials are predominantly analyzed using frequentist methodology by
sponsors and regulators alike. As such, one may fairly ask, if not assurance to guide
better Phase III decision making, then what?
6. SUGGESTED PRINCIPLES FOR GOOD PHASE III DECISION MAKING:
10 BASIC STEPS
Before seeking to employ concepts like assurance, there is much that can and
should be done in terms of basic good science and common sense. While some of
what follows may seem obvious, a cursory glance through the medical literature and
published Phase II studies will quickly suggest that not all decision makers, both
academic and big pharma alike, appreciate the basics.
Design
Step 1. Ensure Phase II is well controlled, randomized, and double-blinded
where possible. If blinding is not possible, consider having the primary endpoint(s)
assessed or adjudicated by an independent third party to minimize the potential for
bias. Where possible, include an active arm reflective of the comparator anticipated
in Phase III. Finally, include more than one dose of drug where possible and ensure
the highest dose provides the maximum possible kinetic exposure to minimize type
II error.
Step 2. Consider performing two Phase II trials. To support feasibility, use
 and  levels consistent with Phase II decision making and not a confirmatory
Phase III trial. Positive outcomes from two Phase II’s of moderate size are generally
more compelling and reliable than a single larger Phase II, especially in settings
with softer endpoints like CNS. Any concerns regarding cost and feasibility may
be allayed if the following is considered. If a single Phase II is designed with 2 =
24z + z5, as compared to two Phase IIs each with 2 = 224z + z5, then  = 1−
ê84z + z5/
√
2− z9. Therefore, if  = 001 and 1−  = 0090400805, then 1− 2 =
009114008295, meaning that two Phase II’s with 10% significance and N/2 patients
together carry greater power than a single Phase II with N patients. Similarly, if
 = 0005 and 1−  = 0090400805, then 1− 2 = 008874007935 so, again, two Phase
II’s with N/2 patients provide similar power to a single Phase II with N patients.
Step 3. Choose the most sensitive patient population relevant to the
purported mechanism of action for efficacy. Failure to do so obviously increases
the probability of a type II error. Ensure the patient population also reflects that
anticipated in Phase III.
Step 4. Predefine the Phase III go/no-go decision rule for “success” and,
importantly, stick to it.
Step 5. In addition to the use of assurance or expected power in sizing Phase
III, also present sample size based upon a regular conditional power calculation.
This will help Phase III decision makers understand the impact on size, cost, and
risk of seemingly minor deviations in the value of the hypothesized treatment effect.
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Analysis and Interpretation
Step 6. Analyze efficacy variables on an intention-to-treat (ITT) basis to
ensure results are reflective what is expected in Phase III. Do not ignore drop-outs;
include them as failures to respond in the analysis.
Step 7. Try to avoid multiple interim analyses in Phase II, particularly
when the study is open and/or where results maybe seen by the sponsor and/or
investigator at midstream. The potential for serious (if unintentional) bias is
obvious, as is the unfortunately tendency for researchers to see what they hope
to see. If interims are desired, ensure they are properly planned in advance with
clear decision rules and, preferably, governed by a fully independent IDMC. The
advantage of the latter is that objective judgements regarding study conduct are
made possible, thereby helping to preserve the integrity of the study.
Step 8. Stick to your predefined go/no-go decision rule. If the primary fails
the go/no-go, do not look for “signals” elsewhere in data; do not look to salvage
by means of extensive (post hoc) analyses in subgroups; do not retrospectively
substitute the primary endpoint with some other secondary endpoint; do not seek
to substitute primary with a subset of some secondary endpoint; and do not look to
retrospectively alter or fudge the predefined go/no-go criteria.
Step 9. Ensure that senior leaders and decision makers are talented, well-
experienced drug developers with a proven track record of getting a drug
through development to approval with the likes of the Food and Drug
Administration (FDA)/European Union (EU)/Japan. Decision makers must have
relevant experience and a sound appreciation of good experimental design,
data analysis, and interpretation. Excellent, enthusiastic scientists, project leaders,
and product champions are not the best decision makers—evangelic belief
often supplants a rational, sober assessment of the data and impairs objective
judgement.
Step 10. Include an experienced, technically expert statistician in the heart
of the decision making process. It is not helpful if the statistician is no longer
practicing, having “left the bench early,” and consequently possesses little or no
contemporary statistical knowledge or technical skill. Sadly, without a highly
capable statistician, strange decisions can be, and are, very easily made. While Step
8 may seem obvious to the statistician, these kinds of issues do occur. Making
retrospective excuses for failure is sadly not uncommon, especially when under
pressure to replenish an ailing pipeline (Arrowsmith, 2011b). The notable learning
point here is, few drugs have failed well-designed, well-conducted, properly analyzed
and appropriately interpreted Phase II trials only to proceed to Phase III and be
positive. But many Phase IIIs have failed on the back of questionable Phase II
data, design, and analysis. Examples of convincing Phase III failures on the back of
seemingly impressive Phase II data include TC-5214 (s-mecamylamine) in depression
(Dunbar, 2009; AstraZeneca Plc., 2012), dimebon (latrepirdine) in Alzheimer’s
disease (Doody et al., 2008; Medivation, Inc, 2010), AGI-1067 (succinobucol) in
acute coronary syndromes (AstraZeneca Plc., 2004; Tardif et al., 2008), and iniparib
in breast cancer (O’Shaughnessy et al., 2011a,b).
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7. CONCLUSIONS
The concept of assurance is appealing in the context of Phase II to Phase III
decision making. It makes sense to formally incorporate prior Phase II data into
Phase III design. Averaging Phase III power over the distribution of treatment effect
observed in Phase II seems like a reasonable approach. However, assurance has
several idiosyncrasies and counterintuitive properties that make it difficult for the
nonstatistician, and even some statisticians, to trust and understand. Examples of
this are Phase III assurance being capped at the 1 minus one-sided p-value observed
in Phase II even when Phase III includes an infinite number of patients, and two
independent Phase III trial outcomes being correlated when integrated over the
Phase II data. A more fruitful approach to solving the high failure rate in Phase III
may be a return to the basics of drug development, and good Phase II trial design,
conduct, analysis, and interpretation. Statistics and statistical methodology can go
a long way to enhancing sound decision making, but not all the way. In the end it
boils down to a matter of relying on the experience and sound scientific judgment
of the decision makers to make rational, data-driven decisions in the best interests
of their organizations, patients and physicians.
One way to assist this from a statistical perspective is to have highly
experienced, technically capable statisticians sitting at the decision-making table. In
this way it might just be that some poor Phase II to Phase III, decisions are averted
resulting in higher success rates, albeit among fewer Phase III programs.
APPENDIX A
corr4w21 w35 = corr4w11 w25corr4w11 w35
Let v11 v2 and v3 be i.i.d N(0,1) random variables. Define
w1 = v1
w2 = v1 + v2
√
1− 2
w3 = v1 + v3
√
1− 2
Then 
w1w2
w3

 ∼ N
(00
0

 1

1   1 
  1

)
APPENDIX B
f4x1 y5 =
∫ +
−
f4x1 y1 5d =
∫ +
−
f4x  5f4y  5f45d
f4x1 y5 = 1√
22
1√
22
1√
2s2
e
− x2
22 e
− y2
22 e
− m2
2s2 ×
∫ +
−
e
− 2−2x
22 e
− 2−2y
22 e
− 2−2m
2s2 d
f4x1 y5 = A
∫ +
−
e
− 12
{
242s2+25−24xs2+ys2+m25
2s2
}
d
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where
A = 1√
22
1√
22
1√
2s2
e
− x2
22 e
− y2
22 e
− m2
2s2
f4x1 y5 = A
∫ +
−
e
− 12
42s2+25
2s2
{(
− xs2+ys2+m2
2s2+2
)2
−
(
xs2+ys2+m2
2s2+2
)2}
d
f4x1 y5 = Ae 12
42s2+25
2s2
(
xs2+ys2+m2
2s2+2
)2√
2
s2 + 2
2s2 + 2
f4x1 y5 = 1
24s2 + 25
√
1− 2
e
1
2
42s2+25
2s2
(
xs2+ys2+m2
2s2+2
)2
e
− x2
22 e
− y2
22 e
− m2
2s2
where
 = s
2
s2 + 2
f4x1 y5 = 1
24s2 + 25
√
1− 2
e
− 1
22s2
{
4xs2+ys2+m252
2s2+2 −x
2s2−y2s2−m22
}
f4x1 y5 = Be−
1
2
[
4s2+252
242s2+25
]{
4x−m52
s2−2 +
4y−m52
s2+2 −
2s24x−m54y−m5
4s2+252
}
where
B = 1
24s2 + 25
√
1− 2
f4x1 y5 = 1
24s2 + 25
√
1− 2
e
− 12
[
1
1−2
]{
4x−m52
s2−2 +
4y−m52
s2+2 −2
2s24x−m54y−m5
s2+2
}
Hence
f4x1 y5 ∼ N
[(
m
m
)(
s2 + 2 s2
s2 s2 + 2
)]
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Abstract 
Barriers to clinical development in oncology: The impact of new 
thinking around non-inferiority  
K. Carroll and R. Milsted 
AstraZeneca, Macclesfield, United Kingdom  
6082  
Background: While it is hoped that novel, biologically targeted anticancer agents will offer 
significant advantages over standard therapies in terms of improved tolerability, they may not 
always demonstrate increased efficacy. Therefore, active-control, non-inferiority trials to compare 
the new agent with a standard agent are likely to be necessary, the conventional aim being to 
show no clinically relevant loss of efficacy. Methods: Rothmann et al (Stat Med 2003; 22: 239–
64) recently described non-inferiority sample size and data analysis methods, which are 
increasingly being used by regulators in the USA and Europe. We illustrate the impact of 
Rothmann's approach on trial size and, thus, development of novel anticancer agents. Results: 
For example, if a standard treatment was previously shown to double survival (eg hazard 
ratio=0.5, p=0.02), and the goal for a new, better-tolerated therapy is to retain at least half of this 
effect, a conventional sample size calculation shows that a total of 350 deaths is required to 
provide 90% power at the 1-sided, 2.5% significance level. Applying Rothmann's method 
increases the number of deaths required, and so sample size, by almost 9-fold to 3082 deaths, 
which would result in impractical trials in many settings. Conclusions: As shown, use of 
Rothmann's method has enormous consequences. We suggest the first purpose of non-inferiority 
trials should be to prove that a new agent would have been better than placebo, had placebo 
been included. The second purpose should be to estimate (indirectly) the size of the effect of the 
new agent relative to placebo. Both aims are achievable with Rothmann's approach, with some 
small modifications. This philosophy does not require prespecification of a percentage effect 
retention (although the result can be displayed as the likely fraction of standard effect retained) 
and concentrates on estimating the degree of benefit over placebo. Fisher et al (Am Heart J 
2001; 141: 26–32) describe a related approach in patients at risk of ischaemic events. This 
approach focuses on absolute rather than relative efficacy, and, in future, may be a more 
appropriate model to apply to trials of oncology agents.  
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LETTER TO THE EDITOR
Design and analysis of non-inferiority mortality trials
in oncology
by M. Rothman, N. Li, G. Chen and G.Y.H. Chi, Statistics in Medicine 2003; 22:239–264
We would like to draw your attention to the implications for oncologic drug development of
the article by Rothmann et al. published in the January 2003 special edition of SIM on non-
inferiority trials [1]. The methods described in this article are increasingly used by regulators
in the U.S.A. and Europe to evaluate the design and analysis of trials of new agents. The
consequences for trial size are enormous. Shlaes and Moellering have expressed closely related
concerns for anti-infective drug development [2].
There has been something of a paradigm shift in the approach to cancer treatment over
recent years. Academia and industry alike are now fully engaged in the discovery, research
and development of novel, well tolerated, biologically targeted (cytostatic) anticancer agents.
It is hoped that these new treatments will oer signicant advantages to patients in terms
of improved tolerability, but they may not always demonstrate increased ecacy. This nat-
urally leads to the use of active-control, non-inferiority trials to compare the new agent
with a standard agent, the conventional aim being to show no clinically relevant loss of
ecacy.
Such trials are often designed to demonstrate that the new treatment retains some fraction
of the established eect of the standard, say at least 1/2. Note that this fraction is essen-
tially arbitrary and no regulatory guidance currently mandates this as the minimum amount
either to demonstrate clinical non-inferiority or to secure regulatory approval. If the stan-
dard treatment was previously shown to double survival in a particular disease setting (haz-
ard ratio = 0:50; p=0:02, say), and the goal for a new, better tolerated therapy is to re-
tain at least 1/2 of this eect, a routine sample size calculation shows that a total of 350
events is required to provide 90 per cent power at the one-sided, 2.5 per cent signicance
level.
There are several important issues associated with the design and analysis of non-inferiority
trials, including ‘constancy’—the extent to which the standard treatment performs as it did
in previous trials—and ‘assay sensitivity’—the ability of a non-inferiority trial to detect a
real dierence between the treatments compared. Much has been published in this area. The
regulatory guidelines ICH E9 and E10 describe the issues in detail and provide some general
guidance with respect to trial design and conduct [3; 4].
An issue not addressed in these guidelines arises from the fact that the standard eect is an
estimate from earlier work and so is not known with certainty. Sample size calculations often
ignore this uncertainty. Hung et al. have shown that this approach increases the probability
of erroneously accepting the ecacy of a truly inferior drug [5].
The approach oered by Rothmann tackles this issue. Assuming constancy of the eect
of the standard and accepting assay sensitivity, Rothmann proposes a formal statistical com-
Copyright ? 2004 John Wiley & Sons, Ltd.
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parison between the historical data characterising the standard eect and the data arising in
the non-inferiority trial, thereby explicitly incorporating the uncertainty (i.e. SE) around the
standard eect estimate. This is in fact akin to the putative or virtual placebo comparison
approach described by Wang et al. [6]. Operationally, Rothmann’s approach is equivalent to
conventional methodology using not the point estimate for the standard eect, but, rather, a
lesser eect somewhere between the point estimate and its lower 97.5 per cent condence
limit. This reduced eect is chosen so that the chance of falsely approving an inferior drug
is exactly 2.5 per cent, thereby managing the regulatory risk.
The key problem for researchers, physicians and patients alike is that, with Rothmann’s
approach, there is a dramatic increase in the size of the trial required, often rendering the trial
completely infeasible. Applying this methodology to the example above increases the number
of events required from 350 to 3082, a near nine-fold increase. This size of the increase
derives from a combination of the (arbitrary) eect retention fraction (50 per cent in this
example) and the strength of prior characterization of the standard eect, which is reected in
the (historical) p-value. As illustrated in the table below, the application of this methodology
may actually require more events than there are patients with the disease Table I:
This serves to illustrate that even with a highly signicant standard eect estimate, p∼ 0:001
say, Rothmann’s approach can double the size of a non-inferiority trial. Importantly, if the
standard treatment has only just reached statistical signicance, this approach implies that no
new drug can ever be approved via the non-inferiority route in that group of patients on the
basis of clinical benets other than ecacy; superiority in ecacy to the standard treatment
would have to be shown.
Thus, the use of Rothmann’s approach, coupled with the arbitrary 50 per cent eect retention
requirement, would result in impracticable trials in many settings, notably those where the
standard was approved on the basis of a relatively small evidence base. Assuming that direct
comparisons with placebo are unethical, we are forced to contemplate non-inferiority trials
too large ever to be mounted, eectively removing non-inferiority as a viable tool in the
evaluation and ultimate approval of new cancer medicines. This outcome is identical to the one
faced by those developing anti-infective agents which has contributed toward a decline
Table I. The number of deaths required to prove a new treatment retains 1/2 of the eect of standard
treatment (HR=0:50) using Rothmann’s methodology (true HR new:standard is unity, 90 per cent
power,  2.5 per cent one-sided).
(Historical) p-value for Upper 95 per cent CI for HR Approx No. deaths
standard vs placebo of new-to-standard required to prove 50 per cent
must be less than: retention
0.049 1.004 3 000 000
0.02 1.12 3082
0.01 1.18 1563
0.001 1.27 735
0.0001 1.31 572
0.00001 1.33 505
0.000001 1.35 459
≪0.000001∗ 1.41 350
∗Equivalent to the conventional approach i.e. the standard eect is known with (virtually) complete certainty.
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in the number of companies investing in antibacterial research and development and, conse-
quently, in the number of new antibiotics to treat serious infections [2]. Some fundamental
re-thinking in this area is called for to avoid the obvious adverse impact on the future devel-
opment of new cancer medicines.
One way forward is to argue that there should be no dierence between the standards of
evidence required in a superiority setting and in a non-inferiority (or active-control) setting.
Hence the rst purpose of the non-inferiority trials in question should be to prove that a
new agent would have been better than placebo if placebo had been included. The second
purpose should be to estimate (indirectly) the size of the eect of the new agent relative to
placebo. Both of these aims are achievable with Rothmanns’ approach and assumptions, with
some small modications. In well-conducted trials with hard endpoints, little non-compliance
and complete follow up, there should be no need to require 50 per cent retention of eect
to demonstrate superiority to placebo. When estimating the size of the eect, attention could
focus on the point estimate in the usual manner, and not on the lower condence limit
alone. An approach along these lines has been nicely illustrated by Fisher et al. [7] and
does not require pre-specication of a percentage eect retention though, having obtained the
data, the result can easily be displayed in relation to the likely fraction of the standard eect
retained. Concentrating on estimating the degree of benet over placebo, albeit through indirect
measures, seems more in line with the ecacy standards required by U.S. and European law,
both of which call for substantial evidence of ecacy to be established, with no requirement
on relative ecacy with respect to existing agents. This approach is in fact consistent with
the recently issued draft CPMP guidance on non-inferiority trials [8].
The scientic and statistical debate on how best to draw inferences from active-control,
non-inferiority trials should not be considered complete. Rothmann’s approach serves to
highlight that considerable statistical, methodological and philosophical issues remain. Fail-
ure to consider these issues constructively will, at the very least, lead to ever increasing
drug development times and, thus, delay the availability of new therapeutic options to pa-
tients with life-threatening diseases. At worst, the barriers posed will discourage drug de-
velopment where it otherwise might have been feasible and so prevent potentially useful
new medicines becoming available to patients. We sincerely hope that the scientic commu-
nity together with regulatory bodies worldwide will give this important area further careful
thought.
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Author’s Reply†;‡
Sir—I would like to thank you for the opportunity to reply in writing to comments of Mr
Carroll, Dr Milsted and Professor Lewis [1]. This reply will respond to the premise of the
Carroll et al. commentary that it is dicult to design a non-inferiority trial based on 50 per
cent retention of the survival eect of a standard therapy using the methodology in Rothmann
et al. [2] when the estimate of the standard therapy vs placebo survival hazard ratio is
0.5, discuss powering a non-inferiority trial for survival, discuss the adequacy of comparing
survival between a test therapy and placebo when a standard therapy has been approved for
survival, and elaborate on the content of some of the papers referenced in Reference [1].
With respect to the article by Shlaes and Moellering [3], I invite the readers to read the
comments by Powers et al. [4], the comments by Gilbert et al. [5], the reply by Shlaes
[6], and the transcript of the February 19–20, 2002 Division of Anti-Infective Drug Products
Advisory Committee meeting [7], which Dr Shlaes was a participant. Much of the commentary
of both References [5; 6] centers on the discussions of that advisory committee meeting and
how these discussions claried concerns given previously in Shlaes and Moellering. Dr Shlaes
states in their reply ‘The FDA should be congratulated for organizing a very informative and
extremely useful meeting. At this meeting, the FDA succeeded in dening a number of issues
and in achieving some early consensus for several of these issues.’ Dr Shlaes then lists some
of the highlights of the discussions.
According to Carroll et al. it is too dicult to design a non-inferiority trial when the
estimated standard therapy vs placebo survival hazard ratio is 0.5. Examples that they pro-
vide attribute very little precision to such an estimate and less precision than required for
a regulatory approval based on survival. An example Carroll et al. bring up twice in text
would have this standard therapy vs placebo survival hazard ratio estimate of 0.5 based on 45
events (p-value = 0:02; 45 events based on a one-to-one randomization). Carroll et al. discuss
and apparently prefer that the estimate of 0.5 based on 45 events from one trial should be
treated with complete certainty as the true theoretical value of the standard therapy vs placebo
†The views expressed in this article do not necessarily represent those of the U.S. Food and Drug Administration.
‡This article is a U.S. Government work and is in the public domain in the U.S.A.
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Publication 10: Carroll, Milsted, Lewis 2004
191
  
11. Carroll KJ. Active-controlled, non-inferiority trials in oncology: arbitrary limits, 
infeasible sample sizes and uninformative data analysis. Is there another way?  
Pharmaceutical Statistics, 2006; Vol 5(4): 283-293. 
  
192
PHARMACEUTICAL STATISTICS
Pharmaceut. Statist. 2006; 5: 283–293
Published online 18 May 2006 in Wiley InterScience
(www.interscience.wiley.com) DOI: 10.1002/pst.218
Active-controlled, non-inferiority trials
in oncology: arbitrary limits, infeasible
sample sizes and uninformative data
analysis. Is there another way?
Kevin J. Carroll*,y
AstraZeneca Pharmaceuticals, Global Clinical Information Science, Alderley Park,
Macclesfield, UK
In oncology, it may not always be possible to evaluate the efficacy of new medicines in placebo-controlled
trials. Furthermore, while some newer, biologically targeted anti-cancer treatments may be expected to
deliver therapeutic benefit in terms of better tolerability or improved symptom control, they may not
always be expected to provide increased efficacy relative to existing therapies. This naturally leads to the
use of active-control, non-inferiority trials to evaluate such treatments. In recent evaluations of anti-cancer
treatments, the non-inferiority margin has often been defined in terms of demonstrating that at least 50%
of the active control effect has been retained by the new drug using methods such as those described by
Rothmann et al., Statistics in Medicine 2003; 22:239–264 and Wang and Hung Controlled Clinical Trials
2003; 24:147–155. However, this approach can lead to prohibitively large clinical trials and results in a
tendency to dichotomize trial outcome as either ‘success’ or ‘failure’ and thus oversimplifies interpretation.
With relatively modest modification, these methods can be used to define a stepwise approach to design
and analysis. In the first design step, the trial is sized to show indirectly that the new drug would have
beaten placebo; in the second analysis step, the probability that the new drug is superior to placebo is
assessed and, if sufficiently high in the third and final step, the relative efficacy of the new drug to control is
assessed on a continuum of effect retention via an ‘effect retention likelihood plot’. This stepwise approach
is likely to provide a more complete assessment of relative efficacy so that the value of new treatments can
be better judged. Copyright # 2006 John Wiley & Sons, Ltd.
Keywords: active-control trials; non-inferiority; oncology; percent preservation; effect retention likelihood
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1. INTRODUCTION
The design and analysis of active-controlled,
non-inferiority trials continues to be a topic of
discussion and methodological development in the
literature [1,2] with recent issues of both Statistics
in Medicine and Biopharmaceutical Journal being
largely devoted to papers relating to non-inferior-
ity [3,4]. Articles by Hung et al. and Wang and
Hung and, most notably, by Rothmann et al deal
with non-inferiority by requiring that at least a
predefined percentage of the established control
effect is retained by a new drug [1,2,5–8]. The
effect preservation or retention method described
by these authors explicitly incorporates the un-
certainty around the estimate of the historical
control effect and, in doing so, maintains the one-
sided type I error rate, a, at 2.5%. This is achieved
under the assumption of ‘constancy’, that is
assuming the control treatment performs as it did
in previous trials, an assumption which is implicit
in all active-controlled trials. This approach is less
conservative than the use of the lower 95%
confidence limit of the point estimate as the
historical control effect, but, nevertheless, can still
lead clinical trials of an infeasible size [5,9]. The
consequences for oncologic drug development can
be considerable. Shlaes and Moellering [10] have
expressed closely related concerns for anti-infec-
tive drug development.
The purpose of this article is to briefly review the
percent effect retention method and, in doing so,
to suggest an alternative philosophy to sizing
active-controlled, non-inferiority trials and also
offer a simple yet informative way of analysing and
presenting the resulting data, so that better
informed decisions can be made regarding the
efficacy of a new drug relative to the active control.
2. SIZING AN ACTIVE-
CONTROLLED TRIAL
Suppose an active-controlled trial is proposed to
compare a new drug (T) with an active control
drug (C) in terms of overall survival. It is assumed
that effectiveness of C has been previously
established in a placebo (P) controlled clinical
trial(s). The estimate of the effect of C is captured
in the hazard ratio, HR[P:C], with an associated
standard error, SE ln{HR[P:C]}. The aim, as
typically stated in such trials, is to assess whether
T is non-inferior to C and, in line with Jones et al.
and recent examples in oncology, the hypothesis to
be tested is that T retains at least 1
2
of the active
control effect [11–13]. Thus, the null and alter-
native hypotheses are
H0 : ln HRðT : CÞ5
1
2
ln HRðP : CÞ vs:
H1 : ln HRðT : CÞ5
1
2
ln HRðP : CÞ
More generally, the fraction of the control effect to
be retained, d, say, can be defined as per
Rothmann et al. [1] as
d ¼ 1ÿ
ln HRðT : CÞ
ln HRðP : CÞ
so that the null and alternative hypotheses become
H0 : ln HRðT : CÞ5ð1ÿ dÞ ln HRðP : CÞ vs:
H1 : ln HRðT : CÞ5ð1ÿ dÞ ln HRðP : CÞ ð1Þ
Suppose C was previously shown to significantly
increase survival in a particular disease setting
with HRðP : CÞ ¼ 1:5; p ¼ 0:005; say. It is desired
to demonstrate that the new treatment T retains 1
2
of the control effect. Assuming T and C are truly
equal in effectiveness, the number of deaths
required in the trial of T compared to C to achieve
this aim can be derived in a number of ways:
(i) If the uncertainty in the estimate of the
control effect is ignored, a routine sample size
calculation shows that a total of 1023 deaths is
required to provide 90% power at the one-sided,
2.5% significance level [14]. Non-inferiority will be
concluded if the upper 95% confidence limit (CL)
for HR (T:C) is 1.23 or less, where 1:23 ¼ 1:501=2:
(ii) Clearly, ignoring the uncertainty in the
estimate of the control effect is problematic and
inflates the type I error [5]. An alternative
approach that has been used in oncologic drug
evaluation has been to use the lower 95% CL for
the HR(P:C) as the estimate of the control effect
and demonstrate preservation of 1
2
of this effect
[10–12]. Here the lower 95% CL for
HRðP : CÞ ¼ 1:13: If used, then just over 11 200
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deaths are required to provide 90% power at the
one-sided, 2.5% significance level and non-
inferiority will be concluded if the upper 95%
CL for HR (T:C) is 1.06 or less, where 1:06 ¼
1:131=2: However, this approach has been shown to
be very conservative and should be avoided if at all
possible [5, 6].
(iii) Rothmann et al offers a simple linear
combination of the data arising in the active-
control trial and the historical data on the control
to test the null [1]. The test statistic, z*, is given as
zn ¼
ln H #RðT :CÞ ÿ ð1ÿ dÞln H #RðP:CÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
S #E
2
ðln H #RðT :CÞÞ þ ð1ÿ dÞ2S #E
2
ðln H #RðP:CÞÞ
q ð2Þ
Under the assumption of constancy, |z*|>1.96
leads to a rejection of the null and so a conclusion
that T retains more than 100d% of the control
effect and the type I error is maintained at 2.5%
one-sided. The number of deaths required to
achieve a given power can be calculated via
[Reference 1, equation (12), p. 254].
Using this approach, a total of 3220 events are
required to provide 90% power at the one-sided,
2.5% significance level. Non-inferiority will be
concluded if the upper 95% CL for HR (T:C) is
1.12 or less, being intermediate between (i) and (ii).
The 1.12 limit is derived using equation (9), p. 251
of Reference [1].
Thus the above approach appears attractive.
Assuming constancy of the effect of the control
and accepting assay sensitivity, a formal statistical
comparison is proposed between the historical
data characterizing the control effect and the data
arising in the trial comparing new to control,
thereby explicitly incorporating the uncertainty
(i.e. SE) around the control effect estimate.
Operationally, this approach is equivalent to
conventional methodology using not the point
estimate for the control effect, but, rather, a lesser
effect somewhere between the point estimate and
its lower (two-sided) 95% confidence limit. This
reduced effect is chosen so that the chance of
falsely approving an inferior drug is exactly 2.5%,
thereby managing the regulatory risk.
However, while sample sizes are smaller than
would be the case with the use of the lower 95%
CL for the control effect estimate, this approach
can still result in very large trials. This derives from
a combination of the (arbitrary) effect retention
fraction (50% in this example) and the strength of
prior characterisation of the control effect, which is
reflected in the (historical) p-value (0.005 in this
example). As illustrated in Table I, the application
of this methodology may actually require more
events than there are patients with the disease [9].
In reply to these concerns, it has been suggested
that, rather than assuming T and C are equal in
effectiveness, active control trials could be pow-
ered at alternatives where T is a little better than C
and it has been further recommended that survival
trials intended to support regulatory approval
should not have fewer than 200 deaths [15]. While
both suggestions would result in a lower sample
size requirement for the active-controlled trial,
they are somewhat problematic. In the absence of
Table I. The number of deaths required to prove a new treatment retains 1
2
of the effect of control treatment (HR=0.50)
using Rothmann et al methodology (true HR new:control is unity, 90% power, a 2.5% one-sided).
(Historical) p-value for
control vs placebo
Upper 95% CI for HR(T:C)
must be less than
Approx No. of deaths required
to prove 50% effect retention
0.049 1.004 3 000 000
0.02 1.12 3082
0.01 1.18 1563
0.001 1.27 735
0.0001 1.31 572
0.00001 1.33 505
0.000001 1.35 459
550.000001a 1.41 350
aEquivalent to the control effect being known with (virtually) complete certainty.
Active-controlled, non-inferiority trials in oncology 285
Copyright # 2006 John Wiley & Sons, Ltd. Pharmaceut. Statist. 2006; 5: 283–293
DOI: 10.1002/pst
Publication 11: Carroll (2006)
195
data to the contrary, to assume T is a little better
than C would be to reduce power and so increase
the risk of an equivocal result and, therefore, risk
exposing patients to trial procedures without a
realistic prospect of obtaining a clear answer. With
respect to a recommendation that survival trials
should not have fewer than 200 deaths, there does
not appear to be any regulatory guidance, peer
reviewed publication or statistical text that argues
for a threshold on the number of events to support
a time-to-event analysis. It seems more reasonable
to argue that considerations of plausible effect size,
type I and II error are, and should remain, the
determinants of the number of deaths needed to
secure a meaningful analysis in a survival trial.
3. AN ALTERNATIVE APPROACH
While it is hard to argue that, in both planning and
analysing an active-control, non-inferiority trial,
the uncertainty around the estimate of the control
effect can be ignored, it has been argued by Senn
that pre-specification of a non-inferiority limit
(here captured in the form of a given percent of the
control effect to be retained) is of little value in
analysing and interpreting such trials [16]. Rather,
the judgement as to what is and is not an
unacceptable loss of effectiveness of the control
treatment should lie with the ‘consumer’, that is
with physicians and their patients or the regulatory
authority acting on the patients behalf. This is akin
to the usual approach to interpreting data arising
in superiority trials, where the hypothesis sensibly
advanced in the planning stage to size the trial is
seldom, if ever, taken into account when judging
the clinical value of an observed, significant
difference. Further, Senn provides a simple exam-
ple where two sponsors compare their new drugs
(say T1 and T2) against the active control (C), the
first sponsor specifying a more liberal non-
inferiority limit (say a HR(T1:C)=1.30) than the
second (say HR(T2:C)=1.15). If the upper 95%
CL is 1.25 for HR(T1:C) and 1.20 for HR(T2:C)
then the rather odd conclusion is that T1 is non-
inferior while T2 is not, despite being able to rule
out a lesser for disadvantage for T2.
In the context of approaches where an indirect
comparison is made between historical data and
data arising in the trial of T compared to C, the
application of a margin imposes a burden on the
active-control trial greater than that which would
be applied if a direct comparison to placebo was
feasible. It could be argued that there should be no
difference between the standards of evidence
required in a superiority setting and in a non-
inferiority (or active-control) setting. As stated in
the recent CHMP guidance on non-inferiority
trials, the first purpose of an active-control trial
should be to provide evidence that a new agent
would have been better than placebo if placebo
had been included [17]. The second purpose of an
active-control trial should be to estimate (indir-
ectly) the size of the effect of the new agent relative
to control. Both of these aims are achievable with
the effect preservation approach and assumptions,
with some small modifications.
This thinking leads to an alternative approach
which does not require pre-specification of a
percentage effect retention (and hence, a non-
inferiority limit) though, having obtained the data,
the result can be easily displayed in relation to the
likely fraction of the standard effect retained.
Examples that mirror this kind of approach have
been given by Fisher and by Simon where the
effect of drug relative to placebo, T:P, has been
estimated by combining the effect of T:C, #bT :C say,
estimated from the active-control trial with histor-
ical data estimating the effect of P:C, #bP:C
say, [18,19]. Fisher considers only the contrast
#bT :C ÿ #bP:C as an estimate of the effect of drug
relative to placebo with variance #V
ÿ
#bT :C

þ
#V
ÿ
#bP:C

whereas Simon also considers the contrast
#bT :C ÿ ð1ÿ dÞ #bP:C with variance #V
ÿ
#bT :C

þ
ð1ÿ dÞ2 #V
ÿ
#bP:C

for different values of effect
retention, 04d41:
Expanding on the previous example, to prove
efficacy over placebo indirectly with 90% power
and 2.5% one-sided significance, 800 events would
be required in a head-to-head comparison of the
new treatment with the standard. To understand
the origin of this calculation, examination of (2)
reveals that if d ¼ 0 the null hypothesis being
tested is HRðT : PÞ ¼ 1: Thus, effect preservation
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methodology with a zero effect retention is
equivalent to testing indirectly whether drug is
superior to placebo. The number of events
required to achieve a desired power can therefore
easily be obtained either via equation (12), p. 254
of Reference [1] or, equivalently, via equation (8),
p. 487 of Reference [19]. Working again through
equation (9), p. 251 of Reference [1], it is
straightforward to show that indirect efficacy of
T over P would be concluded if the upper 95% CL
for the HR (T:C) was 1.26 or less.
4. THE EFFECT RETENTION
LIKELIHOOD
Once complete, the data from the active-control
trial can be displayed in the form of an ‘effect
retention likelihood’ plot, through which the
probability of the new drug retaining a given
fraction of the control effect can be gauged.
Operationally, the effect retention likelihood is
easily obtained from (2). Given the historical data
on the control effect and the data arising in the
trial of T compared to C, a range of values can be
inserted for d, the fraction of the control effect to
be retained, from d ¼ 0 which is equivalent to
demonstration that T is superior to (putative)
placebo, through to d ¼ 1 which is equivalent to
demonstration that T is superior to C. For each
value of d inserted, fÿ1 (z) gives the likelihood that
T has retained at least this fraction of the efficacy
of C, where fÿ1(.) is the inverse cumulative density
function for the standard normal distribution.
Continuing the example above, examples of
possible effect retention likelihood plots are
displayed in Figure 1.
Graphical display of the data in this fashion is
more informative than the usual analysis asso-
ciated with active-control, non-inferiority trials.
For example, it can be discerned from Figure 1
that, if the observed hazard ratio was unity, then
there is a 99.4% chance that the T would have
beaten placebo if a placebo controlled trial would
have been possible, a 97.8% chance that 50% of
the effect of C has been retained and a 90% chance
that 75% of the effect of C has been retained. In
line with CHMP guidance, it may be more
informative to interpret effects not as percentages,
but in terms of a unique HRs and differences in
median survival [17]. To see how this might be
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Figure 1. Effect retention likelihood plot: historical control effect, HR ¼ 1:5; p ¼ 0:005; active-control trial
design with 800 events, 90% power, 2.5%, one-sided a level.
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achieved, the null hypothesis in (1) can be restated
as H0: HR(T:P)5HR(P:C)
d. Hence, if we insert
the historical point estimate for HR(P:C), zero,
50% and 75% effect retentions correspond to the
likelihood that the hazard ratio HR (T:P) is 51,
50.82 and 50.74 respectively. Further, if, for
example, median survival on placebo was 6
months and assuming exponentially distributed
survival times, then these hazard ratios would
translate to the likelihood that the difference
between T and P in median survival was >0,
>1.4 and >2.1 months respectively.
5. EXAMPLES
5.1. 2nd line treatment of advanced non-small cell
lung cancer (NSCLC)
In terms of a more concrete example, consider a
new drug, T, for the treatment of 2nd line
advanced NSCLC. The current approved standard
of care in the USA is docetaxel 75mg which, on
the basis of a 104 patient trial, was shown to
significantly improve survival over best supportive
care (BSC), with HR (docetaxel:BSC)=0.56, 95%
CI (0.35, 0.88), p ¼ 0:01 so that the SE lnHR
(docetaxel:BSC) is approximately 0.23 [20,21].
Ignoring uncertainty in the estimate of the
docetaxel effect, a clinical trial comparing T to
docetaxel which aims to show retention of 1
2
of the
docetaxel effect with 90% power and 2.5%, one-
sided significance would require around 500
deaths, already substantially larger than the
original trial supporting approval. Application of
Reference [1], equation (12), p. 254, to show
retention of the same amount of the docetaxel
effect would result in a trial requiring 2840 deaths.
The alternative method proposed above would
require 625 deaths to prove efficacy over BSC
indirectly with the same power and significance
level. Assuming a range of outcomes for the trial,
examples of the possible associated effect retention
likelihood plots are displayed in Figure 2.
For example, we can discern from Figure 2 that,
if the observed hazard ratio was unity, then there is
a 99.1% chance T would have beaten BSC if a
BSC controlled trial would have been possible, a
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Figure 2. Effect retention likelihood plot: historical control effect HR ¼ 0:56 p ¼ 0:01; Active control trial
design with 625 events, 90% power, 2.5%, one-sided a level.
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98.1% chance that 50% of the docetaxel effect has
been retained and a 92.9% chance that 75% of the
docetaxel effect has been retained. In terms of
hazard ratios these numbers correspond to the
likelihood the hazard ratio HR (T:P) is51,50.75
and 50.65, respectively.
5.2. Pemetrexed in the treatment of 2nd line
advanced NSCLC
Building on the previous example, it is informative
to consider pemetrexed which was compared to
docetaxel in a randomized phase III trial in 571
patients with advanced NSCLC [22]. The aim of
the protocol was to show non-inferiority of
pemetrexed to docetaxel in terms of survival. As
prospectively stated in the protocol, non-inferior-
ity was to be concluded if the upper 95% CL was
less than 1.11. A rationale for the 1.11 limit is not
provided in the cited paper but corresponds to
observing at least 78% retention of the docetaxel
effect. The reported analysis was conducted with
409 deaths (target number of deaths was 385). The
HR (pemetrexed:docetaxel) was 0.99, 95% CI
(0.82–1.20) and median survival for pemetrexed
was 8.3 vs. 7.9 months for docetaxel.
These data were reviewed in an open Oncologic
Drugs Advisory Committee (ODAC) in July 2004
[23]. The discussion and debate on the data and
non-inferiority issues in general was extensive. On
the basis of the data, FDA concluded that
pemetrexed was not proven to be non-inferior to
docetaxel; the upper 95% CL for the HR
(pemetrexed:docetaxel) was 1.20 and so exceeded
the pre-defined non-inferiority limit of 1.11.
However, ODAC panel members voted in favour
of approval of the drug on the basis that it
appeared to have similar survival to docetaxel and
a different, more favourable side effect profile. This
apparent divergence of views might have been
avoided to some degree if the data had been
presented as in Figure 3.
Figure 3 indicates that there is a 99.1% chance
pemetrexed would have beaten BSC if a BSC
controlled trial would have been possible, a 97.6%
chance that 50% of the docetaxel effect has been
retained and a 91.2% chance that 75% of the
docetaxel effect has been retained. As before, these
numbers correspond to the likelihood the hazard
ratio HR (pemetrexed:BSC) is 51, 50.75 or
50.65 or better, respectively. With respect to the
1.11 limit in the protocol, corresponding to
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Figure 3. Effect retention likelihood plot for pemetrexed vs. docetaxel.
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observing 78% effect retention, the data show
there is an 89% chance that this degree of the
docetaxel effect has been retained by pemetrexed.
Hence, by examining the data in terms of the effect
retention likelihood, it is clear that the trial data
provide confidence that pemetrexed is a efficacious
drug and, further, that there is a high chance that
pemetrexed retains a large fraction of the docetax-
el effect. It is interesting to note that the
interpretation of data that results from this
approach is entirely consistent with the European
Public Assessment Report on pemetrexed which
states that ‘although non-inferiority was not
formally established, the data submitted are robust
enough to conclude that a clinically significant
inferiority of pemetrexed to docetaxel in terms of
efficacy in this population is unlikely’ which is a
rather more complete assessment of the data than
a statement that non-inferiority has not been
met [24].
6. SITUATIONS WHERE THERE ARE
NO TRIAL DATA DEMONSTRATING
THE EFFECTIVENESS OF THE
CONTROL RELATIVE TO PLACEBO
In all of the above scenarios it is assumed that
there are historical data on the control treatment
to provide an estimate of the effectiveness of the
control over placebo (or some other agent).
However, there may be some situations, most
frequently in oncology, where treatments are
prescribed in practice but no trial data exist that
demonstrate efficacy relative to placebo. An
example of such a situation might be the drug
methotrexate which is commonly used to treat
recurrent head and neck cancer. How one should
proceed in such situations is problematic though
the newly issued CHMP guidance does suggest an
interesting way forward in which a trial is powered
to compare T to C for modest superiority, but with
a more liberal significance level than the conven-
tional 2.5% one-sided [17]. For example, if it was
hypothesized that the HR (T:C) was 0.80, then 528
deaths would be required for 90% power with one-
sided a level of 10%. This means that an observed
HR of 0.89 or better would be required to show T
was superior to C with 90% probability. The
situation is illustrated graphically in Figure 4 via a
Normal probability density function with mean
ln(0.89) and variance 4
528
:
In practice this approach will always require the
HR (T:C) to be in favour of the new drug, but, in
an attempt to balance the risk of failing to offer
likely therapeutic advances to patients with few
treatment options in truly life threatening situa-
tions, it does not demand p50:025: This is clearly
an important philosophical change in thinking
that will hopefully prompt healthy and productive
discussion in both the oncologic and regulatory
communities alike and encourage development
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true HR  1
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Trial comparing T to C with 528 deaths,
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Figure 4. Probability density function for T vs C with 528 deaths, observed HR(T:C) 0.89, one-sided a level of 10%.
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of medicines in oncologic indications where
treatments are used but have not been proven to
be effective in placebo controlled trials.
7. DISCUSSION
This paper describes a stepwise approach to design
and analysis of active-controlled, non-inferiority
trials. In the first design step, the trial is sized to
show indirectly that the new drug would have
beaten placebo; in the second analysis step, the
probability that the new drug is superior to
placebo is assessed and, if sufficiently high, in a
final third step, the relative efficacy of the new drug
to control is assessed on a continuum of effect
retention via an ‘effect retention likelihood plot’.
This approach should be considered prospectively
since it is likely to provide a more meaningful
assessment of relative efficacy so that the value of
new treatments can be better judged.
However, issues do remain. Arguably, the most
difficult, often intractable, issues are ‘constancy’
and ‘assay sensitivity’ – the latter being the ability
of a non-inferiority trial to detect a real difference
between the treatments compared. Constancy is
inherently an unverifiable assumption and infla-
tion of the type I error when this assumption is not
met has been well documented [5, 7, 25]. In fact
‘constancy’ and ‘assay sensitivity’ are closely
related concepts, since the presence of ‘assay
sensitivity’ guarantees that the control treatment
will have a non-zero effect and the assumption of
constancy guarantees the size of that effect. The
latter is a quantitative version of the former. Since
ICH E9 and E10 describe these issues in detail and
provide some general guidance with respect to trial
design and conduct, there is little more to add,
though the issue of constancy is worthy of further,
brief comment [26,27].
When a direct comparison to placebo is
impossible or unethical, researchers have no other
choice, but to make indirect comparisons with
historical data. Whether the simple conventional,
effect preservation or the conservative use of the
lower 95% CL for the estimate of the control effect
is used, the problems of indirect comparisons
apply equally. Given that some form of formal or
informal indirect assessment is inescapable for
active-control trials, whether the aim is to show
superiority or to demonstrate efficacy indirectly
versus historical data, it would seem appropriate
to argue that, in drug development, concentrating
on estimating the degree of benefit over placebo,
albeit through indirect measures, is more in line
with the statutory efficacy standard, which calls for
substantial evidence of efficacy to be established,
with no requirements on relative efficacy with
respect to existing agents. Further, it is often
overlooked that the issue of constancy applies
equally to superiority trials, where, while p50:05
will always indicate a difference between treat-
ments, this does not always imply efficacy. In such
trials, if the comparator has not behaved as
expected and is considered to have underper-
formed relative to historical data, then, even
though p50:05; doubts may persist that efficacy
has been shown.
Nevertheless, showing that the new drug is
superior in efficacy to placebo indirectly might still
be considered insufficient, especially by regulatory
authorities when making licensing decisions. The
motivation for requiring demonstration that the
new drug has retained some positive fraction
of the historical control effect is often a way of
compensating for uncertainty about the constancy
assumption. Thus, if the constancy assumption is
in doubt, then showing that you have retained,
say, at least 50% of the historical control effect
provides increased confidence that the new drug is
truly better than placebo, even if constancy is
violated to some degree with the control treatment
underperforming. Unfortunately, attempting to
address concerns about constancy in this way
leads back to the arbitrary pre-specification of a
percent effect to be retained and, hence, to large
and often infeasible trial sizes. A better approach
would be to size the active-control trial to
demonstrate the efficacy of the new drug relative
to placebo indirectly, and then use the effect
retention likelihood plot to judge how much better
than placebo the new drug is likely to be.
Another issue relevant to constancy in oncology
trials is the impact of improvements in the
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standard of care and the introduction of new,
effective therapies for late-stage disease, both of
which are likely to result in better apparent
performance of the control relative to historical
data. There is little that can be done directly to
address this issue but it is worth noting that since
the performance of BSC has typically remained
unchanged in many oncologic settings, this failure
of constancy for the control does not necessarily
increase regulatory risk. Hence, if non-inferiority
is concluded despite a somewhat better perfor-
mance of the control than expected, confidence
may actually be increased rather than decreased
that the new drug is truly efficacious.
As highlighted by a reviewer, recent CHMP
guidelines state that it is preferable to consider
relative efficacy some absolute measure, like the
hazard ratio, since, for example, 50% effect
retention in an adjuvant setting is inherently
different to 50% effect retention in late-stage
disease [17]. As described above, it is possible to
plot the effect retention likelihood on the hazard
ratio or median difference scale and so address, at
least in part, the issue raised in the guidance. This
guidance also suggests that, over and above
indirect demonstration that the new drug is
efficacious relative to placebo, consideration
should also be given to the traditional ‘clinically
unimportant difference’ since this is likely to be
valuable when interpreting trial data when a label
claim of non-inferiority is sought. The approach
offered in this paper does not imply that the usual
approaches to determining this quantity via
literature review, examination of national treat-
ment guidelines and discussion with treating
physicians are not worthwhile but, rather, only
that this does not necessarily have to form the
basis for sizing a trial and, further, should not be
binding in terms of the achievement or not of non-
inferiority since this can be more comprehensively
assessed via the effect retention likelihood plot.
The scientific and statistical debate on how best
to draw inferences from active-control, non-
inferiority trials is ongoing. The recent literature
serves to highlight that considerable statistical,
methodological and philosophical issues remain.
Failure to consider these issues constructively
within the broader oncologic community could
result in ever increasing drug development times
and, thus, delay the availability of new therapeutic
options to patients with life threatening diseases.
The recently issued CHMP guidance on non-
inferiority trials is highly constructive in this
regard, and offers valuable new thinking especially
in situations where a drug is commonly prescribed
but no trial data exist to confirm its efficacy
relative to placebo. It is hoped that the scientific
community together with regulatory bodies world-
wide will continue to give active-controlled, non-
inferiority trial design and analysis further careful
thought and that the approach offered in this
paper will be of some value in this regard.
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Statistical Issues and Controversies in
Active-Controlled, “Noninferiority” Trials
Kevin J. CARROLL
Active-controlled, “noninferiority” (NI) trials continue
to raise many issues and controversies. With placebo-
controlled trials becoming increasingly difficult in areas
like oncology, infection, arthritis and respiratory illness,
the use of active-controlled, “NI” trials to evaluate new
treatments is likely to continue to be an important feature
of drug development. Such trials continue to pose funda-
mental issues, many of which remain without broad scien-
tific or regulatory consensus. These issues range from the
fundamental purpose of an active-controlled NI trial to
determination of the effectiveness of control and sample
size, to issues of assay sensitivity and trial quality, to the
statistical methodologies to be used. In this article, these
matters are reviewed and discussed and observations are
offered regarding the relative merits of the most com-
mon methodologies currently in use for NI assessment.
Opinions are also included occasionally, some perhaps
controversial, with the intention of generating discussion
and debate.
Key Words: Fixed margin; Percent preservation; Putative
placebo; Standard of evidence; Synthesis.
1. Introduction
Active-controlled, “noninferiority” (AC, NI) trials
have been a feature of drug development programs for
many years, yet they continue to raise issues and con-
troversies among researchers and regulators alike. With
placebo-controlled trials becoming increasingly difficult
in areas like oncology and infection, and also in dis-
eases like rheumatoid arthritis and respiratory illness,
AC, NI trials are likely to remain an important feature
of drug development. Such trials continue to pose fun-
damental issues, many of which remain without broad
scientific or regulatory consensus. And this is despite
such trials being subject to multiple regulatory guid-
ances from EMA and FDA (ICH E9 1998; ICH E10
2000; EMA 2005; FDA 2010). Issues range from the
fundamental purpose of an active-controlled NI trial to
determination of the effectiveness of control via histor-
ical data, to sample size determination and matters re-
lating to assay sensitivity and trial quality. A further and
critical area of debate is what statistical methodology
should be used to determine, indirectly, the effectiveness
of a new experimental drug relative to historical control
data.
These matters are crucial to the reliability and infor-
mative value of AC, NI trials. In this review article, these
matters are discussed and observations are offered regard-
ing the relative merits of the most common methodologies
currently in use for “NI” assessment, namely, the “fixed”
margin, preservation of effect, and synthesis methods.
Opinions are also included occasionally, some perhaps
controversial, with the intention of generating discussion
and debate.
C© American Statistical Association
Statistics in Biopharmaceutical Research
August 2013, Vol. 5, No. 3
DOI: 10.1080/19466315.2013.786651
229
D
o
w
n
lo
ad
ed
 b
y
 [
K
ev
in
 J
. 
C
ar
ro
ll
] 
at
 2
3
:5
3
 1
5
 S
ep
te
m
b
er
 2
0
1
3
 
Publication 12: Carroll 2013(b)
205
Statistics in Biopharmaceutical Research: August 2013, Vol. 5, No. 3
2. Is There Really Any Such Thing as a
“Noninferiority” Trial?
The statutory requirement for regulatory approval of
a new drug is (i) that the drug is effective and (ii) that
there is judged to be a positive benefit:risk. Note that
(i) requires demonstration that the drug is more effective
than placebo. This is consistent with the CHMP guid-
ance on NI trials, which states that the first purpose of an
active-controlled trial should be to provide evidence that a
new drug would have been better than placebo, if placebo
could have been included (EMA 2005). Therefore, while
comparative effectiveness might be a later requirement to
secure pricing and reimbursement, new drugs do not have
to be shown to have superior effectiveness to existing, ap-
proved agents to secure licensure (FDA Oncologic Drugs
Advisory Committee 2004). If that was the requirement
then, logically, and in the absence of some other tangible
benefit, only one drug therapy could ever be approved and
available at any given time since the approval of a new
drug would logically necessitate the currently approved
standard to be withdrawn.
There are essentially two ways to demonstrate drug
effectiveness: (i) directly, via a placebo-controlled trial or
(ii) indirectly via an AC trial when a placebo-controlled
trial is either unethical or impractical.
In the latter case, effectiveness is established by ei-
ther showing that the drug is superior to control and,
therefore, the drug is better than placebo, or by showing
indirectly, by reference to historical data, that the drug
is better than placebo. When considered in these terms,
and in line with Brown (2008), it might be argued that
there is no such thing as an NI trial in which we can
conclude “drug is noninferior to control,” rather there
are only AC trials with differing objectives. In terms of
establishing effectiveness, the first objective of an active-
controlled NI trial is therefore not NI, but rather is to
establish indirectly that the new drug would have beaten
placebo if a placebo-controlled trial could have been in-
cluded. As discussed later, this is directly equivalent to
the FDA’s M1 margin, defined as “the entire effect of
the active control” estimated from historical data (FDA
2010). Examination of the relative effectiveness of a drug
to control by, for example, showing a given fraction of the
control effect (often times 50%; Simon 1999; Hasselblad
and Kong 2001; Wang and Hung 2002; Hung et al. 2003;
Rothmann et al. 2003; Wang and Hung 2003a; Wang and
Hung 2003b; Snapinn 2004; Hung et al. 2005) has been
retained is an additional, arbitrarily higher hurdle, and is
broadly equivalent to FDA’s M2 margin defined as “the
largest clinically acceptable” loss of effectiveness of drug
relative to control (FDA 2010).
The author would argue that this higher hurdle repre-
sents a differentially higher effectiveness standard based
merely on study design (Carroll, Milsted, and Lewis 2004;
Peterson et al. 2010). It would seem preferable to maintain
a single standard and address critical issues such as con-
stancy using appropriate methodology such as discount-
ing (though this itself is equivalent to the use of a lower
p-value for “NI” and, hence, a higher standard). Neverthe-
less, examination of relative effectiveness is valuable in
the judgment of benefit/risk, and may further be of value
to reimbursement authorities (FDA 2010). However, in
terms of establishing the effectiveness of a new drug, it
could be considered as a subsidiary objective (Carroll
2006).
3. Some Disadvantages of Indirect
Comparisons
The fundamental problem with AC, NI trials as a
vehicle to establish drug effectiveness is that many expe-
rienced scientists, statisticians, and regulators have an
understandable mistrust of indirect comparisons. The
absence of randomization and blinding affords little
protection against bias and increases the probability of
erroneous licensing decisions. The situation can be com-
pounded when the historical evidence of control effec-
tiveness is relatively little (as can be the case in end stage
cancer treatment), or uncontrolled (again as is not uncom-
mon in oncology), or antiquated (Fleming and Powers
2008; Dane 2011). And when there are more substantial
historical data, often in terms of several clinical trials of
similar design, the evidence has to be aggregated using
meta analytic methods, which raises a further set of is-
sues including possible selection and publication biases
in addition to debate around the appropriateness of fixed
versus random effects meta analyses. Crucially, one must
assume that the historical data not only are relevant to
the population studied in the current active-controlled
trial, but that the true effectiveness of control is identical
in the historical setting and the current trial. This “con-
stancy” assumption is inherently unverifiable and poten-
tially poses a serious problem to any AC trial regardless
of objective (Carroll 2006). And, finally, there is a closely
related concept of “assay sensitivity,” which guarantees
control will have a nonzero effect, whereas the assump-
tion of constancy guarantees the size of that effect. “Assay
sensitivity” therefore relies on the quality of trial design,
conduct, and completeness of patient follow-up (Carroll
2006). A poorly conducted trial with, for example, many
protocol violators and deviators, and/or where there are
many dropouts who are not followed for key trial end-
points, obviously provides little, if any, reliable evidence
upon which to make credible inferences (Fleming 2008).
And while the argument is often that such trials tend to
bias toward the conclusion of NI, this may be not so
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since confidence intervals widen as variability increases.
In summary, the underlying issues relating to trial quality
apply to any AC trial, since any AC trial of manifestly
poor conduct will be of little, if any, inferential value.
4. Establishing the Control Effect via
Historical Evidence
The upfront provision of data in support of the rele-
vant effectiveness of control is an absolute necessity when
planning an active-controlled NI trial, and is a task that
requires considered, experienced statistical input (Flem-
ing and Powers 2008). In the author’s experience, when
discussing trial design, regulators often raise concerns if
there are only limited data supporting the effectiveness of
an approved control drug (FDA Oncologic Drugs Advi-
sory Committee 2004). This is not infrequently the case
in advanced oncological disease, an example being do-
cetaxol in advanced lung cancer (FDA/CDER New and
Generic Drug Approvals, Taxotare 2011). While this may
seem a reasonable regulatory concern, one has to ask if
the prior trial data were judged sufficient to support ap-
proval of control, then why are the same data not sufficient
to support an analysis to demonstrate, indirectly, a new
drug is efficacious? If the weight of evidence for control is
considered too weak to do so, then one might legitimately
ask on what evidentiary basis was control approved in the
first place?
4.1 Comparison of Current Approaches
to NI Assessment
To explore the issues in AC, NI trials further, the
following notation will be used. Let θcp denote the true
effect of control relative to placebo estimated as θˆcp with
variance Vcp. Similarly, let θec denote the true effect of
experimental to control estimated as θˆec with variance
Vec. Under constancy, the true effect of experimental to
placebo θep is therefore estimated indirectly as θˆcp + θˆec
with variance Vcp + Vec. The fundamental hypothesis to
be tested is therefore:
H0 : θep = 0 versus H1: θep > 0. (1)
In the context of powering for an “NI” assessment, the
alternative in (1) is replaced by H1 : θep > 1. Further, the
hypothesis in terms of θec may be stated as
H0 : θec < 0 versus H1: θec = 0, (2)
where, again, for the purposes of powering, the null is
replaced by H0 : θec < −1. If 1 = θcp, then hypotheses
(1) and (2) correspond directly to the synthesis approach.
In this approach, the historical control effect estimate
and its SE are combined directly with the control versus
drug effect estimate from the current AC trial under the
assumption of constancy (EMA 2005; FDA 2010; Schumi
and Wittes 2011).
To determine effectiveness of the experimental treat-
ment with (1−β) power and one-sided Type I error rate
α using the synthesis approach, and assuming θˆcp and θˆec
are Normally distributed, then
Vec(synthesis) =
[
θec + θcp
zα + zβ
]2
− Vcp, (3)
where zω represents a standard Normal deviate and α is
one-sided. Equation (3) follows directly from the basic
power equation (δ1 − δ0)2 = V (zα + zβ)2 relating to the
hypotheses H0 : δ = δ0 versus H1 : δ = δ1(> δ0), where
H0 is rejected when T > zα
√
V , where T a sufficient test
statistic such that T ∼ N (δ, V ). In practice in Equation
(3), θcp and Vcp would be replaced by their estimates θˆcp
and Vˆcp.
Due to concerns regarding constancy, Equation (1)
is often modified to demonstrate that experimental drug
retains some fraction f of the historical control effect so
that the alternative is replaced by H1 : θep ≥ f θcp with
0 ≤ f ≤ 1. In this case, the synthesis approach morphs
into the preservation of effect method with θec − (1−
f )θcp in Equation (2) (Simon 1999; Hasselblad and Kong
2001; Wang and Hung 2002; Rothmann et al. 2003; Hung
et al. 2003; Wang and Hung 2003a; Wang and Hung
2003b; Snapinn 2004; EMA 2005; Snapinn and Jiang
2008; FDA 2010). Then,
Vec(preservation) =
[
θec + (1− f )θcp
zα + zβ
]2
− (1− f )2Vcp.
(4)
And, again, θcp and Vcp would be replaced by their
estimates in Equation (4).
For the “fixed” margin approach, 1 is set to
η(θˆcp − zα
√
Vˆcp), where 0 ≤ η ≤ 1 is arbitrarily chosen
to insert conservatism in terms of the effectiveness of con-
trol (EMA 2005; FDA 2010; Schumi and Wittes 2011).
Most commonly η = 0.5. For this approach, it follows
that
Vec(fixed) =

η(θˆcp − zα
√
Vˆcp)
zα + zβ


2
. (5)
Examining (3)–(5), we can see that, under the usual
assumption θec = 0,
• The synthesis method is always more efficient than
the preservation of effect method for testing indi-
rectly the hypothesis a new drug is efficacious. This
follows since Vec(preservation) ≤ Vec(synthesis); that is,
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the synthesis method requires a lower N (or num-
ber of events) to test hypotheses (1) and (2).
• To determine effectiveness of experimental with
(1−β) power, both synthesis and preservation of
effect methods require θˆcp − (zα + zβ)
√
Vcp > 0;
that is, that the historical data provide an estimate
of the control effect with p < 28−1{−(zα + zβ)},
meaning a historical control effect with p< 0.0012
is required to achieve 90% power.
• The maximum power achievable to test indirectly
the hypothesis that a new drug is efficacious via ei-
ther the synthesis or preservation of effect methods
is 8−1{|zCP| − zα}, where zCP is the z-value for the
historical control effect estimate.
• The same issues and power cap do not apply
to the “fixed” margin approach where any level
of power can theoretically be achieved providing
θˆcp − zα
√
Vcp > 0; that is, the estimated control
effect is significant with p < 0.05.
• For the common choice f = η = 0.5, the “fixed”
approach is less efficient than the preservation of
effect method when the control effect has signifi-
cance p < 28−1{−0.5zα{(1+ zβ/zα)2 + 1}}, or p
< 0.00025 when 90% power is desired.
• Otherwise, the “fixed” approach is more efficient.
A key observation is therefore that while the synthesis
method is always more efficient than the preservation of
effect approach, both require a historical control estimate
with a p-value ≤0.0012 to provide at least 90% power
to test, indirectly, whether experimental drug is effective.
This may suggest that there is little need to further dis-
count data on historical control (Snapinn 2004; Snapinn
and Jiang 2008). And, with 0.00025 < p ≤ 0.0012 for
historical control, the “fixed” margin approach is more
efficient than preservation of effect approach, and this
reverses with p ≤ 0.00025.
To illustrate these observations, consider, without loss
of generality, a control drug with hazard ratio (HR) ver-
sus placebo of 0.667 95% CI (0.524, 0.849), p = 0.0010
for overall survival, representing a 50% increase in the
event rate for placebo relative to control based on 264
events. The “fixed” NI limit would typically be= 0.8490.5
= 0.921. Via Equation (5) and assuming constancy, an
active-controlled trial would require 6270 events (≈24×
more than the 264 events characterizing the historical
effect of control) to deliver 90% power to test, indi-
rectly, the effectiveness of drug. The preservation of ef-
fect method (4) with f = 0.5 would require 35,073 events
(≈130× more than for historical control) while the syn-
thesis method (3) would require 8768 events (≈33×more
than for historical control). The sensitivity of the power
calculation to the strength of historical evidence charac-
terizing the control effect estimate is further illustrated in
Table 1.
In most oncological and infection settings, AC trials
using either a “fixed” margin or a preservation of effect
method would be infeasible, and the synthesis approach
would be a severe challenge (Carroll, Milsted, and Lewis
2004; Dane 2011). In cardiovascular (CV) outcome set-
tings, again the “fixed” margin or preservation of effect
approaches would prove very challenging, while the syn-
thesis method may be more feasible.
It should be noted that some authors have advo-
cated hypothesizing some small benefit for drug relative
to control under the alternative (Fleming 2008). If so,
then Equation (2) becomes H0 : θec = −1 versus H1 :
θec = +ξ1, where ξ is some small, positive number
such that ξ ≪ 1. Then the required sample size is re-
duced by a factor (1+ ξ )−2. While this approach may at
Table 1. Comparison of sample size requirements in an AC trial to test indirectly at the one-sided 2.5% α level the hypothesis that a new drug is
efficacious
Historical data Number of events required in AC trial
Historical Assumed “Fixed” Max power
HR No. of Two-sided true HR NI for
for C:Pa Events V CP
b 95% CI p-value for E:Cc F or η limit Synthesis “Fixed” Preservation efficacye
0.667 100 0.0400 (0.451, 0.987) 0.04289 1 0.5 0.994 –d 1,000,128 – 53%
0.667 200 0.0200 (0.506, 0.880) 0.00419 1 0.5 0.938 – 10,297 – 82%
0.667 264 0.0152 (0.524, 0.849) 0.00100 1 0.5 0.921 8768 6273 35,073 91%
0.667 327 0.0122 (0.537, 0.828) 0.00025 1 0.5 0.910 1185 4747 4740 96%
0.667 500 0.0080 (0.560, 0.795) 0.00001 1 0.5 0.892 526 3188 2103 99%
0.667 1000 0.0040 (0.589, 0.755) <0.00001 1 0.5 0.869 345 2129 1378 100%
NOTE: aHistorical estimate of the control effect, C = control, P = placebo.
bV CP = variance of the historical control estimate.
cHypothesized effect for drug versus control effect, E = drug.
dVariability of historical control effect estimate too great to achieve 90% power to test indirectly the hypothesis that a new drug is efficacious.
eMaximum power achievable to test indirectly the hypothesis that a new drug is efficacious versus placebo.
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first seem appealing, unless there is a very good scien-
tific rationale for assuming drug is, in truth, marginally
better than control, the author would caution the use of
this approach since artificially manipulating the sample
size downward in this way results in a reduced power of
8−1{(zα + zβ)(1+ ξ )−1 − zα} to test the arguably more
realistic hypothesis (2).
Overall, it can be seen that both the “fixed” margin
and preservation of effect standard approaches transfer
a considerable burden onto sponsors and academic or-
ganizations trying to bring forward new medicines with
equal effectiveness but different or improved tolerabil-
ity or other perceived benefits (Snapinn and Jiang 2008;
2011; Peterson et al. 2010). The synthesis method offers
a more reasonable alternative and, under constancy, di-
rectly assesses the fundamental hypothesis of interest, (1)
or (2), with Type I error α (Simon 1999; Hung et al. 2003;
Rothmann et al. 2003; Peterson et al. 2010).
4.2 When There are No or Very Old Historical Data
While the situation is difficult when some historical
data do exist, it is near impossible when there are no prior
data quantifying the effectiveness of control, or where
the historical data are from a completely different era,
as is the case in for some infectious diseases where the
only placebo-controlled data are around six decades old
(Fleming and Powers 2008; Dane 2011). In such situa-
tions the historical evidence is subjectively discounted,
down-weighting the observed effectiveness of control to
such an extent that the resultant NI margin becomes some-
thing of a guess, forcing trials that are ever higher in size
(Snapinn 2004; Fleming and Powers 2008; Dane 2011).
Another approach might be to consider the EMEA guid-
ance that encourages the use of active-controlled trials
with a superiority objective with perhaps a somewhat
more liberal α level for “significance” in those situations
where using the usual 0.025 one-sided level results in
impractical trial sizes. In this way, licensing decisions
can be made on the basis of some randomized, controlled
evidence of effectiveness rather than no evidence at all
(EMA 2005; Carroll 2006).
5. A Comment on Pre-Protocol Versus
ITT Analyses
It is well known and captured in regulatory guidelines
that the primary analysis set in an NI trial is preferred to
be per-protocol (PP) with an intent-to-treat (ITT) analy-
sis being supportive (ICH E9 1998; ICH E10 2000; EMA
2005; FDA 2010). In the author’s view, this may be chal-
lenged for several reasons: PP (or “modified ITT” which
is not, incidentally, ITT) results in a comparison that is
data driven and unsupported by randomization. In trials
with morbidity and mortality endpoints, a PP analysis
makes little sense as it could result in the exclusion of
patient deaths and/or other morbid events. It is crucial
that phase III confirmatory clinical trials are generaliz-
able, and reflect what might happen in clinical practice.
Analyses that attempt to “clean up” the patient popula-
tion and exclude those who deviated from the protocol in
some way, or even who never received randomized treat-
ment, do not necessarily reflect reality and, hence, are of
questionable value and meaning. And while it is often
required that the PP and ITT analyses give qualitatively
similar results, as highlighted by a referee, this seems
odd given that these analyses have differing objectives,
namely, to estimate efficacy (PP) and effectiveness (ITT)
(Sheiner and Rubin 1995).
Rather, what is needed are valid, unbiased analyses
based on the randomization. In relation to AC, NI trials,
ICH E9 (1998) stated that
“. . . it is especially important to minimise the in-
cidence of violations of the entry criteria, non-
compliance, withdrawals, losses to follow-up, missing
data and other deviations from the protocol, and also
to minimise their impact on the subsequent analyses.”
So, for those who rightly worry about violators, devi-
ators, and dropouts, the solution is not to cut them out of
the analysis in a PP approach, but rather to execute AC
trials to rigorous and exacting standards, to minimize pro-
tocol nonadherence and ensure full ITT follow-up of all
randomized patients so the trial evidence generated is of
the highest completeness and quality (Fleming 2008). In
this way, regulators and the scientific community can rely
upon the data and what they show. This goes to the heart
of “assay sensitivity,” as mentioned previously, ensuring
that the AC trial is of the highest possible scientific stan-
dard, regardless of whether the objective is superiority or
“NI.”
6. A Comment on FDA’s Draft NI Guidance
FDA’s recent draft NI guidance lays out the challenges
with AC, NI trials and, in so doing, raises many issues for
debate (FDA 2010). Unfortunately the guidance is rather
long and perhaps a little confusing at times and, con-
sequently, misses the opportunity to provide very clear,
concise, and consistent guidance to sponsors. However,
FDA has begun to tackle the longstanding issues associ-
ated with AC, NI trials, and that is to be applauded. The
most contentious part of the current draft guidance is,
arguably, the introduction of not one, but two NI margins:
M1 and M2, being as defined previously.
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M1 is constructed such that it establishes the effec-
tiveness of drug indirectly versus putative placebo, which,
in principle, makes sense. M2, however, is a different mat-
ter. It is a “fixed” margin based upon clinical judgment,
shaped by prior historical data. As raised previously, the
problem with this margin is that it represents an arbi-
trarily higher standard of effectiveness based on trial de-
sign (Carroll 2006; Peterson et al. 2010). Furthermore,
the notion that it is a “fixed” margin representing some
known and acceptable loss of effectiveness, and there-
fore is treated as a constant in both powering and analysis
seems rather strange. Since the margin is obviously based
on the available evidence quantifying the effectiveness of
control, and since that evidence has uncertainty associ-
ated with it, the margin itself is hard to call “fixed.” ICH
guidance calls for a justification of the margin, which
must take us back to the historical data and their uncer-
tainty. To ignore the underlying uncertainty in the data
giving rise to the margin is arguably improper statisti-
cally. Use of the synthesis method is more satisfying in
this regard as the uncertainty in the control effect esti-
mate is directly accounted for. Further, there should only
be one standard for drug effectiveness, being effective-
ness versus placebo at the 0.05 level, which equates to M1
(Peterson et al. 2010). If a higher standard is required, say
akin to the single trial level of evidence, then this boils
down to M1 with p < 0.01, or lower, say, and hence there
appears to be little need, per se, for M2 in establishing
effectiveness of drug. If, for the likes of reimbursement,
it is desired to describe the relative effectiveness of drug
to control, then this can be achieved using methodology
such as the effect retention likelihood (Carroll 2006); this
is discussed further in Section 8.
7. Logical Problems With Preservation of
Effect and “Fixed” Margin Approaches
Putting aside for now arguments relating to the need
for a “fixed” margin M2, if one decides that this is the
route to take then it should be noted that there are rather
serious problems with both this approach and the related
preservation of effect method, problems that could lead
to rather odd licensure decisions.
Consider Figure 1 based on Snapinn and Jiang (2008)
and Peterson et al. (2010).
Here a fictitious drug developer, EfficsFarma, say, has
been required by the regulator to use the preservation
of effect method in order to show that their new drug,
Bettapill, retains a fraction f of the effectiveness of the
control drug, Mediocredex. Mediocredex was previously
shown to be better than placebo by TitanicFarma in a
small Phase III study. The effectiveness of Mediocredex
relative to the (indirect) effectiveness of Bettapill is il-
Figure 1. 95% confidence intervals for Mediocredex versus placebo
and Bettapill versus placebo.
lustrated in Figure 1 by their respective 95% confidence
intervals, and the desired fraction of the Mediocredex ef-
fect to be retained is also shown, labeled f × θˆmp. The
results indicate that both Bettapill and Mediocredex are
superior to placebo, and they suggest that Bettapill may
be even better than Mediocredex, but since Mediocredex
was approved first, the preservation of effect criterion
logically requires that Bettapill cannot be approved since
its 95% CI does not exclude the desired fraction of the
Mediocredex historical effect.
A similar kind of illogical consequence for the “fixed”
margin approach was highlighted by Senn (2005). Sup-
pose now that TitanicFarma and EfficsFarma compare
their new drugs Mediocredex and Bettapill against some
established active control, Proventrt say. Assume, with-
out loss of generality, the endpoint is a time to event
with treatment effects expressed as HRs. Suppose Titan-
icFarma specifies a fixed limit of 1.30 and EfficsFarma a
limit of 1.15. Further, suppose the upper 95% CL for the
estimated Mediocredex:Proventrt effect is 1.25, and for
Bettapill:Proventrt is 1.20. The unfortunate conclusion is
that Mediocredex is noninferior, while Bettapill is not,
despite being able to rule out a lesser disadvantage for
Bettapill relative to Mediocredex.
8. Example Design, Analysis, and
Presentation of an AC NI Trial
Recognizing the issues highlighted above, the obvious
question is: If not the standard “fixed” and preservation of
effect approaches, then what? The most straightforward
answer is, unsurprisingly, to use the synthesis method
to both size and analyze the AC, NI trial since, under
constancy, this approach provides a test of exactly size 2α
to test the most relevant hypothesis, (1) (Peterson et al.
2010).
In terms of design, Equation (3) above provides the
number of patients or events required to demonstrate ef-
fectiveness of drug relative to putative placebo at the one-
sided α level with (1−β) power. Also critically required
at the design stage (as an appendix to the protocol), and
not several months or years after the trial has commenced,
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is a clear and transparent documentation of the historical
body of evidence supporting the effectiveness of control
and the clinical relevance of this evidence to the setting
of the proposed AC, NI study. This approach is consistent
with ICH E9 (1998), which states that
Active comparators should be chosen with care. An
example of a suitable active comparator would be a
widely used therapy whose effectiveness in the relevant
indication has been clearly established and quanti-
fied in well designed and well documented superiority
trial(s) and which can be reliably expected to exhibit
similar effectiveness in the contemplated active con-
trol trial. To this end, the new trial should have the
same important design features (primary variables,
the dose of the active comparator, eligibility criteria,
etc.) as the previously conducted superiority trials
in which the active comparator clearly demonstrated
clinically relevant effectiveness, taking into account
advances in medical or statistical practice relevant to
the new trial.
Having conducted the AC trial to exacting standards
of quality and patient follow-up, standards that are laid out
in advance as part of the study protocol in line with Flem-
ing (2008), the statistic z = θˆec−θˆcp√
Vep+Vcp
provides an indirect
test of effectiveness via the synthesis method (Peterson
et al. 2010). Clearly, constancy is a major concern and
inclusion of analyses that discount the historical control
data can be helpful and informative. In a manner similar
to that proposed by Rothmann et al. (2003), one simple
approach might be to discount θˆcp by some amount based
on judgment taking into consideration the amount, age,
and relevance of the historical data. In this case, it may be
of interest to calculate the maximum degree of discount-
ing that would still provide θˆep with one-sided p < 0.025.
Finally, it is helpful if the presentation of results is simple
and transparent, as is hoped by example in Table 2 and
Figure 2.
Beyond Table 2 and Figure 2, there is often interest in
the relative effectiveness of drug to control. An approach
to display the full range of relative effectiveness on a
continuum, from drug better than placebo to drug better
than control, has previously been described in terms of an
effect retention likelihood plot (Carroll 2006). Figure 3
Figure 2. Active-controlled, NI analysis.
shows the likelihood effect retention for the preceding ex-
ample, both for discounted and nondiscounted historical
data.
Graphical display of the data in this fashion is more
informative than the usual analysis associated with active-
control, “NI” trials. We can discern from Figure 3 that
there is a 99.98% chance that the drug is effective versus
putative placebo; a 99.5% chance that 50% of the effect of
control has been retained; and a 65.8% chance that 100%
of the effect of control has been retained; that is, that
the drug is superior to control. Similarly, if the historical
control effect is discounted by as much as 43%, there is
a 97.5% chance that the drug is effective versus putative
placebo and a 93.7% chance that 50% of the effect of
control has been retained. Discounting further would not
allow rejection of H0 : θep = 0. Hence, by examining the
data in terms of the effect retention likelihood, it seems
clear that, in this example, the AC trial data provide
confidence that drug is efficacious and, further, there is
a high chance that drug retains a large fraction of the
control effect.
9. Summary and Recommendations
This article attempts to draw out and discuss issues
and controversies associated with AC, “NI” trials. In line
with Brown (2008), the issue of whether there is really
such a thing as an AC, NI trial in which it can be stated
that “noninferiority was established,” is not merely an
Table 2. Example presentation of active-controlled, “NI” analyses
HR Discount factor Discounted HR No. of events SE logHR Lower 95% CI Upper 95% CI p-Value
C v P 0.667 1 0.667 400 0.1000 0.548 0.811 0.00005
E v C 0.970 1 0.970 713 0.0749 0.838 1.123 0.68426
E v P∗ 0.647 0.647 0.1249 0.506 0.827 0.00049
C v P 0.667 0.53 0.807 400 0.1000 0.663 0.982 0.03185
E v P∗ 0.647 0.783 0.1249 0.613 1.000 0.04980
NOTE: ∗Indirect estimate.
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Figure 3. Effect retention likelihood plot for C v P HR = 0.67 (0.55, 0.81) and E v C HR = 0.97 (0.84, 1.12).
idiosyncrasy of nomenclature; it goes directly to the heart
of what is trying to be achieved by conducting an AC trial.
In terms of the statutory requirement for licensure, the pri-
mary goal is to establish effectiveness of the experimental
drug, and this is achieved by indirect comparison via an
AC trial in settings where it is unethical or infeasible to
incorporate placebo. The dislike of indirect comparisons
to historical data is entirely understandable—experienced
statisticians would typically prefer the security of a ran-
domized comparison to ensure both comparability and an
absence of bias.
Without randomization, regulators are left uneasy, and
consequently have tended to impose punitively conserva-
tive methods such as a “fixed” margin based on the 50%
of the lower 95% CI, or a requirement for at least 50% re-
tention of the control effect. Both of these approaches are
subject to serious illogicalities, which arguably render
them unsuitable for licensing decisions (Peterson et al.
2010). Even if the shortcomings are ignored and these
methods are used, two undesirable outcomes flow as a
consequence. First, a disproportionately large burden is
transferred to the sponsor or research organization who
is required to conduct large, often infeasible AC trials
to offset the quantity of historical evidence, which ulti-
mately could lead to fewer therapeutic advances in the
future. Second, these methods represent an arbitrarily
higher standard for effectiveness based purely upon trial
design.
These and many other issues are covered in FDA’s
draft guidance. While much could be discussed in rela-
tion to this guidance, the single most important issue is
the proposal for two NI margins, M1 and M2. While M1
makes sense in terms of establishing effectiveness of ex-
perimental drug, M2 imposes an arbitrarily higher hurdle
based upon clinical judgment. The latter again represents
a higher standard of effectiveness, this time determined
subjectively by clinical judgment.
It would seem the only solution to the plethora of is-
sues assailing AC, NI trials is pragmatism. In terms of
design and analysis, it makes most sense to employ the
synthesis method, thereby foregoing the need for a “fixed”
margin or percent preservation target. Under constancy,
this approach provides a test of size 2α to evaluate the
most relevant hypotheses relating to drug effectiveness.
While concerns regarding assay sensitivity and constancy
are well founded, the latter cannot be tested statistically
and is inherently unverifiable (Carroll 2006). Neverthe-
less, some discounting of the historical control estimated
effect can be explored to ascertain how much discount-
ing could be imposed and yet still demonstrate indirectly
that experimental is effective. Further, critical to instilling
confidence in the reliability of an AC, NI assessment is
careful, a priori examination of the relevance of historical
control data to the setting of the proposed AC trial (ICH
E9 1998; Fleming 2008). And, with respect to assay sensi-
tivity, the solution is not to resort to patient exclusions and
nonrandomized PP analyses, but rather to establish strin-
gent standards for trial conduct and execution that serve
to enhance close adherence to the protocol and deliver
full patient follow-up (ICH E9 1998; Fleming 2008).
Statistical leadership can help substantially in the mat-
ters, by ensuring the right thinking takes place upfront,
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and that this thinking is reflected in the protocol. This
means ensuring that
(i) all the relevant data on the historical control ef-
fect are laid out objectively and transparently,
and are combined using statistically appropriate
analytic techniques,
(ii) the relevance of the historical data to the setting
of the proposed AC trial is carefully evaluated
and documented, and
(iii) that metrics are laid down in advance to deliver
the highest quality AC data by enhancing proto-
col compliance and minimizing violations, de-
viations and patient loss to follow-up.
In addition, statisticians can make a further, telling
contribution by ensuring the primary hypotheses to be
tested, (1) and (2) as provided in Section 4.1, are clearly
stated in the protocol at the outset and are understood by
nonstatistical colleagues. Statisticians can also contribute
by ensuring the sample size and powering to test, indi-
rectly, for drug effectiveness and the associated method of
analysis are also captured and understood by all. Finally,
the statistician needs to guarantee a transparent presenta-
tion of the analysis, where direct and indirect estimates
of effect are clearly displayed side-by-side, and perhaps
where methodologies are employed that illustrate the rel-
ative effectiveness of drug to control on a continuum from
drug better than placebo to drug superior to control.
The scientific discussion around AC, NI trials is very
active due to the many issues and controversies that re-
main unresolved, some of which are highlighted in this
article. The intention is not to offer a set of answers to
these issues, but rather to try cast some of these issues
in a newer light, in the hope that this might spark further
debate and discussion between researchers, sponsors, and
regulatory agencies. In so doing, it is hoped that pragmatic
approaches and solutions might be found that enable AC,
“NI” trials of feasible dimension and excellent design to
be conducted as part of drug development programs seek-
ing to bring forward therapeutic alternatives to existing
treatments.
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Abstract
In the analysis of survival data arising in clinical trials, Cox’s proportional hazards regression
model (or equivalently in the case of two treatment groups, the log-rank test) is firmly established
as the accepted, statistical norm. The wide popularity of this model stems largely from extensive
experience in its application and the fact that it is distribution free—no assumption has to be made about
the underlying distribution of survival times to make inferences about relative death rates. However,
if the distribution of survival times can be well approximated, parametric failure-time analyses can
be useful, allowing a wider set of inferences to be made. The Weibull distribution is unique in that
it is the only one that is simultaneously both proportional and accelerated so that both relative
event rates and relative extension in survival time can be estimated, the latter being of clear clinical
relevance. The aim of this paper is to examine the use and utility of the Weibull model in the analysis
of survival data from clinical trials and, in doing so, illustrate the practical benefits of a Weibull-
based analysis. F 2003 Elsevier Inc. All rights reserved.
Keywords: Survival data; Proportional hazards regression; Weibull model; Hazard ratio; Event time ratio
Introduction
Cox’s proportional hazards regression model (or equivalently in the case of two treatment
groups, the log-rank test) has become the statistician’s mainstay in the analysis of survival
data [1–6]. Its predominance stems from 3 decades of application and experience, together
with the fact that it is distribution free; no assumption has to be made about the underlying
distribution of survival times to make inferences about relative death rates. While this is a key
* Corresponding author: Kevin Carroll, AstraZeneca Pharmaceuticals, Biostatistics Group, Global Clinical
Science, Alderley Park, Macclesfield, SK10 4TG, UK. Tel.: 144-1625-515234; fax: 144-1625-518537.
E-mail address: kevin.carroll2@astrazeneca.com
0197-2456/03/$—see front matter F 2003 Elsevier Inc. All rights reserved.
doi:10.1016/S0197-2456(03)00072-2
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strength of the model, it does introduce some limitations. Specifically, a direct quantification of
the improvement in survival time is not possible, except in the special case of truly
exponentially distributed lifetimes where the reciprocal of the hazard ratio estimates the ratio
of median times to event [7]. However, lifetimes are seldom truly exponential in their
distribution, so statisticians have tended to rely on Kaplan-Meier estimates of the underlying
survivor function to read off estimated percentiles. The reliability and precision of these
estimates depends upon the number of deaths and patients remaining at risk at any given
time point on the curve. Median survival time is often used as a measure of improvement
in time, though this measure is often unavailable at the earlier analyses of longer-term trials
with relatively low event rates. Even when median survival can be estimated from the
Kaplan-Meier curve, tests for differences in medians between treatments are generally approx-
imate and do not directly link with tests for parity of hazard rates [8].
The Weibull model provides an alternative, fully parametric approach to the Cox model.
Both these models are, in fact, closely related; both assume proportional hazards and both
provide asymptotically unbiased, equally efficient estimates of the hazard ratio between two
treatments. The Weibull model, in addition to being proportional, is simultaneously an
accelerated failure-time model (AFT), and is the only parametric distribution to possess both
properties [4,9]. AFT models simply examine survival times via a log-linear model so that
treatment effects are expressed in terms of the relative increase or decrease in survival time.
The Weibull, being both accelerated and proportional, therefore allows the simultaneous
description of treatment effects both in terms of hazard ratios and also in terms of the relative
increase or decrease in survival time; we might conveniently refer to this latter quantification
of treatment effect as an “event time ratio,” if only to illustrate the close parallel with the
better known hazard (or event) rate ratio. Cox has suggested that these kinds of analyses
are most favorable when a direct interpretation of the treatment effect is desired [10].
It is important to recognize that the Weibull and other AFT models are not new, having
previously been described in the literature [11]. A good, accessible overview can be found
in Colette [4]. Prentice and Kalbfleisch [9] and Wei [12] have discussed the potential use
of AFT models in survival analyses and, more recently, Chen and Wang [13,14] have discussed
AFT models alongside a new class of models, the “accelerated hazards model,” which models
how the underlying hazard changes over time.
Despite such coverage in the literature, the Weibull model is rarely used in the routine
analysis and reporting of clinical trial data. Given that the Weibull allows simultaneous
estimation of both the usual hazard ratio and an event time ratio, in addition to allowing a
more thorough examination of proportionality and providing a means for predicting how
data might mature over time, further consideration of its use and usefulness seems worthwhile.
The remainder of this paper is therefore structured as follows: the next section provides an
overview of the Weibull model, including its form, estimation of hazard and event time ratios,
examination of proportionality, and prediction of data maturation. After this a comparison of
Cox and Weibull models in the analysis of real clinical trial data is made, followed by a
brief discussion on the need for an exact distributional match when using the Weibull model.
A brief summary of key results is then followedby the final section discussing the practicalvalue
and application of the Weibull and related models in the analysis of survival data in arising
clinical trials.
Publication 13: Carroll 2003
217
K.J. Carroll/Controlled Clinical Trials 24 (2003) 682–701684
The Weibull model
Before describing the Weibull model, it is helpful to consider a general distribution for
lifetimes for which proportionality holds.
Let T 5 t denote the time to some event of interest; this could be time to death or
progression-free survival in an oncology setting. If f(t) denotes the probability density function
of T, S(t) the survivor function, and h(t) the hazard function, then, as is well known,
f(t)5h(t)e2e0t h(u)du
Under proportionality, hA(t) 5 qhB(t), so that SA(t) 5 [SB(t)]q, where q is the hazard ratio
and A and B denote two independent treatment groups.
The maximum likelihood estimate of the hazard ratio is the easily derived:
qˆpara 5 e
gˆ para
5
o
NB
e
ti
0
h(u)du
o
NA
e
ti
0
h(u)du
dA
dB
(1)
and
Vˆ (gˆpara) 5 1dA
1
1
dB
(2)
where dA and dB denote the total number of deaths observed in treatment groups A and B,
respectively. Full details of this result are given in the appendix.
Armitage and Berry give an estimate of the hazard ratio associated with the Cox (log-
rank) model [6],
qˆCox 5 e
gˆ Cox
5
dA
EA
EB
dB
5
dA
oriA
di
ri
oriB
di
ri
dB
(3)
where, at time ti, there are a total of di events out of ri subjects at risk with diA events out
of riA at risk in group A and diB events out of riB at risk in group B so that E(diA) 5
(riA) di/ri; and dA and dB denote the total number of deaths in groups A and B, respectively.
If γ is small then,
Vˆ (gˆCox) 5 1dA
1
1
dB
(4)
Under the assumption of proportionality, Eqs. (2) and (4) show that the standard error
for the log hazard ratio is asymptotically the same for all underlying distributions, f(t), and
is the same as that for the Cox model estimate. Thus, the use of parametric analyses does
not lead to any asymptotic loss of efficiency compared to the log-rank or Cox analysis under
the assumption of proportionality [2,9]. Furthermore, upon close examination of Eqs. (1)
and (3), we can see that, under the assumption of proportionality, both quantities are estimating
the average risk of death on treatment A relative to that on B. Hence, any parametric analysis
where proportionality is assumed to hold, such as the Weibull (or simpler exponential), will
give rise to an estimated hazard ratio very similar to that from a conventional Cox analysis.
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Fig. 1. The Weibull hazard function.
In general, therefore, we should not be concerned in employing parametric models, such
as the Weibull, when proportionality holds.
Now, returning to the specifics of the Weibull model. If T represents the time-to-event
variable, then the probability density function of the Weibull distribution is given by
f(t) 5 alta21 e2lta (5)
where l . 0 is the event rate parameter and a. 0 is the scale, or shape parameter. Thus,
S(t) 5 e2λtα and h(t) 5 altα21. Note that the variable Y 5 Ta is a simple exponential with
parameter λ. An illustration of h(t) is given in Fig. 1. An alternative parameterization of the
Weibull is given by setting
a 5
1
s
, and li 5 e2(m1b′xi )/s (6)
where the influence of the covariates, xi, for the ith individual is modeled through the event
rate parameter, λi. (The software package SAS uses this parameterization when fitting the
Weibull in the procedure PROC LIFEREG [15].) We shall now consider the important
features of this distribution.
The hazard ratio
Based on the parameterization in Eq. (5), the hazard ratio for two treatments is given by
q(t) 5 aAlA
aBlB
taA2aB (7)
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Hence, if aA ≠ aB, hazards are not proportional. When proportionality does hold,
q5 lA /lB.
Based on the parameterization in Eq. (6), the log hazard ratio for an individual with
covariates xi relative to an individual with covariates xj is
2β′(xi2xj)
s
(8)
In the case of just two treatments, the log hazard ratio is therefore given by 2b/s. In
SAS the variance of the estimated log hazard ratio, 2bˆ /sˆ, is not given directly but can be
easily derived from the variance-covariance matrix via Taylor’s expansion [6],
Vˆ (2 bˆsˆ) ≅ (bˆsˆ)2{V(bˆ )bˆ 2 2 2Cov(bˆ ,sˆ)bˆ sˆ 1 V(sˆ)sˆ2 }
As was noted above, under proportionality a Weibull analysis will give rise to an estimated
hazard ratio and standard error very similar to that obtained from a conventional Cox analysis.
This close matching of outcomes is easily verified by simulation. Table 1 shows the results of
a simple simulation study where deviates from a range of Weibull distributions were randomly
generated and analyzed in SAS by Cox’s proportional hazards regression and also by assuming
a Weibull distribution. For each Weibull shown, 1000 datasets were simulated, for sample
sizes of 250, 100, and 25 in each of two treatment groups. A random amount of censoring
(10%) was incorporated. A hazard ratio of 0.8 was used throughout.
Table 1. Simulated Weibull data: analysis by Cox and by Weibull
Cox analysis Weibull analysis
Event rate 5th and 95th SEc 5th and 95th SE
na Shape on treatment A HRb percentiles log HR HR percentiles log HR
250 α 5 1/3 λA 5 0.5 0.801 0.679, 0.934 0.0991 0.802 0.681, 0.935 0.0983
λA 5 2 0.801 0.685, 0.938 0.0966 0.800 0.686, 0.935 0.0955
α 5 3 λA 5 0.5 0.803 0.692, 0.937 0.0949 0.804 0.692, 0.937 0.0946
λA 5 2 0.796 0.685, 0.924 0.0914 0.796 0.685, 0.920 0.0912
100 α 5 1/3 λA 5 0.5 0.805 0.624, 1.034 0.1529 0.804 0.624, 1.023 0.1516
λA 5 2 0.801 0.629, 1.027 0.1508 0.801 0.620, 1.024 0.1493
α 5 3 λA 5 0.5 0.794 0.612, 1.034 0.1550 0.794 0.692, 1.034 0.1539
λA 5 2 0.801 0.629, 1.047 0.1540 0.801 0.636, 1.040 0.1520
25 α 5 1/3 λA 5 0.5 0.786 0.451, 1.345 0.3261 0.782 0.460, 1.334 0.3209
λA 5 2 0.799 0.483, 1.353 0.3127 0.800 0.494, 1.347 0.3079
α 5 3 λA 5 0.5 0.795 0.473, 1.363 0.3231 0.789 0.461, 1.349 0.3205
λA 5 2 0.810 0.485, 1.366 0.3202 0.805 0.474, 1.363 0.3151
a Number per group.
b Hazard ratio.
c Standard error.
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Percentiles and the event time ratio
The percentiles of a Weibull are easily derived,
e2lt
a
5 p ⇒ tp 5 [log( 1p )λ ]1a
where tp denotes the time taken to reach the pth percentile. The relative difference in
the time to achieving the pth percentile between treatments A and B is
tAp
tBp
5
λ
1
αBB
λ
1
αAA
which, under proportional hazards, simplifies to the acceleration factor or event time ratio,
k 5 [lBλA]
1
a
5 [1q]
1
a (9)
Again, based on the parameterization in Eq. (6), the log event time ratio for an individual
with covariates xi relative to an individual with covariates xj is β′(xi2xj). In the case of just
two treatments, the log event time ratio is simply given by β.
Note that Eqs. (8) and (9) demonstrate that, under proportionality, parameters describing
changes in the log event time ratio are simply a scalar multiple of those describing changes
in the log hazard ratio. As event time and event rate ratios are therefore linked by the shape
parameter, it follows that if the hazard ratio can be estimated in a Weibull analysis, then so
can the event time ratio.
Assessing proportionality in a Weibull analysis
In the analysis of survival data, graphical methods are routinely employed to assess the
extent to which proportionality holds [4]. These methods may also be supplemented by a
simple test for proportionality [16]. If data follow a Weibull distribution, then a direct, model-
based test of proportionality can easily be achieved by comparison of shape parameters. If
a Weibull is fitted separately for each treatment group, the two shape parameters, s1 and
s2, say, together with their variances, can be independently estimated and compared.
To test the hypothesis H0 : sˆ1/sˆ2 ≠ 1, then
[log(sˆ1sˆ2)]
2
[Vˆ (sˆ1)
sˆ1
2
1
Vˆ (sˆ2)
sˆ2
2 ]
can be compared to a χ12 distribution. If shape parameters are found to differ significantly,
then the null hypothesis of proportionality is rejected. In practice it may be more sensible to
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examine the confidence interval for the possible extent of nonproportionality rather than
relying on a significance test. This is because relatively mild departures from proportionality,
such as late divergence of survivor functions, have little impact on inferences, especially if
interpretation is confined solely to the time period of observation. Thus, in the analysis
of clinical trial data, even when there is some modest departure from proportionality, it may
still be reasonable to conclude that the event rate and event time ratio estimates show, on
average, treatment differences over the period of study follow-up.
Assessing treatment differences when proportionality does not hold
While some interpretation of treatment effect estimates may be possible in the presence
of modest nonproportionality, some statisticians will rightly feel unease in drawing conclu-
sions. This being the case, the Weibull allows the hazard ratio to be plotted as a function
of time, via Eq. (7). From this description of the hazard ratio, it is possible to compare
treatments in terms of the average or integrated hazard over some time interval (02T).
The integrated hazard is given by λTα21 so that the ratio of average hazards is given by
(λA/λB)TaA2aB. If a Weibull model is again fitted to each treatment group separately, the variance-
covariance matrices can again be used to derive the standard error of the log of this quantity:
SˆE log[λAλB T aA2aB] ≅ √ or5A,BV[log(λˆ r)] 1 T2V[(αˆr] 1 2TCov[log(λˆ r), αˆr]
The ratio of average hazards may then be plotted, with confidence limits, against time in
order to explore how the averaged hazard ratio evolves with follow-up.
Predicting data maturation
The Weibull has been used in the field of engineering to predict the proportion of future
failures after having observed a failure process to a given point in time [17]. In the context of
clinical trials, predicting how deaths are likely to accumulate over time is often important,
especially in the many trials designed with prespecified, event-driven interim analyses. In
such trials, it is of great interest to accurately predict the time course of emerging deaths so
that the appropriate resources can be put into place and to forewarn that perhaps additional
follow-up beyond that envisaged at the outset, or at the previous analysis, is required to
achieve the desired level of data maturity.
This can either be achieved in aggregate, for each treatment group, via simple extrapolation
of the estimated survivor function, e2λˆrtαˆ, r 5 A, B, or by a more complex, individual patient
based analysis as follows:
1. Assume an analysis has been performed with a mean follow-up time F, at which time
d patients have died and c 5 n2d are censored.
2. Consider the individual i with covariates xi , censored at time F. The probability that
this individual survives to time F1S is
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p(T .F1S/T .F) 5 e
2li(F 1 S)a
e2liF
a
so that
F 1 S 5 [2ln(1 2 U)li 1 Fa]
1
a (10)
where U , U(0,1).
3. Survival times for the c censored individuals can be predicted if c deviates are randomly
sampled from a U(0,1) distribution, and substituted into Eq. (10). If, for the ith patient,
predicted survival exceeds F 1 S, then the patient remains censored; otherwise the
patient is predicted to have died in the interval (F, F 1 S].
4. Repeating 3, say, 1000 times, and averaging over repeats, provides an estimate of the
number of additional deaths expected in the interval (F, F 1 S].
This approach allows individual patient covariates to be used in predicting survival time,
and so overall data maturity at a time S following the earlier analysis at time F. If a given
level of maturity is required at the next analysis, the amount of additional follow-up needed
can be estimated by trial and error.
An example
Analysis by both Cox’s regression and the Weibull model is illustrated in the following
example [18]. Patients with early prostate cancer were randomized to one of two treatments,
active (bicalutamide 150 mg) or placebo. The primary endpoint was progression-free survival.
The analysis took place at a minimum of 2 years and a median of 3 years follow-up.
All patients were followed to disease progression or death irrespective of withdrawal of
randomized therapy or addition of other, systemic therapies. Patients who remained progres-
sion free, or who were lost to follow-up at some earlier point in time, were censored. In
addition to randomized treatment, four important, prospectively identified prognostic factors
were included as covariates: these were primary background therapy (surgery, radiotherapy,
or observation); log prostate-specific antigen level at diagnosis; stage of disease (either
localized or locally advanced); and the degree of differentiation of disease (well, moderate,
or poorly differentiated). The effect of primary therapy was captured in terms of contrasts
between surgery versus radiotherapy and surgery versus observation. Similarly, the effect of
degree of differentiation was captured in terms of contrasts between well versus moderately
differentiated and well versus poorly differentiated.
A total of 1798 and 1805 patients were randomized to active and placebo treatments,
respectively. At the time of the analysis, 181 and 293 events had accrued on active and
placebo, respectively.
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The results of the analysis are presented in Tables 2 and 3. Fig. 2 shows the Kaplan-
Meier curves for the treatment groups, together with the fitted survivor function estimates
from the Weibull analysis.
In Table 2, it is immediately obvious that both analyses provide very similar results, this
being expected as discussed above. As the Weibull models log time, the parameter estimates, βˆ ,
represent event time ratios on the log scale. For example, patients with poorly differentiated
disease were associated with a reduction in event time of approximately 33% (since
e20.3973 5 0.67) relative to those with well differentiated disease. As indicated in Eq. (8),
division of bˆ by 2sˆ converts Weibull parameters from log event time ratios to log hazard
ratios. Informal comparison of 2bˆ /sˆ and gˆ indicates a close match between the Cox and Weibull
models. This is as expected given that the Weibull distribution provides a close fit to the data.
Table 3 provides estimates of the treatment effect, both in terms of a hazard ratio and an
event time ratio. From these results it can be seen that treatment with bicalutamide 150 mg
significantly reduces the risk of progression compared to placebo by approximately 43%
and, in doing so, significantly increases the progression-free survival interval by approxi-
mately 50%.
In terms of predicting how events might accrue over time, application of Eq. (10) indicates
expected maturities of 21%, 28%, and 35% with additional follow-up of 1, 2, and 3
years, respectively.
The affect of departures from the Weibull distribution
Concerns may arise when using Weibull-based analyses in that the data collected may
not conform exactly to a Weibull distribution. Simple graphical checks can be used to assess
the extent to which data have a Weibull distribution and residual diagnostics can be also
examined to assess goodness of fit [2,4].
Nevertheless, concerns may still be present that without a close distributional match,
inferences based on a Weibull analysis may be misleading. However, for modest departures
Table 2. Results of Weibull and Cox analyses
Weibull: modeling event time ratio Cox: modeling log hazard ratio
bˆ SEabˆ t 2bˆ /sˆ gˆ SEgˆ t
Intercept, µ 8.977 0.158
Shape, σb 0.7275 0.0307
Randomized treatmentb 0.4022 0.0706 5.70 20.5529 20.5544 0.0947 25.85
Log PSAc at diagnosis 20.2005 0.0352 25.70 0.2756 0.2772 0.0471 5.89
Disease stage 0.3802 0.0746 5.10 20.5226 20.5265 0.1002 25.25
Radiotherapy 20.3184 0.0987 23.23 0.4377 0.4382 0.1347 3.25
Observation 20.6184 0.0837 27.39 0.8500 0.8548 0.1096 7.80
Moderately differentiated 20.1456 0.0891 21.63 0.2001 0.1977 0.1222 1.62
Poorly differentiated 20.3973 0.0937 24.24 0.5461 0.5500 0.1275 4.31
a Standard error.
b Covariance between scale and treatment parameters was estimated to be 0.00047305.
c Prostate-specific antigen.
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Table 3. Estimated hazard (HR) and event time ratios (ETR) for active relative to placebo
Cox Weibull
HR SEa 95% CIb HR SE 95% CI ETR SE 95% CI
0.574 0.0947 0.477, 0.692 0.575 0.0947 0.477, 0.693 1.495 0.0706 1.302, 1.717
a Standard error.
b Confidence interval.
from a true Weibull, such concerns may largely be unwarranted, especially for hazard ratio
estimation under proportionality.
To investigate hazard ratio estimates achieved via Weibull and Cox analyses irrespective
of the true distribution for survival times, the following simulation approach was used.
Clinical trial data were simulated from lognormal, gamma, and piecewise exponential
distributions. In each case, two treatments, A and B, say, were assumed and a random amount
of censoring (10%) was incorporated. Parameters for each distribution were chosen so that the
mean on treatment A was 6 months, say, and also so that variance of the lognormal and
gamma distributions coincided. For the piecewise exponential, both treatmentswere assumed to
have a common event rate for the first 3 months, diverging thereafter. Treatment differences,
in terms of ratio of means, of 1.25 and 1.50 were used. To further reflect the clinical trial
situation, uniform patient accrual over a 6-month period was simulated and a data cutoff
Fig. 2. Kaplan-Meier plot for progression-free survival with fitted Weibull survivor function estimates.
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was employed whereby all event times were truncated at a given point in follow-up; the
data cut-off time used was 12 months.
The lognormal and gamma survivor functions are illustrated in Figs. 3(a) and 3(b). Survivor
function for the piecewise exponential distribution is illustrated in Fig. 3(c).
Data were then analyzed assuming a Weibull distribution via PROC LIFEREG in SAS.
Both the hazard ratio and event time ratio were estimated. The data were also analyzed via
PROC PHREG again in SAS to estimate the conventional Cox’s hazard ratio. One thousand
trial datasets, each of size n 5 400 (200 in each treatment group), were simulated and the
mean and variance of resulting log hazard and log event time ratios were calculated. A
summary of results is provided in Tables 4–6.
These data suggest that even when data are known not to follow a Weibull distribution,
analysis assuming a Weibull distribution provides results that are similar to those obtained
by conventional Cox analysis. For the piecewise exponential, the Weibull analysis tends to
give slightly larger log hazard ratio estimates (in absolute terms) compared to the Cox
analysis, although the standard errors also tends to be slightly larger. Student t values were
thus little different, perhaps being slightly higher for the Weibull analysis. With respect
to the estimated event time ratio, this tends to be a little less than the known ratio of
median times to event in the cases where the true median exceeds 3 months. If the 12-month
data cutoff truncation is removed, then the resulting event time ratios are higher, as would
be expected, and more in line with the known ratio of median times to event. For both
lognormal and gamma data, results from Weibull and Cox analyses are virtually indistin-
guishable. The estimated event time ratio again tends to be less than the known ratio of
median (or mean) times to event. Removal of the 12-month data cutoff truncation results in
estimated event time ratios of 1.25 and 1.5, in exact concordance with the known differences
in times to event.
This study suggests that hazard ratio estimates obtained via a Weibull analysis will tend
to be similar to that obtained from a conventional Cox analysis, even when the Weibull does
not provide an exact distributional match to the data. The importance of this is that for those
data where it is considered reasonable to apply Cox regression to estimate the underlying
hazard ratio, it should also be reasonable to apply a Weibull analysis to estimate the hazard
ratio and, using the estimated scale parameter, to transform the hazard ratio to provide an
estimated event time ratio. If the Weibull is considered only to provide a moderate fit to the
data, then both the hazard and event time ratios can still be interpreted as the averaged risk
of death and averaged increase in time on treatment A relative to treatment B. However,
the estimation of percentiles, as described above, and the scale parameter are more dependent
upon an adequate fit to the data. If a reasonable fit to the Weibull cannot be achieved, then
it is recommended that percentiles be estimated directly from the Kaplan-Meier curves.
Summary
This paper has shown the Weibull model can provide a useful, parametric alternative to
conventional Cox’s regression modeling in the analysis of survival data. In addition to the
hazard ratio, Weibull analysis provides a means of directly estimating the relative
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improvement in survival time, the event time ratio. This quantification of treatment effect is
of some clinical relevance and is likely to be better understood by some nonstatisticians than
the conventional hazard ratio. Further, it has been shown that when data follow a Weibull
distribution, Weibull analysis is asymptotically as efficient as Cox regression; both approaches
give rise to similar hazard ratio estimates with the same standard error. Even when data are
known not to follow a Weibull distribution, analysis assuming a Weibull distribution can
Fig. 3. (A) Lognormal survivor function. (B) Gamma survivor function.
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Fig. 3. (C) Piecewise exponential survivor function.
give very similar results, in terms of the hazard ratio, to those obtained by conventional
Cox regression.
Key results in relation to the Weibull presented in this paper are thus:
1. Weibull analysis allows simultaneous characterization of the treatment effect in terms
of the hazard ratio and the event time ratio, being a direct measure of the relative
improvement in survival time.
Table 4. Simulation of piecewise exponential: analysis by Cox and by Weibull
Cox analysis Weibull analysis
SEe SE SE
λ1a mA/mBb m˜A/m˜Bc HRd ln HR t HR ln HR t ETRf In ETR t
0.01 1.25 1.13 0.834 0.1199 21.51 0.826 0.1185 21.62 1.099 0.0585 1.62
0.01 1.50 1.26 0.716 0.1270 22.64 0.702 0.1251 22.83 1.191 0.0612 2.86
0.10 1.25 1.10 0.872 0.1142 21.19 0.874 0.1073 21.25 1.115 0.0868 1.25
0.10 1.50 1.21 0.783 0.1195 22.05 0.784 0.1123 22.16 1.221 0.0920 2.17
1 1.25 1.00 0.995 0.1096 20.05 0.982 0.1341 20.33 1.033 0.1568 0.14
1 1.50 1.00 0.987 0.1127 20.12 0.967 0.1407 20.25 1.043 0.1658 0.25
a Common event rate over first 3 months.
b Ratio of mean times to event; µA 5 6 months throughout.
c Ratio of median times to event.
d Hazard ratio.
e Standard error.
f Event time ratio.
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Table 5. Simulation of longnormal: analysis by Cox and by Weibull
Cox analysis Weibull analysis
SEc SE SE
µA/µBa σ2 HRb ln HR t HR ln HR t ETRd ln ETR t
1.25 0.288 0.676 0.1156 23.39 0.662 0.1236 23.33 1.209 0.0559 3.40
1.5 0.288 0.489 0.1158 26.23 0.472 0.1203 26.24 1.397 0.0515 6.49
1.25 1.386 0.833 0.1111 21.64 0.827 0.1165 21.64 1.199 0.1104 1.64
1.5 1.386 0.720 0.1128 22.91 0.711 0.1154 22.95 1.376 0.1075 2.97
a Ratio of mean times to event 5 ratio of median time-to-event for lognormal data. µA 5 6 months
throughout.
b Hazard ratio.
c Standard error.
d Event time ratio.
2. Weibull and Cox analyses coincide when data follow a Weibull distribution; both
approaches are asymptotically equally efficient.
3. The Weibull provides an adequate fit in many situations. Even when data do not follow
an exact Weibull distribution, a Weibull-based analysis can give results that are very
similar to those obtained from a Cox analysis. However, the estimation of percentiles
and the event time ratio is more dependent upon an adequate fit to the data. If a
reasonable fit to the Weibull cannot be achieved, then it is recommended that percentiles
be estimated directly from the Kaplan-Meier curves.
4. Weibull analysis allows direct assessment and quantification of proportionality, or
lack thereof.
5. If the data display nonproportional hazards, then a Weibull analysis provides a descrip-
tion of the hazard ratio (and event time ratio) over time and, depending on the circum-
stances, an analysis of hazards averaged over time.
6. Weibull analysis offers the opportunity to predict how data might mature over time,
something that is of great interest within oncology trials, especially where a series of
interim analyses are planned.
Table 6. Simulation of gamma: analysis by Cox and by Weibull
Cox analysis Weibull analysis
SEc SE SE
µA/µBa α HRb ln HR t HR ln HR t ETRd ln ETR t
1.25 3 0.679 0.1075 23.60 0.675 0.1084 23.62 1.212 0.0540 3.63
1.5 3 0.494 0.1170 26.03 0.490 0.1141 26.24 1.415 0.0539 6.45
1.25 1/3 0.897 0.1125 20.96 0.901 0.1038 21.00 1.258 0.2302 1.00
1.5 1/3 0.821 0.1189 21.65 0.828 0.1103 21.72 1.522 0.2441 1.72
a Ratio of mean times to event 5 ratio of median time-to-event for gamma data. µA 5 6 months
throughout.
b Hazard ratio.
c Standard error.
d Event time ratio.
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Discussion
The key implication of this paper is that in those very frequent instances where two or
more treatments are to be compared for survival (or some other time-to-event endpoint) with
adjustment for one or more baseline prognostic factors, the Weibull is at least as informative
as a corresponding Cox analysis, and probably more so. Use of the Weibull provides research-
ers and data analysts with an estimate of treatment effect as per routine Cox analysis but,
furthermore, provides a clinically useful, alternative representation of the treatment difference
in terms of the event time ratio—consistency, in terms of statistical significance, is assured
as both measures of treatment effect have essentially the same p-value. On this basis, and as
the primary objective of clinical trials with survival as the primary endpoint is the simple
comparison of survival distributions, it seems reasonable to argue that a Weibull-based
analysis would likely serve data analysts and clinical researchers better than a corresponding
Cox-based analysis in most circumstances.
The assumption of proportionality is often an issue that rightly concerns statisticians when
analyzing via Cox, being explored heuristically via graphical methods. The use of the Weibull
offers the ability to explicitly examine the degree and nature of proportionality and, further,
allows a simple, direct test for its presence. These model utilities are likely to be valuable
tools in the routine analysis of clinical trial data.
The quantification of the treatment effect along the time axis is, in the author’s experience,
one of the most common requests from clinicians and other nonstatisticians in the analysis of
survival and other time-to-event data and, thus, is one of the most common disappointments
with Cox-based analyses. Simultaneous estimation of effects in terms of both rate and time
is therefore a key strength of Weibull-based analyses. Unless data follow an exponential
distribution, the common use of the reciprocal of the hazard ratio as an estimate of the
relative difference in the median times to event is incorrect as easily evidenced via the
above example discussed previously where the reciprocal of the hazard ratio would suggest a
1.7-fold increase in progression-free survival time, whereas a more appropriate Weibull
analysis gives an event time ratio of 1.5 [7]. The routine use of Kaplan-Meier curves as a
descriptive aid to Cox or log-rank analyses is both standard and sensible, but all too often
is taken by nonstatisticians to be the literal interpretation of the analysis, such that the p-
value is “attached” to the curves rather than to the hazard ratio, a practice which can be
misleading. Weibull analysis allows the survivor function to be estimated, which, when
plotted, more accurately reflects the estimated treatment effect. This in turn allows predic-
tion versus data maturation, something that is of considerable practical value in the ongoing
management of clinical trials with time-to-event endpoints, and yet another feature that does
not readily flow from conventional Cox-based regression.
In applying a Weibull analysis, concerns may arise regarding degree of model fit. The
simulations carried out in this paper would suggest that the Weibull provides an adequate fit
in many situations such that even when data do not follow an exact Weibull distribution, a
Weibull-based analysis gives results similar to those obtained from a corresponding Cox
analysis. Upon reflection, it is not surprising nor unexpected that a time-to-event model with
the flexibility of both a shape (λ) and a scale parameter (α) would provide a good fit in
many situations just as it is not surprising that the normal distribution, with both location (m)
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and scale (s) parameters, provides an adequate fit to interval data in a wide variety of appli-
cations.
While the majority of time-to-event analyses in clinical trials are univariate in nature,
multivariate data often arises and a reasonable question is whether a Weibull-based approach
can offer advantages here, too. Extensions of Cox-based regression for repeated event data
have been developed, such as the commonly used Andersen and Gill model, which assumes
the risk of a repeat event is unaffected by earlier events and follows the proportional
hazards assumption [19]. A comprehensive overview of Cox-based models for multiple
failure-time data has been offered by Wei and Glidden [20]. These authors note that while Cox-
type regression has been widely used for multivariate failure-time data, it may not fit data
well, and AFT models offer a useful alternative. They also note that AFT models can
accommodate repeat events without natural ordering, being in contrast to the Andersen and
Gill approach where natural ordering is assumed. Indeed, as the Weibull and other AFT
models are simply log-linear models with error distributions reflective of time-to-event data,
existing and well-developed theory in relation to generalized linear models and multivariate
data analysis can be applied [12].
Whenwishing toexplore the relationship betweenmultipleevents, random effectsor“frailty”
analyses can be considered. While extensions to Cox-based analyses in the form of time-
dependant covariates are possible, Weibull and AFT models are preferred by some authors [20].
Keiding et al have suggested it would be advantageous to upgrade AFT approaches alongside
conventional approaches for random effects survival analyses, emphasizing intuitive inter-
pretation of the Weibull model [21].
In addition to extension to multivariate failure-time data, the Weibull and other parametric
models have been found to be useful in other areas also, such as data monitoring and analysis
of failure-time data when cure is possible [22]. Sposto has examined parametric cure
models, concluding that they are at least as good as Cox-based approaches and are to
be preferred when proportionality fails to hold, allowing simultaneous assessment of covariate
effects on both the proportion cured and the failure rate among those not cured [23].
Despite the many appealing features of Weibull-based analyses, the author does advo-
cate wholesale replacement of Cox’s proportional hazards regression model for routine,
univariate failure-time analyses. Albeit at the cost of assuming proportionality, Cox’s regres-
sion offers the advantage of being distribution-free and can readily accommodate time-
dependent covariate analysis. Rather, a Weibull analysis offers the statistician the opportunity
to supplement and enrich routine Cox regression analyses, especially when a direct quantifica-
tion of improvement in survival time is desired or a more thorough evaluation of proportional-
ity is warranted. Indeed, when such matters are of primary interest, one may reasonably
argue that a Weibull-based approach is to be preferred, being at least as informative as Cox
regression with no loss of power or sensitivity under proportional hazards. Therefore, the
use of the Weibull, or other parametric models, in the analysis of survival data in clinical
trials, at very least, should not be overlooked and even be promoted to sit with equal status
alongside routine Cox-based analyses.
It is interesting to note that model-based analyses are the norm and have been for many
decades, in the analysis of normally distributed data, where analysis of variance to multivariate
analysis of covariance to complex nonlinear mixed effects modeling approaches are routinely
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employed, with nonparametric alternatives mainly taking a supporting role. Similar comments
can be made in relation to binary and ordered categorical data where model-based data
analysis prevails. For survival and other time-to-event data, however, the approach presently
taken is the inverse in many ways; nonparametric analyses are considered standard while
potentially more informative model-based approaches are seldom seen. This may, in part,
be due to past difficulties in computationally applying these models.
However, widely available software packages, such as SAS and S-Plus, have simple
procedures devoted to data analysis via the Weibull and other parametric models such as
the gamma and lognormal [24]. Application of the Weibull-based analyses described in
this paper is therefore very straightforward and not an area where specific, homegrown software
has to be written to affect an analysis. Hence, it is fair to say that statisticians have simple and
readily accessible software on their desks and are thus well poised and better equipped than
ever before to reap the benefits that Weibull and other parametric-based approaches have to
offer in the day-to-day, practical analysis of survival data arising in clinical trials.
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Appendix: The hazard ratio for a parametric failure-time distribution under
proportional hazards
Let T denote the time-to-event variable with probability distribution function f(t), and
survivor function S(t). Under proportional hazards
hx(t) 5 h(t)ea1xg
where x 5 1 for treatment group A, x 5 0 for treatment group B.
Assuming NA patients in group A with dA events and NA2dA censored. Employing
similar notation for group B, the likelihood for the data observed is
L 5 Π
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Hence, Eqs. (11) and (12) give
eaˆ 5
dB
o
NB
e
ti
0
h(u)du
eaˆ1gˆ 5
dA
o
NA
e
ti
0
h(u)du
so that the hazard ratio, for any probability density function, f(t), under the assumption of
proportionality, is given by
egˆ 5
o
NB
e
ti
0
h(u)du
o
NA
e
ti
0
h(u)du
dA
dB
and Eqs. (13), (14), and (15) give
V 5 E[2I21]
2I21 5 [X 1 Y YY Y]21 5 1XY [ Y 2Y2Y X1Y]
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where
X 5 eao
NB
e
ti
0
h(u)du and Y 5 ea1go
NA
e
ti
0
h(u)du
Therefore, the variance of the log hazard ratio, under the assumption of proportionality, is
given by
Vˆ (gˆ) 5 E[1X 1 1Y] 5 [ 1
eaˆo
NB
e
ti
0
h(u)du] 1 [ 1eaˆ1gˆoNA eti0 h(u)du] 5 1dA 1 1dB
If g is small, then
Vˆ (gˆ) ≅ 4/d where d denotes the total number of events across both groups.
References
[1] Cox DR. Regression models and life tables (with discussion). Journal of the Royal Statistical Society, Series
B 1972;34:187–220.
[2] Kalbfleisch JD, Prentice RL. The statistical analysis of failure-time data. New York: Wiley, 1980.
[3] Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall, 1984.
[4] Collett D. Modeling survival data in medical research. London: Chapman and Hall, 1994.
[5] Peto R, Peto J. Asymptotically efficient rank invariant test procedures (with discussion). Journal of the
Royal Statistical Society, Series A 1972;135:185–207.
[6] Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Scientific Publications,
1987.
[7] Sylvester R, Collette L. When do statistics lie? UroOncology 2001;1:185–194.
[8] Kim J. Confidence intervals for the difference of median survival times using the stratified Cox proportional
hazards model. Biometrical Journal 2001;43:781–790.
[9] Prentice RL, Kalbfleisch JD. Hazard rate models with covariates. Biometrics 1979;35:25–39.
[10] Reid N. A conversation with Sir David Cox. Statistical Science 1994;9:439–455.
[11] Byar DP. Analysis of survival data: Cox and Weibull models with covariates. Statistics in Medical Research
1982;12:365–401.
[12] Wei LJ. The accelerated failure-time model: a useful alternative to the Cox regression model in survival
analysis. Stat Med 1992;11:1871–1879.
[13] Chen YQ, Wang M-C. Analysis of accelerated hazards model. J Am Stat Assoc 2000;95:608–618.
[14] Chen YQ, Wang M-C. Estimating a treatment effect with the accelerated hazards model. Control Clin Trials
2000;21:369–380.
[15] SAS/STAT User’s Guide. Version 6, 4th ed, Volume 2. Cary, NC: SAS Institute Inc., 1989.
[16] Gill RD, Schumacher M. A simple test of the proportional hazards assumption. Biometrika 1987;74:289–300.
[17] Nelson W. Weibull prediction of a future number of failures. Quality and Reliability Engineering International
2000;16:23–26.
[18] Wirth M, Tyrrell C, Wallace M, et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients
with localized or locally advanced prostate cancer significantly reduces risk of disease progression (with
Editorial comment). Urology 2001;58:146–151.
[19] Andersen PK, Gill RD. Cox’s regression model for counting processes: a large sample study. Ann Stat
1982;10:1100–1120.
Publication 13: Carroll 2003
234
K.J. Carroll/Controlled Clinical Trials 24 (2003) 682–701 701
[20] Wei LJ, Glidden DV. An overview of statistical methods for multiple failure-time data in clinical trials.
Stat Med 1997;16:833–839.
[21] Keiding N, Andersen PK, Klein JP. The role of frailty models and accelerated failure-time models in
describing heterogeneity due to omitted covariates. Stat Med 1997;16:215–224.
[22] Lecoutre B, Mabika B, Derzko G. Assessment and monitoring in clinical trials when survival curves have
distinct shapes. Stat Med 2002;21:663–674.
[23] Sposto R. Cure model analysis in cancer: an application to data from the Children’s Cancer Group. Stat
Med 2002;21:293–312.
[24] S-PLUS 6 Guide to Statistics, Vol. 2. Seattle, Washington: Insightful Corporation, 2001.
Publication 13: Carroll 2003
235
  
14. Carroll KJ.  Back to basics: explaining sample size in outcome trials, are statisticians 
doing a thorough job?  Pharmaceutical Statistics, 2009; 8: 333–345.  
  
236
PHARMACEUTICAL STATISTICS
Pharmaceut. Statist. 2009; 8: 333–345
Published online 29 January 2009 in Wiley InterScience
(www.interscience.wiley.com) DOI: 10.1002/pst.362
Back to basics: explaining sample size in
outcome trials, are statisticians doing a
thorough job?
Kevin J. Carroll,y
AstraZeneca Pharmaceuticals, CMOs Office, Alderley Park, Macclesfield, UK
Time to event outcome trials in clinical research are typically large, expensive and high-profile affairs.
Such trials are commonplace in oncology and cardiovascular therapeutic areas but are also seen in
other areas such as respiratory in indications like chronic obstructive pulmonary disease. Their
progress is closely monitored and results are often eagerly awaited. Once available, the top line result
is often big news, at least within the therapeutic area in which it was conducted, and the data are
subsequently fully scrutinized in a series of high-profile publications. In such circumstances, the
statistician has a vital role to play in the design, conduct, analysis and reporting of the trial. In
particular, in drug development it is incumbent on the statistician to ensure at the outset that the
sizing of the trial is fully appreciated by their medical, and other non-statistical, drug development
team colleagues and that the risk of delivering a statistically significant but clinically unpersuasive
result is minimized. The statistician also has a key role in advising the team when, early in the life of
an outcomes trial, a lower than anticipated event rate appears to be emerging. This paper highlights
some of the important features relating to outcome trial sample sizing and makes a number of simple
recommendations aimed at ensuring a better, common understanding of the interplay between sample
size and power and the final result required to provide a statistically positive and clinically persuasive
outcome. Copyright r 2009 John Wiley & Sons, Ltd.
Keywords: outcome trials; sample size; power; hypothesized effect; critical value
1. INTRODUCTION
An ‘outcomes’ trial has been defined as a large-
scale, long duration clinical trial with hard clinical
endpoints as outcomes, typically morbidity
and mortality [1]. As such, they are invariably
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expensive and high-profile affairs. Such trials are
commonplace in oncology and cardiovascular
drug development but are also seen in other
therapeutic areas such as respiratory in indications
like chronic obstructive pulmonary disease. They
tended to be closely monitored and results
are often eagerly awaited. Once available, the
top line results are often big news, at least within
the therapeutic area in which the trial was
conducted, and the data are subsequently fully
scrutinized in a series of high-profile publications.
In such circumstances, the statistician has a
vital role to play in the design, conduct, analysis
and reporting of the trial. In particular, in
drug development it is incumbent on the statisti-
cian to ensure at the outset that the sizing of the
trial is fully appreciated by their medical, and
other non-statistical, drug development team
colleagues and that the risk of delivering a
statistically significant but clinically unpersuasive
result is minimized. The statistician also has a key
role in advising the team when, early in the life of
an outcomes trial, a lower than anticipated event
rate is emerging.
This paper highlights some of the key features
relating to outcome trial sample sizing and makes
a number of simple recommendations aimed at
ensuring a better, common understanding of the
interplay between sample size and power and the
final result required to provide a statistically
positive and clinically persuasive outcome. The
remainder of the paper is therefore structured as
follows: Section 2 examines the statistical issues
relating to sample sizing in the context of a
hypothetical dialogue between a medic and a
statistician. Section 3 discusses how the statistician
might better explain sample size calculations and
their consequences to their non-statistical drug
development colleagues and, in so doing, offers
some simple recommendations. Section 4 then
examines the role of the statistician in advising the
drug development team when, some time after the
trial is initiated, a lower than anticipated event rate
appears to be emerging. Section 5 then closes
paper with a brief summary of the main points
raised.
2. A TYPICAL CONVERSATION RE-
GARDING SAMPLE SIZE FOR ANOUT-
COMES TRIAL
2.1. A typical, if somewhat simplified, conversation
Throughout this paper, issues in outcomes
trial sizing are highlighted and discussed by
means of a simple, hypothetical example. All that
follows is therefore framed generically and the
principles outlined apply equally to outcome
trials in across therapeutic areas including oncol-
ogy and cardiovascular where such trials are
commonplace.
Suppose an outcomes trial is being considered
for a new drug. A conversation ensues between the
medic and statistician.
Medic: ‘We need to show that ‘Efektiv’ is
better than the current standard of care treatment
in terms of clinical outcome. We need at least
a 15% reduction in risk of the outcome to
convince the medical community, regulators and
formularies alike that ‘Efectiv’ is a genuine
candidate to replace the current standard in
managing patients. How big a trial are we looking
at?’
After some thought, the statistician responds:
‘We’ll need 1,591 events to provide 90% power at
the 2-sided 5% significance level. Further, assum-
ing 10% of patients have an outcome event after 1
year, and with plans for a 1 year accrual period
and a 1 year minimum follow-up period, 11 800
patients will need to be randomised’.
Hence, we are done. A total of 1591 events
are needed and, assuming 10% of patients have
an outcome event within 1 year, this translates
to 11 800 pts. In this simple example, no allowance
is made for dropouts as outcome studies are
usually governed by the intent-to-treat principle so
that outcomes are ascertained for all patients
irrespective of dropout or early cessation of
randomized therapy. That said, what follows
would apply just as well if some allowance for
dropouts were made. In addition, the 10% of
patients with an event at 1 year is assumed to be a
reasonable estimate, being based on relevant prior
experience or literature.
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2.2. Taking a closer look at the required number of
events
The preceding calculation flows from the standard
result for the log-rank test that the total number of
events, d, is given by
d ¼
4ðza þ zbÞ
2
y2
ð1Þ
where y is the log hazard ratio (HR) hypothesized
under the alternative, a is the 1-sided significance
level, 1ÿb is power and zg ¼ f
ÿ1ð1ÿ gÞ is the
100(1ÿg)th percentile of the standard Normal
distribution, this following from the result the
estimated log HR is approximately N y; 4=d
ÿ 
[2–5]. Hence,
Varðy^Þ ¼
4
d
ð2Þ
For planning purposes, if the expected fraction of
patients with an event at some fixed time T is qi,
say, then
y ¼ log
logð1ÿ qEÞ
logð1ÿ qCÞ
 
ð3Þ
where E and C denote the experimental and
control treatments [6]. Having conducted the trial,
it is worth noting that the HR can be estimated
directly from the statistics of the log-rank test as
y^ ¼
d
4
fdE ÿ E½dE g ð4Þ
where dE and E½dE  are the observed and expected
number of events on the experimental treatment,
E, respectively [7]. From (1) and (2) it immediately
follows that the critical value of the test, the
threshold value for the HR, eycrit , say, that flips the
outcome between p0.05 and p40.05, is given by
eycrit ¼ eÿ2za
ﬃﬃﬃﬃﬃ
dÿ1
p
ð5Þ
For the example above, this critical value is 0.906,
i.e. a 9.4% risk reduction. It is worth considering
this a while, as this is where problems and
misunderstandings can start to emerge.
In his conversation with the statistician, the
medic is clear that he needs a 15% reduction in
risk to convince physicians to change their usual
practice. In response, the statistician has designed
a trial to test the hypothesis H0: y5 0 versus H0:
y5 log(0.85). Now, it is not uncommon for the
medic to assume that this means that if the trial
delivers an HR of 0.85 or better, then pr0.05,
otherwise the p-value will be ‘NS’, not significant.
However, the trial will in fact yield pr0.05 for an
HR of 0.906 or better, i.e. a 9.4% risk reduction or
better; if a 15% risk reduction is observed, then it
follows from (1) that
p ¼ 2ð1ÿ fðza þ zbÞÞ ¼ 0:0012 ð6Þ
Thus, there is a danger that the trial, as currently
sized, will yield a statistically significant but
clinically irrelevant result since the medic is
blissfully unaware that differences smaller than
the minimum difference required to be clinically
persuasive will yield pr0.05.
This basic misunderstanding between what is
minimally desired in terms of a convincing out-
come and powering based on a hypothesis test that
places this minimal requirement under the alter-
native is the main reason why so many times
medics and other researchers turn to statisticians
and say ‘our trial was over-powered’ or ‘why do
we need 1000 patients when a competitor achieved
po0.05 in their trial with 500 patients?’ It is the
job of project statisticians working in drug
development to explain as simply as possible why
these apparent contradictions arise and to ensure
complete transparency in terms of what hypothesis
the trial is testing and what this translates to in
terms of the threshold difference to yield a
positive, pr0.05 outcome for the trial.
Hence, what might be done to improve this
situation, to do a more thorough job at pointing
out and communicating the issues and implica-
tions of our sample size calculations? This question
is covered in Section 3 but, before then, it is
informative to take a brief look at how, given the
target number of events d, the overall sample size,
N, is determined.
2.3. A brief comment on N
Given the number of target number of outcome
events, d, the total number of patients to be
randomized, N, is given by N ¼ d=pbar where pbar
is the average probability of an event across E and
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C over the trial period. Typically, for the purposes
of calculating N, the time to an outcome event is
assumed to be exponentially distributed, though
other, non-parametric methods are available
[8–10]. In addition, the accrual pattern is usually
assumed to be smooth, with patient entry times
following a Uniform distribution over the accrual
period (0, A) [11–13]. Under these assumptions it
has been shown that
pi ¼ 1ÿ
eÿliF ½1ÿ eÿliA
liA
ð7Þ
where A is the length of the accrual period, F is the
minimum follow-up period, li is the outcome event
rate with i5E, C and y ¼ lE=lC [14]. If li is small,
then
pi  1ÿ e
ÿlið
A
2
þFÞ ¼ 1ÿ eÿliðmean follow-up timeÞ ð8Þ
Further, with exponentially distributed times to
event, if the fraction of patients with an event at
some fixed time T is qi, say, then
li ¼ ÿ
logð1ÿ qiÞ
T
ð9Þ
and
pbar ¼ 2ðp
ÿ1
E þ p
ÿ1
C Þ
ÿ1 ð10Þ
i.e. pbar is the harmonic mean of pE and pC [4]. In
the example above, lE and lC are 0.0896 and
0.1054, respectively, and, thus, pE and pC are
0.1254 and 0.1458. Hence, pbar5 0.1348, giving
N ¼ 1591=0:1348 ¼ 11 803: As is clear, the esti-
mate for N is built on the two key assumptions of
uniformly distributed entry times and exponen-
tially distributed times to event. One or both of
these can be relaxed to a degree to arrive at a more
general form for pi. For example, if times to event
were assumed to follow a Weibull distribution
[6] with shape parameter k, say, so that
f ðtÞ ¼ kltkÿ1eÿlt
k
, t40, l40, k40, and entry
times were assumed to follow some distribution
f(a), with 0rarA, then
pi ¼
Z A
a¼0
Z AþF
t¼a
f ðtjaÞf ðaÞ dt da
¼ 1ÿ Ea½e
ÿliðAþFÿaÞ
k
 ﬃ 1ÿeÿliðAþFÿE½aÞ
k
ð11Þ
with the approximation applying when li is small
[15]. In this formulation, the form of f(a) does not
matter since all that is needed is E[a] to provide an
estimate of pi Nevertheless, if so desired, a simple
choice for f(a) might be
f ðaÞ ¼
ZaZÿ1
AZ
; 0aA ð12Þ
where Z is the measure of non-uniformity in entry
times, 0oZoN, and E½a ¼ AZ=ðZþ 1Þ: Hence,
Z5 1 corresponds to uniformly distributed entry
times and values Z41 indicate slow initial recruit-
ment that accelerates towards the end of the
accrual period. If event times are exponential,
then, for this choice of f(a), evaluating equation
(11) gives
pi ¼1ÿ e
ÿliF
 ðÿ1ÞZÿ1
Z!
ðliAÞ
Z
XZÿ1
s¼0
ðÿliAÞ
s
s!
ÿ eÿliA
" #( )
;
Z ¼ 1; 2; 3; . . . ð13Þ
More generally, if times to event are exponential
with li small, so that the approximation (8) can
be used, and accrual was expected to be less
than perfect, as it almost always the case in
practice [16,17], with mean entry times anticipated
of, for example, 2
3
A (corresponding to Z5 2 in
for f(a) in equation (12)) rather than 1
2
A for
Uniform accrual, then the follow-up period F
would have to be extended by around 1
6
A to
make up for the loss in patient exposure. In the
example above, this would mean extending follow-
up from 1 year to approximately 14 months. In
this fashion, the impact of failing to meet
assumptions of Uniform patient entry and/or
exponential times to event can begin to be
explored and explained.
3. SUGGESTIONS TO ENHANCE THE
WAY WE DESCRIBE SAMPLE SIZE
3.1. So, what might we try do a little better?
In terms of communicating the issues and implica-
tions of sample size calculations, what we might do
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a little differently? Perhaps a good start might be
to routinely
(i) Point out that if a specific log HR advantage
needs to be realized of at least y , with a result
less than y not being clinically persuasive even
if it reached statistical significance, then the
need is to hypothesize not y but y0 ¼ ð1þ
zbz
ÿ1
a Þy under the alternative.
From equations (1) and (5), if an observed
advantage at least y is required with pr0.05 then
it follows that
y0 ¼ ð1þ zbz
ÿ1
a Þy ð14Þ
needs to be hypothesized under the alternative.
Thus, if a 15% risk reduction is required as in the
example above, the need is to hypothesize not 0.85
but 0.851.655 0.764. The practical consequence of
this is that fewer events are required; in fact
E0 ¼ Eð1þ zbz
ÿ1
a Þ
ÿ2 ð15Þ
events are needed representing a saving of
100f1ÿ ð1þ zbz
ÿ1
a Þ
ÿ2g% in trial size relative to
hypothesizing y. With respect to the example above,
E0 ¼ 582; a saving of 63% in trial size. The
implications of hypothesizing y0 as opposed to y
would need to be carefully articulated to the
development team; the jump in expectation could
be considered biologically implausible, even to such
an extent as to render the entire trial non-viable. If
so, reconsideration of the minimally desired out-
come to be convincing will very likely be necessary.
(ii) Always provide ycrit as in (5).
This is particularly informative when judging
the merits of a range of trial size and power
options. In the example above ycrit ¼ 0:906:
(iii) Translate ycrit into more meaningful terms
by stating what this means in terms of the
anticipated split of events between E and C.
From (3), and given N, y and d, it follows that
dC ¼
N
2
1ÿ
2dC
N
 ey
ÿ1
( )
þ d ð16Þ
with dE5 dÿdC. If the expected event rate is low,
then (16) simplifies to provide the approximation
dC ﬃ
d
ey þ 1
ð17Þ
Using the example above, substituting ycrit for y in
(16) gives 832 events on C versus 759 events on E,
a difference of 73 events. Hence, to achieve pr0.05
an excess of at least 73 events needs to be observed
on C relative to E. If the approximation in (17) is
used, then the spilt is slightly over stated at 835
events on C versus 756.
3.2. Saying a little more about the calculation
Returning to the hypothetical dialogue between
the medic and the statistician, given the recom-
mendations above, it would be hoped that after
‘y11 800 patients will need to be randomised’ the
statistician would consider adding a little more
along the following lines: ‘ythough you should
realise that in this trial I’m hypothesising a risk
reduction of 15% which means that a lesser
observed difference at the end of the trial would
give pr0.05; a risk reduction of at least 9.4%,
corresponding to a difference in events of at least
832 (14.1%) versus 759 (12.9%), i.e. a difference of
at least 73 (1.2%) events, would be significant. If
the end result was actually a 15% risk reduction
[corresponding to 855 (14.5%) versus 736 (12.5%)
events, a difference of 119 (2%) events] the p-value
would be well below 0.05; it would be around
0.0012. I’ve prepared a table with the details and a
few other scenarios to look aty’ Table I illustrates
the kind of information that would most likely be
of value to the medic and broader team.
This simple dialogue and illustration raises the
question as to whether the non-statisticians in drug
development, in particular medical, regulatory and
commercial leaders and overall product develop-
ment team leaders, conceptually appreciate what
hypothesis testing and power really are, and how
these concepts relate to sample size and the
p-value. The situation is not helped by the regular
and unfortunate use of loose language in the
statistical community when referring to trials as
being ‘sized [or designed] to detect a difference of y
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with 90% power at the 2-sided 5% significance
level’ rather than more correctly stating that the
trial is ‘sized [or designed] to test the hypothesis
H
0: the true difference5 0 versus H1: the true
difference5 y with Type I and II errors of 5% and
10% respectively’.
In trying to help colleagues come to grips with
these matters, it can be helpful to frame the
problem in simple terms, perhaps as follows: It
might be supposed that there is a very large jar
with over 100 000 beads, say. Beads are black or
white and the fraction of black beads is unknown.
A statistician hypothesizes that the fraction is 10%
(the null) and his medic colleague hypothesizes it is
30% (the alternative). A sample of 100 beads is
(blindly) taken from the jar and the number of
black beads noted. The beads are returned and the
procedure repeated a further nine times, say. Now,
if the 10 trials result in a consistently low number
of black beads, say, mostly in the range 0–15, with
a mean fraction of, for example, 12%, then it
seems likely that the statistician is correct and the
true fraction of black beads is 10%. However, if
the trials result in a consistently higher number of
black beads, say, mostly in the range 25–40, with a
mean fraction of, for example, 28%, then it seems
likely that the medic is correct and the true
fraction of black beads is 30%. It’s important to
note that (i) due to the play of chance, trials with
fewer than 30 beads and a mean fraction of less
than 30% are not necessarily inconsistent with the
medics view – one does not have to observe a
fraction of exactly 30% (or better) to conclude the
medic’s hypothesis is most likely; (ii) there must
therefore be critical pivot point for the observed
fraction of black beads somewhere between 10%
and 30% that favours the medic’s hypothesis over
the statistician’s hypothesis. Intuitively this might
be 20%; an observed fraction lower than this
supporting the statistician’s hypothesis, and higher
the medic’s. This pivot point is corresponds
conceptually to ycrit (as in equations (5)) and is
why a trial does not have to yield a result equal to
the hypothesized effect to give a positive (pr0.05)
outcome. See Figure 1 for a simple graphic thatT
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has proven useful in describing the basic idea to
non-statisticians.
With respect to power, it may further be
explained that if the true fraction of black beads
in the jar is 30%, power is the number of times
the observed fraction in repeated trials crosses the
pivot point in favour of the medic (i.e. the
alternative). The larger the sample size, the less
likely the play of chance will throw up trials with a
low number of black beads, so that higher sample
sizes mean higher power.
Finally, there remains the question as to how
large a sample should be taken? One answer
might be not so small that you wish it would have
been larger, and not so large than you know it
could have been smaller. In practice it can be
explained that the sample size is calculated by the
statistician to control the probability of false-
positive (concluding the fraction of black beads in
the jar is 30% when the true fraction is actually
10%) and false-negative (concluding the fraction
of black beads in the jar is 10% when the true
fraction is actually 30%) findings at some pre-
determined levels, typically 5% and 10%, respec-
tively, corresponding to 5% (two sided)
significance and 90% power. If the probability of
false-positive and false-negative findings are set to
be equal, then it follows from (14) that ycrit ¼ y=2;
if, as is more usual, false-positive and false-
negative findings are fixed at 5% and 10%,
ycrit  0:6 y; whereas if they are fixed at 5%
and 20%, ycrit  0:7 y:
Taking a little time upfront to refresh memories
on the key concepts of hypothesis testing, power
and sample size is likely to prove invaluable further
down the line. In particular, a common apprecia-
tion of these ideas is likely to be very useful when
tackling the thorny and not infrequent problem of
what to do when, several months into the trial,
events appear to be accumulating at a lower rate
than expected and concerns are growing that the
target number of events, d, will not be achieved
over the planned duration of the trial, A1F. How
the statistician might help in working through this
problem is the topic of the next section.
4. THE BEST LAID PLANS OF MICE
AND MEN...
The trial discussed between the medic and
statistician is underway. A total of 1591 events
are targeted and 11 800 patients are to be recruited
over 1 year at a rate of just fewer than 1000
patients per month, with an additional year of
follow-up after the last patient is entered. How-
ever, a problem has arisen. Nine months into the
trial, the (blinded) event rate has been assessed
over the first 6 months of accrual for which up-to-
date data are available (all patient visits over the
first 6 months have been monitored and the
presence/absence of events verified) and it is lower
than expected. Of the 5900 patients randomized
over the first 6 months, there are 104 events
(1.77%). Based on initial assumptions, the statis-
tician reveals the expected number of events at this
time is 141 (2.38%). This represents a shortfall in
the 1-year rate from 10% to 7.5%. Extrapolating
forward, this means a total of 1200 events are now
expected by the end of the trial. The question for
the drug development team is what should be
done? The options appear to be
1. Keep N at 11 800 but extend follow-up to
compensate to achieve 1591 events – question
for the statistician is thus how much should
follow-up be extended?
2. Keep the overall trial duration at A1F and
but increase N to compensate to achieve 1591
events – question for the statistician is how
much should N be increased?
Figure 1. The weight of evidence: hypotheses, trial data
and the critical value.
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3. Some combination of 1 and 2.
4. Do nothing. Check again in 6 months and
hope the event rate has picked up.
5. Accept the lower event rate, do not change N
or extend follow-up, and settle for the lower
number of events, now expected to be 1200 –
question for the statistician is what are the
implications in terms of achieving a positive
outcome for the trial?
Firstly, given r events out of N patients
over some time period T, the event rate easily
derived via (7) or (8) when the event rate is small.
In practice, the Kaplan–Meier curve would also
be drawn to show how events have emerged over
time and a best-fit model could be fitted to predict
how future events were likely to accrue [6].
However, for the purposes of what follows,
exponentially distributed times to event are
assumed as they were in the original sample size
calculation.
With respect to Option 1, if the event rate is
small and reduced by 100o%, then, from (8), to
compensate minimum follow-up F must be in-
creased by approximately (oÿ1)ÿ1 times the
overall duration of the trial A1F, i.e.
F ! F þ
A
2
þ F
 
ðoÿ 1Þÿ1 ð18Þ
Alternatively, with respect to Option 2, if the
overall duration of the trial remains fixed, then N
must be increased by approximately
100(oÿ1)ÿ1% to N(oÿ1)ÿ1, i.e.
N ! Nð1ÿ oÞÿ1 ð19Þ
An intermediate question for the team is now
which of Options 1 and 2 is worse? According to
(18), minimum follow-up should increase by
approximately 0.33 185 6 months, taking the
overall duration from 24 to 30 months. On the
other hand, (19) says the number of patients
entered should increase by approximately 33%, i.e.
by 3900 patients, to around 15 700 pts. In practice,
an extension of follow-up is likely to be favoured
over an increase in N if only due to issues relating
to the feasibility of boosting recruitment in
existing sites within the remaining accrual period,
and logistical issues relating to the speed with
which new sites could be added and made
operational. A hybrid approach might be to
increase N to 13 500 and follow for an additional
3 months which, based on the observed event rate,
would deliver 1591 events by the end of the trial.
Option 4 is certainly a realistic option, given that
relatively little data are available. However, in face
of what appears to be a potentially serious shortfall
in the event rate, it is unlikely little else would be
done in practice. It is more likely that some change
to N and/or minimum follow-up would be proposed
with the event rate continuously monitored such
that if it was to pick up, plans to increase trial size
and/or follow-up of could be revisited.
Option 5 is likely to be viewed as least
favourable by the typical project team. The
resultant lost of power is often difficult to
accept and external factors, like trial Steering
Committees (usually consisting of the Principal
Investigators and senior sponsor personnel) and
other thought leaders in the scientific community,
tend to want to meet the predefined event
total. However, anxiety around settling for fewer
events is often founded upon a poor appreciation
of what is really being lost in terms of outcomes to
yield significance or, conversely, what is really to
be gained by pushing for the original target
number.
Table II shows that while power is reduced to
approximately 80%, there is actually little prac-
tical difference between 1591 and 1200 events in
terms of the hypothesized effect to provide 90%
power and ycrit, the threshold value to achieve
pr0.05. With 1200 events, an observed HR of
0.893 (10.7% risk reduction) will provide a
positive result, which is little different to the HR
of 0.906 (9.4% risk reduction) for 1591 events. In
terms of the anticipated spilt of events, these HRs
translate to 832 (14.1%) versus 759 (12.9%)
events, an absolute difference of 73 (1.2%) events,
for 1591 total events as compared with 632
(10.7%) versus 568 (9.6%) events, an absolute
difference of 64 (1.1%), events for 1200 total
events. Further, with 1200 events, if the HR
observed was 0.906, then the split of events would
be 628 (10.6%) versus 572 (9.7%), a difference of
Copyright r 2009 John Wiley & Sons, Ltd. Pharmaceut. Statist. 2009; 8: 333–345
DOI: 10.1002/pst
340 K. J. Carroll
Publication 14: Carroll 2009
244
56 (0.9%). Hence, while the additional 391 events
from 1200 to 1591 buy an extra 10% power, they
do not provide as great a gain in practical terms
as one might at first think; these extra events
provide a slack of just eight events in terms of
the outcome to provide a positive, pr0.05
result. Seen in these terms, the drug development
team may now view Option 5 as a more realistic
option in the face of a lower than expected event
rate.
Figures 2 and 3 illustrate the degree of gain in
accumulating events in an outcomes trial. From
(1), once around 1000–1200 events are exceeded,
Figure 2 shows the relationship between the
‘detectable’ HR and the number of events is
shallow so that relatively large jumps in the
number of additional events provide little extra
in terms of the HR that can be detected
with a given power, which is in line with the
example above. Figure 3 perhaps illustrates the
situation better, plotting the first derivative of (1)
with respect to ey to give the rate of change in the
HR as a function of total events. Again, it is clear
that once around 1000–1200 events have been
exceeded, the rate of change is close to zero,
meaning again that substantial jumps in the
number of additional events beyond around 1000
events are required to make meaningful inroads
into the ‘detectable’ HR. The situation is of course
much different for smaller numbers of events
where relatively small increments have a larger
impact.
5. SUMMARY AND
RECOMMENDATIONS
Outcome trials are a very important component of
drug development for new products across a
number of therapeutic disease areas. They are
typically very large-scale trials of long duration
with hard clinical endpoints as outcomes, typically
morbidity and mortality. As such, they are
invariably expensive and high-profile trials with a
critical impact on the clinical, regulatory and
commercial fate of the drug. The drug develop-T
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ment statistician therefore has a vital role to play
in the design, conduct, analysis and reporting of
such trials. In particular, the statistician must do
all they can at the outset to ensure that the sizing
of the trial is fully appreciated by their medical,
and other non-statistical, drug development team
colleagues and that the risk of delivering a
statistically significant but clinically unpersuasive
result is minimized. Equally, the statistician has a
key leadership role in guiding the team when a
lower than anticipated event rate appears to be
emergent.
In order to make the most effective contribution
possible to the drug development team and process,
it is therefore recommended that statisticians
1. Avoid the use of loose and imprecise language
when describing basic sample size and power;
Figure 3. Rate of change in the ‘detectable’ hazard ratio versus total number of events.
Figure 2. The ‘detectable’ hazard ratio versus total number of events.
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in particular, statisticians should avoid state-
ments such as ‘the trial is sized [or designed] to
detect a difference of y with 90% power at the
2-sided 5% significance level’ and rather use
more correct language such as ‘ the trial is
sized [or designed] to test the null hypothesis
H0: the true difference5 0 versus the alter-
native H1: the true difference5 y with Type I
and II errors of 5% and 10%, respectively [or
with a 5% 2-sided significance level and 90%
power]’.
2. Take a little time upfront to refresh their
colleagues appreciation of the true nature of
hypothesis testing, sample size and power and,
thus, help avoid confusion when the trial
subsequently delivers a significant result for an
observed outcome less than that which was
hypothesized.
3. Always and routinely provide the critical value
of the test, ycrit, equation (5), when describing
sample size and power.
4. Point out that if a specific advantage of, say, at
least y, needs to be realized to be persuasive in
clinical, regulatory and commercial terms,
with a result less than y not being meaningful
even if it reached statistical significance, then
the need is to hypothesize not y but rather
y0 ¼ ð1þ zbz
ÿ1
a Þy; equation (14); and that this
results in a reduction in the number of events
required from E if y is hypothesized to E0 ¼
Eð1þ zbz
ÿ1
a Þ
ÿ2 when y0 is hypothesized,
equation (15); this being a reduction of
100f1ÿ ð1þ zbz
ÿ1
a Þ
ÿ2g% in the required num-
ber of events. The implications of hypothesiz-
ing y0 as opposed to y should to be carefully
explained to the development team as the
jump in expectation could be considered
biologically implausible to such an extent as
to render the entire trial non-viable. If so,
reconsideration of the minimally desired out-
come to be convincing will be necessary.
5. State that, if y is hypothesized and is realized,
the resultant p-value will be considerably less
than p5 0.05; it will in fact be p5 0.0012,
equation (6).
6. Translate ycrit into more meaningful terms by
stating what this means in terms of the
anticipated split of events between E and C,
equations (16) and (17).
7. Point out that, when the event rate is relatively
low, and early blinded trial data suggest the
event rate may be reduced by 100o% relative
to initial expectations, then to compensate
either the minimum follow-up F must be
increased by approximately (oÿ1)ÿ1 times
the overall duration of the trial, A1F,
equation (18), or the target number of events
must be increased by approximately
100(oÿ1)ÿ1%, equation (19).
8. State that, once around 1000–1200 events are
achieved, the practical gain in accumulating
further events in is marginal, Figure 3, such
that substantial jumps in the number of
additional events beyond 1000–1200 events
are required to make a meaningful difference
to the ‘detectable’ HR.
By following these simple recommendations it is
hoped that statisticians involved in drug develop-
ment will make an even more thorough contribu-
tion to the drug development team.
However, issues do, and will, remain. It could be
argued that, despite best intentions, the drug
development team cannot know at the outset the
minimum degree of efficacy that must be observed
to make for a persuasive result in the future.
However, given the link between the threshold value
for significance and the effect hypothesized under
the alternative (as in (14)), if the minimum degree of
efficacy to be observed to make for a persuasive
result cannot be set in advance, then, logically, it is
not possible to postulate a meaningful alternative
hypothesis, since these quantities are two sides of the
same coin. A similar sort of problem was gratefully
highlighted by an anonymous reviewer who pointed
out that while a clinician or commercial colleague
might state at the outset what they feel is the
minimally acceptable for a new drug, that is, what
the new drug needs to ‘deliver’ at a minimum to be
both clinically worthwhile and commercially viable,
this ‘target drug profile’ often changes as the
development programme unfolds. It is not uncom-
mon for the target drug profile to demand high
efficacy from a new drug at the outset, only for
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expectations to be lowered sometime later in
response to accumulating data or changes in the
competitive landscape. Then a lesser, yet still
clinically meaningful, threshold for effectiveness
may well be viewed as acceptable so that, in turn,
a smaller point estimate for efficacy might become
acceptable. If, in the end, the observed treatment
effect was somewhat less than that stated as
important at the outset but was nevertheless
consistent with revised expectations around efficacy,
the sample size will not be large enough to produce
a significant p-value, and the drug development
teammay well be very unhappy. It is indeed possible
for target drug profile expectations to change during
a development programme, but, at the start, it is
impossible to know if, or when, expectations will
change, and, if they do, whether they will be weaker
or stronger. All the statistician can reasonably do at
the outset is to ensure that the appropriate dialogue
takes place within the team to design a trial to
deliver what is felt, at that time, to be a clinically
and commercially persuasive result. If expectations
change during the course of the trial, then the
obvious and correct course is for the Team to
reconsider the trial design, making adjustments to
size and/or duration of follow-up as necessary.
Before closing, another common, event-related
generic issue in outcome trials briefly worth a
mention is the practice of analysing adverse event
(AE) data as ‘time to event data’, where patients
who withdraw early from the trial or die without
experiencing the AE of interest are censored
despite the obvious issues of informative censoring
and competing risks. This is particularly proble-
matic in outcome trials where drug is found to
significantly improve overall survival relative to
control. For example, if the ’time to event’
analysis for a given AE provides a HR of 1.33,
drug:control, and yet the HR for overall survival is
0.75, drug:control, how do we interpret the data?
Given that patients are living longer on drug, they
are obviously more likely to experience a higher
proportion of other events than patients treated
with control and, thus, the HR of 1.33 for the AE
does not necessarily mean that the drug is
associated in a 33% increase in the risk of the
AE. It is therefore generally better, and arguably
more meaningful and easier to interpret, to plan to
look rather at ’event-free survival’ for an AE, i.e.
the time to the first of the AE or death. The
resulting analysis is free from the complexity of
competing risk and informative censoring due to
death and can be meaningfully interpreted un-
conditionally, as the length of time patient is alive
and free from the AE of interest, which is quantity
likely to be of interest to both patients and
physicians alike.
Overall, and notwithstanding the issues that
remain, it is hoped that the statistician, in following
the simple recommendations offered in this paper,
will help their clinical, commercial, regulatory and
other non-statistical drug development team leaders
to better appreciate the nuances of outcome trial
size determination and powering. It is therefore
hoped the whole team will have a more complete
appreciation of what the outcome trial will and will
not deliver and, thus, will be better equipped to deal
with those tricky and not infrequent situations when
the initial event rate assumption seems perhaps to
have been a little optimistic, requiring careful
consideration of the options going forward.
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Abstract
The fraction of patients who respond to treatment and the duration of response in the subset of responding patients are
commonly evaluated in oncology trials of cytotoxic compounds. While formal, comparative analysis of the fraction of patients
responding to treatment is straightforward in a randomised trial, analyses that attempt to compare treatments in terms of the
duration of response in responding patients are likely to be biased since the groups being compared are defined by the post-
treatment outcome of response rather than by randomisation. Subsets of responding patients may not be comparable with respect to
baseline prognostic factors and, consequently, formal comparative analysis is discouraged by the European Medicines Evaluation
Agency. In an attempt to combine both the fraction of patients responding to treatment and the duration of response in responding
patients, Temkin considered the probability of being in response function (PBRF) as a description of the treatment difference. Begg
and Larson subsequently developed a parametric version of the PBRF under the exponential assumption. This paper briefly
considers the PBRF as a means of estimating the expected duration of response across all randomised patients, thereby allowing a
formal and unbiased comparison of treatments for duration of response. Building on earlier work, a more general and flexible
approach to estimating the expected duration of response is offered to generalise beyond the exponential distribution.
© 2007 Elsevier Inc. All rights reserved.
Keywords: Duration of response (DoR); Probability of being in response function (PBRF); Expected DoR (EDoR)
1. Introduction
It is common in oncology trials of cytotoxic drugs
that some patients will respond to treatment, as defined
by some percentage reduction in tumour mass, say, as
per RECIST criteria [1]. Responding patients will
subsequently experience progressive disease (or die in
the absence of progression) or reach the end of the trial
without progression. Hence, the duration of response in
responding patients will be known for some and
censored for others. The fraction of patients who
respond to treatment and the duration of response in
responding patients are widely evaluated in oncology
trials and both measures are considered clinically
important determinants of therapeutic value by practis-
ing oncologists and regulatory authorities alike [2–5].
While comparative analysis of the fraction of patients
responding to treatment is straightforward in a rando-
mised trial, analyses that attempt to compare treatments
in terms of the duration of response in responding
patients are likely to be biased since the groups being
compared are defined by the post-treatment outcome of
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response rather than by the randomisation schedule [6].
Subsets of responding patients may not be comparable
with respect to baseline prognostic factors and, conse-
quently, formal comparative analysis is discouraged by
the European Medicines Evaluation Agency [5,7].
Another problem is that response rates and duration of
response may show trends in opposite directions, for
example a higher response rate in the control therapy but
a longer duration of response in the experimental
therapy. Such separate results may be difficult to
interpret in terms of which treatment is preferred.
In an attempt to combine the fraction of patients
responding to treatment and the duration of response in
responding patients, Temkin considered the probability
of being in response function (PBRF) [8]. Subsequently,
Begg and Larson examined the PBRF using a simplified
parametric model in which each of the different sojourn-
time distributions is assumed to be exponential [9].
This paper attempts to build on this earlier work and is
structured as follows: Section 2 considers the PBRF as a
means of estimating the expected duration of response
across all randomised patients, thereby allowing a formal
and unbiased comparison of treatments for duration of
response. In Section 3, an alternative, more general ap-
proach to estimating the expected duration of response is
offered. Section 4 then closes with a summary of the ideas
discussed and offers recommendations for the presentation
and analysis of response data in Oncology trials.
2. The probability of being in response function
(PBRF) and the expected duration of response
2.1. The expected duration of response
Temkin defined the PBRF as the fraction of patients who
would be in response as a function of time after study entry if
censoring were eliminated [8]. This provides a useful,
descriptive way of visualising the difference between
treatments in terms of the likelihood of being in response
at any point during follow-up. The area under the PBRF, if
available to infinity,measures themean or expected duration
of response (EDoR) across all patients and so could be used
to formally compare treatments. Resamplingmethods could
then be used to provide a confidence interval for the
difference in expected response durations together with a
p-value [10]. In practice, however, the PBRF is unlikely to
be well defined at later follow-up times making estimation
of the EDoRby area under the PBRFpotentially unreliable.
Begg and Larson build on Temkin's approach by
considering a stochastic process in which a patient must
start in an initial state 0 and eventually progress to an
absorbing state, 2 (progression or death in the absence of
progression), possibly passing through a transient state, 1
(response) [9]. Response and duration of response are
assumed to be independent and different sojourn-time
distributions are assumed to be exponential so that
transition between states is governed by constant hazards:
k1: 0Y2; k2: 0Y1; k3: 1Y2;
Begg and Larson show the time to first event has an
exponential distribution with hazard λ1+λ2 and the
probability that this first event is a response is λ2 / (λ1+
λ2), being independent of the time the event occurred.
Further, if P(t) is the probability that a patient is in
response at time t, it is shown that
P tð Þ ¼ k2 exp $k3tð Þ 1$ exp $btð Þf g=b if b ¼ 0
tk2 exp $k3tð Þ if b ¼ 0
where β=λ1+λ2−λ3.
Importantly, the area under P(t)=λ2 / {(λ1+λ2)λ3} is
the EDoR based on all patients, not just the subset of
responding patients. Hence, the EDoR, if estimated
together with its standard error for both treatments in a
randomised trial, could form the basis of a formal,
unbiased comparison of treatments across all patients for
their relative effect on response duration.
2.2. Estimation
To provide an estimate of the EDoR, defineU to be the
sum of all observed times to the first event, including the
observed times of patients censored while in the initial state
and letW be the sum of all response durations including the
times of patients censored while in response. Then, let
n1 number of patients who progress without
response
n2 number of patients who respond and are then
censored
n3 number of patients who respond and then
progress
n4 number of patients who are censored without
response or progression
The maximum likelihood estimates (MLEs) of λ1, λ2
and λ3 are provided by Begg and Larson; they are,
respectively, n1 /U, (n2+n3) /U and n3 /W. The estimated
EDoR, ÊDoR, say, is therefore given by n2þn3
n1þn2þn3 ( Wn3 :
Note that, in the formulation offered by Begg and
Larson patients who remain in state 0 who neither progress
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nor achieve a response (and thus are censored without
response or progression at the end of the trial follow-up
period), are considered uninformative and do not con-
tribute when estimating the EDoR. Bearing this in mind, it
can be seen that ÊDoR is a product of the estimated
fraction of patients with a response, p ¼ n2þn3
n1þn2þn3, and
the mean duration of response in responding patients, W
n3
.
Since the distribution of event times is assumed to be
exponential, it is preferable to consider the EDoR on the
log scale. Since ln(EDoR)=ln(λ2)− ln(λ1+λ2)− ln(λ3),
then the estimated variance of ln(ÊDoR) is given by
Vˆar ln EˆDoR
! "h i
i
P3
i¼1
Var kˆi
! "
( Aln EDoRð Þ
Aki
j
ki ¼ ˆk i . Sub-
stituting the MLEs for λ1, λ2 and λ3,
Vˆar ln EˆDoR
! "h i
i
1
n3
þ 1
n2 þ n3 $
1
n1 þ n2 þ n3 ð1Þ
Thus, in a randomised trial comparing a new drug, E,
with a control, C, the hypothesis that the EDoR is equal
for E and C can be assessed by testing
H0 : R ¼ EDoREEDoRC ¼ 1 vs: H1 : R ¼
EDoRE
EDoRC
p1
using
z ¼
ln Rˆ
! "
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ˆVar ln Rˆ
! "h ir
¼
ln EˆDoRE
! "
$ ln EˆDoRC
! "
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ˆVar ln EˆDoRE
! "h i
þ ˆVar ln EˆDoRC
! "h ir
ð2Þ
as the test statistic and comparing to a standard Normal
(0,1) distribution.
2.3. An example
Suppose 200 patients are randomised to either
treatment E or C on a 1:1 basis. Suppose further that, on
treatment E, 70 patients progress without a response and
the remaining 30 patients experience a response and, of
these 30 responders, 10 are censored in response at the end
of the trial follow-up period. Thus n1=70, n2=10, n3=20
and n4=0. The mean duration of response in the 30
responding patients is 6 months. Suppose further that the
corresponding figures on C are 80 patients progressing
without a response, 20 patients experience a response and,
of these, 5 are censored in response. Thus n1=80, n2=5,
n3=15 and n4=0. The mean duration of response in the
20 responding patients is 3 months. Hence, the estimated
EDoR is 30100( 6 ¼ 1:8 for treatment E and 20100( 3 ¼ 0:6
for treatment C. The approximate standard errors (SEs)
for the log of these estimates are
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
20þ 130$ 1100
q
¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ0:0733p
for ln(ÊDoRE) and
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
15þ 120$ 1100
q
¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ0:1067p for ln(ÊDoRC).
Therefore, z ¼ 1n 1:8ð Þ$ln 0:6ð Þﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:0733þ0:1067p ¼ 2:589, so that the 2-sided
p-value is 0.0096.
This example is extended in Table 1 to illustrate the
interplay between the fraction of patients responding, the
duration of response in responding patients and the EDoR.
3. An alternative approach to estimating the EDoR
3.1. Duration of response as mixture distribution
In the above formulation of the EDoR, event times are
assumed to be exponentially distributed. However, it is
possible to consider a more flexible approach that
generalises to other distributions as follows. Let x repre-
sent duration of response and let p be the probability of
response. Let g(x) denote the probability density function of
Table 1
Examples of comparing treatments on the basis of the expected duration of response
Example Treatment E (N=100) a Treatment C (N=100) a Comparison
Number
responding
Number
responding
censored in
response
Mean
DoR b in
responders
(months)
EDoR c SE d ln
EDoR
Number
responding
Number
responding
censored in
response
Mean
DoR in
responders
(months)
EDoR SE ln
EDoR
Ratio of EDoR
and 95% CI e
p-value
1 30 10 6 1.80 0.271 30 7 3 0.90 0.258 2.00 (0.96, 4.17) 0.0641
2 30 15 6 1.80 0.300 20 5 6 1.20 0.327 1.50 (0.63, 3.58) 0.3606
3 30 15 6 1.80 0.300 20 5 3 0.60 0.327 3.00 (1.26, 7.16) 0.0132
4 30 15 6 1.80 0.300 40 5 3 1.20 0.209 1.50 (0.73, 3.07) 0.2672
5 30 15 3 0.90 0.300 20 5 6 1.20 0.327 0.75 (0.31, 1.70) 0.5165
a All non-responding patients are progressors; there are no patients without a response or progression, hence n4=0 throughout.
b DoR = Duration of response in responding patients; exponential distribution assumed.
c EDoR = Expected duration of response.
d SE = standard error.
e CI = Confidence interval.
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x, fp(x) denote probability density function ofx in responding
patients and f1−p(x) denote probability density function of x
in non-responding patients. Then g(x) is a simple mixture
distribution such that g(x)=pfp(x)+(1−p)f1−p(x). The
EDoR is therefore Eg(x)=pEfp(x)+(1−p)Ef1 − p(x) where
Es(x) denotes expectation over s(x). If the duration of
response in non-responding patients is defined as zero,
then x=0 with probability 1 and f1−p(x)=0 for xN0 and
hence Ef1 − p(x)=0. Consequently, the EDoR reduces to
pEfp(x) which is, again, the product of the estimated
fraction of patients with a response and the mean duration
of response in responding patients. If the EDoR is
considered on the log scale, then ln(EDoR)=ln(p)+ ln(Efp
(x)) and, further, if pˆ and Eˆfp(x) denote the MLEs of p and
Efp(x), then
Vˆar ln EˆDoR
! "h i
i
1
pˆ2
Vˆar pˆð Þ þ 1
Eˆfp xð Þ
) *2 Vˆar Eˆfp xð Þ) *
ð3Þ
Consider as before a randomised trial comparing treatments
E and C in NE and NC patients per group. Let pE and pC
denote the true response rates and ME and MC the true
meanDoR in responding patients. ThenR ¼ EDoREEDoRC ¼
pEME
pCMC
so that ln Rð Þ ¼ ln pE
pC
! "
þ ln ME
MC
! "
. Substituting estimates
for pE, pC,ME andMC,
ln Rˆ
! "
¼ ln pˆE
pˆC
+ ,
þ ln MˆE
MˆC
 !
ð4Þ
and, thus, from Eq. (3),
ˆVar ln Rˆ
h i
¼ 1$ pˆE
NE pˆE
þ 1$ pˆC
NC pˆC
þ 1
Mˆ
2
E
Vˆar MˆE
h i
þ 1
Mˆ
2
C
Vˆar MˆC
h i
ð5Þ
Note the last two terms in Eq. (5) represent the
variance of the estimated ratio of mean response
durations in responding patients and applies when each
treatment group is examined separately. The hypothesis
that the EDoR is equal for E and C can be tested by:
H0 : R ¼ EDoREEDoRC ¼ 1 vs: H1 : R ¼
EDoRE
EDoRC
p1
using
z ¼
ln Rˆ
! "
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Vˆar ln Rˆ
! "h ir ð6Þ
as the test statistic which is equivalent to Eq. (2) above.
3.2. Comparison to Begg and Larson
It is of interest to compare the estimate of the EDoR
achieved via amixture distribution to that achieved byBegg
and Larson via a stochastic model. If fp(x) is exponential
with hazard rateλ, thenEfp(x)=1/λ so that the EDoR=p /λ.
If it is assumed that subjects who do not respond or
progress are uninformative, then pˆ=(n2+n3) / (n1+n2+n3)
and Eˆfp(x)=n3 /W, being the same as the estimate for λ3
above. Hence, ÊDoR=(n2+n3) /{(n1+n2+n3)}×n3 /W,
which is the same as the estimate achieved by Begg and
Larson. Further, since Var pð Þ ¼ 1$p
p n1þn2þn3ð Þ, then
1
pˆ2
Vˆar pˆð Þ ¼ n1
n2 þ n3ð Þ n1 þ n2 þ n3ð Þ
¼ 1ðn2 þ n3Þ $
1
n1 þ n2 þ n3ð Þ
and Vˆar ln Eˆfp xð Þ
! i
¼ 1
n3
h
, so that
Vˆar ln EˆDoR
! "h i
¼ 1
n2 þ n3ð Þ $
1
n1 þ n2 þ n3ð Þ
þ 1
n3
which is, again, as per Begg and Larson.
3.3. Application in practice
Since the above formulation gives the EDoR to be the
product of the fraction of patients with a response and
the mean duration of response in responding patients, it
is straightforward to compare treatments in practise as
follows:
(i) Estimate pE as
rE
NE
and pC as
rC
NC
, where rE and rC
are the number of patients responding to E and C
respectively.
Note the exclusion of patients who have neither
responded nor progressed from the denominator when
estimating the fraction of patients responding to
treatment is problematic. For example, suppose of 50
patients are treated, 10 respond, 20 progress without a
response and 20 neither progress nor respond. Typically
in an oncology trial, the fraction of responding patients
is calculated as the number responders divided by the
number of patients treated. Thus, in the current example,
this fraction would be 20% (10/50). If, however, those
who neither progress nor respond during follow-up are
excluded from the denominator, the apparent fraction of
responding patients is increased, in this example to 33%
(10/30). If all 40 of the non-responding patients did not
progress during follow-up, the fraction of responding
patients would be quoted as 100%. Excluding patients
who neither progress nor respond during follow-up
when estimating the fraction of patients responding to
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treatment allows the number of patients in the
denominator to be determined by a post-treatment
event (or, more precisely, by the absence of an event).
This approach results in an inflated estimate for the
fraction of patients responding to treatment (and thus an
inflated estimate for the EDoR) and should be avoided.
(ii) Estimate ME and MC and their standard errors.
This will depend on the probability distribution for
the duration of response in responding patients, fp(x).
Given a sample of responding patients, some of whom
may be censored in response, estimates of ME and MC
and their standard errors can be calculated separately for
each treatment group for a range of commonly used time
to event probability distributions such as the simple
exponential, the Weibull, the gamma, the Normal and
the log Normal. This is easily done using software such
as SAS® PROC LIFEREG, where the mean duration of
response together with its variance can readily be
estimated for any member of the generalised gamma
family of distributions [11]. Derivations for the Weibull
and log Normal are provided in the Appendix.
(iii) Combine the estimates in (i) and (ii) to provide
estimates of R and Var[ln(R)] and the difference between
E and C is then assessed using Eq. (6).
3.4. A theoretical example
To illustrate the above approach, a 1000 patient
dataset was simulated with patients randomised on a
1:1 basis to one of two treatment groups, E and C.
Underlying time to response, duration of response and
time to progression were simulated from exponential
distributions with medians for the control group of 4, 3
and 5 months respectively. The maximum follow-up
time was 10 months. Of those patients randomised to
E, 253 responded and of those randomised C, 153
patients responded. Fig. 1 displays the PBRF which
shows that initially patients treated with E are more
likely to be in response than those randomised to C [8]
although towards the end of the curves this is reversed.
Response durations were analysed assuming exponen-
tial, Weibull and log Normal densities. Fig. 2a–c show
the Kaplan–Meier curves for the duration of response
in responding patients with curves assuming an
exponential, Weibull and log Normal distributions
for duration of response superimposed. Given the
fraction of patients responding to each treatment, the
estimated mean durations of response in responding
patients and their associated standard errors, Table 2
shows how the data can be displayed in a simple,
transparent fashion so that the calculation of the EDoR
can be easily seen and understood. In this example,
assuming exponentially distributed response durations,
the EDoR is 3.1 months and 2.3 months for E and C
respectively and comparing gives a ratio of 1.37, 95%
CI (0.98 to 1.90), p=0.065. An alternative analysis
assuming a Weibull distribution gives a broadly
similar result. As evident in Fig. 2c, the log Normal
distribution provides a poor fit to the data and
consequently overestimates the EDoR.
Fig. 1. Probability of being in response as a function of follow-up time. Example data.
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3.5. A real example
Response and duration of response were measured in
a randomised, double-blind trial of gefitinib+doublet
chemotherapy vs. placebo+doublet chemo therapy in
the treatment of advanced lung cancer [12]. A total of
345 patients were randomised to 250 mg gefitinib, 347
patients to 500 mg gefitinib and 345 patients to placebo.
For the purposes of illustration, we shall focus on the
500mg and placebo arms. The data are shown in Table 3,
together with the EDoR in all patients assuming expo-
nential, Weibull and log Normal densities. The PRBF for
500mg vs. placebo is shown in Fig. 3 and Kaplan–Meier
curves for response duration in responding patients are
Fig. 2. (a) Duration of response for responding patients with an exponential distribution: Simulated example data. (b) Duration of response for
responding patients with a Weibull distribution: Simulated example data. (c) Duration of response for responding patients with a log Normal
distribution: Simulated example data.
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shown in Fig. 4a–c. It is clear from these data that the
exponential distribution is a poor fit and therefore does
not provide a reasonable estimate of mean DoR in
responding patients, and thus, the EDoR. The Weibull
and log Normal distributions are clearly better, with the
log Normal fitting the latter part of the survival curves a
little better than the Weibull. For the Weibull, EDoR is
estimated to be 40 days on placebo and 53 days on
gefitinib. The difference between treatments approaches
significance with an EDoR ratio of 1.32, 95% CI (0.98 to
1.78), p=0.07. For the log Normal, EDoR is estimated to
be 42 days on placebo and 62 days on gefitinib. The
difference between treatments now reaches significance
with an EDoR ratio of 1.49, 95% CI (1.03 to 2.16),
p=0.04.
4. Summary and recommendations
The major concern with comparing the duration of
response between treatments in oncology trials is that
the comparison is frequently based on a subset of
patients determined after randomisation. Subsets of
Table 2
Comparison of treatments for expected duration of response using simulated data
Exponential Weibull Log normal
Treatment C
(N=500)
Treatment E
(N=500)
Treatment C
(N=500)
Treatment E
(N=500)
Treatment C
(N=500)
Treatment E
(N=500)
Response rate, % [1] 50.6% 30.6% 50.6% 30.6% 50.6% 30.6%
Mean DoRa [2] 4.5 10.2 4.7 12.1 12.9 57.6
SEb DoR 0.08 0.13 0.09 0.22 0.23 0.53
EDoRc [1]x[2] 2.27 3.11 2.40 3.71 6.57 17.62
Ratio of EDoR and 95% Cld 1.366 1.547 2.681
(0.981 to 1.903) (0.944 to 2.534) (0.859 to 8.365)
P=0.065 P=0.08 P=0.09
aDoR = Duration of response in responding patients, months.
bSE = standard error.
cEDoR = Expected duration of response, months.
dCI = Confidence interval.
Fig. 2 (continued ).
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responding patients may not be comparable with respect
to important prognostic factors and, consequently, a fair
and unbiased comparison of treatments cannot be
guaranteed. Furthermore, response rate and duration of
response are particularly difficult to interpret if, for
example, one treatment gives a high response rate with a
short duration of response but the other treatment gives a
low response rate but those patients that do respond
achieve a durable, long lasting response. The question as
to which is the better drug is then unclear.
The approach discussed in this paper has been to build
on earlier work that attempted to tackle this problem by
combining information on the response rate with infor-
mation on the duration of response in responding patients.
By considering the problem in terms of a simple mixture
distribution, the expected duration of response can be
calculated based on all patients and not only those who
responded. A formal comparison of treatments can then be
affected by assuming some underlying distribution for the
duration of response in responding patients. The suitability
of the assumed probability distribution can be assessed
using published diagnostics. To avoid post-hoc choice of
the probability distribution and the associated criticisms,
the choice should be made based upon grouped, overall
data prior to unblinding or data analysis.
Therefore, in situations where a formal statistical
comparison of treatments is desired in terms of impact
on duration of response, it is recommended that
(i) the PBRF is used to display the data
(ii) response rates are provided with NE and NC used
in the denominator
Fig. 3. Probability of being in response as a function of follow-up time: gefitinib 500 mg vs. placebo, INTACT 2.
Table 3
Gefitinib vs. placebo, INTACT 2. Comparison of treatments for Expected Duration of Response using exponential, Weibull and log Normal densities
Exponential Weibull Log Normal
Gefitinib N=347 Placebo N=345 Gefitinib N=347 Placebo N=345 Gefitinib N=347 Placebo N=345
Response rate, % [1] 30.6% 29.9% 30.6% 29.9% 30.6% 29.9%
Mean DoRa [2] 221.6 148.8 173.7 134.7 202.6 139.5
SEb DoR 0.137 0.115 0.083 0.057 0.131 0.074
EDoRc [1]x[2] 67.7 44.4 53.1 40.2 61.9 41.7
Ratio of EDoR and 95% Cld 1.524 1.320 1.486
(1.003 to 2.313) (0.977 to 1.783) (1.025 to 2.155)
P=0.048 P=0.07 P=0.04
aDoR = Duration of response in responding patients, days.
bSE = standard error.
cEDoR = Expected duration of response, days.
dCI = Confidence interval.
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(iii) descriptive data are provided for the duration of
response in responding patients, including the
associated Kaplan–Meier curves (without any
formal comparison or p-value attached)
(iv) the expected duration of response is derived as the
sole basis to formally compare treatments statis-
tically and
(v) the data are laid out as per the example provided in
Table 2.
In following these recommendations the aim is to
ensure treatments are formally compared not in the
subset of patients who responded but on the basis of all
randomised patients and, further, to ensure the data are
Fig. 4. (a) Duration of response for responding patients with an exponential distribution: gefitinib 500 mg vs. placebo, INTACT 2. (b) Duration of
response for responding patients with a Weibull distribution: gefitinib 500 mg vs. placebo, INTACT 2. (c) Duration of response for responding
patients with a log Normal distribution: gefitinib 500 mg vs. placebo, INTACT 2.
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presented and displayed in a transparent and intuitive
fashion so that statisticians and non-statisticians alike
can better appreciate the relative difference between
treatments.
Appendix. Derivation of mean duration of response
and estimated variance for selected distributions
when analysing using SAS® PROC LIFEREG
For the patients who have responded the SAS®
procedure LIFEREG provides a straightforward means
of analysing the duration of response assuming a range
of common distributions. The procedure provides pa-
rameter estimates, typically the intercept, μ, and scale,σ,
together with the estimated covariance matrix. Depend-
ing on the distribution selected for analysis, these pa-
rameter estimates can be combined to provide estimates
of the mean duration of response together and its var-
iance as follows:
(i) For the Weibull distribution, f(t)=λαtα −1e−λtα,
LIFEREG parameterises such that a ¼ 1$ and k ¼
e$
%
$ so that mean duration of response is estimated
as eμˆΓ (1+σˆ) withVˆar ln e %ˆG 1þ $ˆð Þ/ 0) *¼Var %ˆð Þþ
digamma 1þ $ˆð Þf g2Var $ˆð Þþ2(digamma 1þ$ˆð ÞCov %ˆ; $ˆð Þ:
(ii) For the log Normal distribution, f tð Þ ¼ 1ﬃﬃﬃﬃ
2p
p
$t
e
$ 1
2$2
ln tð Þ$%
$
n o2
, the mean duration of response is esti-
mated as e %ˆþ
1
2 $ˆ
2
with Vˆar ln e%ˆþ12 $ˆ2
n oh i
¼ Var %ˆð Þþ
$ˆ2Var $ˆð Þ þ2 $ˆCov %ˆ; $ˆð Þ:
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